Fusogenic Liposome Based Vaccines against some Infectious Diseases by Mallick, Amirul Islam
^B£S1^ 
FUSOGEWIC LIPOSOME BASED VACCINES 
AGAINST SOME INFECTIOUS DISEASES 
ABSTRACT 
. THESIS 
SUBWIITTED FOR THE AWARD OF THE DEGREE OF 
Bottor of $i)tlO!Sopiip 
IN 
BIOTECHNOLOGY 
BY 
AMIRUL ISLAM MALLICK 
ciS 
INTERDISCIPLINARY BIOTECHNOLOGY UNIT 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (INDIA) 
2007 
' • ! > 
V * ^ a ^ ^ . ^ 
\^ . 
t* 
These days zoonotic diseases have invited a global interest^some of them have 
started posing altogether a new kind of health hazards. The recent threats in the form 
of AIDS, SARS and bird flu have enforced the scientific community to think and 
devote their maximum efforts to eradicate these dreadful diseases from the universe. 
Various strategies to counter them include introduction of novel prophylactic and 
chemotherapeutic measures to cure all the globally important zoonotic ailments on 
priority basis. 
Keeping into consideration the serious and fatal drawbacks associated with 
currently available control measures against intracellular pathogens, safe and 
efficacious delivery of prophylactic and chemotherapeutic agents are the best way to 
combat the current scenario. 
Among various important zoonotic diseases. Brucellosis is known to be a 
major bacterial zoonosis of global importance that causes abortion and infertility in 
cattle, and undulant fever, arthritis, endocarditis, orchitis and meningitis in human. 
Despite the numerous biotechnological improvements, brucellosis remains a major 
worldwide public health problem. The most appropriate method to control 
brucellosis is the immunization of susceptible hosts. However, the efficacy and 
safety of the available vaccines are questionable due to several drawbacks. 
Presently, not a single vaccine is available against human brucellosis, vaccines for 
animal brucellosis, although existing, are far from ideal. 
In order to overcome the problems associated with currently available live 
attenuated vaccines viz. S-19, RB51, or Revl etc., proteins oiB. abortus S-19, an 
attenuated strain that is antigenically similar to virulent strains, were being used as 
antigen and the vaccine potential was evaluated by using varieties of adjuvants. 
In spite of rapid development of antigen delivery systems, many of the newer 
adjuvants have improved upon some of the poorer aspects of traditional vaccine 
formulations (poor safety and efficacy). There are several important issues that act 
as driving forces for the methods by which future vaccines will be formulated and 
delivered in an effective way to overcome current deficiencies ensuring in improved 
efficacy of vaccines. 
In this regard, fusogenic nature of E. coli cell wall lipid made liposome 
known as escheriosome was studied extensively by many workers and found to 
effectively fuse with the membrane of the macrophages leading to the delivery of 
entrapped solutes to their cytosol. In the present work we have tried to evaluate the 
adjuvant potential of escheriosome and its possible use as effective drug delivery 
vehicle against experimental murine brucellosis. 
In the first part of this present work, we have evaluated the immunogenic 
potential of sonicated cytosolic protein (BCP) of Brucella S-19 after encapsulation 
in liposomes. We found that, proteins of B. abortus S-19, an attenuated standard 
vaccine strain that is antigenically similar to virulent strains, showed anticipated 
results and revealed some promising aspect of possible use of fusogenic liposome 
(escheriosome) as a successful carrier of Brucella immunogens. The escheriosome 
have the potential to be a novel vaccine candidate against brucellosis. But, one 
crucial aspect of dealing with such type of vaccine formulation is that that many 
unwanted protein fractions, are often incorporated in acellular vaccine preparation, 
which are non immunogenic and even toxic that leads to poor protective efficacy as 
well as undesirable side effects. 
Selection of potentially protective immunogens of Brucella using targeted 
delivery system to obtain a protection level closer to that offered by currently used 
live attenuated or acellular vaccine could be a successfiil alternative in the 
immunoprophylaxis against brucellosis. 
Advances in molecular biology and unprecedented development of 
molecular techniques such as recombinant DNA technology allow the investigation 
of pathogen from new perspective and provide a variety of fiindamentally new 
approaches for the development of new generation vaccines. Among various 
strategies to develop improved Brucella vaccine, recombinant, subunit or live vector 
vaccine are the prime objectives of vaccinologists. In this concern, many 
immunogenic proteins have been tried as recombinant subunit or synthetic vaccines 
in the last decade. As Brucella ribosomal L7/L12 (rL7/L12) gene has already been 
identified as a major immunodominant gene, we have cloned this particular gene, 
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expressed in prokaryotic expression vector to yield relatively abundant quantities of 
antigens and protein thereof. 
Keeping into consideration the unique ability of escheriosome to deliver 
entrapped antigen to the cytosol of the target cells and also because of their strong 
immunadjuvanticity, we have evaluated the vaccine potential of escheriosome 
entrapped Brucella rL7/L12 protein in mice model. The data of the present study 
explicitly suggests that escheriosome-based vaccine induces early and strong 
activation of cell mediated as well as humoral immime response in the immunized 
animals as compared to standard S-19 vaccine. 
The results of the present study also revealed that immunization of animals 
with escheriosomes encapsulated antigen protected them against virulent Brucella 
abortus 544 {B. abortus) infection as revealed by increased survival, and reduced 
bacterial burden in vital organs. The data of the present study suggests that 
escheriosomes can emerge as an effective vehicle for intracellular delivery of 
antigen and thus hold promise in development of escheriosome based vaccine 
against brucellosis and other intracellular infections. 
In spite of the fact that vaccination against brucellosis is the best way to 
protect the host and save huge economical loss due to its serious impact on human 
and animal health, therapeutic use of antimicrobial agents remain the first choice in 
many developing counties like India mainly because of several socio-economic 
factors. In relation to this concern, the second part of the present study, we have 
therefore tried to develop novel drug formulation exploiting the unique properties of 
conventional, non fusogenic as well as fusogenic liposome against Brucella 
infection. For this we have chosen conventionally used antibiotic of known anti-
Brucella activity (Gentamycin) as well as some new generation cephalosporins 
(Ceftrioxne, Cefotaxime, Cefepime) and their therapeutic potential were evaluated 
after encapsulating them in liposomes and used against experimental murine 
brucellosis. 
Treatment with escheriosome encapsulated Gentamycin interestingly showed 
better efficacy than any other formulation. Furthermore, the present study suggests 
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that combination therapy of escheriosome encapsulated new generation 
cephalosporins would be promising alternative than currently available combination 
therapy against brucellosis. 
In conclusion, results of present study indicate the possible use of 
escheriosome-based delivery of recombinant protein as a potential candidate subunit 
vaccine able to elicit both cell mediated as well as humoral immune responses 
against experimental murine Brucellosis. Present study also indicates promising 
aspect of escheriosome to be potential drug delivery vehicle in terms of conferring 
better protective efficacy against Brucella infection. 
Future study is proposed for better insight of mechanisms of action of 
escheriosome which will certainly made it possible to design antigen-escheriosome 
or drug-escheriosome combinations capable of inducing desirable protective 
response against wide range of infectious diseases. 
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Abstract 
Brucella abortus, a facultative intracellular pathogen, is of tremendous zoonotic importance because of its ability to induce spontaneous 
abortion in cattle and other hvestock. It is also known to cause persistent undulant fever, endocarditis, arthritis, osteomyelitis and meningitis in 
humans. The available vaccines against this dreadful infection suffer from limitations like short-term immunity, increased risk of hypersensi-
tivity and low prophylactic index in the recipients, In the present study, we have demonstrated that liposomal form of a recombinant ribosomal 
L7/L12 protein, a B-T cell antigen of B. abortus, activates strong immune response in the host. In contrast, free antigen generates moderate 
immune response in the immunised animals. The liposomisation of rL7/L12 protein causes tremendous increase in cell-mediated immune 
response in terms of delayed type hypersensitivity, T-cell proliferation and up-regulation in type I cytokine expression, etc. Moreover, the 
liposome encapsulated antigen elicited stronger humoral immune response as compared to standard vaccine (S-19) or 1FA-L7/L12 combina-
tion in the immunised animals. The effectiveness of liposome-based vaccine was also substantiated by better systemic clearance of bacterial 
load after challenging the animals with B. abortus 544 pathogen. The results of the present study suggest the potential of liposome-based 
rL7/L12 antigen as prospective and efficient candidate vaccine capable of eliciting both cell mediated as well as humoral immune responses 
against experimental murine brucellosis. 
© 2007 Published by Elsevier Ltd. 
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1. Introduction 
Brucellosis is an emerging global disease of public health 
and economic importance [1]. Brucellae are Gram-negative, 
non-motile, facultative, intracellular bacteria and considered 
to be one of the most common causes of abortion in ani-
mals. The pathogen receives remarkable attention because of 
its zoonotic nature characterized by a multitude of somatic 
complaints including fever, sweat, anorexia, fatigue, malaise 
weight loss, prolonged frontal or occipital headaches, abdom-
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inal pain and arthralgia in affected patients [2]. The pathogen 
responds seemingly well to the available antibiotics, however 
high relapse rates as well as development of less suscepti-
ble isolates disapprove chemotherapy as the lone strategy 
to control the infection [3]. Moreover, the treatment with 
chemotherapeutic agents could be proved risky, when dealing 
with the pregnant females, as their delayed on set of action 
let the bacterifd population to induce abortion. These limita-
tions certainly argue in favour of vaccination as prophylactic 
approach to control brucella infection. 
Incidentally, not many effective vaccines are available to 
impart protection against human brucellosis. In fact, animal 
vaccines those are in practice cannot be recommended in 
humans because of virulence factor. Although a highly 
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attenuated strain oi Brucella abortus 19-BA had been used 
in former USSR and China to vaccinate the people who are 
at higher risk of infection [4], A similar was the case with 
Brucella melitensis, where a polysaccharides fraction was 
reported to induce substantial protection with mild/minimal 
reaction but its availability is uncertain [5]. In fact, short 
immunity, requirement of annual booster dosing, increased 
risk of hypersensitivity and little prophylactic index in 
recipient [6,7] are some of the salient limitations that argue 
in favour of development of more efficacious vaccines to 
combat human form of the infection. In fact, the situation 
with animal vaccines is also not very promising. Various 
research programmes are in the process of developing safe 
and successful vaccines against animal brucellosis to reduce 
its occurrence. B. abortus S-19 and RB 51 are the WHO 
recommended vaccine against brucellosis in cattle f8], 
however of limited application, as they may induce abortion 
when administered to pregnant animals [9.10]. Additional 
disadNianiages include cross-reaction with natural infection 
during sero-diagnosis [11-15]. Besides, S-19 is also reported 
to be pathogenic to human being [15]. Some of the immuno-
genic brucella proteins such as p39 [16], Cu-Zn SOD [17], 
L7/L12 [18-22] GroEL and GroES [23], YaJC [24] have 
also been tried as recombinant subunit or synthetic vaccines. 
Several efforts were made to use these immunodominant 
protein in combination with adjuvants, such as MBP with 
rL7/L12 protein [22], OMP with monophosphoryl Lipid A, 
trehalose dicorynomycolate and PEC microparticles, etc. 
[25,26]. CpG oligodeoxynucleotides were also reported 
to possess strong adjuvant activity eliciting cell-mediated 
immune response when co-administered along with antigens. 
Nevertheless, immunopotentiating effect induced by live 
attenuated vaccine was far more effective than CpG-OPN 
adjuvanted form of the vaccine [16]. Beside, live vaccines 
have been shown to offer a long-term protection against 
brucellosis than CpG-ODN adjuvanted vaccine [16]. 
Among various antigenic proteins, brucella rL7/Ll2 
protein has been identified to induce mixed Thl and Th2 cel-
lular immune responses in the immunised animals [19-22]. 
Although immunogenic, rL7/L12 subunit vaccine was found 
to tender modest protection against B. abortus infection 
[20]. This simply implies that protection offered by rL7/Ll2 
monovalent vaccine could be further improved by the co-
administration along with superior adjuvant or by use of 
efficient antigen delivery systems. 
IVIany of the newer adjuvants have improved upon some of 
the poorer aspects of traditional vaccine formulations (poor 
safety and efficacy), but do not address other limitations like 
their intrinsic toxicity, undesirable skewing towards Th 1/Th2 
responses etc. There are several important issues that act as 
driving forces for the methods by which future vaccines are 
ought to be formulated thereby overcome their current defi-
ciencies and shortcomings. A better insight of the modalities 
of the immune system reveals that besides intrinsic immuno-
logical properties, the induction of humoral or cell-mediated 
immunity to protein antigen also depends upon the factors 
such as cytokine milieu, route of administration, dosage and 
mode of delivery of antigen, etc. [27]. As we cannot manip-
ulate fundamental properties of a given antigen, it is always 
imperative to play upon above-mentioned factors to formu-
late effective vaccine. In this regard, liposome-based vaccines 
may be of great significance as they have been claimed to 
widely amend immunological responses of variety of anti-
gens [28-31]. 
In the present report, we have demonstrated that the egg 
phosphatidyl-choline/cholesterol (egg PC/chol) liposome 
encapsulated recombinant rL7/L12 protein could generate 
strong antigen-specific humoral immunity and CD4* T-
helper cell response. The liposomal rL7/L12 vaccine induces 
early activation of cell mediated as well as humoral immune 
response in the immunised animals compared to free or 
IFA adjuvanted form of the antigen. Beside immunologi-
cal behaviour, we have also tried to establish prophylactic 
potential of lipomised rL7/L12 protein against B. abortus 
544 infection in female BALBIc mice as well. 
2. Materials and methods 
2.1. Animals 
Inbred female BALBIc mice (4—5-weeks old), weigh-
ing 20±2g , were obtained from the Laboratory Animal 
Resources, CDRI, Lucknow, India. All the mice were housed 
in biosafety level (BL)-3 facility. A set of two rabbit was pro-
cured from our unit's animal facility for raising hyperimmune 
sera. The Institutional Animals Ethics Committee approved 
the experimental protocols. All the mice were housed under 
standard conditions at the institute's animal facility having 
free access to the pellet diet and water ad libitum. 
2.2. Chemicals and reagents 
All the reagents used in the study were of the highest 
purity available. Cholesterol (Choi) was purchased from Cen-
tron Research Laboratory, Bombay, India, and crystallized 
three times with methanol prior to its use. Bicinchoninic acid 
(BCA) protein assay kit was procured from Sigma Company 
(USA). 
2.3. Bacterial strain 
B. abortus 544 and Brucella Strain-19 were obtained firom 
Division of Biological Standardization, Indian Veterinary 
Research Institute (IVRI), Izatnagar, India. 
2.4. Expression and purification of recombinant r 
L7/L12 protein 
2.4.1. Bacterial strain andplasmid 
To clone rL7/L12 ribosomal protein gene, B. abortus 
544 was cultured on Tryptose phosphate agar and Tryptose 
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phosphate broth for 48 h at 5% CO2 atmospheric pressure. 
For recombinant protein production, a prokaryotic expres-
sion vector pQE31 (Qiagen, USA) was used. Escherichia 
coli M15 and E. coli DH5a strain were used as host for 
pQE31 expression vector and pTZ57R/T (InsT/A Cloning 
Kit, MBI Fermentas, Canada) cloning vector, respectively. 
The required antibiotic ampicillin and kanamycin were added 
to Luria Bertani, Miller (HiMedia, India) media according to 
the standard reference [32]. 
2.4.2. Isolation of chromosomal DNA from B. abortus 
544 
Chromosomal DNA was prepared as per standard pro-
tocol [32]. Briefly, B. abortus 544 was grown for 48 h in 
Tryptose phosphate broth and kept at 70 °C in water bath 
for 30 min to get inactivated cell pellet. The cells were then 
resuspended in 1 x GTE buffer (Tris 10 mM, EDTA 1 mM, 
pH 8) containing lysozyme (lOmg/ml) and lysed with 10% 
SDS containing proteinase K (20mg/ml). It was then incu-
bated at 37 °C for 1 h with 5M NaCl and CTAB solution 
to extract the chromosomal DNA. The cell debris and other 
proteins were removed by phenol:chloroform:isoamyl alco-
hol (25•.24:1) mixture. DNA was precipitated by isopropanol 
as small thread and spooled out with glass rod. It was washed 
with 70% ethanol, dried and dissolved in TE buffer. The quan-
tity and quality of the purified genomic DNA were assayed 
by 0.8% agarose gel electrophoresis (in 0.5 x TBE buffer) 
and spectrophotometrically (260 nm/280 nm), respectively. 
2.4.3. DNA amplification 
Brucella abortus DNA encoding rL7/L]2 protein gene 
was amplified by polymerase chain reaction. DNA amplifi-
cation reaction was carried out by taking 50 jil of reaction 
mixture containing 10 mM Tris-HCl (pH 8.3), 1.5 mM 
MgCh, 80 mM KCl, 0.5 |xM dNTPs, 50 ng of genomic DNA, 
2 units of Taq DNA polymerase and 2 |jil (0.5 p-M) each 
of forward and reverse rL7/L12 gene-specific primer. The 
reaction was carried out in DNA thermal cycler (Eppendorf, 
Germany) with thirty cycles of thermal reaction and denat-
uration temperature at 94 °C for 1 min, primer annealing at 
55 °C for 1 min and primer extension at 72 °C for 1 min fol-
lowing final extension at 72 °C for 5 min. The PCR product 
was analysed by electrophoresis in 1 % agarose gel in 0.5 x 
TBE buffer and visualised in ethidium bromide staining on 
UV transluminator (Fotodyne Incorporated, USA). 
2.4.4. Cloning ofrL7/L12 gene in bacterial expression 
vector 
PCR amplified product was cluted from agarose gel by 
Qiagen gel extraction kit (Qiagen, USA) following manu-
facturers protocol. Eluted DNA was ligated to pTZ57R/T 
vector. The newly formed recombinant was designated as 
pTZL7. E. coli DH5a competent cells were prepared by cal-
cium chloride method and used for transformation. Briefly, 
2 p,l plasmid pTZL7 was added to the competent cells. After 
proper mixing and incubation, 100 ^ j.1 of culture was plated on 
Luria Bertani agar containing ampicillin supplemented with 
X-Gal and IPTG and grown overnight at 37 °C. Recombi-
nant clones were screened based on blue/white colour single 
colony. After confirmation of cloned insert by sequencing, 
the rL7/L12 gene insert was subcloned in Sail and Pstl site 
of pQE-31 expression vector (Qiagen, USA) and transformed 
in E. co/( M15 cell. Finally, the expression level of the recom-
binant protein was checked by 15% SDS-PAGE. 
2.4.5. Purification of recombinant rL7/L12 protein by 
Ni-NTA column chromatography 
Polyhistidine tagged fusion protein was purified under 
denaturation condition by metal chelate affinity chromatog-
raphy (Qiagen protocol) with certain modification introduced 
in our laboratory. Recombinant E. coli harbouring rL7/L12 
gene was used for the production of recombinant antigen. 
Briefly, the cells were allowed to grow in Luria Bertani broth 
containing ampicillin (50 |jLg/ml) and kanamycin (20 p-g/ml) 
and incubated over night at 37 °C. The inoculum was trans-
ferred into 300 ml fresh LB broth and kept in shaker for 2 h. 
Isopropyl beta-D-thioglycoside (1 mM) was used for induc-
tion and the cells were allowed to grow for 6 h at 37 °C in 
shaker. After visualising sufficient growth, the culture was 
centrifijged at 8000 x g for 10 min at 4°C and pellet was 
collected. The pellet was mixed in lysis buffer (8 M urea, 
0.1 M NaH2P04, 0.01 M Tris-HCl, pH 8.0) and incubated 
at 37 °C for 2h. Lysaie was collected after centrifugation at 
10,000 X g for 20 min at 4 °C. The supernatant contained the 
solubilized inclusion bodies, which was subjected to purifi-
cation by Ni"^-NTA affinity column. One millilitre of 50% 
Ni^-NTA slurry was added to 4 ml of lysate and mixed 
gently by shaking for 30 min at room temperatiu'e. The mix-
ture was loaded into a syringe column and the flow was 
collected. After washing with Buffer C (8M urea, O.IM 
NaH2p04,0.01 M Tris-HCl, pH 6.3) containing 20 mM imi-
dazole, protein was eluted with elution buffer (8M urea, 
0.1 M NaH2P04, 0.01 M Tris-HCl, pH 4.5). Fractions col-
lected after various time periods were checked by 15% 
SDS-PAGE. 
2.4.6. SDS-PAGE analysis of the protein 
SDS-PAGE analysis was carried out as described by 
Laemmli [33] in a vertical mini-gel electrophoresis appara-
tus (ATTO, Japan) using 15% resolving gel having a stacking 
gel of 5% concentration. Electrophoresis was carried out at a 
constant current of 18 mA, until the tracking dye reached the 
bottom of the gel. The gel was taken out from the plates and 
stained with 0.25% (w/v) Coomassie Brilliant Blue R-250 
prepared in methanol, glacial acetic acid and water (45:10:45) 
and destained with destaining solution (20 parts methanol, 10 
parts glacial acetic acid and 70 parts distilled water). 
2.4.7. Estimation of concentration of expressed 
recombinant protein 
Finally, the eluted fraction was dialysed against phos-
phate buffered saline (1.5 M, pH 7.4) and concentration 
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of recombinant rL7/L12 protein was estimated by BCA lated using a standard curve of BSA plotted in the presence 
method—against standard curve of BSA. of Triton X-100. 
2.5. Preparation of liposome-based rL7/L12 vaccine 2.6. Immunisation 
2.5.1. Isolation of egg phosphatidylcholine 
Egg phosphatidylcholine (PC) was isolated and purified 
following the published procedure with slight modification as 
standardized in our laboratory [35,36]. Briefly, hen egg yolk 
was separated and washed with acetone for five to six times to 
get rid off the coloured impurities. The resulting white solid 
was dried in vacuum for 2 h to remove traces of the resid-
ual solvent. Lipid extraction was performed by stirring the 
solid mass with absolute alcohol followed by filtration. The 
filtrate was then evaporated off by rotary evaporator (Hei-
dolph, Germany) at 45 °C. The sticky mass thus obtained 
was dried under high vacuum to remove traces of the solvent 
and dissolved in minimum amount of petroleum ether (b.p. 
60-80 °C) and poured onto chilled acetone to obtain a white 
sticky precipitate. The solvent from the precipitated mate-
rial was removed by decantation. The sticky solid precipitate 
was redissolved in petroleum ether and again poured onto 
the chilled acetone. The process was repeated three times to 
obtain crude PC. The crude PC was then chromatographed on 
a neutral alumina (grade III) to get pure form of PC. The purity 
was ascertained by thin layer chromatography using silica gel 
G-60 TLC plates and the spots were visualised with the help 
of phosphate spray reagent. Finally, it was passed through 
Sephadex LH-20 using chloroform:methanol (1:1) as eluants 
to obtain purified form of the egg phosphatidylcholine. 
2.5.2. Preparation of dried rehydrated vesicles (DRVs) 
Egg PC in combination with cholesterol was used to pre-
pare dried reconstituted vesicles (DRVs) using published 
method [37]. Egg PC/cholesterol (2:1 molar ratio, total 
20 mg) was reduced to thin dry film under N2 atmosphere. 
The film was then hydrated, followed by sonication in a 
bath type sonicator (Hwashin Technology Co., Korea) for 
1 h at 4 °C. The liposomes thus formed were mixed at this 
stage with an equal volume of recombinant rL7/L12 pro-
tein (Img/ml). The mixture was flash frozen and thawed 
(five cycles) and then lyophilized. The free-flowing, dried 
powder thus obtained was rehydrated with distilled water 
(120 (xl) and finally re-constituted with PBS. The prepara-
tion was centrifiiged at 14,000 x g and the pellet was further 
washed at least three times with PBS to remove the traces of 
the unentrapped solute. 
2.5.3. Determination of entrapment efficiency 
The protein entrapped in the liposomes was estimated as 
described elsewhere [38]. Briefly, the liposomes (given vol-
ume) were lysed with 10% Triton X-100 solution (the final 
concentration of Triton X-100 was maintained 1%). BCA 
reagent was added to the lysed liposomes (released protein) 
and then incubated at 37 °C for 45 min. The absorbance was 
measured at 570 nm and the protein concentration was calcu-
The immunological studies were performed in inbred 
female BALBIc mice. Each group was consisted of fifteen 
animals. The immunisation schedules adapted for administra-
tion of rL7/L 12 protein varied from experiment to experiment 
depending upon nature of the study, and described accord-
ingly. Different groups of experimental animals were injected 
separately, through subcutaneous route, with a total three 
doses (immunisation on days 0, 21 and 28) of egg PC/chol 
liposome entrapped rL7/L12 protein (P-Lip-L7), Freund's 
adjuvant emulsified rL7/L12 protein (IFA-L7), rL7/LI2 
protein alone (free form, F-L7) and sham egg PC/chol lipo-
some (without antigen). Mice vaccinated with Brucella S-19 
(5 X lO^CFU/mice) were included in this study as posi-
tive control, while another set of animal (negative control) 
received only PBS treatment. Animals were immunised 
with priming dose of 50 p-g recombinant protein/animal and 
boosted with 30 p-g/animal subsequently on days 21 and 28. 
2.6.1. Collection of sera 
Mice were bled through retro-orbital puncture with glass 
capillary tubes and blood was collected in sterile eppendorf. 
Blood was incubated at room temperature for an hour and 
subsequently kept at 4 °C for retraction. Finally, serum was 
collected carefully and centrifuged at 5000 x g for 10 min at 
4°C to get rid off residual blood cells. The final preparafion 
was kept at - 2 0 °C fill further use. 
2.6.2. Raising hyperimmune sera 
Hyperimmune sera against purified recombinant protein 
were raised in 8-weeks old two New Zealand White rab-
bit procured from Institutes' Animal Facility. Hyperimmune 
serum was used to confirm the antigenicity and specificity 
of purified protein. Approximately lOOjjig of protein was 
emulsified with equal volume of complete Freund's adju-
vant (CFA) and injected subcutaneously at different sites on 
the shaven back of the rabbit. Booster was given with anti-
gen emulsified in incomplete Freund's adjuvant (IFA). After 
3rd booster, rabbits were bled through ear vein and serum 
was separated. Finally, serum was analysed for presence of 
antigen-specific antibodies by Western Blot. 
2.6.3. Determination of antigen-specific antibody by 
Western Blot 
The production of antigen-specific antibodies in hyper-
immune sera of the rabbit immunised with rL7/L12 protein 
was determined by Western Blot analysis as described ear-
lier [34]. Briefly, purified and dialyzed recombinant rL7/L12 
protein was run with prestain marker on 15% SDS-PAGE 
and subsequently electroblotted on nitrocellulose membrane 
at 2 mA/cm'^  constant current for an hour using semidry elec-
tro blot assembly (ATTO, Japan) containing transfer buffer 
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(25 mM Tris, 192 mM glycine and 20% methanol). The mem-
brane was blocked with 2% Bovine serum albumin (Sigma, 
St. Louis) for 4h at 4°C and washed five times with PBS-
Tween. The membrane was cut into strips and incubated with 
(1:100) dilution of pre-immune sera in plastic bags on rocker 
for 2 h at 4 °C. The strips were washed with PBS-Tween and 
incubated with 1:1000 dilution of HRP conjugated goat anti-
rabbit IgG antibody for 1 h on rocker at 4 °C. The strips were 
finally washed with PBS-Tween and developed with diamino-
benzidine (10mg/6ml D.W.) in the presence of 20 fxl of 30% 
H2O2. 
2.6.4. Determination of antigen-specific 
immunoglobulin and their isotypes by indirect ELISA 
Sera of the immunised mice were collected at regu-
lar interval to monitor the level of antibodies by indirect 
ELISA method as described earlier |39]. Briefly, the puri-
fied recombinant rL7/L12 protein was diluted to 5 jxg/ml 
in carbonate-bicarbonate buffer (0.05 M, pH 9.6) and used 
to coat the wells of polystyrene plates (100 [xl/well; Nunc-
Immuno plate with Maxisorp Surface). The plates were 
incubated at 4 °C for overnight and next morning washed 
thrice with PBS-T (phosphate-buffered saline containing 
0.1% Tween-20). Blocking was done with 1% BSA in PBS 
and incubated for 6 h at 37 '^ C. Plates were then washed thrice 
with PBS-T and finally incubated with 100 JJLI of specific dilu-
tions of test and control sera in each well at 37 °C for 2 h. After 
excessive washing of the plate, it was further incubated with 
50 JJLI biotinylated HRPO-conjugated rabbit anti-mouse IgG, 
IgGl and lgG2a antibodies (at 1:2000 dilution). The plates 
were washed again before addition of 50 |j,l OPD substrate 
and were finally incubated at 37 °C for 20 min. The reaction 
was terminated by the addition of 50 p.1 of 1 M H2SO4. The 
absorbance was read at 492 nm with a microtitre plate reader 
(Eurogenetics, Torino, Italy). 
2.6.5. €04* T-lymphocyte proliferation assay 
T-lymphocyte proliferation assay was performed using 
published protocol |36J. On day 7 after last booster, four mice 
from each group were used to perform T cell proliferation 
assay. Spleens were aseptically removed from anaesthetized 
mice and washed with PBS-D. Splenocytes were obtained 
by maceration of spleen of immunised animals following 
published protocol as standardized in our lab. Erythrocyte in 
spleen cell preparation were lysed by treatment with Gey's 
solution (Sigma, USA) (two parts of spleen preparation in 
one part of Gey's solution) and centrifuged at 1400 x g for 
20 min. Interface containing splenocytes were collected and 
washed with RPMI 1640 (Sigma, USA) media containing 
10% fetal bovine serum by centrifugation at low speed. 
Finally, pure population of €04"^ T-lymphocytes was isolated 
following procedure as described elsewhere [351. Viable cells 
were counted by 0.1 % Trypan Blue dye exclusion method. 
The FACS analysis demonstrated that isolated cells were 
CD4'*" with 99% purity. To perform proliferation assay, total 
cells were adjusted 4 x 10^/100 jjil per well in 96-wcll flat 
bottom micro well plate. Cultures in quadruplicate were 
stimulated with various forms of recombinant rL7/L12 pro-
tein, Concanavalin A (ConA) and plain RPMI were used as 
positive and unstimulated control, respectively. Cells were 
incubated for 72 h at 37 °C with 5% CO2 in CO2 incubator 
(Binder, Germany). The cells pulsed with 0.5 |xCi [^H]-
thymidine/well (^H-Tdr, Specific activity 18 Ci/mol, BARC, 
India) for 16 h before harvesting the cells with automatic 
cell harvester (Skartron, Tranby, Norway). [^H]-Thymidine 
incorporation was measured by a standard liquid scintilla-
tion spectroscopy with a Betaplate counter (WALLAC OY, 
Turku, Finland). The stimulation index (S.I.) was calculated 
as mean cpm values of triplicate culture by the following 
formula: 
S.L = [^ H] thymidine counts of experimental group [^ H] thymidine counts of unstimulated group 
2.6.6. In vitro assay for IFN-y production by spleen cells 
Gamma-interferon (IFN-7) was estimated by antigen cap-
ture ELISA method using BD Biosciences assay kit (BD 
Bioscience, San Diego, CA, USA). The presence of IFN-
7 was assayed in the culture supematants of spleen cells 
collected after 48 h of antigen stimulation. Particulate and 
aggregates of culture supernatants were removed by spinning 
at approximately 1000 x g for 10 min. Gamma-interferon 
was detected in triplicate by enzyme linked immunosor-
bent assay using microplate (Nunc, Denmark), coated with 
capture antibody (anti-mouse IFN-7). After proper wash-
ing, wells were blocked for 1 h at room temperature with 
250 (JLI of PBS (pH 7.0) containing 10% FCA per well. 
Cell culture supernatant was then plated in 1:10 dilution 
in blocking buffer and incubated for 2 h at room tempera-
ture. The plates were washed five times with PBS-0.05% 
Tween-20. Then, biotinylated anti-mouse IFN-7 and Avidin 
horseradish peroxidase conjugate were used according to the 
manufacturers instruction and colour production was evalu-
ated by TMB substrate. Plates were read at 450 nm within 
30 min after adding stopping solution (2M H2SO4). The 
concentration of IFN-7 in the culture supematants was cal-
culated for each experimental group using a linear-regression 
equation obtained from the absorbance values of the 
standards. 
2.6.7. Lymphocyte migration inhibition test (LMIT) 
Lymphocytes were isolated from blood of immunised ani-
mals on day 7 post-last booster following standard protocol 
[40J with slight modification in our lab. Briefly, the hep-
arinsed blood was diluted in equal volume of calcium and 
magnesium free PBS, Diluted blood was then centrifuged 
at 2000 Kg for 15min and the buffy coat was separated 
and layered over histopaque at 2:1 ratio followed by cen-
trifugation for 15 min. The interface containing lymphocyte 
was collected carefully and washed with equal volume of 
PBS at least three times and the cell viability was calculated 
by 0.1% Trypan Blue dye exclusion method. Viable cells 
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were collected as described earlier and adjusted 4x10^ cells 
per ml in RPMI-1640 culture medium supplemented with 
10% fetal calf serum, which was previously incubated for 
12 h. Non-heparinsed capillary of uniform size and diam-
eter (Hawskly and Sons Ltd., UK) were packed with cell 
suspension and plugged at one end with platicine. The cap-
illaries were centrifuged at 800 x g for 3 min and the cell 
fluid interface was cut with diamond cutter. Each stub was 
placed in greased wells of migration plate (Laxbro). The 
wells were then loaded in duplicate with matching form of 
antigen in previously incubated media, another with growth 
media only (negative control). Wells were then covered with 
circular grease free cover slip and incubated for 19 h at 
37 °C under humid atmosphere. The migration in each cir-
cle was viewed and plotted on graph paper by using Camera 
Lucida and percent migration was calculated by the following 
formula: 
Percent migration inhibition 
/ migration in presence of antigen \ 
\ migration in absence of antigen j X 100. 
3. Results 
3.1. SDS-PAGE profile and immunoblot analysis of 
recombinant rL7/L12 protein 
To obtain large amount of recombinant protein, rL7/L12 
gene encoded polypeptide was expressed in E. coli using 
pQE31 expression vector system. E. coli harboring pQE 31-
rL7/L12 construct was induced and purification of expressed 
protein was achieved by affinity chromatography with 
Ni"^-NTA column. SDS-PAGE analysis of the cell lysate and 
various fractions collected after elution showed the expres-
sion of expected 19 kDa recombinant protein (Fig. la). Alter 
dialysis, the concentration of recombinant protein was found 
out to be 1 mg/ml. To determine the purity, antigenicity and 
specificity of purified recombinant rL7/L 12 protein. Western 
Blot analysis was performed using antigen-specific hyper-
immune rabbit sera and it illustrates the specific interaction 
between anti-rL7/L12 rabbit antibody and purified protein 
(Fig. lb). 
3.2. Humoral immune response 
2.6.8. Delayed type hypersensitivity reaction (DTH) 
The DTH response was assessed by measuring footpad 
thickness of immunised mice as well as control (unimmu-
nised) animal. Recombinant rL7/L12 protein was injected 
intradermally in right footpad of mice belong to various 
immunised groups and left one was kept as control that 
received PBS only. Increased footpad thickness was mea-
sured by digital Vernier Calipers at 0, 12, 24, 36,48 and 72 h 
interval of post-injection. 
2.6.9. Protection study against challenge with B. 
abortus 544 infection 
One week after last immunisation, the mice were chal-
lenged with a virulent culture of B. abortus 544 (2 x 10^ 
cfu/0.2ml of saline solution/mice) intraperitoneally. After 
7, 15 and 30 days post-challenge, three mice from each 
group were euthanasised, spleens were removed aseptically 
and triturated with 2 ml of 1.5 M PBS (pH 7.4) containing 
0.1%TritonX using sterile sand (Molecular biology grade). 
A ten fold serial dilutions of spleen lysate were prepared in 
Tryptose phosphate broth and 10 p-l from each dilution was 
plated in triplicate. For S-19 vaccinated mice, dilution was 
made on TS A-YT with 0.1% Erythriotol for differentiating S-
19 and B. abortus 544. All the plates were incubated at 37 °C 
with 5% CO2 pressure. Three days after incubation colonies 
were counted and expressed as logio CFU per spleen. 
2.7. Statistical analysis 
The data were analysed by one-way analysis of variance 
(ANOVA) following Student's f-test. P-values <0.05 and 
<0.01 were considered statistically significant. 
The production of antigen-specific antibodies was mea-
sured in the sera of the immunised mice. Sera were collected 
from immunised mice on weekly interval to monitor total 
IgG level. No significant antibody titre was found upto day 
14 post-first immunisation (Fig. 2). Significantly (P<0.05) 
high (A492 ~ 0.821) titre of antibody (IgG) was detected on 
day 21 post-immunisation in sera of the animals, which 
were primed with P-Lip-L7 form of the antigen. On the 
other hand, antibody titre was significantly less (P<0.05) 
in the animals immunised with S-19 (A492 ~ 0.509) or IFA-
L7 (/4492 «= 0.527) combination (Fig. 2). As evident from 
Fig. 2, high antibody response was maintained in P-Lip-
L7 antigen immunised mice following each booster, and 
it got maximised on 35th day after the first immunisation 
(A492»= 1.7539) as compared with S-19 (A492«> 0.921) and 
IFA-L7 (A492 «= 0.750) immunised mice {P<0.Q5). 
The sera, colleted on day 35 post-immunisation, were 
further assessed for IgGl and IgG2a isotypes of recom-
binant rL7/L12 protein specific antibodies. As shown in 
Fig. 3, P-Lip-L7 form of antigen elicited higher IgGl 
(A492« 0.798) and IgG2a (^492*^ 0.869) isotypes, which 
was statistically significant (P<Q.Q5) as compared with the 
IFA-L7 (A492«= 0.338 and 0.369) group. Surprisingly, S-19 
vaccinated animals showed higher (A492 «= 0.398 and 0.478) 
isotype antibody titre as compared with IFA-L7. There was 
no significant expression of IgG 1 and IgG2a response in the 
animals immunised with free form of the antigen. Further, 
IgG2a isotype was more abundant than the IgGl in P-Lip-
L7 immunised group of animals, indicative of a clear shift 
towards a Th 1 type response. 
It was observed that after 42 days of post-first immunisa-
tion, P-Lip-L7 group still expressed significantly higher titre 
of IgGl (A492~0.823) and IgG2a (^492^0.987) (P<0.01, 
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Fig. 1. Expression and purification of recombinant rL7/LI2 protein using metal affinity column. Brucella abortus rL7/L12 gene was cloned in E. coli and 
expressed after induction with IPTG. The protein profile of various stages in expression of desired protein was observed by SDS-PAGE analysis and the 
amigeiticity of the protein was confirmed by Western Blotting, (a) SDS-PAGE showing expression of recombinant rL7rt-12 protein and steps involved in its 
purification. Lane 1. uninduced control; Lane 2, induced; Lane 3, elution of recombinant rL7/Ll 2 protein through Ni*-NTA column; Lane 4, standard molecular 
weight protein marker, (b) Western Blot analysis of recombinant rL7/Li 2 protein immunostained with anti-rL7/LI2 sera raised in rabbit. Lane i, prestained 
protein marker; Lane 2, probing presence of recombinant rL7A^12 protein using rabbit anti-rL7/L12 antibodies. 
Control versus P-Lip-L7). Mice immunised with IFA-L7 
could not induce furttier enhancement in antibody level. 
Antibody response in mice immunised with S-19 vaccinated 
group showed remarkably higher IgG2a antibody titre (IgG 1; 
/4492 ~ 0.384 and IgG2a; /I492 ~ 0.528) as compared to its 
level determined on days 35 post-immunisation. However, 
it was still significantly less (P<0.05) to that of P-Lip-L7 
induced antibody titre in the immunised animals. 
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3.3. CD4* T-lymphocyte proliferation response 
Since the cellular arm (Thl response) of the immune 
system is essential for controlling intracellular pathogens, 
the splenocytes proliferation response was assessed in the 
immunised animals. The lymphocytes were stimulated with 
various forms of rL7/L12 protein to evaluate their vaccine 
potential. As shown in Fig. 4, immunisation with P-lip-
L7 resulted in rLll\-Al specific T-cell proliferation (S.l. 
3.85). The S.l. value for P-Lip-L7 was statistically signifi-
cant (P<0.05) as compared with the S-19 immunised mice 
(S.I. 2.45) or IFA-L7 (S.I. 2.28). Splenocytes collected from 
free antigen injected mice or sham liposome failed to elicit 
a detectable proliferative response against rL7/L12 antigen 
(S.I.<2.0, f<0.001). The control group (immunised with 
PBS only) gave a background level of <2000cpm value 
of [^H]-Thymidine incorporation. Splenocytes isolated from 
various immunised animals responded to the stimulant Con A 
(positive control). Interestingly, S.I. value obtained in ConA 
stimulated splenocytes was of the same order to that of P-
Lip-L7 group (data not shown). 
3.4. Detection of gamma-interferon (IFN-y) level in 
immunised mice 
Fig. 2. Analysis of serum antibody titre (Total IgG) in BALBlc mice immu-
nised with various forms of brucella recombinant rL7/LI2 protein. Sera 
(1;100 dilution) obtained from various experimental groups on days 14, 
21, 28, 35 and 42 posl-immonisation were assayed individually by ELISA 
method as described in Section 2. The level of igG WHK expressed as 
absorbance (/I492) of the coloured complex developed in the immunosor-
bent assay. The values are means of three different experiments ± standard 
deviation. P-values (on day 42 post-immunisation); Control vs. P-Lip-
L7<0.00l; S-19 vs. P-Lip-L7<0.01; 1FA-L7 vs. P-Lip-L7<O.OI; F-L7 v.s. 
P-Lip-L7< 0.001. 
To evaluate the production of IFN-7, expeiiment was set 
in a manner same to that of T cell proliferation assay. Spleens 
from four mice were collected 1 week after the last immuni-
sation. The splenocytes obtained from various groups were 
CO cultured in presence of matching form of rL7/L12 pro-
tein. PC Liposomal rL7/L12 protein (P-Lip-L7) was found 
to express high level of IFN-7 (1.96 ng/ml) production after 
stimulation with corresponding antigen preparation. Among 
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Fig. 3. Analysis of IgG isotype response in BALBIc mice immunised with 
various forms of brucella recombinant rL7/L12 protein. Sera (1:100 dilu-
tion) obtained from various experimental groups on days 35 (a) and 42 (b) 
post-immunisations were assayed individually by ELISA as described in 
Section 2. The level of IgG isotypes was expressed as absorbance (/I49;) 
of the coloured complex developed in the immunosorbent assay. The val-
ues are means of three different experiments. Control mice were immunised 
with PBS only. P-values (on day 42 post-immunisation): Control vs. P-Lip-
L7<0.001; S-l9 vs. P-Lip-L7<0.01; IFA-L7 vs. P-Lip-L7<0.01; F-L7 vs. 
P-Lip-L7< 0.001. 
the other form of antigen preparation, only IFA-L7 could 
show significant level IFN-7 production (1.04 ng/ml) as com-
pared with P-Lip-L7 group (P<0.Q5). Animals immunised 
with S-19 or free rL7/L12 antigen were failed to elicit sig-
nificant level of IFN-7 (/'<0.001) (Fig. 5). In addition, no 
detectable amount of lymphokines was observed in control 
animals injected either with PBS or sham egg PC/chol (no 
antigen). 
3.5. Release of migration inhibition factor (MIF) 
To determine the level of macrophage migration inhibi-
tion factor (MIF) in the lymphokines of different immunised 
animals, in vitro migration of macrophages was studied. The 
highest inhibition (56.5%) of lymphocyte migration (LMI) 
was delected in the stimulated lymphokines collected from 
mice vaccinated with P-Lip-L7 (Fig. 6). On the contrary, 
%LMI in S-19 or IFA-L7 immunised group were 44 and 
33.75%, respectively (P < 0.05). No significant inhibition was 
found in other experimental group. 
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Fig. 4. T cell proliferation response of CD4+ T cells derived from immu-
nised mice vaccinated with various forms of recombinant rL7/L12 protein. 
CD4* T-lymphocytes were co-stimulated with matching formulation of the 
recombinant rL7/L12 protein. After 72 h '[H]-thymidine was added and its 
incorporation was measured after 16 h incubation by liquid p scintillation 
spectroscopy. The stimulation index (S.I.) was calculated by counting mean 
cpm values of stimulated culture/mean cpm values of unstimulated culture. 
Animals immunised with Brucella S-19 were used as reference. The T lym-
phocytes obtained from S-19 immunised rtiice were co-stimulated with S-19 
vaccines in a manner to that of experimental group. Control cultures, con-
taining cells obtained either from animals immunised with free form of 
antigen or the groups immunised with PBS or egg PC/chol sham liposome 
(no antigen), gave background level of <2000cpm of ^[H]-thymidine incor-
poration. Data represent the mean ± standard deviation of the quadruplicate 
from four mice each belonging to various groups. P-values: Control vs. P-
Up-L7 <0.001; S-19 vs. P-Lip-L7 <0.05; IFA-L7 vs. P-Lip-L7 <0.01; F-L7 
vs. P-Up-L7< 0.001. 
3.6. Delayed type hypersensitivity response 
Another immunological feature of liposomal delivery sys-
tem was assessed on the basis of its ability to elicit delayed 
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Fig. 5. Effect of immunisation with various forms of recombinant rL7/LI 2 
protein on production of IFN--y in BALBIc mice. The level of IFN-7 was 
determined in the supernatant of spleen cells stimulated with matching form 
of antigen after 1-week post-last immunisation. The concentration of IFN-
7 in the culture supcrnatants was calculated for each experimental group 
using a linear-regression equation obtained from the absorbance values of 
the standards and expressed in ng/ml. The data represented the mean of 
three different experiments ± standard deviation. f*-values; Control vs. P-
Up-L7<0.00l; S-19 vs. P-Lip-L7< 0.001; IFA-L7 vs. P-Up-L7<0.05; F-
L7 vs. P-Lip-L7< 0.001. 
3700 A.!. Mallick el at. / Vaccine 25 (2007) 3692-3704 
E ( ot i t i i i l 
D S - 1 9 
c i ' ( -i.i|)-i; 
B IIA-1,7 
m I- 1.7 
Kxperintciital <;f(iu|)s 
Fig. 6. Effect of immunisations with recombinant rL7/L]2 protein on pro-
duction of lympliocyte migration inhibition factor (MIF) in BALBIc mice. 
The percent of migration inhibition (%LMI) of macrophage (isolated on day 
7 post-last booster) was assessed in four mice of each group vaccinated with 
various forms of recombinant rL7/L12 protein. Mice immunised with S-19 
were used as reference. Control mice were treated with PBS only. The data 
represented the mean of three different experiments ± standard deviation. 
P-values: Control vs. P-Lip-L7<0.001; S-19 vs. P-Lip-L7<0.05; IFA-L7 
vs. P-Up-L7<0.01; F-L7 vs. P-Lip-L7<0.001. 
type of hypersensitivity response. We found that footpad 
thickness after intradermal injection of protein increased 
exponentially, attained maxima at specific time period and 
then decreased down to normalcy (Fig. 7). Administration 
of P-Lip-L7 ensured significant (P<Q.Q\) rise in foot-
pad thickness as compared with the other group at 36 h 
post-inoculation. While in S-19 vaccinated mice, maximum 
increase in footpad thickness was observed at 24 h that was 
fallen down subsequently. Nevertheless, the overall thick-
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Fig. 7. DTH response in mice immunised with various forms of brucella 
subunit vaccines. The DTH response was determined by injecting 50 \i.% 
of various forms of recombinant rL7A-12 protein in hind left footpad of 
mice, while right footpad was administered with saline (control) only. The 
thickness of footpad was measured by Vernier Calipers on various time 
intervals post-injection. DTH value (in mm) was expressed as the absolute 
increase in footpad thickness. P-values (at 36 h post-injection): Control vs. P-
Lip-L7 < 0.001; S-19 v.v. P-Lip-1.7 < 0.01; IFA-L7 vs. P-Lip-L7 < 0.01; F-L7 
vs. P-Lip-L7< 0.001. 
ness was more prominent in P-Lip-L7 combination during 
the course of immune response. No change in footpad thick-
ness was observed in the mice belonging to control (PBS 
only; /*< 0.001) or those immunised with free antigen or 
sham liposome (P< 0.001). 
3.7. Protection against B. abortus 544 challenge in 
immunised mice 
To determine the whether the immunisation with liposo-
mal preparation induced protection against B. abortus 544 
infection, immunised mice were sacrificed on days 7, 15 
and 30 post-challenge. Protection was defined as a signifi-
cant reduction in the number of bacteria in spleen of various 
immunised group. The vaccine efficacy was calculated as 
the logio of protection. On day 7 post-challenge with infec-
tion, the bacterial burden in P-Lip-L7 immunised mice was 
log 4.23, while it was log 4.70 in IFA-L7 immunised ani-
mals (P<0,05) (Fig. 8). Conventional S-19 vaccine imparted 
same level of splenic clearance (log 4.65) as that obtained 
with IFA-L7 form of the antigen. 
On day 15 post-challenge of infection, P-Lip-L7 immu-
nised mice showed significant (f <0.05) reduction of 
bacterial load in the spleen (from log 4.23 to log 3.51) as com-
pared with the IFA-L7 immunised animals (from log 4.70 to 
log 4.28). In contrast, the reduction in the number of CFU 
in S-19 vaccinated mice was decreased down from log4.65 
to log 3.97 unit. Interestingly, days 30 post-infection, splenic 
bacterial load in mice immunised with P-Lip-L7 (log 2.99) 
was nearly same level to that of S-19 immunised mice 
(log 2.93). Total splenic load of B. abortus 544, at various 
time interval showed that none of the other combinations (IFA 
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Fig. 8. Protection level in various groups of experimental and control BALBIc 
mice against virulent form of Brucella abortus 544 infection. Experimen-
tal groups were immunised with Brucella S-19, egg PC/chol liposome 
entrapped recombinant rL7/L12 protein, IFA emulsified rL7/L12 and free 
form of rL7/L12 protein. The mean CFU/spleen in three mice from each 
group was calculated on days 7, 15 and 30 post-challenge with infection. 
The data represent the mean CE^ (logio)± standard deviation. The data 
are representative of five different experiments giving same pattern of the 
data. P-values (on 30 days post-challenge): Control vs. P-Lip-L7< 0.001: 
S-19 vs. P-Up-L7<O.OI; IFA-L7 v*. P-Lip-L7<0.01; F-L7 vs. P-Lip-L7< 
0.001. 
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emulsified antigen, sham liposome, etc.) as well as free form 
of the antigen could induce protection against B. abortus 544 
infection. The results of the present study explicitly suggests 
that PC liposomal antigen engendered early and long lasting 
protection against brucella infection in BALBIc mice which 
is comparable to the protection levels offered by B. abortus 
S-19 vaccination. 
We also assessed splenomegaly of the animals challenged 
with B. abortus 544 infection (data not shown). Prominent 
splenomegaly was observed in the animals that were exposed 
to infection without prior immunisation, while spleen size of 
the animals from protected groups was of the same order 
to that of healthy animals (unimmunised and unchallenged 
with infection). Moreover, superficial multiple foci, discol-
oration of surface and granuloma formation were also found 
to present in the spleen, collected from control (unimmunised 
but challenged with infection) group of mice. In contrast, no 
macroscopic lesions were found in the protected group of 
animals. 
4. Discussions 
The protective immunity against brucellosis relies more 
on Th 1 (T helper) subset of T lymphocytes that play a promi-
nent role in induction of cell-mediated immune responses. 
Currently available subunit vaccines against brucellosis are 
considered to be of limited value, as they do not impart protec-
tion from subsequent infections [41^3]. In order to develop 
an effective vaccine against brucellosis, the identification of 
major immunodominant antigen and its adequate delivery 
to the immune system of the host seem to be ordeal of the 
demand. 
Most of the presently available antigen delivery sys-
tem, viz. ISCOMs, virosomes, pH-sensitive liposomes, etc., 
although claimed to induce strong immunoadjuvant activity, 
cannot be recommended because of the constraints such as 
cost factor, toxicity as well as elicitation of immunological 
responses against structural components (protein and carbo-
hydrate) of the delivery vehicles. Interestingly, liposomes, 
made up of naturally occurring egg PC, have been widely 
employed as vehicle to deliver drug and other biologically 
active substances to cells both in vivo and in vitro. Of late, 
they have also been reported to possess strong potential to 
activate immune system of the host against encapsulated 
antigen but not to their intrinsic structural components (c/ 
phosphatidyl-choline, etc.) [35]. 
In search of suitable antigen that can impart effective 
immunity against brucellosis several proteins have been 
investigated [16-18,23,24]. Among them, rL7/L12 protein 
(when used in free form) has been shown to activate immune 
system (B-T cell response) of the host with rriodest response 
[18,21]. This warrants development of suitable delivery sys-
tem as a vehicle/carrier for the antigen or its co-formulation 
with suitable adjuvant to achieve desirable protective immune 
responses. 
Our present study is mainly focused on the possible 
use of liposomal delivery of recombinant rL7/L12 pro-
tein, as a novel vaccine candidate against brucellosis in 
murine model. We demonstrated that the recombinant pro-
tein in combination with liposomal formulation conferred 
protective immunity in BALBIc mice against brucellosis. 
We jjerformed systematic immunological studies to establish 
immune potential of liposomised recombinant rL7/L12 pro-
tein in terms of both humoral and cellular immune responses. 
Immunisation with PC liposome encapsulated antigen 
generates high antibody titre as revealed by ELISA as com-
pared to S-19 vaccine or IFA adjuvanted delivery of the 
antigen. Significant rise in the total IgG level at various time 
points in comparison to the standard vaccine (S-19) group 
is an indication of superiority of the liposomal delivery of 
recombinant protein. On the contrary, free antigen was unable 
to induce significant IgG titre. This suggests that liposomised 
form of the antigen acquires ability to evoke B cell activation 
for the production of desirable antibodies. 
Since specific types of cytokines secreted by CD4'^  helper 
T cells regulate the isotype subclass of IgG, we assessed litres 
of both IgGl and IgG2a isotypes antibody generated in the 
immunised animals against various preparation of rL7/L12 
protein. A significant higher level of IgGl and lgG2a was 
detected in the sera of the mice immunised with P-Lip-L7. In 
fact a continuous higher IgG2a level was maintained in the 
animals immunised with P-Lip-L7 as compared to its IgGl 
counterpart. 
Considering the intracellular residence of the pathogen, 
our next move was directed to prime the cellular counterpEirt 
of the host immune system. The induction of cell mediated 
immune response after immunisation with various forms of 
recombinant rL7/L12 was evaluated by measuring T cell pro-
liferation response by in vitro stimulation of splenic cells 
with purified recombinant rL7/L12. As evident from data of 
the present study, immunisation of animals with P-Lip-L7 
resulted in significantly higher T cell proliferation as com-
pared to those resulting from immunisation with S-19 or IFA 
adjuvanted groups. CD4"^  T-lymphocyte mediated activation 
of the immune system plays a key role in up-regulation of 
bactericidal activity of macrophages [43]. Our results are in 
agreement with MBP-adjuvanted immune response of same 
recombinant protein in murine model that ensued induction 
of appropriate cell mediated immune responses [44]. 
Induction of a strong IFN-'y response along with relative 
predominance of IgG2a antibodies in the P-Lip-L7 immu-
nised mice suggests that antigen entrapment in PC liposome 
elicits Thl type of immune response in the host. The impor-
tance of lFN-7 in resolution of brucellosis has been supported 
by many of the earlier studies [45,46]. These results are in 
agreement with the previous work indicating that protective 
antigens against B. abortus infection induce T-cell prolifera-
tion and IFN-'Y secretion [ !6-l9]. 
Capillary tube migration inhibition has been reported 
to possess noticeable correlation with the cell-mediated 
immunity [47—49]. This assay is extremely specific and is 
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complementary to the immunological diagnosis of brucel-
losis [SO]. Keeping into consideration the fact that migration 
inhibition factor, a type of cell free soluble material, has an 
in vitro attribute for delayed type hypersensitivity reaction 
[49,51-53], we also looked for its presence in the culture 
supematants. The egg PC/chol liposome entrapment of anti-
gen caused more than 50% migration inhibition compared 
with the other preparations, suggestive of the fact that lipo-
some mediated delivery of antigen might have primed the 
lymphocytes thereby releasing the desirable lymphokines in 
circulation. 
Finally, to estabUsh vaccine potential of P-Lip-L7, we 
performed protection studies in terms of bacterial burden in 
spleen of the immunised mice. At each time point, mice vac-
cinated with P-Lip-L7 antigen showed significantly higher 
protection than other control groups. For example, the pro-
tection conferred by IFA adjuvanted antigen (log 0.066 units, 
CFU; log 3.94 on day 30 post-challenge with infection) was 
not at par in terms of quality or duration of the protection 
induced by the PC liposomal vaccine (log 1.61 units; CFU: 
log 2.99). It was found that bacterial load determined on day 
7 and day 15 post-infection showed poor efficacy of estab-
lished S-19 vaccine as compared to egg PC liposome-based 
vaccine. Most importantly, it was only after 30 days post-
immunisation that established S-19 vaccine (used as control) 
could confer nearly same level of protection to that of P-Lip-
L7. This could be explained on the premise that, in contrast 
to P-Lip-L7, S-19 induced delayed activation of protective 
immune response. 
Interestingly, a good correlation was found between higher 
IgG2a level and suppression of the infection in the immu-
nised animals. P-Lip-L7 vaccinated mice ensured maximum 
protection level that was accompanied with higher induc-
tion of IgG2a level in the immunised animals (Fig. 9a-c). In 
contrast, the S-19 vaccine showed low level of IgG2a induc-
tion on days 7 and 15, post-infection ensuing poor protection 
response against infection. However, with commencement of 
S-19 induced expression of IgG2a response (on day 30 post-
infection), there was remarkable suppression in the bacterial 
burden of the immunised mice. Earlier, passive transfer of 
B. abortus oligopolysaccharides (OPS)-specific monoclonal 
antibody was reported to protect mice from B. abortus infec-
tion [54-56]. Incidentally, the isotype determination of the 
antibody reveals that it has got IgG2a phenotype. In general, 
mice with higher IgG2a level showed the best protection on 
individual level, whereas those with low litre of lgG2a iso-
types showed less resistant against brucella infection [57]. 
A detailed study on the protective ability of IgG2a strength-
ens the observation made in the present study. The IgG2a 
is crucial because the binding of their Fc portion to the Fc 
receptors present on the surface of phagocytes activates a 
broad spectrum of antimicrobial response, viz. cytokine syn-
thesis, release of various inflammatory mediators, generation 
of reactive oxidant species, etc. [58], 
As demonstrated by others and us, normally egg PC lipo-
somes switch Thl/Th2 polarization in favour of Th2 response 
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Fig. 9. Scatter diagrain showing relationship between IgG isotypes with 
splenic load (CFU) of Brucella abortus 544 in 12 n\ice immunised with 
P-Lip-L7 protein. The level of IgG isotypes was expressed as absorbance 
(A492). Total CFU was determined in the spleen at days 7 (a), 15 (b) and 30 
(c) post-challenge. 
mainly [36,39]. However, in the present set of study, we 
demonstrated that P-Lip-L7 form of the antigen success-
fully induces Thl cells as well. This could be explained 
on the premise that liposome/bilayer structure acts as strong 
immunoadjuvant and they function in harmony with intrin-
sic immune properties of given antigen. Ribosomal L7/L12 is 
basically Th 1 type antigen; its co-administration in lipomised 
fonn does not alter its intrinsic properties rather it causes 
enhancement in overall immune response of the antigen. 
In spite of the rapid advances in the strategies for control-
ling brucellosis, the prevalence of the disease continues to 
rise exponentially in developing countries. Though the new 
vaccine such as SRB51 and Brucella suis S-2 are of some 
promise to control the disease, however lot of concerns have 
to be cleared about their efficacy and safety before their rou-
tine use [59]. To our knowledge, this is the first description 
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of PC liposome-based subunit vaccine offering significant 
protection against murine brucellosis. Our data clearly offer 
promising approach for developing liposome-based recom-
binant vaccine against brucellosis, 
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Abstract 
These days zoonotic diseases have invited a global interest, some of them have 
started posing altogether a new kind of health hazards. The recent threats in the form 
of AIDS, SARS and bird flu have enforced the scientific community to think and 
devote their maximum efforts to eradicate these dreadful diseases from the universe. 
Various strategies to counter them include introduction of novel prophylactic and 
chemotherapeutic measures to cure all the globally important zoonotic ailments on 
priority basis. 
Keeping into consideration the serious and fatal drawbacks associated with 
currently available control measures against intracellular pathogens, safe and 
efficacious delivery of prophylactic and chemotherapeutic agents are the best way to 
combat the current scenario. 
Among various important zoonotic diseases. Brucellosis is known to be a 
major bacterial zoonosis of global importance that causes abortion and infertility in 
cattle, and undulant fever, arthritis, endocarditis, orchitis and meningitis in human. 
Despite the numerous biotechnological improvements, brucellosis remains a major 
worldwide public health problem. The most appropriate method to control 
brucellosis is the immunization of susceptible hosts. However, the efficacy and 
safety of the available vaccines are questionable due to several drawbacks. 
Presently, not a single vaccine is available against human brucellosis, vaccines for 
animal brucellosis, although existing, are far from ideal. 
In order to overcome the problems associated with currently available live 
attenuated vaccines viz. S-19, RB51, or Revl etc., proteins of 5. abortus S-19, an 
attenuated strain that is antigenically similar to virulent strains, were being used as 
antigen and the vaccine potential was evaluated by using varieties of adjuvants. 
In spite of rapid development of antigen delivery systems, many of the newer 
adjuvants have improved upon some of the poorer aspects of traditional vaccine 
formulations (poor safety and efficacy). There are several important issues that act 
as driving forces for the methods by which future vaccines will be formulated and 
delivered in an effective way to overcome current deficiencies ensuring in improved 
efficacy of vaccines. 
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In this regard, fusogenic nature of E. coli cell wall lipid made liposome 
Icnown as escheriosome was studied extensively by many workers and found to 
effectively fuse with the membrane of the macrophages leading to the delivery of 
entrapped solutes to their cj^osol. In the present work we have tried to evaluate the 
adjuvant potential of escheriosome and its possible use as effective drug delivery 
vehicle against experimental murine brucellosis. 
In the first part of this present work, we have evaluated the immunogenic 
potential of sonicated cytosolic protein (BCP) of Brucella S-19 after encapsulation 
in liposomes. We found that, proteins of B. abortus S-19, an attenuated standard 
vaccine strain that is antigenically similar to virulent strains, showed anticipated 
results and revealed some promising aspect of possible use of fusogenic liposome 
(escheriosome) as a successful carrier of Brucella immunogens. The escheriosome 
have the potential to be a novel vaccine candidate against brucellosis. But, one 
crucial aspect of dealing with such type of vaccine formulation is that that many 
unwanted protein fractions, are often incorporated in acellular vaccine preparation, 
which are non immunogenic and even toxic that leads to poor protective efficacy as 
well as undesirable side effects. 
Selection of potentially protective immunogens of Brucella using targeted 
delivery system to obtain a protection level closer to that offered by currently used 
live attenuated or acellular vaccine could be a successful alternative in the 
immunoprophylaxis against brucellosis. 
Advances in molecular biology and unprecedented development of 
molecular techniques such as recombinant DNA technology allow the investigation 
of pathogen from new perspective and provide a variety of fimdamentally new 
approaches for the development of new generation vaccines. Among various 
strategies to develop improved Brucella vaccine, recombinant, subunit or live vector 
vaccine are the prime objectives of vaccinologists. In this concern, many 
immunogenic proteins have been tried as recombinant subunit or synthetic vaccines 
in the last decade. As Brucella ribosomal L7/L12 (rL7/L12) gene has already been 
identified as a major immunodominant gene, we have cloned this particular gene, 
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expressed in prokaryotic expression vector to yield relatively abundant quantities of 
antigens and protein thereof. 
Keeping into consideration the unique ability of escheriosome to deliver 
entrapped antigen to the cytosol of the target cells and also because of their strong 
immunadjuvanticity, we have evaluated the vaccine potential of escheriosome 
entrapped Brucella rL7/L12 protein in mice model. The data of the present study 
explicitly suggests that escheriosome-based vaccine induces early and strong 
activation of cell mediated as well as humoral immune response in the immunized 
animals as compared to standard S-19 vaccine. 
The results of the present study also revealed that immimization of animals 
with escheriosomes encapsulated antigen protected them against virulent Brucella 
abortus 544 (B. abortus) infection as revealed by increased survival, and reduced 
bacterial burden in vital organs. The data of the present study suggests that 
escheriosomes can emerge as an effective vehicle for intracellular delivery of 
antigen and thus hold promise in development of escheriosome based vaccine 
against brucellosis and other intracellular infections. 
In spite of the fact that vaccination against brucellosis is the best way to 
protect the host and save huge economical loss due to its serious impact on human 
and animal health, therapeutic use of antimicrobial agents remain the first choice in 
many developing counties like India mainly because of several socio-economic 
factors. In relation to this concern, the second part of the present study, we have 
therefore tried to develop novel drug formulation exploiting the unique properties of 
conventional, non fusogenic as well as fusogenic liposome against Brucella 
infection. For this we have chosen conventionally used antibiotic of known anti-
Brucella activity (Gentamycin) as well as some new generation cephalosporins 
(Ceftrioxne, Cefotaxime, Cefepime) and their therapeutic potential were evaluated 
after encapsulating them in liposomes and used against experimental murine 
brucellosis. 
Treatment with escheriosome encapsulated Gentamycin interestingly showed 
better efficacy than any other formulation. Furthermore, the present study suggests 
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that combination therapy of escheriosome encapsulated new generation 
cephalosporins would be promising alternative than currently available combination 
therapy against brucellosis. 
In conclusion, results of present study indicate the possible use of 
escheriosome-based delivery of recombinant protein as a potential candidate subunit 
vaccine able to elicit both cell mediated as well as humoral immune responses 
against experimental murine Brucellosis. Present study also indicates promising 
aspect of escheriosome to be potential drug delivery vehicle in terms of conferring 
better protective efficacy against Brucella infection. 
Future study is proposed for better insight of mechanisms of action of 
escheriosome which will certainly made it possible to design antigen-escheriosome 
or drug-escheriosome combinations capable of inducing desirable protective 
response against wide range of infectious diseases. 
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Historical Aspects of Brucellosis 
According to Hughes (1897), Brucellosis was first described by Hippocrates 
(BC 460). An accurate description of the disease was made in by Marston (1861), 
who was an assistant surgeon in the British Army stationed in Malta, and named it 
Malta fever. Micrococcus melitensis was first isolated by David Bruce in 1887 from 
spleen tissue of human cases that had died as a result of Malta fever. In 1897, 
Bernard Laurits Fredrick Bang, a Danish veterinarian from Copenhagen, identified 
one similar intracellular microorganism in cattle and described as 'Bacillus abortus' 
as it causes abortion in cattle. The disease was named for him, 'Bang's Disease' 
(Bang, 1897). The first report on B. canis in human was in 1968 by the National 
Communicable Disease Center of the United States Public Health Service, in a 
laboratory technician who handled viable organisms (Madkour, 1989). 
Clinical conditions synonymous with brucellosis have been described since 
the time of Hippocrates. Indeed, it has been suggested that organisms resembling 
Brucella have been detected in carbonized cheese from the Roman era (Capasso, 
2002). These observations highlight how both man and animals have lived with this 
disease since the days of early record keeping. The year 2004, marks the centenary 
of the formation of the Mediterranean Fever Commission, assembled to tackle the 
threat of brucellosis to British troops stationed in the Malta. It is believed that one 
such individual was Florence Nightingale, who endured over 25 years of ill health, 
personality changes (neurobrucellosis) and spondylitis which left her bedridden for 6 
years of her life (Young, 1995; Dossey, 1998). The severity of this disease and lack 
of vaccines suitable for use in man has led to the investigation of Brucella as agents 
for bioterrorism. Indeed, the American military weaponized B. suis in 1954 
(Greenfield et al., 2002), however, changing global politics resulted in abandonment 
of these efforts following the biological and toxic weapons convention in 1972. 
Within 2 years its members had not only isolated the causative organism from goats, 
but also drawn the epidemiological link with consumption of goat milk. This led to 
the recommendation that all milk be boiled prior to consumption, which in turn 
reduced the incidence of brucellosis in man (Dalrymple-Champneys 1950a, 1950b). 
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detailed descriptions not only of the undulant fever experienced by these individuals, 
but also, the joint manifestations, particularly spondylitis, neurological 
complications associated not only with personality changes (anxiety, amnesia, 
delusions, hallucinations, delirium, phobias and irritability), but also pronounced 
and prolonged frontal or occipital headaches, anorexia, abdominal pain and 
arthralgia (Dalrymple-Champneys 1950a). 
Brucella Morphology 
The Brucellae are a family of small, nonmotile. Gram-negative, coccobacilli and 
facultatively intracellular bacteria. The organisms are coccobacilli 0.5-0.7 jim wide 
by 0.5-1.5 Jim in length. They can occur as single cells, in pairs or in short chains. 
They do not form spores or true capsules and are aflagellate. They are aerobic and 
do not grow under strictly anaerobic conditions but many strains, especially of the 
species B. abortus and B. ovis, are carboxyphilic and require supplementary CO2 for 
growth. Many Brucella strains those require /-erythritol are fairly resistant to drying 
and can survive in biological material for long periods, especially at low 
temperature. Sensitivity to antibiotics is variable but most strains are sensitive to 
chloramphenicol, gentamycin, tetracyclines and kanamycin in vitro. The Brucellae 
are also inherently resistant to many of the antibiotics generally used for selection of 
plasmid in the laboratory. 
Host Specificity of Brucella 
There are currently six defined species that manifest themselves in a variety of hosts 
and are characterized based on dye and host susceptibilities. B. abortus is primarily 
responsible for infecting cattle and North American wild ruminants while B. 
melitensis infects goats and sheep, B. ovis infects sheep, B. suis infects swine and 
reindeer, B. canis infects dogs, and B. neotomae infects the desert wood rat (Timony 
et al, 1988). Of the six defined Brucella species only four are zoonotic in nature: B. 
melitensis, B. suis, B. abortus, and B. canis (Table 1). Due to the ability of these 
agents to illicit debilitating disease in human and potentially significant damage to 
livestock and food supplies. Brucella species are considered biological weapons^  pf 
mass^pstruction (Horn and Breeze, 1999; Kortepeter and Parker, 1999). 
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Table 1. Biovar differentiation of Brucella sp. 
Pathogenesis of Brucellosis 
Host-Microbial Interactions 
Smooth Brucellae gain entry into the host cells following interaction with cell 
surface micro domains known as lipid rafts. These lipid rafts contain significant 
amounts of glycosyl-phosphatidyl-inositol anchored proteins, glyco-sphingoUpids 
and cholesterol and are believed to play a significant role not only for 
internalization, but also for intracellular replication of brucellae. Investigation of the 
cellular interactions following internalization within macrophages has demonstrated 
that brucellae reside within the acidified phagosome. Indeed, the acidification of this 
environment is an important stimulus for expression of virulence genes of the virB 
operon, essential for expression of components needed for assembly of a type IV 
secretion system required for intracellular trafficking. 
Once inside the host cell phagosome, and after being subjected to the initial 
oxidative burst, the internalized brucellae commence their subversion of the host 
phagosome, termed as "brucellosome" through mechanisms as yet not fiilly 
elucidated. What is known is that the products of virB operon interact with the 
3 
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endoplasmic reticulum in a way that the pH becomes neutral, nitrate ions may be 
utilized for anaerobic respiration and the brucellae undergo regulated multiplication 
Interaction with placental trophoblasts suggests that the ability to acquire iron 
is vital as the brucellae enter their acute replicative stage with placental disruption 
resulting in fetal loss or birth of weak and infected offspring. It is interesting to note 
that iron acquisition is altered in the attenuated vaccine strain of B. melitensis, Revl 
when compared with the virulent strain. 16M Erythritol is believed to be important 
for determining tissue tropism for B. abortus. Indeed, Brucella uses this sugar 
alcohol in preference over alternatives and mutants unable to utilize erythritol are 
severely attenuated in ruminant hosts. Considerable literature suggests that Brucella 
metabolizing erythritol have a heightened requirement for iron, scavenged through 
siderophores such as 2, 3-dihydroxybenzoic acid or brucebactin. This may be linked 
with the requirement for effective iron acquisition for virulence in ruminant hosts. 
Molecular Mechanisms of Brucella Pathogenesis 
The availability of the genomic sequences of B. melitensis, B. suis and B. abortus 
have provided an opportunity to identify the virulence mechanisms of Brucella at 
the molecular level that have previously proven highly elusive. The recent release of 
the Brucella genome sequences verified the absence of "classical" virulence factors, 
as well as virulence or pathogenicity islands commonly found in other intracellular 
pathogens (Del Vecchio et al, 2002a; Paulsen et al, 2002; Hailing et al, 2005). On 
the other hand, some potential sequences for virulence involved in adhesion, 
invasion, immune evasion, adaptation and intracellular trafficking during the course 
of Brucella infection were discovered. 
To be a successful infectious agent, Brucella requires four steps, like other 
pathogenic intracellular bacteria: adherence, invasion, establishment and 
dissemination within the host (Liautard et al, 1996).The bacterial factors and 
cellular receptors implicated in attachment and entry of B. abortus into host cells 
have not yet been fully identified. Thus, the internalization process involve 
widespread ligand(s) since B. abortus is able to invade a broad range of mammalian 
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cell lines, including the murine fibroblasts NIH3T3, the green monlcey kidney vero 
cells, the human epitheloid cell line Hela and Madin Darby Bovine Kidney (MDBK) 
cells (Detilleux et al., 1990; Pizarro-Cerda et al, 1998a). It was observed that 
opsonized Brucella internalized in macrophages and monocytes via complement and 
Fc receptors, where as found non-opsonized Brucella exploits lectin or fibronectin 
receptors, in addition to other unknown receptors to penetrate mammary gland 
macrophage (Harmon el al. 1988; Campbell et al. 1994). In HeLa cells, it seems that 
Brucella is ingested through a mechanism, which involves a discrete recruitment of 
actin filaments at the binding site (Guzman-Verri et al, 2001). 
Brucella genome analysis has implicated a variety of genes in the course of 
attachment and uptake of Brucella in mammalian cells. Three proteins containing a 
domain homologous to auto transporters, such as the Salmonella typhimurium 
fibronectin binding protein hsdA, were identified that may serve as putative 
adhesions mediating attachment before phagocytosis. Additional putative adhesins 
related to the Bartonella Pap31/HbpA proteins and homologues of the Bartonella 
bacilliformis invasion associated proteins lalA and lalB are present in Brucella 
(Paulsen et al., 2002). However, future study is necessary before giving any 
conclusive remarks about the relationship between newly identified gene and entry 
oiBrucella into the host cell. 
The chronic nature of brucellosis is likely to be multifactorial, utilizing both 
the ability of Brucella to evade immune detection and adaptation to intracellular 
survival inside both phagocytic and non-phagocytic cells. This strategy involves the 
inhibition of the phagosomal-lysosomal maturation pathway and the deviation of 
intracellular trafficking, which allows the bacterium to reach its endoplasmic 
reticulum-derived replicative niche (Celli et al., 2003). 
Canning et al. (1986) suggested that an important determinant of Brucella 
virulence is the production of adenine and guanine monophophate, which inhibit 
phagolysosome fusion, degranulation and activation of the myeloperoxidase-halide 
system and production of tumor necrosis factor. The production of these inhibitors is 
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prevented in purE mutants, which are substantially attenuated in consequence. 
Lower biological activity of Brucella lipopolysaccharides (LPS) probably plays a 
substantial role in intracellular survival. 
B. abortus has two component regulatory systems consisting of the Brucella 
virulence-related regulatory (BvrR) and sensory (BvrS) proteins which are highly 
similar to the two component regulatory systems ChvG-ChvI of A. tumefaciens and 
equivalent to Salmonella PhoP-PhoQ and Bordetella bronchoseptica BvgA-BvgS 
systems. Insertional bvrR or bvrS mutants showed reduced multiplication and 
minimal persistence in mouse spleen in vivo and displayed lower level of 
invasiveness and replication in macrophages and HeLA cells in vitro, suggesting the 
inability to inhibit lysosome fusion and defect in intracellular trafficking of brucella 
containing phagosome (Sola-Landa et al, 1998). 
The most recent significant breakthrough in Brucella pathogenesis research 
is the application of signature tagged mutagenesis (STM), where mutants were 
tested in phagocytic and non-phagocytic cells (Foulongne et al, 2000) as well as 
acute and chronic (Lestrate et al, 2000) stages of infection in mice. Many Brucella 
attenuated mutants have been identified and are being characterized individually. B. 
abortus cydQ transposon mutants, attenuated in vitro and in vivo, are defective in 
cytochrome bd oxidase, a high-oxygen-affmity terminal oxidase used by 
Escherichia coli under microaerobic condition (Endley et al, 2001). Compared to 
that of wild-type. Brucella cyd mutants are susceptible to reactive oxygen 
intermediates (ROIs) in macrophages. However, the specific mechanisms of ROI 
susceptibility in cydQ mutants have not been investigated. 
Epidemiology of Brucellosis 
Knowledge of the genome of Brucella spp. helped to simplify many 
experimental approaches to investigative techniques. A variety of predicted 
virulence factors were identified whose experimental characterization may enhance 
our understanding of Brucella pathogenesis. Finally, the response of 5. abortus to its 
host environments, featuring low pH and nitrous oxide, as well as its ability to evade 
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the host immune response, will provide a major challenge for future studies. The 
term brucellosis is applied to a group of closely related infectious diseases, all 
caused by Gram-negative bacterial pathogens in the genus Brucella. Manifestation 
of the disease may range from abortion in the cow and to orchitis or epididymitis in 
the bull. Characteristically, all Brucella species establish persistent infection in the 
reticuloendothelial system of the natural host species. Plans to eliminate ovine, 
caprine and bovine brucellosis by the European Union were expected to receive over 
half of the total European Commission funding for animal diseases control measures 
in 1997 implies the importance of this disease. 
Zoonotic Importance of Brucellosis 
Human brucellosis is a notifiable disease in many countries, but real 
incidence has been estimated to be between 10 and 25 times higher than the reported 
figures due to inaccuracy of official figures, which do not fiilly reflect the number of 
people infected each year. Because of inaccurate diagnosis, cases very often remain 
unrecognized and are thus treated as other diseases or as "fever of unknown origin". 
Animal brucellosis also posses a barrier to trade of animals and animal products and 
Qould seriously impair socio-economic development of livestock owners the most 
vulnerable fraction of many rural populations. The most frequent symptoms of 
human brucellosis are fever, chills or shaking rigors, malaise, generalized aches and 
pains all over the body, joint and low back pain, anorexia, easy tiredness and general 
weakness (Martson, 1861; Bruce, 1889; Madkour, 1989) (Table 2 ). Man almost 
always receives the infection from infected animal; transmission from man to man 
rarely occurs (Thimm, 1982) (Figure 1, 2). Brucellosis in humans and animals is 
increasing in certain parts of the world, especially in developing areas of the 
Mediterranean region. Middle East, Western Asia and parts of Africa and Latin 
America. In Mediterranean and Middle East couritries the annual incidence of 
brucellosis in people varies from less than 1 up to 78 cases per 100 000; however, 
over 550 cases have been reported from confined endemic areas where no animal 
control measures are applied. Up to 77 cases per 100 000 people have been reported 
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from certain communities of south European countries in which animal control 
measures are mandatory. 
From a recent survey in a randomly selected human population of a country 
of the Arabic Peninsula, serological evidence of exposure to Brucella has been 
found to be close to 20%, with more than 2% of these having active disease. Similar 
figures may be expected from most countries in which the disease is endemic in the 
animal population. Higher seroprevalence of brucellosis should also be expected in 
occupationally exposed groups. 
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Table 2. Symptoms and signs of brucellosis in human 
Source Buchnann TM, Faber LC, Feldman RA. Medicine 1974; 6: 403-413. 
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Virulence Factors oi Brucella 
Identification and characterization of antigens that modulate host immune 
system is primary due to the development of a diagnostic test or a vaccine. A 
substantial number of antigenic components of Brucella have been characterized. As 
is the case for other bacterial pathogens, several cellular components contribute to 
the survival and virulence of the Brucella. Research concerning the virulence factors 
expressed by the Brucellae has focused primarily on the structural components of 
the outer membrane. Components are included as virulence factors on the basis of 
the following classification (Lory and Tai, 1984): 
> Components that when inactivated by mutation markedly decrease virulence, 
> Components that mimic pathological effects when administered in purified 
form and 
> Components that elicit a partially protective immune response. 
In contrast to other Gram-negative pathogens, the outer surface of the Brucella does 
not have complex structures, such as pilli or fimbriae, nor does it have capsular 
material. The outer membrane contains only two components that have been 
identified as virulence factors: the lipopolysaccharide (LPS) and the outer membrane 
proteins (OMPs) (Lory and Tai, 1984). 
Surface antigens 
Lipopolysaccharides (LPSs) 
The LPS was founded to be a major immunodominant antigen of Brucella 
(Nielson et al, 1988; Herman et al, 1992). Of the potential virulence factors 
expressed by the Brucellae, the LPSs are the best defined (Moreno et al, 1979). 
Virulence is associated with the smooth colony morphotype, designated S, which is 
known to contain the full complement of Brucella LPS. The rough colony 
morphotype, designated R, arises by dissociation from the smooth form and its 
accumulation is typically observed in vitro. Dissociation is stimulated by changes in 
environmental conditions, including different nitrogen sources or exposure to D-
alanine (Goodlow er al, 1952). The R morphotypes are characterized by their 
opaque appearance and lusterless colony morphology (Henry, 1933). In general, for 
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most Brucella spp, smooth strains are virulent and rough and mucoid strains are not. 
The LPS of smooth strains consists of lipid A, a core region containing glucose, 
mannose, quinovosamine and 2-keto-3'deoxyoctulosonic acid (KDO) and an 0 
chain composed of a homopolymer of about 100 residues of N-formylated 
perosamine (Caroff e/ al., 1984) (Figure 3). 
Differences in uptake of smooth and rough organisms have been 
demonstrated in experiments using guinea pig and bovine monocytes. LPS plays a 
role in enhancing intracellular survival. Experiments performed by Frost et al. 
(1972) indicate that in vivo grown, smooth organisms may have an additional 
membrane component that increases survival and virulence. The mouse model 
system has been investigated extensively with respect to the protective immunity 
induced by antibodies directed against LPS. The protective immunity elicited by 
LPS in the cow has not been clearly established. Winter et al. (1988) have 
demonstrated effective protection in the mouse model using a combination of 0-
polysaccharide covalently linked to Brucella porin. Under identical conditions, porin 
linked to R-LPS did not stimulate a significant level of protection. Montaraz et al. 
(1986) were able to demonstrate effective immunization by passive transfer of 
monoclonal antibodies directed against the 0-antigen, while monoclonal antibodies 
directed against a number of outer membrane proteins induced no significant 
protection. 
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the bovine immune system during the course of infection. Protective immunity 
stimulated by OMPs has been documented for several Gram-negative organisms 
(Wang and Frash, 1984; Isibasi et al., 1988). Protection stimulated by Brucella 
OMPs is still a matter of debate, and despite considerable experimental effort, is far 
from resolved. The doses employed have either been insufficient to produce an 
immune response or presentation of the antigen in the killed vaccines does not 
mimic the situation obtained with a living vaccine strain. 
In vivo antigens 
Evidences that Brucella cells grown in vivo exhibited differences from the 
cells grown in culture media has been has been presented. Proteins related from 
acquisitions are most common ones, heat shock proteins, chaperones, analogs to 
groEL, Hsp62 (Lin and Ficht, 1995) and Htr protein (Tatum, 1992). 
Intracellular antigens 
Various immunogenic antigens have been reported from time to time in this 
organism. They are Cu-Zn Superoxide dis-mutase, a 30 kDa protein, BA 14K, a 18 
kDa cytoplasmic protein, glyceraldehydes-3-phosphate-dehydrogenase, B. melitensis 
ribosome recycling factor (RRF)-homologous protein (CP24) (Chirhart-Gilleland et 
al, 1998; Goldbaum et al, 1999; Cassataro et al, 2002; Rosinha et al, 2002). 
Denoel et al, (1997) purified a 39-kDa protein from Brucellergen by anion 
exchange chromatography on mono Q sepharose fast flow column HR5/5. The 
antigen was immunoreactive and did not cross react with any other bacteria. 
Cytosolic antigens 
The cell surface antigens predominantly stimulating the humoral arm of 
immune response. Identification and characterization of cytosolic antigens which are 
usually processed and presented via MHC to CD4 and CD 8 T cells are important 
in any effort to develop a prophylactic agent against Brucellosis. Brooks-Worels and 
Splitter (1992) separated SDS extracted B. abortus S-19 antigens to several bands 
ranging from molecular weights of 6 kDa to 87 kDa by two dimensional 
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immunoblot. They also partially sequenced n-terminus of al2 kDa protein which 
gave maximum T cell proliferation. Bhongbhibhat et al. (1970) prepared an antigen, 
Brucellein, by cold hypertonic saline (2.7%) precipitation. Alton et al. (1975) 
showed Brucellein contained significant amount of nucleic acids material along with 
this protein. Bachrach et al. (1994a, b) identified and sequenced 12 kDa protein 
from Brucellein and found that the sequence matches with the 12 kDa protioen as 
reported by Brook-Worrel and Splitter (1992). Later the same group identified the 
12 kDa protein as L7/L12 508 ribosomal protein and reported the nucleotide 
sequence of L7/L12 gene in B. melitensis (Bachrach et al., 1994b). Oliveria and 
Splitter (1994) showed that E. coli expressed L7/L12 protien protected mice against 
B. abortus infection. Ercan and Gary (1997) concluded that L7/L12 DNA vaccine 
construct elicit immuno responses in mice against B. abortus. The B. abortus 
L7/L12 protein was also expressed in Lactobacillus lacti for the development of 
foods grade vaccine (Ribeiro et al., 2002). 
Cytosolic L7/L12 ribosomal protein 
The rplJL operon encodes the LIO and L7/L12 proteins, essential for 
ribosomal function and protein synthesis (Oliveria et al., 1994). The rplJL-rpoB 
operon (1-1099 bases) encodes 4 proteins. The first open reading frame (1-129 
bases) encodes rplJ gene. The gene product is ribosomal protein LIO. Bases 280-
654 encodes rplL gene. The product of this gene is the L7/L12 ribosomal protein. 
The bases 900-1009 encodes rpoB gene. The protein product of this gene is RNA 
polymerase beta subunit. 
Structure and function of the L7/L12 ribosomal protein 
Recent crystallography study of the L7/L12 protein have been led to the 
unraveling of the structure and the organization of the protein within the ribosome 
(Sanyal et al., 2000) the L7/L12 protein is associated with the large subunit of the 
ribosome. LI2 protein is associated with the SOS ribosomal subunit whereas L7 is an 
acetylated form of the L12 protein. This acetylation occurs in the N-Terminus of the 
LI2, which become L7. Both L7 and L12 protein form dimmers with each other. 
Four molecules of this acidic protein are present in each ribosome and they exist as 
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two dimmers. Being the only protein present in the each ribosome in more than one 
copy, L7/L12 may become very abundant in multiplying bacteria. Translation 
elongation is a dynamic process in which mRNA and tRNA move successfully on 
the ribosome .It is stimulated by the action of two elongation factor EF-Tu and EF-G 
at a common site of the ribosome termed as "GTPase center" and by coupled GTP 
hydrolysis. Ribosomal protein L7/L12 is an important component of this functional 
center and constitutes a part of the so called transnational engine as investigated 
mainly in Escherichia coli L7/L12 has unique properties whose functional 
significance is not clear yet i.e. there are 4 copies in the ribosome and these 
molecules are flexible in the SOS ribosome subunit. There are four copies (2 
homodimers) of L7/L12 bind to anther protein LIO and form a stable complex 
L10.L7/L12. This complex then binds to the highly conserved RNA domain around 
position 1070 of 23S rRNA. The speed and the error orate of the translation process 
depends on this protein the L7/L12 is required for maximal rate of the synthesis as 
well as for minimal missense error frequency (Perresson and Kurland, 1980). 
Toxins and other factors 
To date, no concrete evidence exists that toxins similar to those produced by 
other organisms (i.e., Vibrio chloera, Corynebacterium diphtheriae, E. coli, Shigella 
dysenteriae, Clostridium botulinum, C. tetani) are produced by the Brucellae. A 
toxin has been postulated to exist due to the severe effects of the disease on the 
central and autonomic nervous systems. Endotoxin, consisting of LPS, has been 
suggested as the causative factor. The Brucellae also produce catalase. Huddleson 
and Stahl (1943) determined that catalase activities decrease with changes from 
smooth to rough morphology. Although the biochemical advantage of expressing 
catalase in Brucella has not been identified definitively, it may not only protect the 
organisms from peroxide, but could also be important in maintaining oxygen tension 
required for survival of the organism (McCuUough, 1970). 
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Immunology and Protection against Brucella 
Brucellosis frequently progresses towards a chronic state involving different 
organs. Once the organism has transgressed the mucous membranes or the skin, it 
tends to localize in the local lymph nodes and then a systemic dissemination occurs 
affecting organs of the mononuclear phagocytic system such as spleen and liver. 
Classic experiments by Mackaness (1964) and Mackaness and Blanden (1967) 
showed the role of cellular immunity and the fundamental part played by activated 
macrophages in resistance to, and in protection against, intracellular pathogens such 
as Mycobacterium sp.. Salmonella sp., Listeria monocytogenes and Brucella sp. 
Innate immunity 
Innate immunity is composed of non-specific immune response in the early 
stage of infection before adaptive immunity, mediated by clonal selection of specific 
lymhocytes, has become established. Thus, the ultimate roles of the innate immune 
system in Brucella infection in vivo are to reduce the initial number of infected 
bacteria without memorization and to provide the environment for generating Thl 
immune response in the host. Complement is a system of plasma proteins that 
interact with bound antibodies or bacterial surfaces to opsonize or directly kill the 
pathogens by forming a membrane attack complex (MAC) with gram-negative 
bacteria.The bactericidal functions contained in macrophages are reactive oxygen 
intermediates (ROIs) and reactive nitrogen intermediates (RNIs) which are induced 
by gamma interferon (IFNy) and tumor necrosis factor (TNF-a). Jiang et al. (1993) 
examined the role of ROIs and RNIs in controlling the load of B. abortus in murine 
macrophage infection and concluded that ROIs play a greater role than RNIs in 
Brucella killing in vitro. Superoxide dismutase (SOD) and nitrate reductase (NarG) 
of Brucella detoxify ROIs and RNIs activity respectively and help brucella reside 
inside macrophages (latum et ai, 1992; Kohler et al., 2002). 
Murine susceptibility to Leishmania, Salmonella and Mycobacterium is 
influenced by natural resistance associated macrophage protein 1 (Nrampl). Nrampl 
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endrose host with natural heritable resistance against intracellular pathogen. Barthel 
et al. (2001) transected bovine Nrampl gene into murine RAW264.7 macrophage 
cells and observed that bovine Nrampl stable transfectants of RAW264.7 cells 
control B. abortus infection better than do parental cell lines in vitro, suggesting that 
natural heritable resistance plays a role in bovine brucellosis. 
Adaptive immunity 
Adaptive immune responses are critical for providing the memory function 
that is the key player in vaccination. Functions of the adaptive immune response in 
brucellosis can be classified into three mechanisms. First, IFN-y produced by CD4" ,^ 
CD8"^ and y5T cells activates the bactericidal function in macrophage to hamper the 
intracellular survival of Brucella. Second, cytotoxicity of CDS"*" and yST-cells kills 
the infected macrophages. Third, Thl type antibody isotypes such as IgG2a and 
IgG3 opsonize the pathogen to facilitate phagocytosis. 
Humoral Immune Responses 
A number of the constituents of Brucella cells are capable of inducing 
specific antibodies in their hosts (Freeman et al., 1970; Moreno et al., 1981; 
Verstreate and Winter, 1984). The classic reports include studies of agglutinins, 
precipitins; complement fixing and blocking antibodies (Glenchur et al., 1963; 
Wilkinson, 1966; Diaz et al., 1968). Previous studies in naturally acquired and 
experimental brucellosis have shown that there is an early marked elevation in the 
serum concentration of agglutinating antibodies. This IgM antibody may be detected 
one week after entry of the bacteria and reaches a peak level four weeks later, at the 
same time that IgG antibody peaks. IgG agglutinating globulin has a delayed 
appearance and, although it is found mixed with IgM, within four weeks following 
the initial antigenic stimulus the IgM agglutinin level always exceeds the IgG 
agglutinin level. A third category of agglutinating globulin, IgA appears later in a 
significant concentration in the serum. IgG agglutinating antibody usually arises a 
few days after IgM antibody and decreases more rapidly. IgM antibodies may persist 
several years after therapy and recovery, whereas IgG is likely to be present in much 
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lower titers one year after the beginning of adequate treatment. IgE levels of 
antibody to Brucella have not been studied extensively, but the work of Escande and 
Serre (1982) indicates that IgE levels may be significantly high in brucellosis 
patients and vaccinated subjects. According to available evidence, the IgE anti-
Brucella antibodies appear somewhat after the IgM antibodies and a little earlier 
than IgG. 
Multiple precipitating antibodies have been reported to be usually detectable 
within 3-4 months of severe or prolonged active Brucella infection (Glenchur et al., 
1962). These antibodies belong mostly to the IgG globulin fraction and they are not 
as long lasting as the agglutinins (Glenchur et al., 1963). The anti-Brucella 
complement fixing activity present in sera has been mainly related to IgG, somewhat 
less to IgM and not at all to IgA (Heremans et al., 1963). Blocking antibodies have 
been studied and reported in cases of human brucellosis (Griffiths, 1947). They 
appear later in the course of the disease than agglutinating antibodies (Zinneman et 
al., 1959). Blocking antibodies are thermo stable, divalent and occur in the IgG and 
IgA fractions (Heremans et al., 1963). Interestingly, both IgG and IgA have been 
reported to act as agglutinating or blocking antibodies. Moreover, both IgG and IgA 
blocking antibody responses are prolonged and sustained. However, a quantitative 
assessment of the relative amounts contributed by each globulin to the blocking 
effect cannot be made (Wilkinson, 1966). For all those characteristics, the blocking 
antibodies have always been related to a long-lasting or chronic brucellosis 
(Glenchur et al, 1961; Kerr et al., 1967; Coombs et al., 1978). In spite of all the 
advances in the study of immunoglobulins, including structure, sequential 
production and persistence after antigenic stimulation, this knowledge has been 
applied only to the diagnosis of brucellosis. As a consequence, it has been the basis 
for the development of supplemental serological tests and for research on the 
identification of cell fractions and the antibody classes reactive with them. 
Nevertheless, very little has been done in this field or in understanding the biological 
role of this especially complex antibody response. Many serum passive-transfer 
experiments suggest the significance of humoral immunity in murine brucellosis. 
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Araya et al (1989) and Winter et al. (1989) showed that passive transfer of sera 
containing anti-LPS antibodies to mice could protect against challenge with virulent 
B. abortus. IgG2a and IgG3 are dominant antibody isotypes detected from the 
infected mice similar to the natural host, suggesting that a Thl immune response to 
Brucella infection occurred (Elzer et al., 1998; Elzer et al, 2001). Opsonization, 
probably coupled with enhancement of intracellular killing, is regarded as the 
principal protective role of antibody against Brucella infection. 
Cell-Mediated Immune Responses 
Antibodies play an important role in eliminating Brucella organisms but the 
development of a solid cell-mediated immune response is fundamental for the 
establishment of a protective state as observed in other infectious diseases caused by 
intracellular pathogens including Brucella sp., Mycobacterium sp. and Salmonella 
sp. The discovery and definition of several T lymphocyte sub-populations (Cantor 
and Boyse, 1975) has permitted the study of the individual response towards the 
different Brucella antigens. Many attempts have been made to identify the antigen(s) 
responsible for the protective immunity as well as the one responsible for the 
chronic state. In that respect, two important sub-populations of T lymphocytes have 
been identified by cellular surface markers and by functional criteria: helper/effector 
cells and suppressor/cytotoxic cells. Studies using cell transfer assays have 
established that T helper cells are responsible for the response that confers 
protection (Kauffmarm et al, 1979). The main function of these helper cells is the 
activation of macrophages, which leads to an increase of the bactericidal capacity 
through the production of soluble factors, e.g. IFNy. The T helper cell population 
activity is controlled by several factors: suppression mediated by soluble factors 
produced by suppressor macrophages and by T suppressor cells. Bacterial antigens 
may stimulate the level of activity by T suppressor cells. In fact, this has been 
observed in other intracellular infections such as leprosy in which the antigenic 
fractions that specifically activate T suppressor lymphocytes have been identified 
(Mehra et al., 1984). All the available experimental evidence points towards the role 
that the cell mediated immune response plays during the procedures of the Brucella 
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infection. Success in elimination of Brucella depends basically on the adequate 
macrophage activation induced by the T lymphocyte response, stimulated by the 
bacterial antigens. Yet, the detailed nature of the mechanism involved in the 
interaction of all the cellular populations involved in this protective response is still 
largely unknown. 
The major role of T-cells in Brucella immunity is secretion of IFNy for the 
activation of bactericidal function in macrophages and cytotoxic T-lymphocyte 
activity as well as IgG2a and IgG3 isotype switching. The significance of CD4"'" 
and/or CDS"^  T-cells in Brucella immunity has been controversial. Recent 
experiments with (3"'" and (32 m''" mice infected with B. abortus strain 19 suggest 
that CDS"*" T cells comprised the predominant protective population (Oliveira and 
Splitter, 1994). Additional experiments with MHC class I-deficient mice as well as 
wild-type-mice suggest that the production of Th-1 type cytokines such as IFN-y and 
IL-2 by CDS"*" T-cells has an important function in controlling brucellosis (Oliveira 
and Splitter, 1994). However, the major T-cell population is CDA'^ T-cells in terms 
of number, and this cell population secretes IFN-y. Thus, the role ofCDA'^ T cells in 
brucellosis should not be ignored. 
Cytokines play two important roles in immune responses (i) to mediate 
innate and adaptive immunity and (ii) to direct the immune response among immune 
associated cells. During Brucella infection several cytokines such as IFNy, TNFa, 
IL-2, IL-10, IL-12 and IL-18 control the intracellular growth of Brucella strains 
within macrophages, whereas IL-la, IL-4, IL-6 and GM-CSF do not have clear 
effects (Golding et al, 200I).Among the various cytokines, IFNy is the most 
relevant for generating macrophages with strong activity for killing intracellular 
Brucella (Murphy et al, 2001). Furthermore, IL-2, IL-10, IL-18 and IL-12 that 
influence the acquired cellular resistance and specifically contribute to control the 
Brucella multiplication seem to work via the IFNy dependent pathway. The 
significance of IL-12 in brucellosis has been well described (Zhan and Cheers, 
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1995). However, the mechanisms of IL-12 induction in those cells have not been 
elucidated. IL-18, originally known as interferon gamma inducing factor (IGIF), 
possesses broad and potent immunomodulatory properties (Dinarello et al., 1998). 
IL-18 has been shown to play a central role in the development of immunity against 
pathogens, by acting on Thl cell differentiation, cell mediated cytotoxicity, and 
inflammation via IFNy production. Its role in protective immunity to intracellular 
parasites, including Salmonella enterica serovar Typhimurium, Mycobacterium 
tuberculosis, Shigella flexneri, Chlamydia trachomatis has been well documented 
(Dybing et al., 1999; Sansonetti et al., 2000; Biet et al., 2002a; Biet et al., 2002b). 
Phagocytosis 
Polymorphonuclear leucocytes (PMNs) 
Ingestion and killing by phagocytic cells is one of the early non-specific 
defense mechanisms against many microorganisms. Brucella included. This activity 
is carried out by polymorphonuclear leukocytes (PMNs) which are attracted to the 
infection site by chemical stimuli originated by or derived from the microorganism 
(Wilkinson, 1980; Birmingham et al., 1982). Once the phagocytic cells arrive at the 
infection site, the ingestion of the bacterium occurs and a series of events takes 
place. These events include an increased consumption of oxygen that leads to the 
appearance of hydrogen peroxide, superoxide radical and other oxygen-derived 
radicals, together with activation of myeloperoxidase. Lysosomes fuse with the 
Brucella-containing phagosomes and release their acid hydrolases, glycosidases, 
proteases and lipases. B. abortus and B. melitensis are equally susceptible to 
phagocytic ingestion by PMN, even more so if the bacteria are opsonized with 
serum factors such as antibodies, complement components and a third group of 
substances defined as thermolabile natural antibodies (Young, 1995). The ingested 
bacteria may survive the destructive mechanisms of the phagocyte, a phenomenon 
apparently related to virulence (Smith and Fritzgeorge, 1964). Events occurring after 
phagocytosis has taken place do not seem to be influenced by opsonins (Elsbach, 
1980), so that resistance or susceptibility of the bacterium seems to be an extrinsic 
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phenomenon. Both attenuated and virulent strains of B. abortus and attenuated B. 
melitensis are eliminated by PMN, while virulent B. melitensis is more resistant 
to21 intracellular death, a property which probably relates to its higher virulence to 
both man and animals (Young , 1995). However, some virulent strains of 5. abortus 
can survive within the PMN. Selective resistance of smooth versus rough strains of 
B. abortus suggests involvement of a surface component in the inhibition of the 
fusion of phagosome lysosome (Riley and Robertson, 1984). Low molecular weight 
substances from B.abortus also specifically inhibit the bactericidal system of 
myeloperoxidase-H202-halide (Canning et ai, 1989). Moreover, strains of B. 
abortus appear not to trigger the burst of oxidative metabolism so that no H2O2 is 
generated for the myeloperoxidase system (Kreutzer et al., 1979). Although PMNs 
are the primary cells involved in the elimination of foreign pathogens, they are 
generally considered of low efficiency against Brucella so that these bacteria are 
able to survive and grow within the PMN. Brucella cells are also transported to 
organs of the mononuclear system and this is considered the reason for the 
persistence of the infection. 
Macrophages 
Polymorphonuclear leukocytes rarely serve as hosts for Brucella, but the 
bacteria thrive within macrophages. To carry out its bactericidal activity the 
macrophage produces most of the oxygen-derived radicals mentioned above. 
Substances derived from T lymphocytes stimulated by bacterial components 
promote macrophage activity in three main ways: 
> By increasing the bactericidal capacity of the macrophage, 
> By attracting circulating monocytes which mature in the tissues into 
macrophages and 
> By inducing the local proliferation of macrophages. 
Although the importance of antibodies in protection against Brucella has 
been clearly established, the exact mechanism has not been elucidated. Armstrong 
and Hart (1971) observed that antibody covering bacilli facilitate the fusion of 
phagosomes with lysosomes in infections by M. tuberculosis. This also seems to be 
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the case of Brucella since antibodies help to reduce dissemination (Plommet and 
Plommet, 1983). In experimental brucellosis the macrophage activation occurs early 
in the infection; therefore it is easy to demonstrate the development of a specific 
cellular response from the third day after infection. This early activation seems to be 
due to contact with bacterial components such as B. abortus lipopolysaccharide 
(LPS) (Birmingham and Jeska, 1981). This activation is notably increased as a result 
of the establishment of the cell-mediated immunity and reaches maximal 
bactericidal ability at the 14'" day. During this activation stage the macrophage 
undergoes a succession of important metabolic and functional changes that allow it 
to eliminate the ingested germ. Thus, an increase in production and liberation of 
lysosomal enzymes occurs, as well as in Fc and complement receptors that facilitate 
the adhesion and ingestion of the bacteria. Also an increased production of 
superoxide and peroxides, and an increase in the chemotactic response which 
produces a greater mobilization of the macrophage occurs to the infection site 
(Birmingham and Jeska, 1981). 
Intracellular survival strategies of Brucella 
The multifaceted dialogue between intracellular pathogen and mammalian 
host continues to be an exciting issue not only from scientific but also public health 
viewpoint. The host microbe relationship is a dynamic process in which the microbe 
attempts to minimize its visibility to ensure survival, whereas the host attempts to 
prevent and eradicate infection with minimal damage to self (Janaway et al, 2002). 
It is widely acknowledged that intracellular pathogen have developed shrewd 
strategies to evade the host defenses so as to survive and replicate and use host 
resources for its survival and persistence. The importance of professional phagocytes 
in acquired resistance against infectious diseases is well established. These 
phagocytes play key role in distinguishing between plethoras of microbial invaders 
from self and inducing the acquired immune response best suited against particular 
pathogen (Metclinikoff, 1905). 
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Intracellular traffic of JS. abortus 
Brucella plays an active role in securing its survival within the phagocytic 
cell. One of the fundamental processes used by the bacteria is to prevent the fusion 
of the phagosome with the lysosome. This effect seems to be mediated by surface 
antigens no related to LPS. These surface components have been found in smooth 
virulent strains butnot in smooth attenuated strains (Frenchick et al., 1985). The 
mechanisms how these Brucella components act has not been elucidated yet. Other 
intracellular parasites such as Toxoplasma gondii, M. tuberculosis (Armstrong and 
Hart, 1971) and M. microti (Lowrie et al., 1975) also avoid phagosome-lysosome 
fusion. Apparently in these cases parasite products interact with lysosomal 
membranes and render them unable to fuse. There are two alternative or 
complementary mechanisms that help B. abortus to survive within the macrophage 
(Corbel, 1990) (Figure 4): 
> Some B. abortus strains avoid the respiratory burst inside the phago-
lysosome, 
> avoiding the consequences of oxygen-derived radical formation 
> B. abortus is able to release cellular products, including RNA that might 
inhibit lysosomal enzymes. 
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Figure 4. Proposed model of the intracellular traffie of J5. abortus in 
Hela cells 
Both virulent strain (B. abortus) 2308 as well as attenuated vaccine strain S-
19 found within 10 min after invasion in an early compartments positive for 
EEAl that is able to fuse with autophagosomess originating from the ER and 
enriched by the LAMP molecules . S-19 is then unable to inhibit the 
maturation of its autophagosomes, which fuses with lysosomes and causes the 
degradation. In contrast b. abortus 2308 diverts the maturation pathway of 
autophagosomes and fuses a retrograde transport system to access the ER, 
where massive replication occurs. 
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Prophylactic Control Over brucellosis 
Control over brucellosis with vaccine constitutes cost-effective measures and 
epidemiologically targeted implementation of Brucella vaccines could diminish the 
morbidity and mortality. Because of the serious economic and medical consequences 
of brucellosis, efforts to prevent the infection through the use of vaccines are still 
going on. 
Live vaccines 
Conventional live vaccines are produced by selecting avirulent 
mutants, which can establish themselves in host, however fail to invoke full-
blown disease. The mutations are generally induced by treatment of the 
organism with mutagens, chemicals, heat or passage in vitro. Following 
these mutational events, avirulent mutants are selected and tested in vivo. In 
most cases, multiple mutations induced, led to the development of attenuated 
form of pathogen although it is often unknown what constellations of genes 
are altered to achieve attenuation. Using this approach, it is difficult to 
modulate the degree of attenuation and if the attenuation happens to be due 
to a single-point mutation, there is a high probability of reversion to 
virulence when organism is administered to the host. A well-known example 
of such reversion was observed in case of oral polio vaccines when virus 
gets virulent upon administration (Minor et al., 1986). This reversion can 
result to full blown disease, especially to the underlying immunosuppressive 
conditions. 
The vaccine that has been most widely used to prevent bovine brucellosis is 
live B. abortus strain 19 (Nicoletti, 1990). This is was first described in 1930 and 
was originally isolated from milk of a Jersey cow as a virulent strain in 1923 but 
after being kept in laboratory at room temperature for over year was found to 
become attenuated (Buck, 1930). This strain was able to induce protective 
immunity in cattle. Efficacy of this vaccine fluctuated depending on a variety of 
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factors including age, dose and route of vaccination and prevalence of brucellosis in 
vaccinated herds. Strain-19 vaccine suffers from safety concerns and some other 
drawbacks like 
> Cross-reaction with natural infection during serodiagnosis, 
> 2. Does not prevent completely udder infection, 
> S-19 is pathogenic to human (Smith and Ficth, 1990, Nicoletti, 1990), 
> In pregnant animal this vaccine strain induces abortion (Corbel, 1997) and 
> Long term persistence of antibodies in serum following administration of this 
vaccine hinders the sero-diagnosis of brucellosis among diseased and vaccinated 
animals. 
Another live vaccine is B. abortus strain 45/20, a rough derivative of 
Brucella abortus smooth strain 45/20, was able to protect guinea pigs and cattle 
from Brucella infection (McEwen, 1940). Unfortunately, when used as a live 
vaccine, strain 45/20 was not stable and tended to revert to the smooth, virulent 
form, thereby defeating the purpose of using rough strains, usually associated with 
attenuation and inability to induce positive, diagnostic serology (Edwards et al., 
1945; Taylor and McDiarmid, 1949). The variability of the reported protection, 
together with unpredictable serological effects and the occurrence of several local 
reactions at the site of vaccine injection in some animals eventually prompted the 
discontinuation of Strain 45/20 vaccination (Schurig et al, 2002). Brucella abortus 
RB51, a rough attenuated strain, was originally derived from a rifampicin-resistant 
mutant of 5. abortus strain 2308 (Schurig et al, 1991), has replaced S19 strain as a 
vaccine candidate in some developed countries. Strain RB51 is very stable, it has no 
or highly reduced abortifacient characteristics (Schurig et al, 1991; Palmer et al, 
1997). It has certain advantages over S-19 like 
> Vaccine is safe until 7"^  month of pregnancy (Cheville et al, 1996) 
> Able to differentiate vaccinated and naturally infected animals by both 
serological and molecular techniques like PCR and pulse field 
electrophoresis. 
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> The organism is cleared swiftly from the host and the longevity of the 
protection is about 1 year. 
> Protective efficacy and immunity induced by strain RB51 is similar to or 
better than that induced by strain 19 (Cheville et al, 1996; Lord et al., 
1995). 
Although strain RB51 has an excellent record of stability, it is still infectious 
to humans and the exact nature of the mutations is not known 
Killed vaccines/antigenic fractions 
A wide variety of preparations have been tested in this area including killed 
field isolates but with the exception of B. abortus strain 45/20, practical acceptance 
of these preparations has been very limited. A variety of reasons including 
production, costs, poor protection, unacceptable local reactions and serological 
problems played a role in forming this attitude (Meyer and Gibbons, 1978). 
Antigenic fractions extracted from Brucella have been tested, particularly in 
association with a variety of adjuvants. Preparations used have included whole killed 
cells (Blasco et al., 1993), outer membrane protein (Montaraz and White, 1986), 
soluble and insoluble residues of sodium dodecyl sulfate (SDS) extracts of cell 
envelopes (Winter and Rowe, 1983; Dzata et al., 1991) and periplasmic proteins and 
salt extractable proteins (Tabatabai et al., 1992). Immunity has been achieved with 
some of these preparations in laboratory animals. 
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Current Approaches to Develop Vaccine Against Brucella 
The various approaches to develop novel vaccines include recombinant 
subunit vaccines; live vector vaccines, synthetic peptide vaccines, and nucleic acid 
vaccines (Robinson, 1997). 
Recombinant subunit vaccine 
Subunit vaccines are defined as those containing one or more pure or 
semi-pure antigens. For this it is crucial to identify antigenic proteins that 
are important for inducing protection and elimination of the pathogens. The 
potential advantages associated with subunit vaccines are the increased 
safety, less antigenic competition, since only a few components are included 
in the vaccine, ability to target the vaccine to the site where immunity is 
required and the ability to differentiate vaccinated from infected animals. 
Although subunit vaccines can be produced by conventional technologies, 
the purification is generally not economic due to the low quantities of 
protective antigens produced by most of the infectious agent. For example, 
Pasteurella haemolytica produces low level of extracellular toxin 
(leukotoxin), which is involved in pathogenesis and tissue, damage in the 
lungs of cattle (Shewen and Wilkins, 1982; Lo et al, 1987). This makes the 
development of neutralizing antibodies a very costly affair. In addition, 
some bacterial proteins required for scavenging nutrients such as iron are 
not expressed at sufficient levels to allow purification of the protective 
component. ^ 
As cell mediated immunity (CMI) is the dominant immune response 
required for protection against brucellosis, the concept of a subunit vaccine in 
brucellosis is based on the generation of memory Thl cells by immunization with T-
cell antigen. The preferred strategy is to identify those Brucella antigens that 
are truly responsible for the induction of a protective CMI response. Various 
in vitro studies such as production of cytokines (IFN, IL-2, IL-12), antigen 
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specific lymphocyte proliferation, T-Cell cytotoxicity toward Brucella 
infected target cells and in vivo assays (delayed hypersensitivity) can be 
used to select putative protective antigens but this approach is by no means 
fool proof and does not guarantee the selection of a protective antigens. 
Recombinant antigens can be delivered with an appropriate vector system or 
could be purified from recombinant bacteria plants or insects viruses 
(baculovirus) and in the presence of appropriate adjuvants and stimulatory 
cytokines. So far, recombinant P39, bacterioferritin, and L7/L12 proteins have been 
purified and tested as subunit vaccines with adjuvants (Oliveira and Splitter, 1996; 
Al-Mariri et al., 2001). Some level of protection have been induced with the 
purified recombinant Brucella L7/L12 protein, indicating that if the 
appropriate antigens is selected, this approach can be successful (Oliveria 
and Splitter, 1996). A group of researcher at the Virginia Tech has been 
using several recombinant vaccinia viruses expressing a variety of Brucella 
antigens including HtrA, GroWL, groES, Cu-Zn SOD and YajC among 
others to induce humoral as well as cell mediated immune response. 
Genetic Vaccines 
A recent novel approach has been the use of DNA that encodes 
specific protective antigen. The basic premise of DNA vaccines involves the 
introduction of gene(s) encoding protein antigens responsible for stimulating a 
protective immune response (Robinson, 1997). The in vitro paradigm for this 
approach lay in the transformation of mammalian cells in culture with a 
plasmid that directs the expression of a vaccine antigen from cells that take 
up the plasmid DNA. Subsequent to its uptake the administered DNA 
encodes antigen(s) that can be secreted or be associated with the cell surface 
in a way that would trigger a humoral or cellular immune response. In the 
early nineties, intramuscular administration of solution of uncoated or 
'naked' DNA encoding a vaccine antigen was found to induce desirable 
immune response (Wolf et al., 1990). Cells take up the DNA, transcribe its 
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expression cassette and synthesize the antigen, which may be processed in a 
similar way to that of administration of DNA subsequent to viral attack. 
Both humoral and cellular immune responses to the encoded antigen are 
elicited. The advantages of using DNA based vaccine involve relatively 
technically easy way of preparation and the ability to direct the synthesis of 
multiple copies of mRNA that eventually results in amplification of both 
antigen synthesis and immune response. DNA vaccines are particularly 
proficient at eliciting cellular immune responses. Nevertheless, clinical 
efficacy for such vaccines remains to be shown. 
DNA vaccine offers immense opportunity for targeting the in vivo expressed 
gene(s) of intracellular pathogen like Brucella. In the field of Brucella vaccines, 
there have been a limited number of studies utilizing this DNA technology. Ercan 
and Gary (1997) studied L7/L12 DNA construct elicit immune responses in mice 
against B. abortus infection. They showed that pcDNA3 expressing L7/L12 
ribosomal protein when given intramuscularly facilated proper antigen presentation 
to the mice immune system which leads to a specific antibody and T cell response. 
DNA vaccines encoding the bacterioferritin or P39 of Brucella were able to induce 
typical Thl dominated immune response in BALB/c mice as demonstrated by the 
presence of interferon-gamma (INFY) and immunoglobulin G isotype (Al-Mariri et 
al, 2001). It has also been shown that B. abortus lumazine synthase (BLS) gene in a 
pCND A3-based vaccine was able to induce a significant level of antigen specific 
immune response in Balb/c mice and induced a humoral response with IgGl as the 
dominant isotype as well as INFy secretion which is basically a Thl response 
(Velikovsky et al, 2002). It was also demonstrated that repeated vaccination induces 
a significant level of protection against a B. abortus 544 challenge in a BALB/c 
mouse model. In a follow up study by Munoz-Montesino et al. (2004) showed that 
intra-spleen vaccination of Balb/c mice with pCDNA-SOD was able to induce 
higher level of protection than intramuscular delivery of same vaccine construct. 
Further, the pcDNA-SOD vaccination was found to be stimulating both CD4+ and 
CD8"^  T-cell populations. 
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Synthetic peptide vaccine 
So far, very few attempts have been made to investigate potential synthetic 
peptide as vaccine candidate. Tabatabai and Pugh Jr. (1994) synthesized three 
peptides derived from the primary stucture of B. abortus Cu-Zn superoxide 
dismutase (SOD), and used these peptides in vaccines against brucellosis. Their 
studies showed that only peptide 3 possesses protective biological activity as 
demonstrated by its ability to modulate both splenomegaly and the extent of 
Brucella infection in the spleen. 
Live vectored vaccine 
The idea of live-vectored vaccine lies in the basis of using unrelated 
attenuated mutants of known pathogen as live vector to express protective antigens 
of other pathogens. Among the attenuated strains of known pathogens Salmonella 
typhimurium and vaccinia virus has been tried as live vectors in Brucella vaccine. 
Stabel et al. (1990) used 5". typhimurium x 4064 expressing a 31 kDa Brucella 
protein for oral immunization of mice and resulting in the production of local and 
serum antibodies to the recombinant proteins although CMI responses were poor. 
Toth et al. (1995) showed that several recombinant vaccinia viruses were able to 
express a variety of Brucella antigens (HtrA, GroEL, GroES, Cu-ZnSOD and YajC). 
Their study revealed that these recombinant vaccinia viruses induced specific 
immune responses to these antigens in mice, but level of protection was not 
significant. 
In conclusion of the above discussion, vaccines can be broadly classified into 
four major groups: - live, killed or inactivated subunit and genetic (Table 3). Each of 
these groups is further divisible into multiple categories, which include recombinant-
derived antigens as well as native microorganisms and their components. In 
addition, there are new enabling technologies such as delivery systems and vectors, 
which can be exploited to achieve coveted goals. Most disease targets, whether 
infectious or noninfectious in origin, can be approached by the application of several 
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different vaccine technologies, as can be tested during the discovery phase of 
research. Comparative properties of active vaccines 
Type of vaccine 
Live vaccines 
Subunit 
vaccines (killed 
inactivated) 
Genetic vaccines 
(DNA-based) 
Salient features 
* Able to replicate in 
the host 
* Attenuated in 
pathogenicity 
* Unable to replicate 
in the host 
* Stimulate synthesis 
of antigens only 
upon administration 
in the cells 
Advantages 
1 .May elicit broader immune responses 
2.May require fewer doses 
3.Generally longer lasting protection 
1 .Cannot multiply or revert to 
pathogenicity 
2. Generally less reactogenic 
3. Non transmissible to another person 
4. Usually more feasible technically 
1 .Elicit cellular immune responses 
2.Standardized method of 
Production 
Table 3. Comparative properties of active vaccines 
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The Role of Adjuvants in Vaccine Development 
Widespread vaccination in animals still remains the most successful method 
to prevent losses in farm animals from infectious diseases (Aucouturier et al., 2001). 
Conventional vaccines have mainly consisted of live attenuated pathogens, whole 
inactivated organisms or inactivated bacterial toxins (Chang et al., 1998). Generally, 
these approaches have been successful for vaccine development due to the induction 
of antibodies, which neutralise viruses or bacterial toxins, inhibit binding of 
microorganisms to cells or promote their uptake by phagocytes. Although attenuated 
forms of the pathogen are used as veterinary vaccines, however, concerns about 
these occasionally reverting to the virulent form still exist. Employing killed 
organisms or parts thereof, is an alternative for these vaccines but they provide 
lesser degree of protection than attenuated forms. Also, non-living vaccines have 
generally proven ineffective at inducing potent cell-mediated immunity (CMI), 
particularly of the Thl type. T helper cells can be classified into Th2 and Thl 
subtypes, mainly based on their production of cytokines in mice, Thl responses are 
characterized by the production of interferon (IFN). In addition, although live 
vaccines can induce cytotoxic T lymphocytes (CTL), live attenuated vaccines may 
cause disease in immunosuppressed animals and some pathogens are difficult to 
grow in culture, making the development of inactivated vaccines impossible. 
As a result of these limitations, several new approaches to vaccine 
development have emerged, which may have significant advantages over more 
traditional approaches. These approaches include recombinant protein subunits and 
plasmid DNA. While these new approaches may offer some advantages, a general 
problem is that these vaccines may not be cost effective for veterinary use and are 
often poorly immunogenic. Traditional vaccines often contain many components 
that can elicit additional T cell help or function as adjuvants, e.g. bacterial DNA or 
LPS in whole cell vaccines. However, these components have been eliminated from 
new generation vaccines, which, therefore, need potent adjuvants. 
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Immunological adjuvants were originally described by Ramon (1924) as 
"substances used in combination with a specific antigen that produced a more robust 
immune response than the antigen alone". This broad definition encompasses a very 
wide range of materials (Vogel and Powell, 1995). However, despite extensive 
evaluation of a large number of candidates over many years, the main adjuvant 
currently approved for human use by the US Food and Drug Administration are 
aluminium based mineral salts (generically called alum). Alum has a good safety 
record, but comparative studies in humans and animals show that it is a weak 
adjuvant for antibody induction to recombinant protein vaccines and induces a Th2, 
rather than a Thl response (Gupta, 1998). 
A key issue in adjuvant development is toxicity, since safety concerns have 
restricted the development of many adjuvants since Freund's adjuvant and alum 
were first introduced more than 50 years ago (Bahenmann and Mesquita, 1987; 
Edelman, 1997). Many experimental adjuvants have advanced to animal trials and 
some have demonstrated high potency, but most have proven too toxic for routine 
use. Some of the main issues that might determine the use of these compounds for 
veterinary and medical applications are injection site reactogenicity, elimination or 
biodegradation of the adjuvant and duration of retention at site of injection. For 
standard prophylactic immunization in healthy animals, only adjuvants that induce 
minimal local and systemic adverse effects will prove acceptable. Additional 
practical issues that are important for adjuvant development include stability, ease of 
manufacture, cost and applicability to a wide range of vaccines. 
Administration and patient compliance, an adjuvant should allow a 
vaccine to be given by a mucosal route. Examples of adjuvants that have 
been evaluated in clinical trials are enlisted in Table 4. Although the 
mechanisms of action of most of the adjuvants are often poorly understood, 
they can be broadly classified on the basis of their principal mode of action. 
However, these classifications become more arbitrary as immunostimulatory 
adjuvants are included in combination of vaccine delivery systems and 
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adjuvants are combined in single formulations. Adjuvants can be used to 
improve the immune response to vaccine antigens in several different ways: 
> adjuvants can increase the immunogenicity of w e^ak antigens; 
> enhance the speed and duration of the immune response; 
> modulate antibody avidity, specificity, isotype or subclass 
distribution; 
> stimulate CMI; 
> promote the induction of mucosal immunity; 
> enhance immune responses in immunologically immature, or 
senescent individuals; 
> decrease the dose of antigen in the vaccine and reduce costs 
The mechanisms of action of most adjuvants still remain only poorly 
understood, since immunization often activates a complex cascade of responses and 
the primary effect of the adjuvant is often difficult to clearly discern. However, if 
one accepts the geographical concept of immune reactivity, in which antigens that 
do not reach the local lymph nodes do not induce responses, it becomes easier to 
propose mechanistic interpretations for some adjuvants, particularly those based on a 
'delivery' mechanism. If antigens, which do not reach lymph nodes, do not induce 
responses, then, any adjuvant, which enhances delivery of antigen into the cells that 
traffic to the lymph node, may enhance the response. A subset of dendritic cells are 
thought to be the key cells which circulate in peripheral tissues and act as 'sentinels', 
being responsible for the uptake of antigens and their transfer to lymph nodes, where 
they are then presented to T cells. Circulating immature DCs are efficient for antigen 
uptake, while mature dendritic cells are efficient at antigen presentation to T cells. 
Hence, promoting antigen uptake into dendritic cells, trafficking to lymph nodes and 
dendritic cells maturation are thought to be key components to the generation of 
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potent immune responses. Dendritic cells are thought to be the most effective 
antigen presenting cells (APC), although macrophages can also function in this role. 
Some selective vaccine adjuvants are enlisted bellow (Table. 4): 
Adjuvant type 
Mineral salts 
Microbial 
Particulate 
Oil emulsions & surfactant-
based 
Synthetic 
Cytokines 
Genetic 
General examples 
Aluminium hydroxide/phosphate, Calcium 
phosphate 
Muramyl dipeptide, bacterial exotoxins (e.g. 
cholera toxin, heat labile enterotoxin)/ endotoxins 
(e.g. monophosphoryl lipid A, bacterial DNA (e.g. 
CpG motif) 
Microspheres, ISCOMS, liposomes, niosome, 
virosomes. 
Freunds adjuvant, MF 59, SAF 
Saponins (e.g. QS 21), Muramyl peptide 
derivatives, non-ionic block co-polymers, synthetic 
polynucleotides 
IL-2,IL-12, GM-CSF,IFN-y 
Cytokine genes or genes encoding costimulatory 
molecules delivered as plasmid DNA 
Table 4. Selected vaccine adjuvants 
Mineral salts 
The mineral salts, which have been used as adjuvants, include 
aluminium hydroxide/phosphate (alum adjuvant) and calcium phosphate. Alum 
has historically served as immunopotentiaters in vaccine development and 
37 
Chapter I Review of Literature 
continued to be most widely used adjuvant. Alum has a good safety record, but 
comparative studies show that it is a weak adjuvant for antibody induction to 
protein subunits and a poor adjuvant for cell-mediated immunity. Not to be on 
very positive side, alum adjuvants can induce immunoglobulin E (IgE) antibody 
responses and have been associated with some allergic reactions (Gupta, 1998). 
Microbia l component s 
Muramyl dipeptide 
N-acetyl muramyl-1 alanyl-D isoglutamine is smallest subunit of the 
mycobacterial cell wall that retains immunoadjuvant activity and referred as 
Muramyl di Peptide (MDP). MDP solution administered in saline induces humoral 
immune responses mainly, while water in oil emulsion (eg. Syntax, emulsion of 
threonyl MDP and squaline) increases antibody and cell mediated immunity (EUouz 
etal. 1974; Wairene/. al 1986). 
Monophosphoryl lipid A 
Monophosphoryl lipid A is less toxic adjuvant active derivative of 
lipopolysaccharide (Ribi et al, 1984). MLA promotes IFN-y production by T-cells 
and thus indirectly aids in production of antibodies (Tomai and Jhonson, 1989). 
MLA preferentially triggers Th-1 cells and direct secretion of IgG2a isotype 
(Takayama et al, 1991). Because of its safety and extensive clinical evaluation, 
MPL is strong candidate for use as an adjuvant for human preventive and therapeutic 
vaccines against infectious and neoplastic diseases. 
Bacterial DNA 
One of the most promising classes of new adjuvant is the immunostimulatory 
sequence in bacterial DNA. These are short nucleotide of DNA containing 
unmethylated guanine and cytosine dinucleotides, so called CpG motifs. They 
trigger B-cell activation and induce cytokine response leading to Th-1 response. 
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CpG oligodeoxynucleotides work for both systemic and mucosally administered 
antigens (McCluskie and Davis, 2000; Weeratna et al, 2000). 
Oil emulsion and surfactant based adjuvant 
Freunds' Adjuvant 
The powerful immunologic adjuvant is composed of a water-in-mineral oil 
emulsion and containing killed mycobacteria as an additional immunomodulator 
(Freund et al, 1937). This adjuvant is known as Freund's complete adjuvant (FCA). 
Although FCA is one of the most effective adjuvants known, is highly reactogenic 
and carmot be used in human vaccines. However, Freund's incomplete adjuvant 
(FIA), which does not contain mycobacteria was employed in an influenza vaccine 
licensed in the United Kingdom and is used in several HIV vaccines under clinical 
evaluation (Jensen et al, 1998). 
MF59 Adjuvant 
MF59 is oil in water microfluidised emulsion composed of stable droplets 
(250nm) of the metabolizable oil squaline (4.3% w/v) and two-surfactant 
polyoxyethylene sorbitan monooleate (Tween 80; 0.5% w/v) and sorbitan trioleate 
(Span 85; 0.5% w/v). MF59 is safe, practical and potent adjuvant for use with 
human vaccines, with more than five million doses distributed. The adjuvant has 
been shown both in animal models and in humans to be a potent stimulator of 
cellular and humoral responses to subunit antigens. Toxicology studies in animal 
models and phase I through IV studies in humans have demonstrated the safety of 
MF59 with HSV, HIV, and influenza vaccines (Podda, 2001; Ott et al, 1995). 
Cytokines as adjuvant 
Since single-protein antigens are normally rather weak immunogens, 
requiring co-adminsitration of an adjuvant to increase the immune response. The 
more common adjuvants, for example, complete or incomplete Freund's adjuvant 
and alum hydroxide, engender colateraJ effects like destruction of tissue in the 
39 
Chapter I Review of Literature 
inoculation site or induction of fever (Allison and Byars, 1991). To avoid these 
problems, other alternatives have been investigated like the use of cytokines because 
they can direct the pattern of the immune response to Thl or Th2 dependent of the 
desired profile (Yip et al, 1999). In the last decade, the use of cytokines as adjuvant 
has been amply studied, particularly in virus model like HIV and HSV. In contrast, 
few studies have been performed using cytokine genes as adjuvants against bacterial 
infections. Hornef e/ al. (2000) studied the modulatory effect of interleukin-2 (IL-2), 
IL-4 and interferon-gamma (IFN-y) co-expressed with the 60 kDa heat shock protein 
(Hsp 60) of Yersinia enterocolitica 0:8. The study revealed that DNA vaccination 
wtih IFN-y-hsp 60 evoked specific humoral and cellular immune response as well as 
reduction of the splenic bacterial load upon challenge with Y. enterocolitica in a 
mouse infection model. They also observed that co-expression of IL-2 or IFN-y 
enhanced Y. enterocolitica specific total IgG and IgG2a antibody responses. 
Wang et al. (2002) investigated the effect of a novel adenoviral granulocyte 
macropahge-colony stimulating factor (GM-CSF) transgene based adjuvant 
formulation on BCG vaccination in Balb/c mice. A marked increase both in the 
magnitude and longevity of anti-mycobacterial type 1 immunity was observed in the 
local draining lymphnodes and spleens by immunization with GM-CSF-adjuvanted 
BCG vaccine. Furthermore, GM-CSF adjuvanted BCG vaccine significantly 
improved immune protection than single BCG vaccine against secondary 
mycobacterial challenge. 
The immunogenicity of an interferon gamma-gpl20 fusion DNA vaccine, in 
the context of a prime boost strategy and in the presence of alum adjuvant resulted 
strong Thl responses, including IgG2a responses to a protein boost (Sonali et al, 
2005). Co-administration of rBoIL-2 with S19 resulted in significant augmentation 
in onset, duration and magnitude of LPS responses to B. abortus antigens following 
challenge (Wyckoff III et al, 2005). 
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Antigen Delivery Systems 
Immunization often activates a complex cascade of responses, and the 
primary effect of the adjuvant is often difficult to clearly discern in vivo. However, 
if one accepts the reently proposed geographical concept of immune reactivity, in 
which antigens, which do not reach the local lymph nodes, do not induce responses, 
it becomes easier to propose mechanistic interpretations of the important effects of 
some adjuvants (Janeway and Medzhitov, 1998). If antigen fails to induce desirable 
immune response, co-administration of adjuvant may help in enhanced delivery of 
antigen for activation of desirable immune response. Antigen delivery may be 
enhanced in several ways; the adjuvant may increase cellular infiltration into the 
injection site, so that more cells can take up antigen, it may directly promote the 
uptake of antigen into antigen presenting cells (APC), or it may contribute to the 
delivery of antigen to the local lymph nodes. Following uptake of antigen and cell 
activation, APCs undergo maturation and migrate to lymph nodes, where they have 
the unique capacity to present antigens to naive T cells. Hence, the principal mode 
of action of a range of particulate adjuvants, or 'antigen delivery systems' e.g. 
microparticles, emulsions, liposomes, ISCOMS etc. may be to promote uptake of the 
antigen by APC at the injection site. The most appropriate adjuvant to use for a 
given vaccine antigen will depend to a large extent on the type of immune response 
that is required for protective immunity. However, for many infectious diseases, the 
correlates of protective immunity have yet to be established. Therefore, in many 
situations, adjuvant selection remains rather empirical. 
Lipid Particles as Antigen Delivery Vehicles 
Liposomes are phospholipid vesicles which have been evaluated both as 
adjuvants and as delivery systems for antigens and adjuvants (Gregoriadis, 1990; 
Alving, 1992). Liposomes have been commonly used in complex formulations, 
often including monophosphoryl lipid A, which makes it difficult to determine the 
contribution of the liposome to the overall adjuvant effect. Immunopotentiating 
reconstituted influenza virosomes are unilamellar liposomes comprising mainly 
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phosphatidylcholine, with influenza haemagglutinin intercalated into the membrane. 
The use of viral membrane proteins in the formation of virosomes offers the 
opportunity to exploit the targeting and fusogenic properties of the native viral 
membrane proteins, perhaps resulting in effective delivery of entrapped antigens into 
the cytosol for CTL induction (Bungener et al., 2000). An alternative approach to 
vaccine delivery which may have some advantages over traditional liposomes has 
been described using 'archaeosomes', which are vesicles prepared from the polar 
lipids of Archaeobacteria (Krishnan et al, 2000a). In some studies, archaeosomes 
have been shown to be more potent than liposomes (Krishnan et al., 2000b). 
Immunostimulatory fractions from Quil A. 
Several groups have evaluated the use of particulate adjuvants, or antigen 
delivery systems, as alternatives to immunostimulatory adjuvants. Particulate 
adjuvants (e.g. emulsions, microparticles, ISCOMs, liposomes, virosomes and virus-
like particles) have comparable dimensions to the pathogens, which the immune 
system evolved to combat (Table 3). Immunostimulatory adjuvants may also be 
included in particulate delivery systems to enhance the level of response, or to focus 
the response through a desired pathway, e.g. Thl or Th2. In addition, foimulating 
potent immunostimulator adjuvants into delivery systems may limit adverse events, 
through restricting the systemic circulation of the adjuvant. 
Microspheres 
Among various polymeric systems developed as pharmaceutical dosage 
forms, poly-lactide co- glycolide (PLGA) microspheres have been widely explored 
in several immunological studies as a controlled delivery system of peptides, native 
and synthetic proteins and lately, nucleic acids (Eldridge et al, 1991; O'Hagan et 
al, 1993; Partidos et al, 1994). PLGA microspheres are composed of a spherical 
shaped polymeric matrix ranging in diameter from 1 to 250 fim. The prerequisite 
factors important for such delivery systems are: 
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> ability to release the entrapped substance in a controlled way, which is 
influenced by polymer molecular weight, monomer ratio and 
morphology (Dorta e/a/., 1993) 
> particle size, which is important in terms of interaction with phagocytic 
cells (Gregoriadis, 1990; Eldridge et al, 1991a,b) 
> safety, which is related to the in vivo polymer degradation and 
> stability, both in terms of shelf life and in the biological fluids (Pistner 
etal, 1993). 
The biodegradable and biocompatible polyesters, the polylactide-co-
glycolides (PLG) are the primary candidates for the development of microparticles 
as adjuvants, since they have been used in humans for many years as suture material 
and as controlled release drug delivery systems. However, the adjuvant effect 
achieved through the encapsulation of antigens into PLG microparticles has been 
demonstrated only relatively recently (Partidos et al, 1994). Microparticles with 
entrapped antigens (ovalbumin and staphylococcal B enterotoxoid) had comparable 
immunogenicity to these antigens dispersed in Freund's adjuvant, the most potent 
adjuvant available (Eldridge et al, 1991b; Maloy et al, 1994). Recent studies have 
shown that microparticles also exert an adjuvant effect for the induction of cell-
mediated immunity (Moore et al, 1995). Microparticles also appear to have 
significant potential as an adjuvant for DNA vaccines (Jones et al, 1997). The 
adjuvant effect of microparticles appears to be largely a consequence of their uptake 
into DC, macrophages and local lymph nodes following intramuscular injection. A 
particularly attractive feature of microparticles is their ability to control the rate of 
release of entrapped antigens. Controlled release of antigen may allow the 
development of single dose vaccines, which would result in improved vaccine 
compliance, particularly in the developing world. Although microparticles have 
significant potential for the development of single dose vaccines, much work is 
needed to ensure the stability of antigens entrapped in microparticles. 
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Immune Stimulating Complex (ISCOMs) 
ISCOMs are spherical, micellar assemblies of about 40nm. They are made of 
the saponin mixture Quil A, cholesterol and phospholipids (Mowat and Donachie 
1991). They contain amphiphilic antigens like membrane proteins. Quil A is a potent 
adjuvant that has been used as such in veterinary vaccines since the early 1970s. 
Results obtained with oral vaccination using ISCOM have been variable, showing 
partial protection/ clearance in some systems (Behbaudi et al., 1996; Dotsika et al, 
1997). ISCOM based vaccines also have the ability to induce CTL which may be 
important in the protection / recovery from viral as well as other intracellular 
pathogens. The induction of CTL against specific antigens has been demonstrated 
for a number of ISCOM based vaccines in both mice and non-human primates 
(Maloy et al, 1995; Takahashi et al, 1990)). Apart from parenteral immunization, 
ISCOMs have been used for mucosal delivery of antigens (Mowat and Donachie, 
1991). They are able to boost both humoral and cellular responses. Antigens from 
viral, bacterial and parasitic sources have been studied. ISCOMs are able to generate 
a broad range of immune responses. These include APC activation (Behbaudi et al, 
1996), increased MHC II expression on APCs, cytokine induction, especially IL-2 
and IFN-Y (Dotsika et al, 1997), CD4'' T-cell responses (Maloy et al, 1995) and 
CD8"^  CTL responses (Takahashi et al, 1990). At the moment, one ISCOM vaccine 
is licensed. It is an anti-influenza vaccine to be used for horses. More than 1 million 
doses have been sold in Sweden. A human phase I study with ISCOM-matrix caused 
mild pain at the injection site (Barr et al, 1998).Some of the particulate antigen 
delivery system employed in vaccine development is discussed below (Table 5): 
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Natural 
pathogens 
Bacteria 
Poxvirus 
Herpesvirus 
HIV 
Influenza virus 
Poliovirus 
Size 
0.5-3 |j,m 
250 nm 
250 nm 
100 nm 
100 nm 
20-30 nm 
Particulate adjuvants 
Microparticles 
Liposomes 
Virosomes 
MF59 
ISCOMS 
Virus-like particles 
Size 
100nm-10|Lim 
50 nm-10 jam 
50 nm-10 [im 
200 nm 
40nm 
20-50 nm 
Table 5 A comparison of the relative dimensions of pathogens and particulate 
adjuvants 
Niosomes 
These are small unilamellar vesicles made from non-ionic surfactants. They 
are also called non-ionic surfactant vesicles (NISV) or Novasomes (Brewer and 
Alexander, 1994; Gupta et al, 1996). BSA in niosomes was shown to be as 
immunogenic as BSA with Complete Freund's adjuvant (Brewer and Alexander, 
1992). The chemical stability of niosomes is higher than the stability of 
phospholipid liposomes. Non-ionic surfactant vesicles have clearly demonstrated 
their ability to function as adjuvants following parenteral administration with a 
number of different antigens and peptides such as OVA (Brewer et al. 1996b), BSA 
(Brewer and Alexander 1992), a soluble T. gondii antigen (Brewer et al. 1994a), a 
synthetic measles peptide (Roberts et al. 1996b). Results from these studies have 
suggested that the immune responses preferentially activated by NISV are of the 
Thl- type, and this is particularly useful for vaccines directed against intracellular 
pathogens, which generally require cell mediated immune responses. NISV have 
been reported to possess extremely low toxicity and enhanced stability hence they 
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appear to be excellent candidates for further development as vaccine adjuvants 
(Roberts and Brewer, 1994). 
Cochleates 
Cochleates are composed of simple, naturally occurring materials; 
phosphatidylserine (PS), cholesterol and calcium. They are stable phospholipid-
calcium precipitates, which are structurally distinct from Uposomes (Papahadjopolus 
et ai, 1975). Their unique structure consists of a large, continuous, solid, lipid 
bilayer sheet rolled up in a spiral, with no internal aqueous space. Cochleates 
formulations have been shown to be simple, safe and highly efficacious mediators of 
the in vivo delivery of proteins, peptides and DNA for the induction of antigen-
specific immune responses following oral, intranasal and intramuscular 
administration. Strong, long-lasting, mucosal and circulating antibody responses are 
generated (Michaleck et ai, 1998). Protection from challenge with live viruses 
following oral or intra muscular administration has been achieved (Gould-Fogerite 
et al, 1998). Thus, this delivery technology appears to be well suited for use with 
subunit vaccines. 
Liposomes 
Liposomes offer an alternative, versatile and universal adjuvant system with 
high safety profiles. Liposomal immunoadjuvants passively accumulate within 
regional lymph nodes and act as antigen depot by slowly releasing encapsulated 
antigenic components. Table 6 provides a list of antigens with which liposomes have 
been used so far. Liposomes have been firmly established as immunoadjuvants by 
potentiating both antigen specific humoral (Alving et al, 1995) as well as cell-
mediated immunity (Owais and Gupta, 2000). 
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Some other advantages of using liposomes for immunopotentiation are as follows: 
• A non-immunogenic substance may be transformed to an immunogenic one. 
• Hydrophobic antigens may be reconstituted. 
• May incorporate multiple antigens and other adjuvants to provide strong immune 
response. 
• Toxicity of the antigens can be reduced or may be eliminated by inclusion into 
the liposomes. 
• Modulation of the immune system. 
• Liposomal vaccines produce higher titers of functional antibodies as well as 
prolonged duration of these antibodies. 
Liposomal Vaccines 
Liposomal vaccines can be developed by incorporating microbes, soluble 
antigens, cytokines or deoxyribonucleic acid in liposomes. Alternatively, antigens 
can be covalently coupled to liposomal membrane for increasing their 
immunogenicity (Wassef e/ a/., 1994). Also for enhanced immunopotentiation, some 
other agents such as muramyl dipeptide (MDP), lipopolysachharide, lipid A and 
tuftsin can also be incorporated into liposomes (Schroit and Fidler, 1986; Singhal et 
al, 1984; Bennett-Guerrero et al, 2000; Richards et al, 1998). Some of the 
commercially available liposomal vaccines are enlisted in Table 7. The first 
liposome based vaccine (against hepatitis A) for human use is IRIV vaccine 
produced by Swiss serum and vaccine institute, Berne, Switzerland known as 
"Epaxal-Berna Vaccine" (Gluck, 1995). 
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Antigen 
Influenza subunit antigen 
Bacterial polysaccharide 
Rabies glycoprotein 
Polio virus peptides 
Cholera toxin 
Toxoid of B. pertussis 
Tetanus toxoid 
Diphtheria toxoid 
Herpes simplex virus 
Hepatitis B virus surface antigen 
Liposome / effect 
Intranasal, protects animals from virus 
Superior immunoadjuvants 
Ag specific IL-2 enhancement 
Enhanced Antibody level 
Superior immunoadjuvants 
Very effective vaccine 
Mannose-mediated liposomal targeting, 
increased antibody titer 
Higher Antibody response 
MLV with lipid A, Enhanced Antibody level 
Humoral and cellular immunity 
Table 6. List of antigens with which liposomes have been used as 
immunoadjuvants 
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System 
Novasomes 
Novasomes 
Novasomes 
Novasomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
Components 
Killed new castle disease virus 
Killed avian retrovirus 
E.coli 0157:H7 (killed) 
Shigella flexneri 
Haemagglutinins/neuraminidase 
from influenza strains 
Inactivated hepatitis A virions 
Genetically engineered Hepatitis A 
and B components(HAV) 
Diptheria and tetanus toxoids 
Diptheria and tetanus toxoids +HAV 
virions 
Target 
disease 
New castle 
disease 
Retroviral 
infection 
E.coli 0517 
infections 
S. flexneri 
infections 
Influenza 
Hepatitis A 
HepatitisA and 
B 
Diptheria and 
tetanus 
Diptheria, 
Tetanus, 
HepatitisA and 
B 
Company 
IGI, Vineland Lab, 
NJ, USA 
IGI, Vineland Lab, 
NJ, USA 
Novavax, USA 
Novavax, USA 
Swiss serum and 
Vaccine Int.,Switz. 
Swiss serum and 
Vaccine Int, Switz. 
Swiss serum and 
Vaccine Int., Switz 
Swiss serum and 
Vaccine Int., Switz 
Swiss serum and 
Vaccine Int., Switz 
Table 7 Liposome based vaccines either approved or licensed for use 
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Virosomes 
Immunostimulating reconstituted influenza virosomes (IRIVs) are spherical, 
unilamellar vesicles with a mean diameter of approx. 150 nm. IRIVs are prepared by 
detergent removal from influenza surface glycoproteins and a mixture of natural and 
synthetic phospholipids containing 70% egg yolk phosphatidylcholine (EYPC), 20% 
phosphatidylethanolamine (PE) and 10% envelope phospholipids originating from 
HlNl influenza virus. The influenza hemaglutinin intercalated in liposomal bilayer 
is responsible for fusion of liposome with endosomal membrane (Tsurudome et al., 
1992). The specific fusion mechanism allows targeting of the MHC I or the MHC II 
class pathway. Antigens linked to the surface of virosomes are degraded upon the 
endosomal fusion within the endosome and are presented to the immune system by 
MHC II class receptors. If the antigens are encapsulated in the virosomes, the 
antigens will be delivered to the cytosol and will enter the MHC class I pathway. 
Therefore, virosomes are able to induce either a B- or T-cell immune response. The 
first liposomal vaccine for human use was licensed in 1996, a virosomal hepatitis A 
vaccine (HAV) and is now registered in nearly all countries of the EU, the Americas 
and Asia (Holzer et al. 1996). In addition to the excellent tolerability, a very good 
long-term protection could also be shown (Holzer et al. 1996). In a placebo 
controlled field trial, the HAV-IRIV vaccine has proven its efficacy (Mayorga et. al. 
1997). A trivalent, IRIV-formulated influenza vaccine has shown a very good 
immunogenicity in all age groups and also excellent tolerability (Conne et al. 1997). 
These IRIV-based vaccines are safe and do not engender any anti-phospholipid 
antibodies against the liposome components of the IRIV (Cryz et al. 1996). The 
IRIV adjuvant represents the first alternative to the problematic old chemical 
aluminum salts (Zrubriggen and Gluck 1999). The inherent property of virosome aid 
in activation of both humoral and cell mediated immune response. It has been 
demonstrated, that a synthetic peptide, enclosed in virosomes is able to induce a 
CTL immune response in mice (Arkema et al. 2000). Therefore, the IRIV-based 
fonnulations appeared to be superior to the alum-based vaccines in terms of 
immunogenicity as well as prophylactic potential. 
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Archaeosome 
Archeosomes are liposomes made up of total polar lipids isolated from 
various archebacteria (Patel and Sprott, 1999). Archeosome display several unique 
properties including enhanced stability against extremes of pH, oxidation, elevated 
temperature and action of lipases that might be expected to impart superior 
properties to them for certain biotechnological applications (Sprott, 1992; Choquet 
et al, 1994; Sprott, et al, 1996). Archeosomes induce strong humoral, cell mediated 
and memory responses (Krishnan et al, 2000).- Moreover both humoral and cell 
mediated immune response generated by archeosome was found to be superior than 
conventional liposomes, alum and freunds adjuvant (Conlan et al, 2001). The 
soluble antigen entrapped in archeosome was able to induce antigen specific CD 8+ 
cytotoxic T- lymhocytes (Krishnan et al, 2000). Archeosome were able to impart 
protective immunity against facultative intracellular pathogen Listeria 
monocytogenes (Conlan et al, 2001). 
Fusogenic Liposomes 
Vaccines based on liposomes formulated with lipid A and Alhydrogel have 
been shown to be potent and safe in humans . However, adjuvants like lipid A or its 
analogs, have the potential of inducing non-specific adjuvanticity, are usually 
associated with toxicity, cumbersome preparation methodology and cost factor 
(Holzer et al, 1996). In contrast fusogenic liposomes can potentially facilitate the 
intracellular delivery of encapsulated molecules (drugs or antigen) by fusing with 
the target cell. A variety of approaches can be envisioned for constructing fusogenic 
liposomes. Membrane lipid, isolated from lower organisms, such as bacteria 
(Nadeem et al, 2001; Sprott et al, 2004) and yeast (Owais et al, 2001) have 
emerged as an alternative delivery system of macromolecules to the cytosol of the 
target cells. 
Liposome made up of E. coli membrane lipid is best known as 
Escheriosome. Escheriosome based vaccines seem to have addressed most of these 
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problems and because of their unique delivery mode, escheriosome can be 
indiscriminately used for patients with varying immunological backgrounds. 
Escheriosome offers a promising approach for developing liposome-based vaccines 
against various infections. Pluschke and Overath (1981) demonstrated that 
membrane lipid composition oi Escherichia coli exhibits a great majority of anionic 
phospholipids that play a pivotal role in membrane-membrane fusion. The study 
conducted by Nadeem et al. (2001) revealed that liposome made of E. coli lipid 
{Escheriosome) undergo fusion with plasma membrane of the target cells including 
the professional antigen presenting cells (APCs). Further it was demonstrated that 
escheriosome mediated delivery of a model antigen (Ovalbumin) to the host APCs 
leads to the activation of strong humoral as well as cell mediated immunity (Faisal et 
al. 2003). Liposome made up of polar lipids from various micro-organisms deliver 
their entrapped macromolecules to professional antigen presenting cells more 
efficiently than conventional liposome as well as other adjuvants (Nadeem et al, 
2001;Owais et al, 2001 ; Faisal et al, 2003; Sprott et al, 2004). In a recent study, 
the potential of E. coli lipid (Escheriosome), against multidrug resistant isolate of 
Plasmodium yoelii nigeriensis in murine model and visceral leishmaniasis in 
hamster model has been evaluated and found that escheriosome entrapped antigen 
performed better than other vaccine formulation as evidenced by strong protective 
immune responses commensurate with enhanced antigen specific CD4 and CDS 
T-cell population as well as enhanced expression level of costimulatory molecules 
(CD80 and CD86) in peritoneal macrophages. In addition, the use of escheriosome 
also leads to the generation of both Thl and Th2 cells. 
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In accord to the above-mentioned in formations, the present work has been 
designed with the following objectives: 
Parti 
®° To purify Brucella sonicated cytosoli cell protein (BCP) from live attenuated 
strain Brucella S-19 
'£* To evahiate the immunogenic potential of liposome mediated delivery of 
BCP against Brucella infection 
Part II 
®°" To clone and express ribosomalL7/L 12 gene of 5. abortus 5AA 
•^ To study the immunogenic potential of escheriosome mediated delivery of 
recombinant rL7/L12 protein 
^artl 
T/vaCuation of Immunogenic <PotentiaCof 
T^scfteriosome mediated (DeCivery of (Brucella 
Sonicated CytosoCic (Protein ((BC<P) 
Introduction 
Chapterl Introduction 
Brucellosis is a major zoonotic disease of global importance that causes 
abortion and infertility in cattle, and undulant fever, arthritis, endocarditis, orchitis 
and meningitides in human (Boschiroli et al., 2002). Despite the numerous 
biotechnological improvements, brucellosis remains a major worldwide public 
health problem. 
The causative organism B. abortus, may affect a wide range of hosts 
including man, cattle, sheep, goats, swine, rodents and marine mammals. In most 
host cases, the disease primarily affects the reproductive system of the host with 
concomitant loss in productivity. In man, infection is associated with protean 
manifestations and characteristically recurrent febrile episodes that led to the 
description of this disease as "undulant fever". The disease is severely debilitating 
and protracted with several documented cases with signs associated with the disease 
lasting for over 30 years. Many of the country regard Brucella as a biological 
weapon against armed forces as well as civilians that has further stressed the need of 
suitable human vaccine against the infection (USBWP, 1977). 
The most appropriate method to control this dreadful disease relies on 
activation of immune system of susceptible hosts. In spite of realizing this fact, not a 
single safe and effective vaccine is available till date. It is mostly because of the fact 
that Brucella sp adopts intracellular parasitism to avoid antibody recognition. The 
best protection against brucellosis is achieved with live vaccine. However, WHO 
recommended S-19 and RB51 live attenuated vaccines against animal brucellosis 
have many untoward effects (Corbel, 1997; WHO Report, 1997). Many drawbacks 
associated with the live vaccines and also with the availability of complete genome 
sequence of Brucella sps (Corbel, 1997; Young, 1995; Dossey, 1998; Greenfield et 
al, 2002; Dalrymple-Champneys, 1950a; Dalrymple-Champneys, 1950b), the 
prospect of the development of an effective acellular vaccine currently constitutes 
prime objectives in most of the research lab. 
In the present study, we have tried to evaluate immunological potential of 
the pathogen that uhimately helps in designing effective vaccine against important 
disease. 
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^ 
LPSs, outer membrane proteins ~an4;:.sev€-jai'-ribosomal and/or cytosolic 
proteins have so far been considered as the main immunogens that can be used in 
development of acellular vaccines and diagnostic reagents. LPSs are the most 
abundant glycolipids of outer membrane of Gram negative bacteria like Brucella 
which act as potent inducers of humoral immune responses. The major problem 
associated with the use of lipopolysaccharides as major vaccine component are as 
followed 
• The Brucella LPS specific antibodies usually cross-react with some other 
gram-negative bacteria such as Yersinia enterocolitica and Escherichia coli 
and remain high titre is maintained after treatment in many patients (Baldi et 
al, 1996) 
• In addition, they can not distinguish between some naturally infected and 
vaccinated animals 
In order to overcome such constrains, proteins of B. abortus SI9, an 
attenuated strain that is antigenically similar to virulent strains, were used as antigen 
and the vaccine potential was evaluated by using different adjuvant by many 
workers. 
Winter et al. (1996) showed that a single dose vaccination with a complex 
porins and smooth lipopolysaccharides from B. abortus strain 2308 provide 
significant protection against challenge with the same strain, equivalent to the 
protection achieved by a vaccination with the live attenuated strain of Brucella S-19. 
In an another effort, Durbey and his co workers extracted B. abortus cell envelops in 
hot sodium dodecyl sulphate and obtained an insoluble fractions (PG) that contained 
peptidoglycan, lipopolysaccharides and proteins (later on recognized as porins) and 
group 3 protein of outer membrane (Dubray and Plommet, 1976; Durbey and 
Bezard, 1980; Winter and Rowe, 1988). PG in saline solution as well as in 
incomplete Freund's adjuvant produced highly effective short term protection 
against murine brucellosis and furthermore long term protection and complete 
elimination was also reported (Bosserey, 1978; Dubray and Bezard, 1980). Previous 
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report that dioctadecylammonium bromide stimulates increased cell mediated and 
low humoral immune response in cattle immunized with B. abortus soluble antigen 
(BASA) and also a combination of DDA and TDM (Trehalose di mycolate) 
potentiate immune response of a soluble B. abortus antigen preparation (Dzata, 
1991). 
Many of the newer adjuvants have improved upon some of the poorer 
aspects of traditional vaccine formulations (poor safety and efficacy), but do not 
address other limitations like their intrinsic toxicity, undesirable skewing towards 
Thl/Th2 responses, etc. There are several important issues that act as driving forces 
for the methods by which future vaccines are ought to be formulated thereby 
overcome their current deficiencies and shortcomings. A better insight of the 
modalities of the immune system reveals that besides intrinsic immuno-logical 
properties, the induction of humoral or cell-mediated immunity to protein antigen 
also depends upon the factors such as cytokine milieu, route of administration, 
dosage and mode of delivery of antigen of interest etc (Mahajan et al, 2005^. As we 
cannot manipulate fundamental properties of a given antigen, it is always imperative 
to play upon above-mentioned factors to formulate effective vaccine. In this regard, 
liposome-based vaccines may be of great significance as they have been claimed to 
widely amend immunological responses of variety of antigens (Janeway et al., 1998; 
Gregoriadis, 1990; Alving ,1992) Liposomes are phospholipids vesicles which have 
been evaluated both as adjuvant and as delivery systems for antigens (Alving, 1992 
and Gregoriadis, 1990). Fusogenic nature of E. coli cell rriembrane lipid made 
liposome known as escheriosome and found to very effectively fuse with the 
membrane of the macrophages leading to the delivery of entrapped solutes to their 
cytosol (Owais and Gupta, 2000; Owais et al, 2001; Faisal et al, 2003; Sharad et 
al, 2006b). 
In the present study, we have evaluated the potential of Brucella sonicated 
cytosolic protein (BCP) antigen entrapped in liposomes as a novel vaccine delivery 
system. The efficiency of vaccine formulations were evaluated by assessing cellular 
and humoral immune response in murine model. Cytosolic proteins of B. abortus S-
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19, an attenuated standard vaccine strain that is antigenically similar to virulent 
strains, showed anticipated results and revealed some promising aspect of possible 
use of escheriosome as a successful carrier of Brucella immunogen and have the 
potential to be a novel vaccine candidate against brucellosis. 
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Chapter I Materials and Methods 
Materia ls 
Media 
Tryptose phosphate broth from Becton, Dickinson and company (USA). For 
growth of E. coli, Luria-Bertani broth, Miller and Nutrient agar of HiMedia (India) 
make were used. For lymphocyte culture RPMI-1640 (phenol red free) growth 
medium was procured from Sigma, USA. 
Chemicals and reagents 
Ammonium per sulphate, acrylamide, bis-acrylamide, P-mercaptoethanol, 
bromophenol blue, calcium chloride, Coomassie brilliant blue 250, magnesium 
chloride, sodium chloride, potassium acetate, tween-20, sodium dodecylsulphate, 
diamino-benzidine, TEMED, glycine,Triton X-100, PMSF, Bovine serum albumin 
were purchased from Sigma, St. louis, USA). Rabbit anti-mouse HRPO conjugate 
were purchased from Sigma-Aldrich, USA. Foetal bovine serum was obtained 
from Life Technologies (Grand Island, NY, USA). Potassium chloride, 
disodium hydrogen orthophosphate, potassium dihydrogen orthophosphate, were 
from Qualigens India, Mumbai. Bicinchoninic acid protein assay Kit was from 
Pierce Chemical Company (CI, USA). Cholesterol (Choi) was purchased from 
Centron Research Laboratory, Bombay, India. 
Glassware and plastic ware 
All glassware and the plasticware used in the study were procured from 
Nunc, Tarson, Borosil (India). Microfuge tubes and micropipette tips were from 
Axygen (USA). Non heparinized capillary tubes were from Hawksly and Sons, U.K 
and migration plates were purchased from Laxbro, USA. 
Bacterial strains 
B. abortus S19 and B. abortus 544 were obtained from Division Biological 
Standardization, IVRI, Izatnagar, India. E. coli K12 (non-pathogenic) strain used 
for lipid isolation was kind gift from Mr. Zeeshan Ansari, Nil, New Delhi. 
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Methods 
Preparation of S-19 vaccine 
The vaccine was produced using B. abortus strain 19 as per the standard 
method described by Hulse et al, (1960). Bacteria were grown on tryptose 
phosphate agar supplemented with 0.1% yeast extract in roux flasks at 37°C for 48 
to 72 hours. The growth was closely observed to ensure uniformity and prevent 
contamination. Roux flasks with uniform colonies were harvested in 8 ml to 12 ml 
sterile phosphate buffer saline (PBS) by gentle agitation. Suspension from each flask 
was harvested in separate containers and tryptose phosphate agar plates. The 
colonies were checked for smoothness. The pure B. abortus S-19 suspensions from 
the containers were pooled and the number of the bacteria per ml of suspension was 
determined serial ten fold dilution plated on Tryptose phosphate agar media. 
Preparation of Brucella sonicated cytosolic protein (BCP) 
B. abortus S19 was cultured in Tryptose phosphate broth and the protein was 
isolated as per standard protocol. Briefly, S-19 was grown in Tryptose phosphate 
broth at 37 °C for 48 hrs. The bacterial suspension was collected by centrifugation at 
5000x g for 10 min, washed with phosphate buffered saline (PBS, pH 7.2). The live 
cells were inactivated with chilled acetone for overnight and then again centrifuged 
at 5000x g. Approximately, 0.25gm of bacterial pellet was resuspended in 1 ml of 20 
mM Tris-HCl (pH 7.2) containing phenyl methyl sulfonyl fluoride (PMSF, ImM), 
EDTA (ImM) and lysozyme (lmg/100 mg of bacterial dry weight) and the sample 
was then incubated overnight at 37 °C with gentle shaking. The solubilized cell 
suspension was the sonicated in at bath type sonicator at 4 °C for one hour. The 
sonicated cell suspension was centrifuged at 12000x g for 20 min at 4 °C. The 
supernatant was collected carefully, dialyzed and stored in small volumes at -20 °C 
until used. 
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Estimation of protein concentration 
The protein content of BCP was estimated using BCA protein estimation kit 
as per the manufacturer's instruction. Briefly, the working reagent was prepared by 
mixing Solution A and Solution B at the ratio of 1:49 and used for estimation of 
protein. One ml of the working solution was mixed with sample solution followed 
by incubation at room temperature for 1 h in dark and the absorbance was read at 
562 nm. The concentration of protein/ ml was calculated against the standard curve 
plotted by using increasing concentration of BSA solution of known strength. 
SDS-PAGE analysis of BCP protein 
Cytosolic protein was analyzed by SDS-PAGE according to the method of 
Laemmli (1970) using a vertical mini-gel electrophoresis apparatus. Electrophoresis 
was carried out at a constant current of 18 mA, until the tracking dye reached the 
bottom of the gel. The standard protein marker of medium range (29-200 kd) was 
also run. The gel was taken out from the plates and silver staining was performed. 
Briefly, the gel was fixed in fixative for 10 min. After washing with distilled water, 
then gel was pretreated with 50 % acetone for 5 min and then with 10 % NaiSiOs for 
one min. After washing, the gel was impregnated with 20 % AgNOs in dark and then 
developed with developer solution 10-20 sec. The color production was stopped 
with 12 % glacial acetic acid. Finally the gel was washed in DW for 10 sec and 
photographed (Figure 5). 
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Figure 5. SDS PAGE profik nf Brucella soaicated cytosoik proteia (BCP) 
1. Moiecular wt marker 
2. Cmde protein 
3 and 4. Purified BSWP (m different protein concentration) 
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Preparation of liposome-based delivery systems 
Isolation and purification of egg Phosphatidylcholine (egg PC) 
Egg PC was isolated and purified following the published procedure 
(Singleton et al, 1965). Briefly, egg yolks of one dozen eggs were separated 
carefully, and washed with acetone (100 ml) in a mixer for 5-6 times to get rid off 
the colored impurities. The resulting white solid was powdered and dried in vacuum 
for 2 hr to remove traces of the solvent. The extraction was performed by stirring 
the solid mass with one liter of absolute alcohol for 2-3 hours. After filtration, the 
residue was re-extracted with another 500 ml of ethanol. The filtrates were mixed 
and evaporated off at 40-45 °C. The sticky mass thus obtained was dried under high 
vacuum to remove traces of the solvent, dissolved in minimum amount of petroleum 
ether (b.p.60-80 °C) and poured onto chilled acetone to obtain a white sticky 
precipitate. The solvent from the precipitated material was removed by decantation. 
The sticky solid precipitate was redissolved in petroleum ether and again poured 
onto the chilled acetone. The process was repeated 2-3 times to obtain crude PC. 
For further purification, it was chromatographed on a neutral alumina (grade 111) 
column. The elution was performed using increasing amount of methanol in 
chloroform. Fractions obtained with 5-7 % methanol in chloroform con-esponded to 
pure PC. It was further purified by chromatography over Sephadex LH-20 column 
(2.5x 100 cm), using chloroform/methanol (1:1 v/v) as the eluant. The elution rate 
was maintained at 60-70 ml per hour. Fractions were collected and checked for the 
presence of pure PC. The purity was ascertained by thin layer chromatography 
using silica gel G-60 TLC plates. The plates w e^re developed using 
chloroform/methanol/water (65:25:4) as the solvent system, and stained with iodine 
vapor followed by molybdenum-blue spray to visualize various phospholipid spots. 
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Isolation E. coli lipids 
E. coli K12 strain (non-pathogenic) cultured in nutrient broth (1 % peptone, 
0.3 % beef extract, 0.3 % yeast extract and 1% sodium chloride; pH 7.4). The cells 
were harvested from mid-log phase (18-20 hrs). Phospholipids were isolated by the 
method of Bligh-Dyer, as modified by Kumar & Gupta (Kumar and Gupta, 1983). 
Briefly, one gram of cell pellet was sonicated in 50ml methanol for one hour at 4°C 
in bath type sonicator. To the cell suspension two volumes of chloroform was added 
and kept on stirrer overnight. The solution was then filtered through Whatmann 
filter paper No. I to remove cell debris. The filtrate was then fractionated three times 
with one-fifth volume of normal saline to remove protein contamination. The 
solution was finally evaporated in round bottomed flask with suitable azeotrope in 
rotary evaporator. The lipid composition was determined as described previously 
and found to be as follows: phosphatidylethanolamine, 82 ± 1.2; 
phosphatidylglycerol, 13.8 ± 0.8; cardiolipin, 4.2 ± 0.6. 
Preparation of egg PC/ChoI-liposome and escheriosome (Dehydration-
Rehydration Vesicles) 
Dried reconstituted vesicles (DRVs) were prepared using published method 
(Kirby and Gregoriadis, 1994). Briefly, egg PC/Cholesterol (2:1 molar ratio, total 20 
mg) or E. coli lipids (20 mg) were reduced to thin dry film under N2 atmosphere. 
The film was hydrated, followed by sonication in a bath-type sonicator for 2 h at 4°C 
under N2 atmosphere. The liposomes thus formed were mixed at this stage with an 
equal volume of BCP protein. The mixture was flash frozen and thawed (3 cycles), 
and then lyophilized. The free-flowing, dried powder thus obtained was rehydrated 
with distilled water (120 |al) and finally re-constituted with PBS. The preparation 
was centrifuged at 14,000x g and the pellet was further washed at least 3 times with 
PBS to remove the traces of the unentrapped solute. The protein entrapped in the 
liposomes was estimated by BCA method (Smith et. al. 1985). Briefly, the 
liposomes (given volume) were lysed with 10 % Triton X-100 solution (the final 
concentration of Triton X-100 was maintained 1 %). The mixture of solutions A and 
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B (1:49) of BCA reagent was added to the lysed liposomes (released protein) and 
then incubated at 37 °C for 45 min. The absorbance was measured at 562 nm and the 
protein concentration was calculated using a standard curve of BSA plotted in the 
presence of Triton X-100. 
Determination of entrapment efficiency 
The protein entrapped in the liposomes was estimated by BCA method 
(Smith et al, 1985). Briefly, the liposomes (given volume) were lysed with 10 % 
Triton X-100 solution (the final concentration of Triton X-100 was maintained 1 %). 
The mixture of solutions A and B of BCA reagent was added to the lysed liposomes 
(released BCP protein) and then incubated at 37 °C for 45 min. The absorbance was 
measured at 570 nm and the protein concentration was calculated using a standard 
curve of BSA, plotted in the presence of Triton X-100. 
Immunization 
Animals 
A total of 90 female Balb/c mice (4-5weeks old), weighing from 18 to 20 
gm, were obtained from Animal House Facility, CDRI, Lucknow. All the mice had 
ad Ubitium access to the pellet diet and drinking water. The Institutional Animals 
Ethics Committee approved the experimental protocol. All the mice were housed 
under standard conditions at the Institute's animal facility. The mice were 
distributed at random into six groups having 15 mice in each. The vaccinal dose of 
live S-19 was standardized (5X10^ /animal) according to the method of Hulse et ah, 
(1960). The amount of live bacteria present in the inoculums was determined by 
enumeration of CPU on Tryptose phosphate agar plate following a standard spread 
plate method. Each mouse in all experimental groups was immunized 
subcutaneously with the following preparation: 
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Experimental groups: 
1. Control: 0.1 ml PBS (Negative control) 
2. Egg PC liposome +0 .Img BCP (P-Lip-Sag) 
3. E.coli. Lioposome +0 .Img BCP (E-Lip-Sag) 
4. Incomplete Freunds' adjuvant + O.lmg BCP (IFA-Sag) 
5. FreeO.lmgBCP(F-Sag) 
6. 5X10^ standard S-19 bacteria (vaccinal control) 
Animals were subsequently boosted on day 21 and 28. Sera were collected at 
regular interval. Seven days of last booster 50 % of the mice from each group were 
challenged with B. abortus 544. On day 30 of post challenge mice were sacrificed to 
determine the splenic clearance. 
Immunological studies 
Collection of sera 
Mice were bled through retro-orbital puncture with glass capillary tubes and 
blood was collected in centrifuge tube. Blood was incubated at room temp for an 
hour and subsequently kept at 4 °C for retraction. Finally, serum was collected by 
centrifugation at 5000 g for 10 min at 4 °C to get rid off blood cells. The final 
preparation was kept at -20 °C till further use. 
Determination of antigen-specific immunoglobulin and different isotypes 
by Indirect ELISA 
Antibody level in immunized Sera collected from different time interval 
was measured in the sera of the immunized mice. The animals were injected with 
free BCP antigen, protein entrapped in the egg PC/Chol and escheriosome and with 
Incomplete Freunds' adjuvant at the dose rate of 100jj,g/animal as immunizing dose 
and subsequent booster was given at the dose rate of 50|ig/animal on 21 and 28 days 
post first immunization. Sera collected at weekly interval to monitor the presence of 
antibodies by indirect ELISA. Briefly, The wells of were coated overnight at 4 °C 
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with BCP at a final concentration of 5|ag/well in Carbonate bicarbonate buffer (pH 
9.4) for overnight at 4°C. After three wash cycles with PBS-T, the plates were 
saturated for 2 hrs at RT with 200 |il of blocking buffer (PBS with 5 % BSA). The 
wells were washed with PBS containing 0.1 %Tween 20. Hundred microliters of 
serially twofold-diluted pooled sera sample of each experimental group starting at a 
1/100 dilution in buffer (PBS with 1.25 % BSA), was added to the plates and 
incubated for 1 h at RT. The serum from non immunized mice was used as a 
negative control. After five washing cycles, plates were incubated with a 2500-fold 
dilution of HRPO-conjugated rabbit anti mouse IgG antibodies. For isotype ELISA, 
1,000-fold-diiuted goat antimouse IgGl and IgG2a antibody was added for IgG 
isotype detection for 1 h at RT. After usual washing biotynilated HRPO conjugated 
rabbit antimouse IgG was added at 2500 fold dilution for 1 hour at 37°C. Finally 
OPD in citrate-phosphate buffer (0.05 M Na2HP04, 0.025 M citric acid, pH 5.0) and 
2 mM H2O2 were added to monitor the peroxidase activity. The reaction was 
stopped after 20 min by addition of 2 M H2SO4. The optical density was measured 
on a 492 nm with a microtitre plate reader (Eurogenetics, Torino, Italy). The end 
point titer was defined as the highest dilution of serum giving an optical reading of 
two times the reading of the negative control. 
CD4^ T lymphocyte proliferation assay 
One week after immunization, 4 mice from each group were selected. 
Spleens of mice belonging to different experimental groups were aseptically 
removed from euthanatized mice and washed with PBS having 5 % dextrose (PBS-
D). Splenocytes were harvested by repeated perfusion with sterile PBS-D in insulin 
syringe. Erythrocytes in spleen cell preparation were lysed with Histopaque-1083. 
(Two part of spleen preparation in one part of histopaque) and centrifuged at 1200x 
g for 30 min. Interface containing mononuclear cells were collected and washed 
with phenol red free RPMI 1690 media containing 10 % fetal bovine serum by low 
centrifugation. Viable cells were counted by 0.1 % Trypan blue dye exclusion 
method. The FACScan analysis demonstrated that isolated cells were CD4'' with 99 
% purity. The cells were cultured at 37 °C with 5 % CO2 in a 96-well flat-bottom 
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plate at a concentration of 2 x 10^  viable cells/well. Cultures in quadruplicate were 
stimulated with increasing concentration of various form of BCP protein (0.001 to 
lOmg per well); Concanavalin A (ConA, 0.25}xg/well) and plain RPMI-1630 were 
used as positive and unstimulated control respectively. Cells were incubated for 72 
hours at 37 °C. with 10 % CO2 in humid atmosphere. The stimulated cells were 
pulsed with 0.5)aCi [-^Hj-thymidine/well (-^ H-Tdr, Specific activity 18 Ci / mole) for 
16 hrs before harvesting the cell with automatic cell harvester (Skartron, Tranby, 
Norway). ["^H]-thymidine incorporation was measured by a standard liquid 
scintillation spectroscopy with a Betaplate counter. The stimulation index (S.I.) was 
calculated as mean cpm values of triplicate culture by following formula: 
S.I. = [ H] thymidine counts of experimental group/[ H] thymidine counts of 
unstimulated group 
Protection study against B. abortus 544 challenge 
Mouse challenge 
One week after last immunization, mice from each group were challenged 
with a virulent culture of B. abortus 544 (2X10^ cfu/mice) intraperitoneally in 0.2 
ml of saline solution. 
Determination of bacterial burden in mice after their exposure to B. abortus 
544 infection 
On day 30 post challenge five mice from each group were euthanatized and 
their spleens were removed aseptically. Spleens were then macerated by grinding 
them in 2 ml of 1.5M PBS (pH 7.4) with 0.1 % Triton X-100 containing sterile sand 
(Molecular biology grade) using a Teflon coated pestle. The cell suspension was 
diluted serially in ten fold dilutions in TPB and five drops of 10 \i\ from each 
dilution were plated out on Tryptose phosphate agar plates. The plates were 
incubated for four days at 37 °C in 5 % CO2 pressure and colony numbers were 
counted. Based on the colony numbers, the values of the average B. abortus 544 log 
cfu per mouse spleen and log protection for each group were determined. For S-19 
vaccinated mice, dilution was made on TPA-YT with 0.1 % erythriotol for 
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differentiating S-19 and B. abortus 544. All the plates were incubated at 37 °C. with 
10 % CO2 pressure. Three days after incubation colonies were counted and 
expressed as log 10 CFU per spleen. 
Statistical Analysis 
The data were analyzed by one-way analysis of variance (ANOVA) following 
Student's t test. P value of less than < 0.05 and < 0.01 were considered statistically 
significant. 
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Analysis of Brucella sonicated cytosolic protein (BCP) specific antibody 
response in the immunized animals 
Sera collected at weekly interval were diluted to 1:400 and analyzed by 
indirect ELISA and the absorbance at 492 nm was read in microtitre plate reader. It 
was found, upto 14 days post immunization, there was no significant rise in 
antibody titre among the different experimental groups. Antibody titre analyzed on 
day 21 post immunization was found to be the highest in the animals immunized 
with E-Lip-Sag (A492~0.782). Sera collected from P-Lip-Sag (A492~0.477) and IFA-
Sag (A492~0.461) immunized mice showed significantly poor antibody titre 
(P<0.05). Rest of the other immunized group of animals were failed to elicit 
detectable antibody titer (Table. 8). 
Total IgG level of immunized mice was also assayed on one week post last 
immunization (on Day 35 P.I.). As shown in the Figure 6, the total IgG titer of the 
sera from mice immunized with E-Lip-Sag reached 1.187 while P-Lip-Sag and 
IFA-Sag immunized mice showed significantly lower antibody titer (A492~0.949, 
and A492~0.847 respectively (P<0.05). Surprisingly, mice immunized with BCP in 
free form of antigen (F-Sag) showed significantly higher antibody titer(A492~0.823) 
as compared with the S-19 vaccinated group (A492~0.653)(P<0.05). 
We have further analyzed the sera on day 49 post immunization and it was 
found that E-Lip-L7 immunized mice consistently maintained the higher antibody 
titre as compared with the other immunized group of animals(A492~0.461, P<0.05). 
To analyze the potential role of IgG subtypes in the mechanism of elicitation 
of protective immune response we have also analyzed the sera collected one week 
post last immunization (on day 35 P.I.) for the presence different IgG subtypes. The 
analysis of IgG subtypes showed a significant increase in IgGl and IgG2a in E-Lip-
Sag (IgGl: 1.99; IgG2a: 1.828) vaccine group as compared with the P-Lip-Sag 
(IgGl:0.905; IgG2a: 0.884) and IFA-Sag (IgGl:1.087; IgG2a:0.934) (P< 0.01) 
(Figure 7). Immunization with protein in free form also elicited increased antigen 
specific IgGl (0.896) and IgG2a (0.817) antibody titre whereas IgGl predominated 
over IgG2a. Among all the immunized groups, only S-19 vaccinated mice elicited 
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better IgG2a (A492~0.949) response than IgGl (A492~ 0.784). The ratio of the Thl-
associated versus Th2-associated IgG subtype also reflected a substantial increase 
in certain IgGl subtypes; thus, the IgG2a/IgGl value for each group was calculated. 
Results showed that the all the experimental groups had higher IgGl subtypes than 
IgG2a counter part with exception of S-19 vaccinated group (Table 9). 
Dilution 1:400 
Experimental 
Groups 
Control 
S-19 
E-Lip-Sag 
P-Lip-Sag 
IFA-Sag 
F-Sag 
Days post immunization 
21 
0.189±0.029 
0.293±0.013 
0.782±0.029 
0.477±0.034 
0.461±0.023 
0.337±0.027 
35 
0.231±0.029 
0.653±0.137 
1.187±0.168 
0.949±0.060 
0.897±0.066 
0.823±0.133 
49 
0.167±0.012 
0.435±0.102 
1.023±0.129 
0.909±0.0342 
0.721±0.0423 
0.701±0.030 
Table 8 
Serum antibody titre (total IgG) in mice immunized with different form 
oiBrucella sonicated cytosolic protein (BCP). 
P values (on day 35 P.I.): Control vs E-Lip-Sag<0.01; P-Lip-Sag vs E-Lip-Sag < 0.5; 
IFA-Sag vs E-Lip Sag < 0.01; F-Sag vs E-Lip-Sag <0.01. 
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Experimental 
groups(l:400) 
Control 
S-19 
E-Lip-Sag 
P-Lip-Sag 
IFA-Sag 
F-Sag 
IgGl 
0.240± 0.038 
0.784+ 0.022 
1.990± 0.127 
0.905+ 0.007 
1.087 ±0.108 
0.896 +0.024 
IgG2a 
0.289± 0.046 
0.949 +0.057 
1.828 ±0.085 
0.885± 0.024 
0.934 ±0.077 
0.817 ±0.086 
Results 
IgG2a/IgGl 
1.21 
0.92 
0.98 
0.86 
0.91 
Table 9 
Analysis of IgG subtypes in mice immunized with different form of Brucella 
sonicated cytosolic protein (BCP). 
P values (IgGl; on day 35 P.I.): Control vs E-Lip-Sag<0.001; S-19 vs E-lip-
Sag<0.01; P-Lip-Sag vs E-Lip-Sag < 0.5; IFA-Sag vs E-Lip-Sag < 0.01; F- Sag vs 
E-Lip-Sag<0.01. 
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Figure 6. Analysis of serum antibody titre (total IgG) in mice immunized with 
different form of BCP antigen 
Analysis of serum antibody titre (total IgG) in Balb/c mice immunized with various 
forms of Brucella sonicated cytosolic protein (BCP). Sera (1:400 dilution) obtained 
from various experimental groups on days 21, 35 and 49 post-immunization were 
assayed individually by ELISA method. The level of IgG was expressed as 
ahsorbance (A4g2) of the coloured complex developed in the immunosorbent assay. 
Each line represents the mean of three determinations +SD. 
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Figure 7. Analysis of IgG subtypes in mice immunized with different form of 
BCP antigen 
Analysis of IgG subtypes and ratios in the sera of mice immunized with various 
forms of Brucella sonicated cytosolic protein (BCP). Sera (1:200 dilution) obtained 
from various experimental groups on days 35 post immunization were assayed 
individually by ELISA method. The level of IgGl and IgG2a was expressed as 
absorbance (A492) of the colored complex developed in the immunosorbent assay. 
Each bar represents the mean of three determinations ±SD. 
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CD4 T-cell proliferative response 
To further investigate tlie cellular immune response induced upon 
immunization with Brucella sonicated cytosolic protein antigen (BCP), we analyzed 
the proliferative CD T-cell response after simulation with the matching fomi 
antigen (s). As shown in Figure 8, immunization with E-Lip-Sag (S.I. 1.313) and P-
Lip-Sag (S.I. 1.233) form of antigen resulted in specific CD T-cell proHferation in 
response to either the related antigen formulation. Immunization with IFA-Sag or 
BCP alone (Sag) summarily failed to elicit antigen specific CD T cell proliferation 
(Table 10). 
Protection against B, abortus 544 challenge in immunized mice 
One week after the last immunization, the immunized mice were challenged 
with intraperitoneal injection of virulent B. abortus 544 strain. Four weeks after the 
challenge, the level of infection in each mouse was evaluated by determining the 
CPU in the spleen and expressed as log 10 CFU/spleen. Data from three independent 
protection experiments demonstrated that immunization with any type of vaccine 
formulation desired level of protection as compared with unvaccinated challenged 
group of animals (PBS Control). Only E-Lip-Sag showed better splenic clearance 
of the pathogen as compared with other vaccinated group (Figure 9). Not 
surprisingly, S-19 vaccinated animals showed least bacterial count log 3.27 with 
1.36 log protection than the controls that received PBS (P <0.001) (Table 11). 
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Figure 8. CD4+T cell proliferation response of immunized mice with 
different form of BCP antigen 
T cell proliferation response of immunized mice vaccinated with various fo^ms of 
Brucella sonicated cytosolic protein (BCP). The stimulation index (S.I.) was 
calculated by counting mean cpm values of stimulated culture/mean cpm values of 
unstimulated culture. Control cultures, containing cells obtained either from 
animals immunized with free form of antigen or the groups immunized with PBS or 
sham liposomes (no antigen), gave insignificant result after stimulation. Each bar 
represents the mean of three determinations ±SD. 
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Figure 9. Level of protection against B. abortus 544 infection conferred by 
immunization with various forms of BCP antigen in mice 
The mean CFU/spleen in 5 mice from each group was calculated on days 30 post-
challenge with infection. The bar represents the mean CPU (loglO)±standard 
deviation. Each bar represents the mean of three determinations ±SD. 
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Experimental groups 
Control 
S-19 
E-Lip-Sag 
P-Lip-Sag 
IFA-Sag 
F-Sag 
Results 
Stimulation Index (SI) 
1.14±0.044 
1.183±0.095 
1.313± 0.112 
1.233±0.072 
1.203±0.092 
1.210±0.043 
Table 10. CD4+T cell proliferation response of immunized mice with 
different form of Brucella sonicated cytosolic protein (BCP). 
P values: Control vs E-Lip-Sag<0.01; Control vs P-Lip-Sag vs E-Lip-Sag < 0.5. 
Experimental group 
(n=5) 
Control 
S-19 
E-Lip-Sag 
P-Lip-Sag 
IFA-Sag 
F-Sag 
Mean loglO CFU ±SD 
in spleen at day 
30 post challange 
4.6310.045 
3.27±0.101** 
3.68±0.059' 
3.80±0.041 
3.94±0.057 
4.12±0.073 
LoglO unit of protection 
at day 30 
post challenge 
— 
1.36 
0.95 
0.83 
0.69 
0.51 
Table 11. Level of protection against B. abortus 544 infection conferred by 
immunization with various forms of Brucella sonicated cytosolic protein (BCP). 
* Significantly different from PBS treated mice (P< 0.5) 
** Significantly different from PBS treated mice (P< 0.01) 
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Chapter I Discussions 
Development of an effective vaccine against brucellosis for human and 
animals is now desirable due to the possibility that Brucella could be used as a bio-
warfare agent (USBWP, 19977). A derivative of Brucella S-19 designated as S-
19BA was developed and used in former USSR and was shown to be protective in 
humans (Bhattacharjee et al, 2006), however when trialed in US volunteers this 
vaccine was found to be insufficiently attenuated (Spink et al, 1962). Brucella S-19 
and RB51 are WHO recommended vaccines for animal but suffered from some 
serious drawbacks as discussed earlier. Protein fractions from such live bacteria as 
acelluar vaccine was tried extensively to overcome the problem associated with the 
safety and efficacy of the present live vaccines. Unfortunately, the development of 
acellular vaccines for brucellosis are also suffering from some serious drawbacks 
mainly due to the fact that subunits vaccines are weekly immunogenic and require 
appropriate adjuvant or delivery vehicles to enhance their immunogenic potential. 
(Thakur and Thapliyal, 2002). 
Liposomal delivery of different antigen(s) has been studied extensively. 
Further, fusogenic liposome mediated delivery of antigen was proved to be 
beneficial in eliciting desirable protective immunity against number of intracellular 
pathogens (Owais et al, 2001, Faissal et al, 2003, Sharma et al, 2006a,b).The 
present study is an attempt to evaluate the immunogenisity of Brucella immunogen 
delivered through liposomes prepared from two different sources and to evaluate 
their adjuvant effect through analysis of serum antibody level as well as cellular 
immune response. 
Consistently higher serum antibody level (total IgG) was maintained in the 
group of mice immunized with escheriosome entrapped BCP protein clearly 
indicates its superiority of escheriosome over other form of antigen formulation. 
Mouse immunized with other preparation viz PC liposomal or IF A adjuvanted 
delivery had antibody response intermediate between E-Lip-Sag and non-
immunized control (PBS) group of mice. 
Further, we found that antigen encapsulated in escheriosome or eggPC/choI 
induced higher antigen specific IgG isotype response with a predominance of IgGl 
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over IgG2a. The IgG2a/IgGl (IgGl>IgG2a) ratio of each immunized group is a 
clear indicative of the fact that vaccine formulation had Th2 response rather Thl 
type. Although the titer of the IgGl and IgG2a are heterologus this could be 
because of the fact that response was too low and could not able to generate 
memory cells or the BCP were insufficient to boost the response. 
Although humoral immune response may contribute to the protection of 
murine model of brucellosis (Winter et ai, 1988), acquired resistance to brucellosis 
requires antigen specific T- cell response and sufficient activation of macrophages. 
In the present study, the cellular immune response was determined by antigen 
specific CDA^ T cell proliferation. It was found that escheriosome entrapment of 
BCP proved to be an effective mode of enhancing cellular immune response as 
compared to eggPC/Chol liposomal form of antigen. Among the other group of 
immunized animals, immunization protocol was Brucella antigen proved to be 
inefficient to induce cellular immunity. Higher lymphocyte proliferation by 
immunization with escheriosome entrapped protein may be due to sustained 
delivery of its content directly into cytosol of macrophages than other formulation. 
Higher antibody titer with poor lymphoproliferative response by free antigen (F-
Sag) immunized animals could be due to higher LPS content which is reported to 
favor higher humoral immune response but down regulate effect on cellular 
immune response. 
Further we have also performed the protection study. The vaccine potential 
of various forms of BCP protein was evaluated on the basis of reduction of CFU 
count in the spleen of mice challenged with B. abortus 544. On day 30 post 
infection, moderate degree of protection was induced only by fraction in 
conjunction with escheriosome whether PC liposomal or IFA mediated or free form 
of antigen elicited poor protective response as evidenced with higher splenic load of 
B. abortus 544. Nevertheless, none of the above vaccine formulation confers 
protection comparable to that of the S-19 vaccinated animals. The reason could be 
that S-19 can infect cells efficiently and producing endogenous antigens in APCs. 
Besides, comparatively higher IgG2a level than IgGl subtype in S-19 immunized 
80 
Chapter I Discussions 
mice may induce protective cytokines those involve in Thl mediated protective 
response (McDiarmida, 1957). 
To summarize, escheriosome entrapped Brucella antigen can elicit higher 
humoral and cellular response and provide better protection for the host against 
Brucella infection. However, immunization with escheriosome encapsulated 
cytosolic protein fraction provided less protection than vaccination with the 
attenuated S-19 strain. It can be concluded that selection of potentially protective 
immunogens of Brucella using targeting delivery system viz. liposome with 
fusogenic potential to obtain a protection level closer to that offered by currently 
used live attenuated vaccine, could be a successful alternative in the 
immunoprophylaxis against brucellosis. 
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Chapter I Introduction 
Brucellosis, a worldwide zoonotic ailment, causes abortion in cattle and undulant 
fever, arthritis, endocarditis and meningitis etc in human being. Presently, no 
vaccine is available against human brucellosis while vaccines for animal brucellosis, 
although existing, are far from ideal. Untoward effects associated with live vaccines 
have restricted their routine use. With the availability of complete genome sequence 
(Del Vechio et al 2002a, Paulsen 2002) the prospect of the development of an 
effective acellular vaccine currently constitutes prime objectives in several 
laboratories across the world 
Among various approaches to develop newer vaccine, recombinant, subunit 
or live vector vaccine were studied extensively. Many immunogenic proteins such as 
OMP 28, OMP 31, p39, Cu-Zn SOD, rL7/L12, GroEL and GroEs have been tried as 
recombinant subunit or synthetic vaccines (Tabatabai et ah, 1994; Bachrach et al., 
1994; Oliveria and Splitter, 1994; VemulapaUi et al, 2000; Schurig et al, 2002; Al-
marari et al, 2001; Luo et al, 2006). Among those, Brucella rL7/L12 protein has 
been identified as a Thl specific antigen that can elicit both humoral as well as 
cellular immune responses in mice. However, its protection efficacy is significantly 
much lower than the live attenuated Brucella S-19 vaccine (VemulapaUi et al, 2000; 
Al-marari et al, 2001; Schurig et al, 2002; Abtahi et al, 2004; Luo et al, 2006). 
This is mostly because of the fact that single-protein antigens are normally weak 
immunogens, and require co-administration of an adjuvant to achieve the desirable 
immune response. 
It can be speculated that co-administration of rL7/L12 in combination with 
suitable adjuvant or its specific delivery to the antigen presenting cells can boost its 
immuno-protective properties. Considerable literatures have documented the 
potential of liposomes as antigen carriers; however antigenic depot provided by 
liposomes ensued in presentation of processed antigens which ultimately results in 
activation of humoral immune response mainly along with MHC class II (Alving et 
al, 1992, Agrewala et al, 1996). In contrast, soluble antigen when delivered into 
cytosol of antigen presenting cells for processing is normally presented along with 
MHC-1 molecule and forms the basis for induction of CTL response. This clearly 
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suggests that antigen delivery vehicles can successfully introduce the entrapped 
antigens to the cytosol of the antigen presenting cells and may offer protective 
immunity against intracellular pathogen like B. abortus. In this regard fusogenic 
liposomes have attracted much greater attention as they fulfill criteria to home 
antigen to MHC I processing and facilitate activation of CTLs and thus holds a great 
deal of promise in vaccine development (Reddy et a/., 1991, Polt Frank et al, 1999). 
The encouraging role of fusogenic liposome as successful delivery system against 
different intracellular pathogens viz. Plasmodium sp, Candida albicans, 
Cryptococcus neoformans, Salmonella typhimurium, gave us impetus to explore its 
efficacy against brucellosis. 
The data of present study demonstrate that antigen encapsulated in 
escheriosomes could be successfully delivered simultaneously to the cytosolic as 
well as endosomal processing pathways of antigen presenting cells, leading to the 
generation of both CD4'^  T-helper and CDS"^  cytotoxic T cell response. In contrast, 
encapsulation of same antigen in egg PC liposomes, just like antigen-Incomplete 
Freund's Adjuvant (IFA) complex, has inefficient access to the cytosolic pathway of 
MHC I dependent antigen presentation and failed to generate antigen specific CD8^ 
cytotoxic T cell response. 
The present study suggests that escheriosome-based subunit vaccine induces 
early and strong activation of cell mediated as well as humoral immune responses in 
the immunized animals as compared to standard S-19 vaccine. 
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Materials 
Chemicals and Reagents 
Agarose, ammonium per sulphate, acrylamide, bis-acrylamide, P-
mercaptoethanol, bromophenol blue, calcium chloride, Coomassie brilliant blue 250, 
magnesium chloride, sodium chloride, potassium acetate, tween-20, isopropyl 
thiogalactose pyranoside (IPTG), X-gal, lysozyme, sodium dodecylsulphate, 
diamino-benzidine, Nitro-cellulose membrane (0.45 jam pore size) TEMED, glycine, 
ethidium bromide, proteinase K, RNase, Triton X-100, PMSF, bovine serum 
albumin and antibiotics (ampicillin and kanamycin) were purchased from Sigma, St. 
louis, USA). Foetal bovine serum was obtained from Life Technologies (Grand 
Island, NY, USA). Rabbit anti-mouse IgG HRPO conjugate was purchased from 
Sigma-Aldrich, USA. Potassium chloride, disodium hydrogen orthophosphate, 
potassium dihydrogen orthophosphate, hydrogen peroxide, certrimide, CTAB and 
glucose were from Qualigens (India, Mumbai). Glycerol, sodium nitrite and 
orthophosphoric acid were from Merck, (India, Mumbai.). Sodium carbonate, 
sodium bicarbonate, isopropanol, phenol, chloroform, ethylene diamine tetra-acetic 
acid, boric acid, glacial acetic acid, isoamyl alcohol, sodium hydroxide, sodium 
acetate, sodium dihydrogen phosphate, magnesium sulphate were procured from 
SRL India, Mumbai. [ H]-thymidine and [ Cr] sodium-chromate were bought from 
Bhabha Atomic Research Center, Mumbai, India. Monoclonal anti-mouse CD4 and 
CDS and their isotype control were from Sigma Immuno Chemicals, St Luis, USA. 
Sandwich ELISA kit (BD Biosciences, San Diego, Calif) was used to estimate 
mouse Gamma-Interferon level. Bicinchoninic acid protein assay Kit was from 
Pierce Chemical (CI, USA). Cholesterol (Choi) was purchased from Centron 
Research Laboratory, Bombay, India. 
Enzymes 
The restriction endonuclease, DNA modifying enymes-T4 DNA ligase, Taq 
DNA polymerase, dNTPs solution and buffers for these enzymes were procured 
from Ambion. Restriction enzymes and DNA marker supplied from MBI Fermentas 
(Germany). 
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Oligonucleotide primers 
Oligonucleotide primers were designed from published sequence of B. 
abortus (Ace No.L19101). The primers BAl (Forward) and BA2 (Reverse) both had 
linner sequences at their 5' ends. 
Restriction site for Sail in the forward primer and Pstl in the reverse primer were 
incorporated for directional cloning. The nucleotide sequences of these primers 
were as follows: 
Primer Forward/ Sequence 
Code Reverse 
BAl Forward 5'- CGC CGT CGA CAT GGC TGA TCT CGC AAA 
GATC - 3' 
BA2 Reverse 5'- GCC CCT GCA GTC TAG ATT ACT TGA GTT CAA 
CCT TGGC-3' 
Molecular weight marker 
Medium range Protein molecular weight marker, Prestain molecular weight 
marker (Sigma) and 100 bp DNA ladder were obtained from MBI Fermentas (USA). 
Bacterial strains and clones 
Brucella.S-l9 and B. abortus 544 were obtained from Division Biological 
Standardization, IVRI, Izatnagar. pQEL7 clone was kind gift from Dr. Pallab 
Chaudhury, GEB Lab, Division of Animal Biotechnology, IVRI, India. E. coli K12 
(non-pathogenic) strain used for lipid isolation, was provided by Mr. Zeeshan 
Ansari, Nil, New Delhi 
Plasmid and host strains 
Expression vector pQE-31 from Qiagen Inc, (USA) and Ml5 strain ofE. coli 
was used as host , Plasmid pTZ57R/T (InsT/A Cloning Kit, MBI Fermentas, 
Canada) was used as cloning vector. E.coli DH5a strain (Life technology, USA) 
was used for cloning experiment. 
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Experimental animals 
Healthy female Balb/c mice, weighing 20 ± 2 g, (4 to 6 weeks age) were 
obtained from Animal House Facility, CDRI, Lucknow. The animals were housed 
in Biosaftey level (BL)-3 facility having free access to the pellet diet and water ad 
libitum. A set of two New Zealand White rabbits was procured from Institute's 
Animal facility for raising hyperimmune sera. The experimental protocol was 
approved by the Institutional Animals Ethics Committee (Registration No. CPSEA 
332). 
Methods 
Culture of B. abortus and E. coli 
B. abortus 544 was grown and maintained at 37 °C on Tryptose phosphate 
agar for 48 hrs at 5% CO2. E. coli cells were grown in Luria Bertani (LB) medium at 
37 °C with shaking at 150-200 rpm. For the preparation of LB plates, 1.5 % agar 
powder was added to LB medium prior to autoclaving. E.coli DH5a cells containing 
pTZ57RyT cloning vector were grown in presence of ampicillin 50 fig/ml while E. 
coli M15 cell containing pQE-31 vector were grown in presence of ampicillin 50 
jag/ml and kanamycin 20|,ig/ml. Frozen stock of E. coli were prepared by 
resuspending mid-log cells in fresh LB medium supplemented with 20 % glycerol 
and store at -70°C. 
Isolation of chromosomal DNA from B. abortus 
B. abortus 544 was grown in Tryptose phosphate agar slant at 37 °C. Cells 
were harvested by pelleting them at 6000x g for 10 min. the pellet was suspended in 
TE buffer and washed thrice with IX TE. After resuspending in 3.6ml of IX TE 
containing lysozyme (10 mg/ml) 300 ^1, 400 |il of 10 % SDS and 25|il of proteinase 
K (20 mg/ml) was incubated at 37 °C for 90 min. Further 1ml of 5M NaCl was 
added and 800 \i\ CTAB/NaCl solution was added. The suspension was again 
incubated at 65 °C for 15 min. The cell lysate was extracted once with phenol/ 
chloroform/ isoamyl alcohol (25:24:1) and centrifuged at 13000 rpm for 20 min and 
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finally with chloroform: isoamyl alcohol (24:1). The aqueous phase containing 
genomic DNA was precipitated with 0.6 volume of isopropanol at room temperature 
and spooled out with glass rod. The DNA was washed with 80 % ethanol, dried and 
redissolved in 200 \x\ of TE buffer. Finally, RNase (100 |ag/ml) treatment for 1 h at 
37 °C followed by phenol: chloroform extraction and ethanol precipitation were 
carried out. The DNA pellet was washed with prechilled 70% alcohol and dissolved 
in water. The purity of DNA was determined spectrophotometricaly (OD260/280) 
while quantitative estimation was performed by using the following formula, 
Concentration of dsDNA (|j.g/ml) was calculated as: A260 X 50 X dilution factor. 
Agarose gel electrophoresis 
The DNA preparations were analyzed on 0.8 % agarose gels containing 0.5 
(j.g/ml ethidium bromide at 80 volts using 0.5X TBE electrophoresis buffer. The test 
DNA sample (5 \il) was mixed with 1 i^l of 6x bromophenol blue loading dye and 
the samples were loaded into the wells using a micropipette. Electrophoresis was 
performed at 6 volts/cm and the progress of mobility was monitored by the 
migration of the loading dye. The gels were visualized under UV transillumination 
and documented by photography. 
Amplification of L7/L12 gene by PCR 
The genomic DNA from B. abortus 544 was used as template to amplify 
L7/L12 gene. The amplification reaction was set up in 50 [il reaction volume each 
containing 10 |il (50 ng) of template DNA, 5 |il of Taq DNA polymerase buffer [10 
mM Tris HCl (pH 9.0)], 50 mM KCI, 1.5 mM MgCb and 0.01 (w/v) gelatin, 2 i^l of 
dNTP mixture containing 200 |_im of each dNTP, 2 |il (0.5 ^M) each of forward and 
reverse L7/L12 gene specific primer and 2.0 U of Taq DNA polymerase. The final 
volume was made with sterile distilled water. The reaction was carried out in DNA 
thermal cycler, with the following condition: 5min at 94°C followed by 30 cycles. 
Each cycle consisting of denaturation at 94°C for 1 min, annealing at 50°C, 
extension at 72°C for 1 min and final extension at 72°C for 5 min. The PCR product 
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was analyzed by electrophoresis in 1% agarose gel in 0.5X TBE buffer and 
visualised in ethidium bromide staining on UV transluminator. 
Elution of DNA from Agarose Gel 
The DNA fragment of interest was eluted from agarose gel was carried out 
using Minelute gel extraction kit. The DNA fragment of interest was excised out of 
the gel using a sharp scalpel without exposing the fragment to UV light. The gel 
piece was weighed, sliced and placed in a microfuge tube. After adding QXI buffer 
it was incubated at 50 °C for 10-15 min with vortexing every 2-3 min during 
incubation to solubilize the gel piece. Entire volume of sample was added through 
the spin column by loading 800 |LI1 and centrifuge at 12,000xg for 1 min and the flow 
through was collected in the collection tube. To wash the column bound DNA, 
800)^ 1 of Buffer PE (wash buffer) was added and centrifuged at 12,000x g for 1 min. 
Again the flow through obtained was collected in the collection tube. The empty 
spin column was spinned at 12,000x g for 1 min to remove residual wash buffer 
from the column. The column was taken in the sterile microfuge tube and the DNA 
elution was carried out by adding sterile distilled water to the center of the 
membrane of column and centrifuged at 12,000x g for 1 min. Finally, the eluted 
DNA was collected in the microfuge tube stored at -20 °C. 
Cloning of rL7/L12 gene of B.abortus in pTZ57R/T vector 
Ligation 
About 50 ng of eluted PCR product of rL7/L12 gene were mixed with equal 
volume of pTZ57R vector (InsT/A cloning kit, MBI Fermentas) and allowed for 
ligation uses as per the instruction given in the kit .The reaction was carried out at 
16 °C for 8 h and the resulting recombinant plasmid was designated as PTZL7 used 
for transformation. 
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Preparation of competent cells 
E. coli strain (Ml5) competent cells was prepared by CaCli method. E. coli 
DH5a was grown for 2 hrs in shaking incubator at 37 °C in a 10 ml test tube in LB 
broth without ampicillin till the OD of culture attains value Of 0.20 - 0.35. One ml 
culture was taken in each 1.5 ml tube and pelleted at 6000 rpm for 10 min. The pellet 
was used for subsequent steps. CaCli 200 \x\ of 0.1 M was added in each tube and 
mixed properly. It was followed by centrifugation at 6000x g for 10 min at 4 °C. The 
pellet was recovered and resuspended in 200 \i\ O.IM CaCl2 and kept in ice for 45 
min. Each aliquots of cell was used for transfonnation. 
Transformation 
Competent cells (aliquot) were mixed with ligation mixture and kept in ice 
for 1 h. subsequently cells were exposed to at 42 °C for 90 seconds and then 
immediately transferred back to ice for 5 min. About 800 pi of LB medium was 
added to the transformed cells and incubated at 37 ^C for 45 min. The cells were 
then plated out into the LB agar containing ampicillin, IPTG and X-gal. The plates 
were incubated at 37 "^ C overnight. 
Screening of recombinant clones 
Few colonies were picked at random and incubated in 3 ml LB broth 
containing ampicillin or kanamycin. The broths were incubated overnight at 37 °C 
with constant shaking. Recombinant clones were screened on the basis of 
blue/white single colony and the plasmids were extracted following alkali lysis 
method (Sambrook and Russel, 2001). 
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Screening by PCR 
Plasmid DNA isolated from transformed bacteria was used as template for 
amplification of L7/L12 gene. The PCR mixture consisted of 50 ng of template, 30 
pM each primers BAl and BA2, 200 i-iM of each of dNTPs, 5 i^l of lOX PCR buffer 
and 2.5 units of Taq DNA polymerase. The volume of the reaction was made upto 
50 )j.l with distilled water. PCR was performed using a DNA thermal cycler with the 
following conditions: 5 min. at 94 ^C followed by 30 cycles consisting of 1 min at 
94 OC, 1 min at 50 ^C, 1 min at 72 ^C, finally an extension of 10 min at 72 ^C. 
Amplified product around 10 jal of was analyzed by electrophoresis uses 1.5 % 
agarose gel and stained with ethidium bromide. 
Screening by restriction endonuclease digestion 
Plasmid isolated from transformed bacteria was subjected to double digestion 
with restriction enzymes. Approximately 1.0 \xg of plasmid was digested with 1 unit 
of restriction endonucleases, BamHl andXbal in reaction volume of 20 |a.I. Digested 
plasmid was electrophoresed on 1.0% agarose gel stained with ethidium bromide. 
Sequencing of transformed clones 
After screening by PCR and RE digestion, the recombinant clones were 
sequenced in Delhi University South Campus to confirm the correct reading frame 
and sequenge changes if any. 
Production of recombinant protein from pTZL7 clone 
Subcloning into pQE 31 expression vector 
After confirmation of cloned insert by sequencing, the rL7/L12 gene insert 
was subcloned into Sail and Fstl site of pQE-31 expression vector (Fig 10) and 
transformed in E.coli Ml5 cell. 
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Figure 10. Positions of elements in bases of pQE31 vector 
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Induction of expression 
Recombinant E. coli harbouring rL7/L12 gene was used for the production of 
recombinant protein. Overnight culture of tlie recombinant clone was inoculated in 
500 ml of LB broth containing ampicillin (100 ng/ml) and grown at 37 ^C with 
vigorous shaking. The culture was induced with IPTG (final concentration of 1 mM) 
after attainment at 600 nm 0.5 OD. After 5 hrs, the culture was washed thrice with 
PBS and resuspended in 25 ml of PBS. Then the culture was stored at -20 ^C till 
further use. 
Purification of recombinant rL7/L12 protein 
Polyhistidine tagged (6xHis tag) fusion protein was purified under 
denaturation conditions by metal chelate affinity chromatography (Qiagen Protocol), 
with certain modifications introduced in the purification parameter. 
Briefly, pellet obtained from 50 ml suspension of induced culture was 
resuspended in 4 ml of lysis buffer (buffer B) containing imidazole (20 mM), IM 
NaCl, glycerol (20 %) and Triton X 100 (25 %). It was held at room temperature for 
1 hour with intermittent mixing. The cell debris was removed by centrifugation at 
10,000 rpm for 20 min. The supernatant was incubated with 1 ml of Ni^-NTA resin 
for 40 min and packed into column. Thereafter column was washed thoroughly with 
wash buffer (buffer C). The fusion protein was eluted in 0.5 ml x 4X with the elution 
buffer (buffer E). Five elutes were collected. All the elutes were checked by SDS-
PAGE as described earlier. The elutes were dialyzed against PBS to remove urea. 
SDS-PAGE analysis of the protein 
Expressed recombinant rL7/L12 protein was analysed by SDS-PAGE using 
method of Laemmli (1970), in a vertical mini-gel electrophoresis apparatus using 15 
% resolving gel having a stacking gel of 5% concentration. The resolving gel was 
poured between the glass and overlayred with water-saturated n-butanol. After gel 
polymerization, surface of the gel was washed with MilliQ water and 5 % stacking 
gel was added and comb was inserted carefully in it and was allowed to polymerize. 
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The comb was removed and the wells were flashed with the electrode buffer. The 
eluted fractions were mixed with 2X Laemmli sample buffer (1:1), boiled for 5 min, 
cooled and loaded in the wells. Molecular v/eight marker proteins were prepared 
following the manufacturers protocol and loaded in one well. 
Electrophoresis was carried out at a constant current of 18 mA, until the 
tracking dye reached the bottom of the gel. The gel was taken out from the plates 
and stained with 0.25 % (W/V) Coomassie brilliant blue R-250 prepared in 
methanol, glacial acetic acid and water (45:10:45) and destained with destaining 
solution (20 parts methanol: 10 parts glacial acetic acid and 70 parts distilled water). 
Estimation of concentration of recombinant protein 
Concentration of recombinant rL7/L12 protein was estimated by BCA 
protein estimation kit as per the method described earlier in the Part I, 
Raising hyperimmune sera against recombinant rL7/L12 protein 
Two New Zealand white 8-10 weeks old rabbits were immunized to raise 
antibody against the recombinant rL7/L12 protein. Rabbits were inoculated 
subcutaneous with lOO^ xg of immunogen in 0.5ml PBS (pH to 7.4) with equal 
volume of Freund's complete adjuvant (CFA) and the subsequent boosters of 100 jj.g 
immunogen were given subcutaneous at 2 weeks intervals. The rabbits were bled 
one week after third booster and sera were separated. The sera were stored at -20 °C 
till further use. 
Western blot analysis of rL7/L12 specific hyperimmune rabbit sera 
Western blotting was carried out according to the method of Towbin et al., 
(1979). Purified r-L7/L12 protein was loaded on 15% SDS-PAGE and electro 
blotted on to the nitrocellulose paper (NCP) at 2 mAmp/cm^ constant current for an 
hour, the transfer was carried out in semidry electro blot apparatus containing 
transfer buffer. The membrane was blocked with 2 % Bovine serum albumin for 4 
hrs at 4 °C and washed five times with PBS-T. The membrane was then cut into 
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strips and incubated with (1:100) dilution of pre-immune sera in plastic bags on 
rocker for 2 h at 4 °C. The strips were washed with PBS-T and incubated with 
1:1000 dilution of HRPO conjugated goat- antirabbit IgG antibody for 1 h on rocker 
at 4 °C. The strips were 3 finally washed with PBS-T and developed with 
Diaminobenzidine (10 mg/6 ml of D.W.) substrate in the presence of 30 % H2O2. 
After the optimum color was developed, the NCP was washed with excess water to 
stop the reaction. 
Preparation of escheriosome and eggPC/Chol liposomes 
Escheriosome and egg PC/Chol liposome were prepared following the 
method as described in the previous section (Part I). 
Immunization 
The immunological studies were performed in inbred female Balb/C mice. 
Each group was consisted of fifteen animals. Different groups of mice were injected 
separately, through subcutaneous route, with a total three doses (immunisation on 
day 0, 21, and 28) of escheriosome entrapped r L7/L12 (E-Lip-L7), egg PC/Chol 
liposome entrapped rL7/L12 protein (P-Lip-L7), Incomplete Freund's adjuvant 
emulsified rL7/L12 protein (IFA-L7), rL7/L12 protein alone (free form), egg 
PC/Chol and E. coli lipid sham liposome (no antigen). Positive control group 
(vaccinal control) was immunized subcutaneously on day 0 with B. abortus S-19 
(5X10^ CFU/mice) while another set of animal (negative control) received only PBS. 
Animals were immunised with priming dose 50 p-g/animal recombinant protein and 
boosted with 30 |ig/kg animal subsequently on day 21 and 28. 
Collection of sera 
Serum was collected at weekly interval. Route of blood collection was retro 
orbital plexus of eye with the help of glass capillaries (size 90mm X 1mm). The 
volume of blood collected from individual mouce ranged from 100-200 |il at one 
time and kept in separate micro centrifuge tube having any anticoagulant. The blood 
was allowed to clot at 4 °C for 1 to 2 hrs. After that the tube was kept at RT. Serum 
94 
Chapter I Materials and Methods 
was retracted and collected in micro centrifuge tube and centrifuged at lOOOOx g to 
remove the lysed RBCs. Supernatant collected and kept at -20°C for future use. 
Determination of antigen-specific antibody by dot immunobinding assay: 
The production of antigen-specific antibodies in sera of the animals 
immunized with various vaccine formulations were determined by dot 
immunobinding assay as per published protocol (Batra et al, 1989). Briefly, 
optimum concentration of rL7/L12 protein was blotted on nitrocellulose membrane 
with slot blot apparatus. The NC membrane was dried and blocked with 3 % BSA 
for 2 hrs at 37 °C. After proper washing, the strip was incubated with antisera 
collected from immunized mice of different group at the dilution of 1:100. After 
usual washing, the membrane was incubated with 1:1000 dilution of HRP 
conjugated rabbit anti-mice antibody for Ihr on rocker at 4 °C. Finally strips were 
developed with Diamine benzidine (10mg/6ml D.W.) in presence of 20 [i\ of 30 % 
H2O2. 
Determination of antigen-specific immunoglobulin and their isotypes by 
indirect ELISA 
Sera of the immunized mice were collected at regular interval to monitor the 
presence of antibodies by indirect ELISA method as described earlier (Part I). 
CD4^T lymphocyte proliferation assay 
One week after last immunization, four mice from each group were 
sacrificed and their spleens were removed under aseptic conditions. €04"^ and CDS"^  
T cells were prepared as described elsewhere (Mishell et al, 1980). CD8"^  T cells 
were used as effector cells for CTL while CD4"^  T cells were used in proliferation 
assay. CD4^T lymphocyte proliferation assay was performed as per the method 
described in the previous section. 
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CD8^T lymphocyte response 
Target cells 
Balb/c mice were injected with thioglycollate brotli. On day 4, the 
macrophages were isolated from the peritoneal exudate cells (PEC) by adherence on 
petri plates. The peritoneal macrophages were washed three times with HBSS and 
incubated at 37 °C for 3 to 4 hrs with either free, egg PC/Choi liposome entrapped 
or escheriosome encapsulated forms of rL7/L12. The cells were again washed three 
times to remove residual antigen antigen present in the supernatant. This was 
followed by incubation with ^'Cr (100 ^Ci/2 xlO^ cells) for 45-60 min at 37 °C. The 
cells were finally washed with RPMI solution and were used as target cells. 
Cytotoxicity assay 
The ^'Cr-labelled macrophages (SxlO'^ /well) were used as target cells. The 
antigen primed target cells were incubated with CDS"^  T cells (effector cells isolated 
from the spleen of the four mice, were pooled, and used for assay at an effector to 
target (E/T) ratios of 5:1 to 20:1. The target and effector cells were incubated at 37 
°C for 6 hrs, after completion of incubation period, the cells were pelleted at 3,000x 
g for 15 min at 5 °C and the amount of released ^'Cr was determined by measuring 
the radioactivity in the supernatant. The experiments were performed three times 
and the error bars represent standard deviation of the means from three different 
experiments. Total Cr release was calculated by treating an aliquot of the target 
cells with Triton X-100 (10 % final concentration). The spontaneous release of ^'Cr 
in the supernatant was determined by incubating the labeled macrophages for 6 h. 
Amount of auto-release was subtracted from the total release to determine the extent 
of macrophage lysis. In most of the experiments, the auto-release was less than 25 
%. The percent specific release was calculated as the (mean sample cpm-mean 
spontaneous cpm/mean maximum cpm-mean spontaneous cpm) x 100 %. 
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Detection of Gamma-Interferon (IFNy) level 
Gamma interferon (IFNy) was estimated by antigen capture ELISA using BD 
Biosciences assay kit. Spleen cells from different vaccinated as well as control group of 
animals were cultured and at concentration of 2x10^ and then stimulated with 
recombinant protein (5 |ag/well) in RPMI-1690 containing 10 % FCS. After 48 hours of 
incubation at 37 "C in humidified atmosphere (5 % CO2) the plate was centrifuged at 
400xg at 40°C and the supernatant were alequated. Gamma interferon was detected in 
triplicate by Enzyme linked immunosorbent assay using microplate, coated with capture 
antibody (anti mouse IFNy). After proper washing wells were blocked for 1 hour room 
temperature with 250 i^l of PBS (pH 7.0) containing 10 % FCA per well. Cell culture 
supernatant were plated in 1:10 dilution in blocking buffer and incubated for 2 hour at 
room temperature. The plates were washed five times with PBS-0.05 % Tween 20. 
Biotynilated Anti mouse IFNy and Avidin horseradish peroxidase conjugate were used 
according to the manufacturer's instruction and evaluated by TMB substrate. The plates 
were then read at 450 nm within 390 min of stopping solution with 2N H2SO4. All 
assays were performed in triplicate. The concentration of IFNy in the culture 
supernatants was calculated for each experimental group using a linear-regression 
equation obtained from the absorbance values of the standards. 
Lymphocyte migration inhibition test (LMIT) 
Lymphocyte was separated from blood, of immunized animals by inner 
canthus route in tube containing heparin at day 7 post last booster following method 
described by Boyum (1968). Briefly the heparinsed blood was diluted in equal 
volume of calcium and magnesium free PBS. Diluted blood was then centrifuged 
atl500-2000x g for 15 min and the buffy coat was separated and layered over 
histopaque at 2:1 ratio followed by centrifuged for 15 min. The interface containing 
lymphocyte was collected carefully and washed with equal volume of PBS at least 
tliree times and the cell viability was calculated by 0.1 % Trypan blue dye exclusion 
method. Viable cells were collected as described earlier and adjusted 4X10^Cells 
per ml in RPMI-1640 culture medium supplemented with 10 % fetal calf serum, 
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which was previously incubated for 12 hrs. Non-heparinsed capillary of uniform 
size and diameter, were packed with cell suspension and plugged at one end with 
platicine. The capillaries were centrifuged at 800x g for 3 min and carefully cut at 
the cell fluid interface with diamond cutter. Each stub was placed in greased wells 
of migration plate. The wells were covered with circular grease free clear cover slip 
and incubated for 19 hrs at 37 ''C under humid atmosphere. The migration in each 
circle was viewed and plotted on graph paper by using Camera Lucida and percent 
migration was calculated by the following formula: 
Percent migration inhibition =[1-(Migration in presence of antigen/migration in 
absence of antigen)] X 100 
Delayed type hypersensitivity reaction (DTH) 
The delayed type hypersensitivity response was assessed by measuring 
footpad thickness of immunized mice by the method of Collins and Mackaness 
(1968). Recombinant rL7/L12 protein was injected intradermally in right footpad of 
mice belongs to various immunized groups and left one was kept as control that 
received PBS only. Increase footpad thiclcness was measured by digital Verniar 
calipers at 0, 12, 24, 36, 48 and 72 hrs interval of post injection. 
Protection study against Brucella abortus 544 challenge 
One week after last immunization, the mice belonging to various groups 
were challenged with a virulent culture of B. abortus 544 (2X10^ cfu / mice) 
intraperitoneally in 0.2 ml of saline solution. After 7, 15 and 30 days post challenge, 
four mice from each group were euthanatized and spleens were processed as per the 
method described in previous section. 
Macroscopical lesions of spleen of experimental animal after challenge with B. 
abortus 544 
We also observed the effect of Brucella infection in vaccinated as well as 
unvaccinated mice on days 30 post infection simultaneously with protection study 
and spleen collected from different experimental groups were photographed to 
determine the size, shape and macroscopical features. 
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Statistical Analysis 
The data were analyzed by one-way analysts of variance (ANOVA) 
following Student's t test. P value of less than < 0.05 and < 0.01 were considered 
statistically significant. 
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Expression ofB. abortus rL7/L12 gene in E.coli 
Isolation ofB. abortus genomic DNA 
The organism, B. abortus 544 was grown in Tryptose phosphate broth at 
37°C for 48-72hrs and maintained in Tryptose phosphate agar slant. The cells were 
heat killed at 75 °C for 15 min before the isolation of genomic DNA. The genomic 
DNA was isolated from B. abortus 544 using CTAB method. The purity of the 
extracted DNA was checked by measuring the absorbance at 260 and 280 nm. The 
ratio of OD at 260/280 nm was typically ~1.8. 
Cloning and Sequencing of Brucella rL7/L12 gene 
Escherichia coli Ml5 and DH5a were routinely grown at 37 °C in Luria-
Bertani broth or in agar supplemented with Kanamycin (20 |J.g/ml). The PCR 
amplification of ribosomal rL7/12 gene from B. abortus 544 was achieved by 
polymerase chain reaction using a set of primers which were designed based on the 
sequence. PCR amplification of rL7/L12 gene yielded a specific product of 375 bp 
DNA fragment and analyzed on observed on 1.5 % Agarose gel. No amplification 
was observed in any template control tube. 
PCR amplified product was eluted from agarose gel and ligated to pTZ57R 
cloning vector. The resulted construct was designated as pTZL7. Upon 
transformation of pTZL7 into E.coli M15 competent cells, a large no of recombinant 
clones were obtained which produced white colour colony on LB plate 
supplemented with ampicillin, X-gal and IPTG, 
Screening of recombinant rL7/L12 clones by PCR and restriction enzyme 
digestion 
Presence of correct insert in the recombinant clone was confirmed by the 
release of 375bp insert by digestion of isolated plasmid with Sal 1 and Pst I enzyme. 
On agarose gel electrophoresis, released insert DNA and PCR product showed same 
band size (Figure 11). Recombinant clone has been sequenced at DNA sequencing 
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facility, Deliii University South Campus. The nucleotide sequence of L7/L12 
ribosomal gene from B. abortus 544 contained 375bp open reading frame (ORF) 
which codes for 124 amino acids. DNA sequence was 100% identical to Brucella 
rL7/L12 gene with no base pair substitution. This recombinant clone was named as 
pTZL7. 
Expression of rL7/L12 gene in pQE31 expression vector 
The cloned rL7/L12 gene was excised out from pTZL7 by digestion with 
Sal I and Pst I enzyme. The fragment was sub cloned into prokaryotic expression 
vector pQE31. The resulting plasmid was designated as pQE-L7. E. coli Ml5 cells 
harboring pQE-L7 was picked and grown in LB broth in presence of ampicillin (50 
\iglm\) and Kanamycin (30 ng/ml). The culture was induced with ImM IPTG when 
OD at 600 nm reached to 0.6. After 5 h of IPTG induction, cells were harvested and 
lysed in 2X sample buffer for SDS-PAGE analysis. SDS-PAGE analysis using 15% 
polyacrylamide gel revealed high level expression of 5. abortus rL7/L12 protein. 
The molecular size of the expressed protein was approximately 19 kDa. Un-induced 
cells did not show presence of expressed protein (Figure 12a). 
Purification and quantification of recombinant 5r«ce//a rL7/L12 protein 
Positive clone of E.coli Ml5 cells expressing rL7/L12 protein were induced 
with IPTG. After 6 hours of induction, the culture was pelleted and washed by PBS. 
The cells were then lysed by Buffer 'B' (pH 8.0). The lysate was analyzed for the 
presence of desired protein by SDS-PAGE. The 6x Histidine tagged fusion protein 
was purified under denaturation conditions by metal chelated affnity 
chromatography. No nonspecific band was found in the purified proteins when 
analyzed in SDS-PAGE (Lamelli, 1970). Pure distinct single band at 19 kDa 
position was observed in lane loaded with rL7/L12 protein. The purified proteins 
were subjected to dialysis against PBS. The concentration of the purified dialyzed 
protein was estimated by BCA method as per the method described earlier. And 
found to be 0 .8mg/ml. 
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Immunological characterization of recombinant proteins 
Determination of antigen specific antibody by Western Blot 
To determine the purity, antigencity and specificity of purified recombinant 
rL7/L12 protein, Western Blot analysis was performed using antigen-specific hyper-
immune rabbit sera, according to published procedure (Towbin et a.,11979). Briefly, 
purified and dialyzed recombinant rL7/L12 protein was run with prestain marker on 
15% SDS-PAGE and subsequently transferred to "Nitrocellulose membrane using 
semidry Electro blot assembly. After usual blocking and washing the membrane was 
incubated with (1:100) dilution of test sera in plastic bags on rocker for 2 hrs at 4°C. 
The strips were washed with PBS-Tween and incubated with 1:1000 dilution of 
HRPO conjugated rabbit anti mice antibody for Ihr on rocker at 4°C and finally 
developed with diaminobenzidine in presence of 20ja,l of 30% H2O2. The blotting 
illustrates the specific interaction between anti-rL7/L12 rabbit antibody and purified 
protein (Figure 12b). 
Immunoblot analysis of sera collected from immunized animals 
In blot analysis, recombinant rL7/L12 protein was found to react with the 
sera of different immunized animals on days 28 post immunization. Sera collected 
from E-Lip-L7 and P-Lip-L7 vaccinated animals reacted specifically while sera 
collected from S-19 immunized mice and rest of the other vaccinated animals failed 
to react with the rL7/L12 protein. Moreover, the sera were able to recognize 
recombinant protein in the crude form as well (Figure 13a, b). 
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2.8 
375 
Figure 11 Expression of Brucella ribosomal L7/L12 gene using pTZL7 clone 
Lane] 1 OObp DNA ladder 
Lane2 375 bp PCR amplified L7/L12 gene 
LaneS pTZL7 plasmid digested with Sail and Pstl releasing 375 bp 
L7/L12 gene insert from 2.8 kb pTZ57R plasmid 
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Figure 12 (a, b) Expression and purification of recombinant rL7/L12 protein 
using metal affinity column. 
(a) SDS-PAGE showing expression of recombinant rL7/L12 protein and steps 
involved in its purification. Lane 1 Uninduced control; Lane 2 Induced; Lane 3 
Elution of recombinant rL7/L12 protein through Ni+-NTA column; Lane 4 Standard 
molecular weight protein marker. 
b) Western Blot analysis of recombinant rL7/L12 protein immunostained with anti-
rL7/L12 sera raised in rabbit. Lane 1 Prestained protein marker; Lane 2 Probing 
presence of recombinant rL7/L12 protein using rabbit anti-rL7/L12 antibodies. 
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Figure 13 (a, b) Dot-immunoblot analysis of sera collected from mice 
immunized with E-Lip-L7 and P-Lip-L7 on days 28 post immunization. 
A. E-Lip-L7 
B. P-Lip-L7 
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Analysis of rL7/L12 specific antibody response in the immunized animals 
To evaluate the potential of various vaccine preparations to activate humoral 
immune system of the host, the production of antigen specific antibodies was 
measured in the sera of the immunized mice at different time intervals. Analysis of 
the sera (1:200 dilution) revealed non-significant antibody titre upto days 14 post 
immunization in various groups of immunized mice. Significantly higher 
(A492~0.917) titre of antibody (IgG) was detected on day 21 post immunization in 
sera of animals which were primed with E-Lip-L7 form of the antigen as compared 
with the P-Lip-L7 (A492«0.765) (P<0.05). On the other hand, antibody titre was 
significantly less (P<0.001) in the animals immunized with S-19 (A492«0.414) or 
IFA-L7 (A492~0.456) combination. As evident from the Figure 14, high antibody' 
response was maintained in E-Lip-L7 immunized mice following each booster with 
maximum antibody level on 7* day after the last immunization (A492~1.627) as 
compared with P-Lip-L7 group which was unable to rise to that extent (A492~l .341). 
The antibody response evoked by S-19 (A492~0.609) or IFA-L7 (A492~0.707) was 
significantly less as compared to E-Lip-L7 immunized group (P < 0.001) (Table 12). 
The sera colleted from immunized mice two weeks (on days 42 post 
immunization) after last immunization were also tested for IgGl and IgG2a antibody 
isotypes. As shown in the Fig. 3a, E-Lip-L7 form of antigen elicited higher IgGl 
(A492~0.852) and IgG2a (A492~0.979) antibody isotypes level where as mice 
immunized with P-Lip-17 showed comparatively lower antibody isotypes titre (IgGl, 
A492«0.639; IgG2a, A492~0.777) (P<0.05). ft was found that mice immunized with 
IFA-L7 and S-19 failed to elicit detectable isotype response. As evident from Fig. 
3a, that the IgG2a isotype was more abundant than their IgGl counterpart in both E-
Lip-L7 and P-Lip-L7 immunized group of animals, indicative of a clear skew 
towards a Thl type response. 
The specific antibody isotype response was also analyzed after seven weeks 
post first immunization (days 49 post immunization, Figure 13a). It was observed 
that E-Lip-L7 maintained significantly higher titer of IgG 1 (A492~ 0.837) and IgG2a 
(A492 ~ 1.05) as compared with P-Lip-L7 (IgGl, A492=^ -686; IgG2a, A492 =^ .832) 
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immunized group (P<0.05, E-Lip-L7 Vs P-Lip- L7). Both S-19 as well as IFA-L7 
combination failed to induce significant level of IgGl and IgG2a titre in the serum 
after 42 days post first immunization and the trend was maintained even after days 
60 post immunization (Figure 15b, c) (Table 13a,b,c). 
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Figure 14. Total IgG level in sera of mice immunized with various forms of 
Brucella rL7/L12 protein. 
Sera (1:200 dilution) obtained from various experimental groups on days 14, 21, 28, 
35 and 42 post immunization were analyzed individually by indirect ELISA method 
as described in materials and methods. The level of IgG was expressed as 
absorbance (A4g2) of the coloured complex developed in the immunosorbent assay. 
Each line represents the mean of three determinations ±SD. 
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Figure 15c. 
Figure 15 (a,b,c). Analysis of IgG isotype response in Balb/c mice immunized 
with various forms of Brucella recombinant rL7/L12 protein. 
Sera (1:100 dilution) obtained from various experimental groups on days 42 (Fig. 
15a), 49 (Fig. 15b) and 60 (Fig. 15c) post immunizations, were analyzed 
individually by indirect ELISA as described in materials and methods. The level of 
IgG isotypes was expressed as absorbance (A492) of the coloured complex developed 
in the immunosorbent assay. Each bar represents the mean of three determinations 
+SD. 
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Dilution 1:200 
Experimental 
Groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
I 
14 
0.095±0.006 
0.279±0.001 
0.586±0.004 
0.431±0.007 
0.419±0.005 
0.2025±0.006 
0.214±0.007 
0.102±0.008 
Results 
Days post immunization 
21 
0.179±0.0141 
0.415±0.006 
0.916±0.007 
0.750±0.001 
0.456±0.002 
0.201±0.001 
0.196±0.002 
0.198±0.012 
28 
0.176±0.0070 
0.544±0.008 
1.268±0.009 
0.982±0.004 
0.556±0.004 
0.224±0.005 
0.222±0.006 
0.150±0.005 
35 
0.224±0.004 
0.610±0.002 
1.627±0.02 
1.342±0.0I7 
0.707±0.009 
0.31I±0.004 
0.284±0.02 
0.201±0.010 
42 
0.201±0.014 
0.532±0.014 
1.504±0.034 
1.197±0.024 
0.652±0.039 
0.276±0.030 
0.302±0.032 
0.230±0.019 
Table 12 
Total IgG level in sera of mice immunized with various forms of Brucella 
rL7/L12 protein 
P values: Control vs E-Lip-L7<0.001; S-19 vs E-Lip-L7<0.01; P-Lip-L7 vs E-Lip-
L7< 0.05; IFA-L7 vs E-Lip-L7< 0.01; F-L7 vs E-Lip-L7<0.001; EL+L7 vs E-Lip-
L7<0.001; Sham EL vs E-Lip-L7<0.001 
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Experimental 
groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
42 days 
IsGl 
0,133±0.015 
0.279±0.020 
0.852±0.045 
0.639±0.070 
0.286±0.073 
0.175±0.050 
0.189±0.024 
0.150±0.030 
IgG2a 
O.llSiO.Oll 
0.345±0.028 
0.979±0.026" 
0.777±0.045* 
0.454±0.065 
0.213±0.045 
0.125±0.030 
0.16±0.025 
13a 
Experimental groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
49 days 
IsGl 
0.132±0.011 
0.267±0.031 
0.837±0.067 
0.686±0.051 
0.359±0.057 
0.180±0.028 
0.157±0.022 
0.140±0.024 
IgG2a 
0.139±0.043 
0.333±0.017 
1.05±0.098*' 
0.823±0.095' 
0.489±0.015 
0.234±0.033 
0.130±0.031 
0.157±0.02 
13b 
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Experimental groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
60 days 
IgGl 
0.138±0.025 
0.248±0.067 
0.897±0.122 
0.729±0.041 
0.393±0.070 
0.175±0.035 
0.102±0.023 
0.16±0.021 
IgG2a 
0.140±0.028 
0.320±0.043 
1.067±0.078 
0.863±0.060 
0.526±0.057 
0.192±0.025 
0.134±0.032 
0.123±0.045 
13c 
Table 13 (a,b,c) 
Analysis of IgG isotype response in Balb/c mice immunized with 
various forms of Brucella recombinant rL7/L12 protein 
P-values (on days 42 post immunization): Control vs E-Lip-L7<0.001; S-
19 vs E-Lip-L7<0.01; P-Lip-L7 vs E-Lip-L7<0.5; IFA-L7 vs E-Lip-
L7<0.01; F-L7 vs E-Lip-L7<0.001; EL+L7 vs E-Lip-L7<0.001; Sham 
ELvsE-Lip-L7<0.001. 
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CD4^ T lymphocyte proliferation response 
CD4"^  T cells were isolated and purified from spleens of the mice immunized 
with various forms of rL7/L12 protein. The proliferation of T lymphocytes in 
various immunized animals was found to depend on dose of antigen. It was observed 
that cell proliferation increases exponentially with increase in concentration of 
recombinant rL7/L12. 004"^ T cell proliferation was expressed as stimulation index 
(S.I.) showing the ratio of thymidine incorporation in experimental versus control 
(RPMI only) at a particular concentration of antigen (0.1 |ig/well). As shown in 
Figure 16, immunization with E-Lip-L7 resulted in rL7/L12 specific CD4"^  T-cell 
proliferation (S.I. 1.49) which was statistically significant as compared with the P-
Lip-L7 (S.I. 1.34; P<0.05) as well as S-19 (S.I. 1.21) or IFA-L7 (S.I. 1.22) 
immunized mice (P<0.001). Splenocytes collected from free antigen injected mice 
(F-L7) or sham liposome (no antigen; Sham EL) or sham escheriosome + rL7/L12 
(physical mixture; EL+L7) or animal immunized with PBS only failed to elicit a 
detectable proliferative response against rL7/L12 antigen (Table 14). 
CDS"^  T lymphocyte response 
The potential of escheriosome encapsulated rL7/L12 to induce antigen 
specific CTL activity was evaluated by cytotoxicity assay. It was found that 
immunization with rL7/L12 entrapped in escheriosome generated cytotoxic T cells 
in the immunized animals. The lysis of the target ceils increased with increase in 
ratio of effector cells versus target cells. The phenotype studies revealed that effector 
cells were CD8^ T cells as pretreatment with anti-CD8 antibodies abolished CTL 
response, while anti-CD4 antibodies did not abolish the target cell lysis (Figure 17, 
Table 15). 
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Figure 16. CD4^ T cell Proliferation response of splenocytes derived from mice 
immunized with various forms of Brucella recombinant rL7/L12 protein 
CD4^ T cell Proliferation response of splenocytes derived from control and 
immunized mice vaccinated with escheriosome entrapped rL7/L12 protein, egg 
PC/Chol liposome entrappedrL7/Ll2protein, IFA emulsifiedrL7/L12 andff-ee form 
of rL7/L12 protein. CD4* T lymphocytes were co-stimulated with increasing 
concentration of purified rL7/L12 protein. After 72 h, [^H]-thymidine was added 
and its incorporation was measured after 16 h incubation by liquid scintillation 
spectroscopy. The stimulation index (S.I.) was calculated by counting mean cpm 
values of stimulated culture/mean cpm values of unstimulated culture. Each bar 
represents the mean of three determinations ±SD. 
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Figure 17. CD8^ T cell proliferation response of splenocytes derived from mice 
immunized with Escheriosome encapsulated rL7/L12 
Escheriosome encapsulated rL7/L12 induces CD8^ T lymphocytes in immunized 
mice. Effector cells were obtained from spleen of mice immunized with escheriosome 
encapsulated rL7/L12pretreated with anti-CD4 or anti-CD8 monoclonal antibodies 
followed by treatment with baby rabbit complement. The pretreated effector cells 
were incubated with target cells (PEC) pulsed with escheriosome encapsulated 
rL7/LI2 followed by labelling with Cr as described in the materials and method 
section. The lysis of the target cells was measured by Cr release assay. (^) Anti-
CD8 antibody pretreatment; (*) anti CD4 antibody pre-treatment; (A) pre-
treatment with complement alone; (u) no pretreatment. The results are represented 
as, percent specific lysis f'Cr release) of the target cells. Each line represents the 
mean of three determinations ±S.D. 
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Experimental groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
Stimulation Index (S.I) 
1.027±0.015 
I.207±0.025 
1.487±0.030 
1.337±0.030 
1.223±0.031 
1.113±0.032 
1.089±0.015 
1.030±0.017 
Table 14 
CD4"^ T cell Proliferation response of splenocytes derived from mice 
immunized with various forms of Brucella recombinant rL7/LI2 
protein 
P-values: Control vs E-Lip-L7<0.001; S-19 vs E-Lip-L7<0.01; P-Lip-L7 
vs E-Lip-L7<0.05; IFA-L7 vs E-Lip-L7<0.01; F-L7 vs E-Lip-L7<0.001. 
EL+ L7 vs E-Lip-L7<0.001; Sham EL vs E-Lip-L7<0.001. 
Pretreatment with 
Anti-CD8 antibody 
Anti CD4 antibody 
Rabbit complement 
No pretreatment 
Effector:Terget ratio 
5:1 
7.2±0.46 
9±0.421 
8±0.341 
7±0.439 
10:1 
9±0.479 
24±0.421 
23±0.341 
25±0.589 
20:1 
8.5±0.308 
32±0.609 
34±0.731 
33±0.561 
Table 15 
CD8 T cell proliferation response of splenocytes derived from mice 
immunized with Escheriosome encapsulated rL7/L12 
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Induction of IFNy in immunized mice 
To evaluate the production of IFN^ the splenocytes, collected one week after 
the last immunization, were cultured with matching form of the antigen. 
Escheriosome-rL7/L12 (E-Lip-L7) combination was found to express high level of 
IFNy (2.89 ng/ml) in the stimulated cells. Among other forms of antigen 
preparations, only P-Lip-L7 (1.896 ng/ml) could show significant level of IFNy, 
while it was 1.584 ng/ml in IFA-L7 group (P<0.05). Animals immunized with free 
form of antigen (F-L7) or sham escheriosome + rL7/L12 (physical mixture; EL+ L7) 
failed to elicit significant level of IFNy (P<0.001) (Figure 18). No detectable amount 
of IFNy was found in the control animals inoculated either with PBS or sham 
liposomes (no antigen; Sham- EL) (Table 16, Figure 18). 
Release of migration inhibition factor (MIF) 
The release of macrophage migration inhibition factor (MIF) in the 
lymphokines of different immunized animals were assessed by in vitro inhibition of 
migration of macrophages and was expressed as percent lymphocyte migration 
inhibition (LMI%). The highest inhibition (62.33 %) of lymphocyte migration (LMI 
%) was detected in the stimulated lymphokines collected from mice vaccinated with 
E-Lip-L7 whereas LMI % in P-Lip-L7 immunized mice was 57 %. Mice vaccinated 
with S-19 or IFA-L7 protein showed significantly lower level of MIF (P<0.001). 
Mice immunized with sham escheriosome + rL7/L12 (physical mixture; EL+ L7) or 
antigen in free form (F-L7) failed to elicit detectable response (Figure 19, Table 17). 
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Figure 18. Effect of immunization with various forms of rL7/L12 protein 
on production of IFNy in Balb/c mice. 
The level of IFNy was determined in the supernatant of spleen cell culture stimulated 
with matching form of antigen after 1 week post last immunization. The concentration 
of IFNy in the culture supernatant was calculated for each experimental group using 
linear regression equation obtained from the absorbance value (A450) of standards 
IFNy and expressed in ng/ml. Each bar represents the mean of three determinations ± 
S.D. 
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Figure 19. Effect of immunizations with recombinant rhlllAI protein 
on production of lymphocyte migration inhibition factor (MIF) in Balbic mice 
The percent of migration inhibition (%LMI) of macrophage (isolated on day 7 post-
last booster) was assessed in four mice of each group vaccinated with various forms 
of recombinant rL7/L12 protein. Mice immunised with S-19 were used as reference. 
Control mice were treated with PBS only. Each bar represents the mean of three 
determinations +S.D 
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Experimental groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
Concentration of 
IFNy (ng/ml) 
0.230±0.023 
0.843±0.051 
2.889±0.071 
1.896±0.055 
1.584±0.040 
0.542±0.042 
0.470±0.046 
0.321±0.031 
Table 16 
Effect of immunization with various forms of rL7/L12 protein on production of 
IFNy in Balb/c mice. 
P-values: Control vs E-Lip-L7<0.001; S-19 vs E-Lip-L7<0.01; P-Lip-L7 vs E-Lip-
L7<0.5; IFA-L7 vs E-Lip-L7<0.01; F-L7 vs E-Lip-L7<0.001. EL+ L7 vs E-Lip-
L7<0.001; Sham EL vs E-Lip-L7<0.001. 
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Experimental groups 
Control 
S-19 
E-Lip-L7 
P-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
% Lymphocyte Migration 
Inhibition (LMI %) 
24.0±2.517 
41.6±L527 
62.3±3.512 
57.0±2.641 
34.0±2.646 
2L7± 2.517 
21.1±2.223 
19.2±2.111 
Table 17 
Effect of immunizations with recombinant rL7/L12 protein on production 
of lymphocyte migration inhibition factor (MIF) in Baltic mice 
P-values: Control vs E-Lip-L7<0.001; S-19 vs E-Lip-L7<0.01; P-Lip-L7 vs E-Lip-
L7<0.5; IFA-L7 vs E-Lip-L7<0.01; F-L7 vs E-Lip-L7<0.001. EL+ L7 vs E-Lip-
L7<0.001; Sham EL vs E-Lip-L7<0.001 
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Delayed type hypersensitivity reaction (DTH) 
The potential of various rL7/L12 formulations to induce cell mediated 
immunity was also assessed by their ability to induce DTH response on in the 
footpad of immunized animals. Briefly, recombinant rL7/L12 protein was injected 
intradermally in right footpad of each mouse belonging to various immunized 
groups and left one was kept as control that received same volume of PBS only. 
Increase footpad thickness was measured after 12, 24, 36, 48 and 72 hours post 
injection. Footpad thickness after intradermal injection of protein increased 
exponentially, attained maxima at specific time period and then decreased down to 
normalcy. The mice received E-Lip-L7 experienced significant (P<0.01) rise in 
footpad thickness as compared with the other group except P-Lip-L7 immunized 
mice which showed nearly same level of increase in footpad thickness at 36 hrs post 
immunization (Figure 20), while in S-19 vaccinated mice, maximum increase in 
footpad thickness was observed at 24 hrs that tapered down subsequently. The 
change in footpad thickness, observed in the mice belonging to control (PBS only) 
or those immunized with free antigen (F-L7) or sham liposome (no antigen; Sham 
EL) or sham escheriosome + rL7/L12 (physical mixture; EL+ L7) (P value < 0.001) 
was found insignificant (Table 18). 
Protection against B.abortus 544 challenge in immunized mice 
The potential of escheriosome encapsulated recombinant rL7/L12 protein to 
impart protection was evaluated on the basis of their ability to eliminate bacterial 
load (B. abortus 544) in spleens of immunized mice. The immunized mice were 
sacrificed on day 7, 15 and 30 post challenge with infection. The protection efficacy 
was calculated as the logio value of bacterial load to assess degree of protections. On 
day 7 post challenge with infection, the bacterial burden in E-Lip-L7 immunized 
mice was log 4.25 while it was log 4.28 in P-Lip-L7 immunized animals. On the 
other hand, IFA-L7 (log 4.67) immunized animals and conventional S-19 (log 4.63) 
vaccinated mice imparted same level of protection (Table 19) 
On day 15 post challenge of infection, mice immunized with E-Lip-L7 and 
P-Lip-L7 protein showed significant (P<0.05) reduction in bacterial load in the 
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spleen (from log 4.25 to 3.57 and from log 4.28 to 3.68) while IFA-L7 immunized 
animals was inefficient to reduce bacterial load (from log 4.67 to log 4.32). In 
contrast, the reduction in the number of CFU in S-19 vaccinated mice decreased 
down from log 4.63 to log 3.97 units. 
On 30 days post infection, spleenic load of B. abortus 544 in S-19 
vaccinated mice reduced to log 2.77, which was comparable to the protection 
efficiency conferred by E-Lip-L7 (log 2.93) group and P-Lip-L7 (log 3.01). The 
total spleenic load of B. abortus 544, at various time interval showed that none of 
the other combinations (IFA emulsified antigen, sham liposome (no antigen) or 
physical mixture of sham escheriosome + rL7/L12 as well as free form of the 
antigen could induce protection against B. abortus 544 infection. The results of the 
present study explicitly suggest that escheriosome encapsulated antigen engendered 
early protection against Brucella infection in Balb/c mice comparable to the 
protection levels offered by standard B. abortus S-19 vaccination (Figure 21). 
Macroscopical lesions of spleen of experimental animal after challenge with B. 
abortus 544 
We also observed induction of splenomegaly in the animals challenged with 
Brucella abortus 544 infection. Prominent splenomegaly was observed in the 
animals that were exposed to infection without prior immunization while spleen size 
of the animals from protected groups was of the same order to that of healthy 
animals (no immunization and no challenge with infection). Moreover, superficial 
multiple foci, discoloration of surface and granuloma formation were also noted in 
the spleen, collected from control group of mice (unimmunized but challenged with 
infection). In contrast, no macroscopic lesions were found in the protected group of 
animals. 
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Figure 20. Delayed type cell mediated immune response in mice immunized 
with various forms of Brucella rL7/L12 protein 
The DTH response was determined by injecting 50 fig of purified rL7/L 12 protein in 
hind left footpad of mice, while right footpad was administered with PBS (control) 
only. The thickness of footpad was measured by Vernier calipers on various 
time intervals post injection. DTH value (in mm) was expressed as the 
absolute increase in footpad thickness. Each line represents the mean of three 
determinations ±S.D. 
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Figure 21. Level of protection against B. abortus 544 infection conferred by 
immunization with various form oi Brucella rL7/L12 protein 
The mean CFU/spleen (log 10) in four mice from each group was calculated 
on days 7, 15 and 30 post challenge with infection. Each line represents the 
mean of three determinations ± SD. 
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Hr 
PI. 
12 
24 
36 
48 
72 
Control 
O.048±O.00I 
0,OI6±0.002 
0.014±0.004 
0.016±0.003 
0.012±0.002 
S-19 
0.042±0.00I 
O.I50±0.003 
0,I37±0.002 
0.078±0.003 
0.029±0.003 
P-Lip-L7 
0.071 ±0.002 
0.155±0.002 
0.190±0.004 
O.I50±0.002 
0.079±0.00I 
E-Lip-L7 
0.071 ±0.001 
O.I6I±0.009 
0.2I7±0.003 
0.179±0.006 
0.090±0.003 
1FA-L7 
0.073±0.001 
0.150±0.002 
O.I3I±0.008 
0.090±0.005 
0.042±0.002 
F-L7 
0.0397*0.002 
0.073±0.003 
0.050±0.003 
0.033±0.004 
0.014±0.002 
EL+L7 
0.034±0.002 
0.085±0.004 
0.05±0.004 
0.038±0.005 
0.019±0.003 
Sham EL 
0.032±0.001 
0.018±0.002 
0.0I8±0.004 
0.016±0.003 
Q.013±Q.0Q2 
Table 18 
Delayed type cell mediated immune response in mice immunized with various forms of 
Brucella rL7/L12 protien 
Control vs E-Lip-L7<0.001; S-19 vs E-Lip-L7<0.01; P-Lip-L7 vs E-Lip-L7<0.5; IFA-L7 vs E-
Lip-L7<0.01; F-L7 vs E-Lip-L7<0.00]; EL+L7 vs E-Lip-L7<0.001; Sham EL vs E-Lip-
L7<0.001 
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Experimental 
group (n=4) 
PBS 
S-19 
P-Lip-L7 
E-Lip-L7 
IFA-L7 
F-L7 
EL+L7 
Sham EL 
Mean loglO Brucellae ± SD 
in spleen at days 
Postchallange 
7 15 30 
4.87+0.009 
4.63+0.027 
4.28±0.025* 
4.25±0.043' 
4.67±0.016 
4.85±0.012 
4.75±0.045 
4.78±0.052 
4.88±0.010 
3.97+0.040" 
3.68±0.011** 
3.56+0.019" 
4.32±0.012* 
4.78+0.007 
4.66+0.035 
4.70+0.04 
4.58+0.009 
2.77+0.053" 
3.01+0.022" 
2.93+0.030" 
3.91+0.034* 
4.82+0.015* 
4.78+0/054 
4.68+0.06 
Log unit of 
protection 
at days 30 post 
challenge 
7 15 30 
— 
0.24 
0.59 
0.62 
0.20 
— 
— 
— 
— 
0.91 
1.20 
1.32 
0.59 
— 
— 
— 
— 
1.81 
1.57 
1.65 
0.67 
— 
— 
— 
Table 19 
Level of protection against B. abortus 544 infection conferred by immunization 
with various form of Brucella rL7/L12 protein 
* Significantly different from PBS treated mice (P< 0.05) 
** Significantly different from PBS treated mice (P< 0.001) 
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In search of suitable vaccine against brucellosis, killed vaccines are non-
infectious but they are considered less efficacious than the live vaccines in inducing 
protective immunity against brucellosis. In addition with whole-cell vaccines, the 
regulatory requirements for the exact specification of a vaccine composition and the 
mechanism to obtain protective immunity are difficult to meet. Recombinant subunit 
vaccines have numerous advantages as they are completely inert, their composition 
is predetermined, their co-production can be better controlled and their 
homogenesity is much higher. However, inactivated and purified, soluble antigens 
often are mixture of different proteins some of which are weak immunogens and 
require a safe and effective adjuvant to induce a strong immune response. In fact, the 
success of vaccine depends on the selection of right antigen(s), adjuvant(s) and 
delivery system(s). By optimizing these factors the immune response can be 
successfully tailored against specific pathogens (Bachrach et al., 1994). 
Members of the genus Brucella are small gram negative, 
facultatively intracellular bacteria of tremendous zoonotic importance and are 
causative agents of brucellosis, a chronic disease of animals and humans. In animals, 
this disease often results in infertility and abortions leading to severe economic 
losses to livestock producers. Human acquire the infection by coming in contact 
with the infected materials or by consuming contaminated meat or dairy products. 
Because of the economic losses to the cattle industry caused by B. abortus, as well 
as the zoonotic infections by this bacterial species, great efforts are being made to 
eradicate brucellosis from all over the world. In order to achieve this objective, B. 
abortus S-19 and RB-51 vaccines have been used with relatively good results. 
However, even these vaccine strains are far fi-om ideal, since they present some 
disadvantages, e.g. residual antibody titre, aberrant serologic reactions, inducing 
abortion in pregnant cattle, unsafe to humans, interference in diagnosis, and showing 
a likelihood of changing to a virulent form. These problems haves stimulated the 
interest of development of effective new generation vaccine (Alton, 1997) to 
overcome the disadvantages associated with the currently used live vaccines. 
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The development of vaccine strategies against Brucella represents a difficult 
and exciting challenge particularly because of the complexity of the intracellular life 
style of Brucella within their hosts and because of the complexity of the immune 
responses they elicit. As Brucella is a facultative intracellular bacterium, resistance 
to B. abortus depends mainly on acquired cell-mediated immunity (CMI) (Oliveira 
and Splitter, 1995). It is well established that protective response against 
intracellular infections like brucellosis, tuberculosis, salmonellosis, cryptococcosis, 
candidiasis etc. requires the generation of potent cell mediated immunity linked to 
the induction of a Thl type immime response as a prophylactive measure. 
Considering this fact, recent trends in the development of successful vaccine 
candidate against various intracellular pathogens like Brucella emphasizes on unison 
orchestration of both cellular immunity along with humoral counterpart. 
Therefore, the achievement of a coveted goal to develop effective vaccines 
with against Brucella infection implies both identification of major 
immunodominant antigen and an adequate delivery or adjuvant system to elicit 
appropriate immune response. 
In search of suitable antigen that can impart effective immimity against 
brucellosis several proteins have been tried as candidate antigen (Tabatabai et al., 
1994; Bachrach et al, 1994; Oliveria and Splitter, 1994; Vemulapalli et al, 2000; 
Al-marari et al, 2001; Schurig et al, 2002; Abtahi et al, 2004; Luo et al, 2006). 
Among them, rL7/L12 with suitable adjuvant formulation has been tried to 
overcome the problem associated with currently available live vaccine (Oliveria and 
Splitter 1994; Brooks-Worrel and Splitter, 1992). We used escheriosome which have 
been shown to avidly fuse with the plasma membrane and successfully delivered 
their content to the target cells. Like most other E. coli has predominance of 
fusogenic lipid in their plasma membrane which is composed of amino 
phospholipids (phosphotidylethanolamine) along with cardiolipin and 
phosphtidylglycerol (Pluschke and Overlith, 1981). This unique membrane 
phospholipids composition certainly implies significance of biological importance. 
The characteristics of lipid isolated from E. coli paved the way for delivering 
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antigens into the cytosol of APCs has been well established and found to provide 
protection against no of intracellular pathogens (Owais et al., 2001; Faisal et ah, 
2003; Sharma et al, 2006a,b). 
The present study was undertaken to identify, express and purify the 
immunodominant protective antigen (rL7/L12) and to evaluate the possible use of 
escheriosome encapsulating ribosomal rL7/L12 protein as successful vaccine 
candidate against experimental murine brucellosis. 
We have purified the expressed protein by using Ni^-NTA column 
chromatography due certain advantages. Nickel has property to bind with histidine 
and this property was exploited in the purification of the recombinant protein from 
the cells. The interaction of 6X His tag with the Nickel- nitrilo-acetic acid (Ni^-
NTA) is conformation dependant. The purification was done at affinity 
chromatography using nickel as a chelating agent. The protein was bound to 
Ni"^ "NTA Agarose at pH 8.0. Other cellular protein as well as nucleic acids will also 
bind to the column. These associations are weak which could be removed by 
changing the pH to 6.3 stringent washing conditions at 6.3 removes most of the 
cellular proteins. As the interaction between nickel and histidine is weak at pH 4.5, 
the nickel bound recombinant protein comes out with elute. It was noticed that some 
contaminant till present in elute which was overcome by using IM NaCl, 20mM 
imidazole, 20 mM P mercaptoehtanol, 20 %, glycerol and 0.25% Triton XIOO. 
Addition of NaCl, Triton X-lOO and glycerol removes most of the proteins linked 
with the 6X histidine tagged protein. Imidazole to a low concentration removes the 
non specific low affinity binding of the background proteins and addition of p 
mercaptoehtanol reduces disulfide bonds that might be formed between the 
contaminating agent and recombinant protein. The purified rL7/L12 protein was 
dialyzed and checked on SDS-PAGE. The purity of recombinant rL7/L12 proteins 
were nearly to 99% as little or no contamination was observed in purified lane on 
SDS-PAGE. 
The advantage of studying the cloned gene products obtained from 
recombinant E. coil is that the protein is free from other Brucella proteins as well as 
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Brucella lipopolysaccharides (Sambrook and Russel, 2001). In the present, the 
purified protein was used to raise polyclonal antiserum which was specific for a 
single Brucella antigen. Immunoblot of recombinant rL7/L12 protein as well as B. 
abortus native antigen showed strong immunoreactivity with rabbit anti rL7/L12 
sera. This demonstrates unequivocally that the recombinant rL7/L12 expressed in E. 
coli was identical to that of B. abortus native protein (rL7/L12). Recombinant 
rL7/L12 protein (when used in free form) has been shown to activate immune 
system (B-T cell response) of the host with modest response (Bachrach et ah, 1994; 
Oliveira et al, 1996). This warrants development of suitable delivery system as a 
vehicle/carrier for the antigen or its co-formulation with suitable adjuvant to become 
a successful subunit vaccine against brucellosis. 
Most of the presently available antigen delivery system viz. ISCOMs, 
virosomes, pH sensitive liposomes or fusogenic proteins, although claimed to induce 
strong immuno-adjuvant, can't be recommended because of cost factor, toxicity as 
well as elicitation of immimological responses against structural components 
(protein and carbohydrate) of the delivery vehicles. Interestingly, liposomes, made 
up of naturally occurring phospholipids been widely employed as vehicle to deliver 
drug and other biologically active substance to cells both in vivo and in vitro. 
Moreover, the conventional liposomes, composed of egg-derived 
phosphatidylcholine were found to induce antigen specific humoral immune 
response. Some of the previous work clearly demonstrated in our hands, that cell 
mediated immune response generated by conventional egg PC/Chol liposome based 
vaccines are more or less same to that of antigen-IFA (Incomplete Freund's 
adjuvant) form of the vaccines.(Owais et ah, 2001). 
Keeping into consideration the potential of escheriosome to deliver their 
content in to the cytosol of the APCs, our present study is mainly focused its 
possible use as a successful delivery system of recombinant rL7/L12 protein against 
brucellosis. We found that immunization with escheriosome-encapsulated antigen 
generates high serum antibody (IgG) titre at different time points as compared to egg 
PC/Chol liposome or IFA adjuvanted delivery of the antigen. This is certainly an 
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indication of superiority of the escheriosome-mediated delivery of recombinant 
protein than other form of antigen. Since the subclass of IgG response is generally 
regulated by the pattern of cytokines secreted by CD4^ helper T cells, we assessed 
level of both IgGl and IgG2a isotypes antibody generated against the various 
preparation of rL7/L12 protein in the immunized animals. Significantly higher IgGl 
and IgG2a levels were detected in the sera of the mice immunized with E-Lip-L7. 
Critical analysis of the data revealed the predominance of IgG2a over IgGl in the 
animals immunized with liposomal form of rL7/L12 protein. This indicates a clear 
shift towards Thl type immune response to the antigen in accordance to the previous 
study where rL7/L12 protein, when administered in combination with MDP, was 
reported to induce Thl subpopulation in murine model (Oliveria, 1996). 
Interestingly, the switching in the favour of the IgG2a isotypes upon immunization 
with-E-Lip-L7 was higher than P-Lip-L7 may be due to the physical targeting of the 
entrapped protein to the cj^osol of the antigen presenting cells (Owais et al., 2001). 
In vitro proliferation of CD4^ T lymphocytes collected from E-Lip-L7 
immunized mice after their stimulation with the rLlfLll (E-Lip-L7) protein 
suggests that vaccination with escheriosome entrapped protein could elicit strong T 
cell proliferation response. The immunization of animals with P-Lip-L7 resulted in 
relatively less lymphoproliferative response as compared to E-Lip-L7 immunized 
animals. Nevertheless, the proliferation responses in both the liposomal formulation 
were significantly higher than that of S-19 or IFA adjuvanted groups. It seems that 
because of their particulate nature, P-Lip-L7 could result in higher CD4^ T response 
but still that level remains less than E-lip-L7 immunized animals (Ahmed et ah, 
200lab; Faisal et al, 2003). The results of the present study clearly indicate that 
rL7/L12 protein antigen could adapt different mechanism or identify different 
components of immune system to evoke characteristics effector response depending 
on its delivery mode, for example, rL7/L12 entrapped in escheriosome elicits 
antigen specific CTL generation as well. Phenotype analysis of the effector cells 
were performed by pre treatment of the cells with anti-CD8 antibodies, before using 
them for Cr release assay. The results revealed that such pretreatment abolishes 
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CTL response, which confirms the CDS"^  phenotype of the generated T lymphocytes 
by escheriosome mediated delivery of rL7/L12 protein.The type I and type II 
cytokines have characteristic effects on the development of T helper cell subsets, for 
example, type I cytokines promotes growth of Thl subset; while inhibit the 
development and activity of Th2 subset, an effect known as cross regulation. For 
instance, IFNy (secreted by the Thl) preferentially inhibits proliferation of the Th2 
subset, while IL-4 and IL-10 (secreted by the Th2 subset) down regulate secretion of 
IL-12, one of the critical cytokines that regulate differentiation of Thl subset. 
Interferon-y secreted by the Thl subset in turn promotes production of IgG2a 
production by B-cells but inhibits IgGl and IgE production (Harding et ah, 1991). 
The recombinant rL7/L12 ribosomal protein previously shown to be an 
immunodominant antigen in cattle induced murine CD4"'' T cells to express Thl 
subset of cytokines (Brooks-Worrel and Splitter, 1992; Goldsby et al, 2003). Our 
results showed that the IFNy level was significantly higher (P<0.001) in 
escheriosome entrapped protein immunization than the other experimental groups. 
The potential of in vitro inhibition of lymphocyte migration has been 
reported to possess noticeable correlation with the cell-mediated immunity (Confer 
et al., 1987; Winter and Rowe, 1988; Golding et al, 2001). The escheriosome 
entrapment of antigen showed expression of higher level of macrophage migration 
inhibition factor as compared with the other preparation, suggestive of the fact that 
E. coli lipid liposome mediated delivery of antigen might have primed the 
lymphocytes thereby releasing the lymphokines (MIF) in circulation. We 
demonstrated strong DTH response in terms of footpad thickness in the mice 
immunized with both the liposomal recombinant protein. The strong DTH response 
as well as reversal of lymphocyte migration in E-Lip-L7 preparation might be due to 
the elicitation of strong cellular immunity in accordance with the previous study that 
was performed in guinea pig model using B. abortus recombinant protein GroEL 
(Abtahi et al, 2004). It is also reported that in mouse model, only Thl clones were 
capable of producing an antigen specific and MHC-restricted inflammation reaction 
with characteristics of DTH response (Mandal and Lee, 2002). 
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Finally the escheriosome-mediated protection against virulent B. abortus 544 
further confirmed our hypothesis that it can successfully impart protective response 
against intracellular Brucella infection. There was continuously higher level of 
protection at different time points in the animals immunized with escheriosome-
encapsulated antigen followed by eggPC/Chol liposome entrapped antigen through 
out the experiment. The protection conferred by IFA adjuvanted antigen was not at 
par in terms of quality or duration of the protection induced by the escheriosome or 
PC liposome vaccine. The data from the present study indicates that the extent of 
protection conferred by the S-19 (used as vaccinal control) was comparable with 
those vaccinated with liposomal formulations. However, S-19 could eliminate 
pathogens only after 30 days post challenge as evident from the data that bacterial 
load determined on day 7 and day 15 post infection showed poor efficacy of S-19 
vaccine as compared to escheriosome based vaccine. This is certainly in agreement 
with immunological response elicited by S-19 vaccine observed in the present study. 
The vaccine took considerable time to activate immune system of the host, the 
reason; initially it was not much effective in elimination of Brucella pathogen. 
The present study also reveals that E-Lip-L7 ensured maximum protection 
level in the immunized animals that was accompanied with higher induction of 
IgG2a level. Infact, it was IgG2a isotype of the antibody in the infected animals that 
helped in clearance of pathogens (Figure 22 ). The development of IgG2a isotype is 
crucial because the binding of their Fc portion to the Fc receptors present on the 
surface of phagocytes activates a broad spectrum of antimicrobial response viz. 
cytokine synthesis, release of various inflammatory mediators, and generation of 
reactive oxidant species (Mossman et al., 1986). In general, conventional liposome 
(eggPC/Chol ) switch Thl/Th2 polarization in favour of Th2 response mainly, 
however; in the present set of study we demonsfrated that both E-Lip-L7 and P-Lip-
L7 forms of the antigen successfiilly induce Thl cell response. This could be 
explained on the premise that liposome/ bilayer structure acts as strong 
immunoadjuvant and they fiinction in harmony with intrinsic immune properties of 
given antigen. Ribosomal L7/L12 is basically 
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Figure 22 (a,b,c) Correlation between IgG isotypes with spleenic load of B. 
abortus 544 in Balb/c mice immunized with escheriosome entrapped rL7/L12 
protien 
The level of IgG isotypes was expressed as absorbance (A492). Total CFU (xlOO) 
was determined in the spleen at days 7(a), 15(b) and 30(c) post challenge. 
Thl type antigen; its co-administration in liposomised form does not alter its 
intrinsic properties to activate T cells. Nevertheless, order of magnitude of desirable 
immune response is regulated by immunpotentiating properties of given set of 
liposomes used as adjuvant. In this regard, escheriosome were found to be more 
effective immunopotentiating agents as compared to the egg PC liposome. To 
exclude the possibility of the fact that beside lipid some other structural components 
can be considered as possible factor responsible for observed immunological 
manifestations. This can be ruled out on the premise that no protein or carbohydrate 
residues were found to be present in escheriosome as revealed by their chemical 
analysis. This was further confirmed by SDS-PAGE, which was foimd negative for 
any protein content upon silver staining (Ahmad et al, 2001a,b). Finally, the 
observations made in the present study that both sham escheriosome as well as 
physical mixture of antigen and preformed escheriosome failed to activate T 
lymphocytes clearly support the notion that it is fusogenic properties of the 
escheriosome based delivery system that help in elicitation of immunological 
responses. 
In spite of the fact that E. coli resides as commensal and constitutes a major 
component of gut flora, it is premature to rule out presence of toxic components in 
the lipid isolated fi-om it without performing chronic toxicity test. However, our 
preliminary studies demonstrated no phlebitis like symptoms at the site of injection 
or general discomfort upon its administration in the immunized animals. Beside, 
exposure of? 815 cells (Ix lO^ cells/well) with escheriosome (2\ig lipid P//well) did 
not inflict any toxicity to the cells as revealed by MTT- micro culture tetrazolium 
assay t^ eftbftftl obseivation). Finally, the safely of escheriosome can be further 
by the fact that its incubation with antigen presenting cells did not 
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hamper their physiological activities and they successfully process antigen to 
express them with appropriate major histocompatibility complexes. Moreover E. coli 
is natural habitant of gut flora, suggesting lipid from such bacteria may be more 
readily acceptable from regulatory perspective in vaccine development. 
Recently, fiisogenic potential of yeast lipid liposomes have been established 
and found that immunization with antigen encapsulated in such liposomes can 
successfully activate both humoral as well as cell mediated immune responses 
(Owais et al. 2001). Although, both yeast lipid liposomes as well as escheriosomes 
based antigen delivery systems elicit strong immunological responses, however, 
later may offer several advantages for its possible use as antigen carrier. In fact less 
heterogeneous composition of E. coli lipid is likely to impart less toxicity risk as 
compared to the complex phospholipid profile of yeast membrane lipid. Beside, the 
less generation time of E. coli {cf. 20 min) as compared to yeast {cf. 2 h) will 
certainly be advantageous in harvesting larger amount of the microbe in less time 
period and would be more economical when used for bulk isolation of lipid. 
Moreover, the presence of two-membrane system as well as small size of the E. coli 
yields at least 4-5 times higher amoimt of lipid when isolated from same biomass of 
yeast cells. Besides, vaccine based on liposome formulated with lipid-A and 
alhydrogel gave been shown to be potent and safe but adjuvant like lipid or its 
analogue because of their non specific adjuvanticity can't be used or recommended 
particulate with other autoimmune diseases (Sharma et al., 2006a). 
It may be inferred from the study that due to strong fusogenic character of 
lipids, escheriosome can effectively deliver antigen to both class I and class 11 
processing compartments of antigen presenting cells, thus generating a strong 
antigen-specific T cells. Such considerations, which could selectively enhance 
cytotoxic T cells and T-helper cells are pertinent in designing liposomes based 
vaccines, and hence will subserve in protection against the infectious diseases. 
In spite of the rapid advances in the strategies for controlling brucellosis, the 
prevalence of the disease continues to rise exponentially in developing countries. 
Though the new vaccine such as SRB51 and B. suis S-2 are of some promise to 
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control the disease, however lot of concerns have to be cleared about their efficacy 
and safety before their routine use (Thakur and Thapliyal, 2002). However, despite 
extensive evaluation of a large number of candidates over many years' efforts to 
establish successfiil Brucella vaccine is still going on. In relation to this concern our 
present investigation infers that escheriosome-based delivery system may offer 
several advantages for its possible use as antigen carrier and a novel approach for 
designing liposome based subunit vaccine against brucellosis. 
138 
chapter n 
Chemotherapeutic efficacy of 
'EscfieriosomeT.ncapsulhtedAntieiotics 
Against Infectious (Diseases 
^view of Literature 
Chapter II Review of Literature 
Use of Antibiotics Against Intracellular Pathogens 
S.A.Waksman introduced the term 'antibiotic' in 1942. In forties to sixties, 
the term "antibiotic" was clearly differed from the term "chemotherapeutic drug": 
Antibiotics were natural drugs produced by several fungi or bacteria where as 
chemotherapeutic drugs were man-made substances. Nevertheless the differences 
were abolished after chemical synthesis of some antibiotics has been realized and 
new drugs have been developed from the natural products with binding various side 
chains to the basic structure. From this point of view, the history of antibiotics 
began in 1932 when the first sulfonamide was prepared. The boom of sulfonamides 
appeared thereafter with about 5.000 substances developed during years 1932-1945. 
Sulfonamides were effective in urinary tract infections, shigellosis, pneumococcal 
pneumonia and even in purulent meningitis. But the effect of sulfonamides was 
totally exceeded with penicillin and streptomycin. It was a happy chance that these 
two antibiotics covered the whole spectrum of bacteria. Penicillin was very 
effective against the most danger microbes of that time-pneumococci and 
streptococci-and also against other important pathogens like staphylococci, 
meningococci, gonococci, Corynebacterium diphteriae, or Treponema pallidum. 
The nice ideas of solving the problems of infectious diseases were lost some years 
later because of two new phenomena: 
1) The new bacterial agents were discovered that were not affected with 
penicillin or streptomycin. Typical representatives of such agents were 
mycoplasmata, chlamydiae or rickettsiae. 
2) The much more important phenomenon was the advent of resistance. 
Staphylococci were the first important pathogens that developed 
resistant strains (first described in 1946, 5 years after introduction of 
penicillin) and these resistant variants spread throughout the whole 
world within fifties. 
The other microbes followed up in this way. Both the above-mentioned 
problems seemed to be solved with extensive discovering of new antibiotics. But 
many of them were too toxic (neomycin, colimycin) and/or poorly purified (original 
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form of vancomycin) and their use had to be diminished. A new step in progress 
was done in 1960 when first semi synthetic antibiotics were prepared from the 
penicillin molecule- methicillin and ampicillin. These drugs were active against 
staphylococci and common gram-negative bacteria like E.coli, H. influenzae or 5. 
enterica (including S. typhi ahdominalis). 
Many new antibiotics with high level of compatibility for patients were 
introduced for treatment of community infections as well. Oral cephalosporins, new 
macrolides, doxycyclin and fluoroquinolones are examples of these modem - and 
sometimes fashional drugs. Nevertheless, production of the easy-to-take and 
relatively safe antibiotics often led to the overuse and rapid rise in resistance in 
bacterial populations. Some types of resistance can be reversed with introducing 
new sorts of drugs. Unfortunately, microorganism can race with introduction new 
drugs successfully. In addition, some mechanisms of resistance are not revertible. It 
is clear that the threat of resistant bacteria has been growing in human as well as 
animal population. The problem of resistance can be solved only with accepting 
following demands: 
- Diminishing the overuse of antibiotics, the commonest mistake in the community 
is prescribing antibiotics to patients with an infection of viral origin and/or with a 
mild and easily self-hmited disease. 
- Consistent preference of narrow spectrum antibiotics, 
- Preference of a short course of higher dosed antibiotic to a long course of lower 
dosed drug, 
- Isolation of inpatients or hospital staff in whom infection or colonization with 
multi resistant strain is recognized and 
- Skilled experts must control prescription of antibiotics in both hospitals and 
community. 
Soon after antibiotics were introduced into medical practice, it was also 
pointed out that microorganisms capable of surviving within phagocytic cells may 
be protected from the killing actions of antibiotics with a poor ability to cross the 
eukaryotic cell membrane, leading to therapy failures and disease relapses (Holmes, 
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1966; Mackaness, 1962). Following the pioneering work by Bonventre et al. (1967) 
that showed that mouse peritoneal macrophages were impermeable to streptomycin 
in vitro, the aminoglycosides are been included in such a category. Failure of 
streptomycin and other aminoglycosides to treat infections due to strict or 
facultative intracellular pathogens (e.g., rickettsial diseases, chlamydial diseases, 
brucellosis and typhoid fever) have reinforced this point of view. Also, in vitro 
infected cell systems have been developed to test the activities of antibiotics against 
intracellular pathogens, and in many instances they have shown the limited 
intracellular activity of aminoglycosides compared to their strong bactericidal 
potential in extracellular medium (Jenkin and Benacerraf, 1960; Edson and Terrell, 
1999). 
Brucellosis- an Overview 
Among the many other potential zoonotic bacterial diseases like anthrax, 
leptospirosis, leisterosis, tuberculoais, brucellosis being a constant threat to public 
health. Many animals are potential reservoirs for Brucella species (Corbel 1997; 
Young, 1995). Milk and dairy products are the main sources for human 
contamination. Four serotypes are responsible for human brucellosis: B. melitensis, 
B. abortus, B. suis, and B. canis. Brucellosis most often manifests as an acute 
bacterial disease, and it may be complicated by secondary hematogenous 
localization in almost every organ (Corbel, 1997; Young, 1995). Chronic 
brucellosis is defined as a disease evolving for more than a year, without evident 
secondary localization. Since Brucella species are fastidious bacteria, their 
antibiotic susceptibilities in axenic medium have been usually determined either in 
Mueller-Hinton, tryptic soy, or brucella medium, supplemented with hemoglobin 
and vitamins. The intracellular localization of Brucella makes treatment difficult 
given that most antibiotic which have been seen to be an effective in vitro don't 
actively pass with cellular membrane (Moyer et al.,1995). 
The clinical manifestations of brucella infection have a great variety. Most 
frequent symptoms are fever (95%), anorexia (90%), fatigue (90%), smelly 
perspiration (80%), arthralgias (25-50%), myalgias (25-50%) and weight loss. Less 
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frequent symptoms are joint involvement (15%), splenomegaly (20%), 
lymphadenopathy of the bubonic and cervical area (10-15%), bronchitis, pleuritis 
and empyema, pulmonary abscess (5-10%), orheitis or orchiepididymitis (2-10%) 
Stefanos et al. (2003). 
Current Status of Chemotherapy Against Brucellosis 
Current treatment of acute brucellosis requires combined regimens of 
antibiotics and is conditioned by the fact that Brucellae are facultative intracellular 
parasites; thus, it is important to treat patients with drugs that penetrate 
macrophages. This fact seems to be responsible for the long duration of the disease 
and the high incidence of relapses. 
Freeman and Vana (1958) reported that streptomycin inhibited intracellular 
growth of Brucella spp at a 10 |ig/ml extracellular concentration. In contrast, 
Richardson and Holt (1962) reported that the same antibiotic, used at extracellular 
concentrations ranging from 2 to 50|ag/ml, was not effective in preventing growth 
of a B. abortus strain within bovine uterine mucosal cells despite up to 6 days of 
antibiotic exposure. Goldenbaum et al. (1966) also reported that streptomycin at 5 
|j.g/ml could not inhibit growth of a B. abortus strain within guinea pig peritoneal 
MPs, although the addition of chlorpromazine resulted in a significant intracellular 
killing effect after 24 h and 48 h of incubation of cultures. 
More recently, it was found that streptomycin at an extracellular 
concentration of 100 fig/ml did not affect intracellular growth of B. abortus and B. 
canis strains within murine or guinea pig peritoneal MPs, whereas liposome-
encapsulated streptomycin was highly bactericidal (Fountain et al., 1985). 
However, the activity of streptomycin was evaluated after only 24 h of incubation 
of infected cultures with the antibiotic, which may not have been sufficient to allow 
its intracellular accumulation. 
The most effective antibiotic treatment is the combination of doxycycline 
with streptomycin or rifampin but each of these regimens has disadvantages: the 
relapse rates and the toxicity and side effects, especially in children and pregnant 
women. In addition, twice-daily long-term dosing of oral doxycycline plus 
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intramuscular administration of streptomycin often leads to poor patient compliance 
(Abraham and Duthie, 1946; Baldwin and Winter, 1941). The necessity of 
combined treatment, the length of treatment, and the proportion of therapeutic 
failures with some regimens oblige us to look for new drug (s) or combination of 
drugs for the treatment of brucellosis. 
Fluoroquinolones, as a class, exhibit a broad spectrum of antibacterial 
activity. Their oral bioavailability, high tissue concentrations, evidence of 
intracellular penetration (Bergan, 1998; Easmon et al, 1986) and in vitro activity 
against Brucella spp. (Al-Sibai and Qadri, 1990; Garci'a-Rodn'guez, 1989; Qadri, 
1988; Qadri, 1990; Qadri, 1993) make these antimicrobial agents attractive 
candidates for use against infections caused by intracellular bacteria, such as 
Brucella spp. 
Among the other antibiotic fluorinated quinolones initially had good 
promises but however they lack bactericidal activity against Brucella spp. Moreover 
relapse rates are higher than 80% when human brucellosis is treated with 
ciprofloxacin (Shasha and Rubinstein, 1992). Thus fluorinated quinolones don't 
currently constitute adequate therapy for brucellosis (Garcia-rodriguez et al., 1993). 
However, the marketed fluoroquinolones, such as ciprofloxacin, ofloxacin, 
fleroxacin, and sparfloxacin, have moderate activity and lack effective bactericidal 
activity under intracellular conditions (WHO Report, 1997). 
The in vitro activities of newer fluoroquinolones (levofloxacin, 
trovafloxacin, sitafloxacin, moxifloxacin, grepafloxacin, and gatifloxacin) in 
comparison with ciprofloxacin, ofloxacin, and established agents against 160 strains 
of B. melitensis, including the type strain, B. melitensis (Brinley-Morgan and Corel, 
1990) for the treatment of human brucellosis has been studied extensively. Though 
the anti- Brucella activities of some other fluroquinolones (levofloxacin, 
robrafloxacin and moxifloxacin) were found to be similar to or slightly greater than 
that of ciprofloxacin, their typical pharmacokinetics properties, may warrant study 
for the treatment of human brucellosis (Brinley-Morgan and Corbel, 1990). Also, it 
is necessary to determine the effect of a pH of 5 (the pH of phagolysosomes) on the 
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activity of these fluoroquinolones, considering the lower in vitro activity against B. 
melitensis of other quinolones at that pH ( Garcra-Rodn'guez et al, 1989). 
Since the mid 1980s, laboratory researchers and clinicians have performed 
several microbiological and clinical studies of he possible use of quinolones in the 
treatment of human brucellosis. The activity against intracellular bacteria (Easmon 
et al, 1986), reduced risk of nephrotoxicity, good pharmacokinetic characteristics, 
and lack of a requirement for drug level monitoring represent the main advantages 
of using quinolones in this setting. Moreover, the need for a regimen that would 
eliminate disease relapse further necessitated the use of quinolones. 
Although several studies have been conducted over the past two decades, 
there is no conclusive evidence on the optimum antibiotic therapy for brucellosis. 
Disease relapse still represents one of the most important therapeutic problems. The 
last recommendation by the World Health Organization (WHO) for the treatment of 
acute brucellosis in aduhs was published in 1986 and suggested 600 to 900 mg 
rifampin and 200 mg doxycycline daily for a minimum of 6 weeks (Garcra-
Rodn'guez et a/., 1991). Alternatively, the WHO suggested that rifampin could be 
replacedwith 15 mg/kg of streptomycin, administered intramuscularly for only 2 
weeks. However, a meta-analysis, as well as a prospective randomized trial, both 
performed by Solera et al. (1996) showed that the "good old" combination regimen 
of streptomycin with an oral tetracycline results in fewer relapses than the 
doxycycline-rifampin combination (Solera and Saez 1994; Solera et al., 1995). 
Controlled clinical trials with other antibiotics, including trimethoprim-
sulfomethoxazole, new macrolides, and P-lactams, have shown inferior results or 
involved too few patients for a proper evaluation. Thus, the most widely used 
regimens are the two aforementioned combinations that were recommended by the 
WHO. In addition, rifampin monotherapy is the main option for brucellosis during 
pregnancy, whereas its combination with trimethoprim-sulfomethoxazole is the 
suggested treatment for childhood brucellosis (Khuri-Bulos et al, 1993; Craig, 
1998).Certain focal forms of brucellosis are difficult to treat, and surgery should be 
considered for patients with endocarditis or cerebral, epidural, splenic, or other 
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abscesses (Colmenero et ai, 2002; Mert et al, 2002). Regarding medical treatment, 
although the antibiotics used are essentially the same, prolonged therapy, up to six or 
more months, may be needed for patients with osteoarticular forms of the disease, 
and especially spondylitis (Bosilkovski et ah, 2004; Solera et al. 1999; Yilmaz et al, 
2004). Also, triple antibiotic combinations were found to be of value in some case 
series of brucellar endocarditis, spondylitis, and meningitis (Akdeniz et al, 1998, 
Mert et al, 2002; Yilmaz et al, 2004). Unfortunately, relapse of the disease still 
represents a major therapeutic problem for its focal forms. 
In respect to the above mentioned discussions and the emergence of 
antimicrobial resistance, it is imperative to adopt new strategies or approaches 
against the therapy of brucellosis. Liposomes, the most studied non-toxic colloidal 
drug delivery systems, could be one way of improving the effectiveness of 
antibiotics. The best known advantages of liposome are altered pharmacokinetics 
and bio distribution of the encapsulated drug molecules, giving rise to improved 
efficacy and/or reduced toxicity of chemotherapy (Fountain et al, 1985; Price et al, 
1992; Price et al, 1994). Liposome-encapsulated antimicrobial agents have already 
been successfully used in humans and/or in animal models against protozoal, 
(Alving et al, 1978; Berman et al, 1992) fungal (Lopez-Berestein et al, 1984; Van 
Etten et al, 1993; Ng and Denning, 1995) and bacterial (Klemens et al, 1990; 
Bakker-Woudenberg et al, 1995;Grayson et al, 1995) infections. 
Encouraged by the previous studies using aminoglycosides and cephalosporin 
against intracellular pathogens in liposomised form, our present work was 
concentrated to evaluate the antimicrobial efficacy of fusogenic liposomal mode of 
delivery of antibiotics against experimental murine brucellosis. 
A small account of reviews of previous work, is tried to brief in the following pages: 
A. Aminoglycosides 
Basic characteristics: 
They have very strong, bactericidal effect and they act in several sites of 
bacterial cell (outer membrane, ribosomes). A very important feature of 
aminoglycosides is synergism with the wall-affecting antibiotics like beta-lactams 
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and glycopeptides. This synergism is expressed against some Gram-positive 
(Streptococci, Enterococci) as well as Gram-negative (£. co//,, Pseudomonas) 
bacteria. Aminoglycosides are not effective against anaerobes, spirochetae (genus 
Leptospira, Borrelia, Treponema), obligatory intracellular pathogens (chlamydiae, 
rickettsiae, legionellae), and capsulated pathogens (pneumococci. Salmonella typhi, 
Haemophilus influenzae). 
Pharmacokinetics 
Aminoglycosides are not absorbed from the gastrointestinal tract and their 
penetration across biological barriers is poor. Volume of distribution correlates 
closely with the volume of extra-cellular fluid. The drugs are excreted unchanged 
by glomerular filtration. 
Pharmacodynamics 
The bactericidal effect aminoglycosides is concentration-dependent and it 
relates to the peak concentration of the antibiotic at the site of infection. 
Postantibiotic effect (PAE) lasts several hours depending on the reached peak 
concentration. The effectiveness of aminoglycosides is influenced with pH: it is 
optimal in mild alcalic pH and losses activity rapidly with lowering pH under 6.5. 
Uses 
Aminoglycosides are preferably used in combination with other antibiotics. Typical 
indications for usage aminoglycosides include 
a) Severe infections or sepsis caused by gram-negative microbes, staphylococci, or 
M.tuberculosis: Amonoglycosides are given especially at the onset of therapy, 
for rapid lowering of the massive bacterial load. 
b) Severe infections caused by semi-resistant microbes when monotherapy is not 
bactericidal: In these situations, synergistic effect of aminoglycosides and wall-
affecting antibiotics is often utilized for examples: nosocomial infections caused 
by resistant Gram-negative bacteria, infective endocarditis caused by 
streptococci or enterococci infections in immunocompromised patients in whom 
bactericidal activity of antibiotics is necessary. 
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Undesirable effects 
Allergic reactions as well as gastrointestinal disorders are uncommon and 
local events (irritation, thrombophlebitis) are rare as well. Nevertheless, the drugs 
are nefrotoxic and ototoxic as they can cause necrosis of the proximal tubular cells 
leading to reversible renal failure within several weeks or even days. They can 
cause irreversible hearing loss (cochlear damage) as well. The less feared side effect 
is vestibular toxicity. Another important side effect is neuromuscular blocade that 
can occur in predisposed patients (hypocalcemia, hypomagnesemia, myasthenia 
gravis) or in patients being treated with succinyle choline or other drug interfering 
with neuromuscular transmission. 
Account of drugs 
Streptomycin 
It is an old drug used in the treatment of tuberculosis. There are some more 
indications for the very special situations (severe infections caused by enterococci 
highly resistant to gentamycin). 
Tobramycin, netilmicin 
Tobramycin is somewhat more effective against Pseudomonas. Netilmicin is 
slightly less nefrotoxic. In practice, the difference between these antibiotics is not 
very significant. 
Amikacin, isepamicin 
These antibiotics resist various bacterial destructive enzymes, so can be used 
against some more resistant stems of Gram-negative pathogens. They do not work 
stronger than gentamycin but are somewhat less nefrotoxic. 
Gentamycin 
Gentamycin is a polycationic aminoglycosides antibiotic with broad-
spectrum antibacterial activity. Its use is indicated in several serious intracellular 
bacterial infections requiring hospitalization. The aminoglycosides are freely 
soluble in water and after intravenous or intramuscular administration the majority 
of the drug remains in extracellular locations (Kumana and Yuen, 1994). 
Intracellular infection caused by pathogens such as salmonella. Brucella sp. Listeria 
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sp and Mycobacterium sp. constitute a challenge for classical antimicrobial 
therapies because of the requirement that antibiotic reach therapeutic levels in the 
intracellular site of the infection. 
Marketed form of Gentamicin Sulfate is a water-soluble antibiotic of the 
aminoglycoside group. Gentamicin is obtained from cultures of Micromonospora 
purpurea. It is a mixture of the sulfate salts of gentamycin CI, C2, and CIA. All 
three components appear to have similar antimicrobial activities. The structure is as 
follows: 
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Establishedname: Gentamycin 
Chemicalname: 
0 - 3 - Deoxy - 4 - C - methyl - 3 - (methylamino) - P - L - arabinopyranosyl -
(l^^e) - 0 - [2,6 - diamino - 2,3,4,6 tetradeoxy-a-D-erythro-hexopyranosyl-(l^-4)]-
2-deoxy-D-streptamine. 
Gentamycin - Clinical use 
Gentamycin is active in vitro against many strains of the following 
microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, 
Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae. Neisseria 
gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. 
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Carcinogenesis, Mutagenesis, Impairment of Fertility 
There is no published carcinogenicity or impairment of fertihty studies on 
gentamycin. Aminoglycoside antibiotics have been found to be non-mutagenic. 
Pregnancy 
Pregnancy Category C: Gentamycin has been shown to depress body 
weights, kidney weights, and median glomerular counts in newborn rats when 
administered systemically to pregnant rats in daily doses approximately 500 times 
the maximum recommended ophthalmic human dose. There are no adequate and 
well-controlled studies in pregnant women. Gentamicyn should be used during 
pregnancy only if the potential benefit justifies the potential risk to the fetus. 
Adverse Reactions 
Bacterial and fungal corneal ulcers have developed during treatment with 
gentamicin ophthalmic preparations. The most frequently reported adverse reactions 
are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, 
conjunctival epithelial defects, and conjunctival hyperemia. Other adverse reactions 
which have occurred rarely are allergic reactions, thrombocytopenic purpura, and 
hallucinations. 
B. Cefalosporins 
Cephalosporin antibiotics are divided in four subgroups called generations. 
The individual drugs are arranged into generations according their spectrum of 
antibacterial activity (including the susceptibility/resistance to beta-lactamases). 
More than one hundred cephalosporins have been developed in numerous 
pharmaceutical companies all over the world. 
St 
1 generation 
The drugs are used predominantly against Gram-positive cocci (streptococci 
and staphylococci). Their spectrum further includes corynabacteria, meningococci, 
and some community-acquired stems of Gram-negative rods like Escherichia coli 
or Proteus mirabilis. The drugs are active against anaerobes in the extent similar to 
penicillin. 
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Cefalotin, cefazolin 
Cefalexin - CLX, cefadroxil - CDR, cefaclor - CCL (for oral administration) 
The drugs are predominantly used for treatment skin and soft tissue 
infections, and for prophylaxis in surgical procedures (except colorectal surgery and 
situations when methicillin-resistant staphylococci are spread in the surgery 
department). 
nd 
2 generation 
St 
The drugs contain antibacterial activities of the 1 generation and extend to 
further community-acquired gram-negative bacteria like Haemophilus influenzae, 
Moraxella catarrhalis, or less susceptible strains oiE.coli or similar patogens. 
Cefuroxim, cefamandol 
Cefuroxim-raxetil 
The drugs are prescribed for treatment respiratory tract infections (bacterial 
sinusitis or mesotitis, pneumonia), and urinary and hepatobiliary tract infections. 
They can be used for prophylaxis in surgery as well. 
Cefoxitin 
It is a representative of cefamycines. These antibiotics are closely related to 
true cephalosporins differing in one substituent on cephem nucleus. Their common 
feature is a very good activity against relatively resistant anaerobe Bacteroides 
fragilis. With its antibacterial activity against other microbes, cefoxitin has been 
nd 
joined to the 2 generation cephalosporins. Its typical disposal is intra-abdominal, 
pelvic, and gynecological infections, foot infections in diabetics, infected decubitus 
ulcers and other mixed aerobic-anaerobic infections. Unfortunately, resistance to 
cefoxitin raises quickly in departments where this drug used to be given frequently. 
rd 
3 generation 
The drugs can be divided in two subgroups according to their activity 
against Ps. aeruginosa. The subgroup A consists of antibiotics of similar spectrum 
nd 
as 2 generation but with enhanced activity against gram-negative bacteria and 
weaker effect against staphylococci. 
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Cefotaxime, Ceftrioxne 
These drugs are used for treatment of severe and life-threatening infections 
caused by community gram-negative patogens like E.coli, H.influenzae, 
meningococci, salmonellae etc. The relevant clinical diagnoses are purulent 
meningitis, epiglotitis, sepsis of urinary or hepatobiliary tract origin etc. Ceftrioxne 
is an antibiotic of extreme long half-time (8 hrs) in addition that allows once-daily 
administration. This feature makes the treatment easier but is of especial importance 
in treatment of outpatients or in home treatment. Ceftrioxne, an expanded-spectrum 
cephalosporin, is approved for therapy of pneumococcal infections, including 
pneumonia, bacteraemia and meningitis, ft is effective and widely used for known or 
suspected infections caused by penicillin-resistant pneumococci (Friedland and 
McCracken, 1994) 
Cefetamet-pivoxil,cefpodoxim-proxetil,cefixim,ceftibuten 
The position of these antibiotics is rather problematic. They can be used for 
treatment of mild or moderate community acquired infections but cephalosporines 
nd 
of 2 generation suffice in these situations usually. The only rational indication 
remains infection caused by pathogens of microbiologically verified intermediate 
nd 
sensitivity where 2 generation cephalosporins perform only a weak effect. The 
subgroup B included antibiotics effective against Ps. aeruginosa and other 
"problematic Gram-negative pathogens". However, the stronger is the anti-
pseudomonadal effect, the weaker is the activity against staphylococci and other 
gram-positive microbes. 
Ceftazidim, cefoperazon 
These antibiotics are used in nosocomial infections/sepsis caused by Gram-
negative bacteria. Ceftazidim is strongest anti-pseudomonadal cephalosporin. 
Cefoperazon's unique feature is predominant excretion via the bile: this advocate 
for its usage in hepatobiliary tract infections and in renal insufficiency. Cefaperazon 
is available in a mixture with beta-lactamase inhibitor as well: cefoperazon/ 
sulbactam that can be worthy against Acinetobacter spp. and some "problematic 
pathogens" owing beta-lactamase activity. 
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th 
4 generation 
St nd 
Antibiotics of this group liave a broad spectrum summarizing the 1 ,2 and 
rd 
3 generation. They can resist some potent beta-lactamases. Nevertheless, their 
activity against staphylococci is not better than with cephalotin and activity against 
P. aeruginosa is not better than with ceftazidim. cefopirome, cefepime. These 
antibiotics are used in nosocomial infections of special resistance pattern (stable 
derepression of ampC gene) or in nosocomial sepsis of unknown origin where 
covering the broad spectrum of pathogens is necessary (i.e. febrile neutropenia). 
Depending upon the pharmacokinetic behavior and certain desirable effect 
over the rest of the antibiotics under cephalosporin, Ceftrioxne, cefotaxime and 
cefapime were taken into consideration for the present study. 
Ceftriaxone 
Clinical use 
Ceftriaxone is often used (in combination, but not direct, with macrolide 
and/or aminoglycoside antibiotics) for the treatment of community-acquired 
pneumonia, ft is also a choice drug for treatment of bacterial meningitis. In 
pediatrics, it is commonly used in febrile infants between 4 and 8 weeks of age who 
are admitted to the hospital to exclude sepsis. It has also been used in the treatment 
of Lyme disease and gonorrhea. 
Chemistry 
Ceftriaxone is a yellowish-orange crystalline powder which is readily-
soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. 
The pH of a 1% aqueous solution is approximately 6.7. The 5y«-configuration of the 
methoxyimino moiety confers stability to p-lactamase enzymes produced by many 
Gram-negative bacteria. Such stability to P-lactamases increases the activity of 
ceftriaxone against otherwise resistant Gram-negative bacteria. In place of the 
easily hydrolysed acetyl group of cefotaxime, ceftriaxone has a metabolically-stable 
thiotriazinedione moiety. 
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Ceftrioxne 
Systematic (lUPAC) 
name 
Formula 
Mol. mass 
Half life 
Excretion 
(6i?,7i?,2)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino) 
acetamido)-3-((6-hydroxy-2-metliyl-5-oxo-2,5-dihydro-
1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-l -aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
C.gHigNgOTSs 
554.58 g/mol 
5.8-8.7 hours 
33-67% renal, 3 5 ^ 5 % biliary 
Cefotaxime 
Cefotaxime is a 3'^ '' generation cephalosporin antibiotic. Like other 3'^ '^  
generation cephalosporins, it has broad spectrum activity against Gram positive and 
Gram negative bacteria. In most cases, it is considered to be equivalent to 
ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under 
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various trade names including Claforan (Sanofi-Aventis). The syn-configuration of 
the methoxyimino moiety confers stabiHty to p-lactamase enzymes produced by 
many Gram-negative bacteria. Such stabiHty to P-lactamases increases the activity 
of cefotaxime against otherwise resistant Gram-negative organisms.(Fig.) 
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Cefotaxime 
Systematic (lUPAC) name 
Formula 
Mol. mass 
Half life 
Excretion 
(6i?,77?,Z)-3-(acetoxymethyl)-7-(2-(2-
aminothiazol-4-yl)-
2-(methoxyimino)acetamido)-8-oxo-5-thia-1 -
azabicyclo[4.2.0] 
oct-2-ene-2-carboxylic acid 
CeHnNsOySi 
455.47 g/mol 
0.8-1.4 hours 
50-85% renal 
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Cefepime 
Cefamime is a 4"^  generation cephalosporin antibiotic developed in 1994. 
Cefepime has an extended spectrum of activity against Gram-positive and Gram-
negative bacteria, with greater activity against both Gram-negative and Gram-
positive organisms than 3'^ '^  generation agents. Cefepime hydrochloride was first 
marketed in 1994 and is currently marketed under various trade names including 
Maxipime (Elan Pharma), Maxcef, Cepimax, Cepimex, and Axepim. 
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Cefepime 
Systematic (lUPAC) 
name 
Formula 
Mol. mass 
Half life 
Excretion 
(67?,7i?,Z)-7-(2-(2-aminothiazol-4-yl)-
2-(methoxy imino)acetamido)-3 -
((1 -methylpyrrolidinium-1 -yl)methyl)-
8-oxo-5-thia-l -aza-bicyclo 
[4.2.0]oct-2-ene-2-carboxylate 
C,9H24N605S2 
480.56 g/mol 
2 hours 
Renal 70-99%, 
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Cefepime is usually reserved to treat severe nosocomial pneumonia, 
infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) 
and empirical treatment of febrile neutropenia. Cefepime has good activity against 
important pathogens including Pseudomonas aeruginosa. Staphylococcus aureus, 
and multiple drug resistant Streptococcus pneumoniae as well as against 
Enterobacteriaceae. Though other cephalosporins are degraded by many plasmid-
and chromosome-mediated beta-lactamases, cefepime is stable and is a front line 
agent when infection with Enterobacteriaceae is known or even suspected. 
For treatment of intracellular pathogen that adopt intracellular parasitism as a 
strategy to avoid host defense, the design of liposomal drug delivery systems that 
undergo controlled fusion with cellular or endosomal membranes seem to be an 
interesting preposition. A brief account of liposome and its uses are discussed 
bellow: 
Liposomes as Novel Drug Delivery Vehicle 
In 1964, Bangham and Home first developed lipid vesicles by dispersing 
naturally occurring phospholipid in an aqueous medium. Liposomes were initially 
used as models for studying dynamic properties of biomembranes such as fluidity, 
phase transitions etc. But potentials of these bilayered vesicles have drawn much 
interest in health sciences and biotechnology. Also, it gained much importance in 
agriculture and chemical industry. Several products rely on their colloidal, 
chemical, microencapsulating and surface properties. These products range from 
drug delivery systems (antifungal, antibacterial drugs etc.), vaccines, cosmetic 
formulations (skin care products, shampoos), diagnostics, ecological cleansing, and 
food preparations to novel breakthroughs like gene and enzyme therapy. 
Composition 
Liposomes resemble cellular membranes in being composed of amphiphiles 
such as phospholipid and sphingolipids, which tend to self-organize to form ordered 
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structures in aqueous environment. This assembly proceeds to avoid interaction of 
hydrophobic portions with surrounding water molecules. Geometrically, 
amphiphiles can be characterized based on their Packing Parameter, i, such that 
i =V/x.Lc 
where, V stands for hydrophobic volume, 
X for average surface area occupied by polar region at air/water 
interface, and 
Lc for fully extended length of hydrophobic region. 
Lipids with packing parameter close to 1.0 form best-characterized 
liposomes, and examples of the type include phosphatidylcholine, 
phosphatidylserine, phosphatidylinositol, sphingomyelin, dicetylphosphate etc. 
Other candidates are sulfatides, gangliosides, di alkylphosphates etc.Liposomes can 
also be prepared from mixture of phospholipid, and the mean packing parameter is 
evaluated as weighted average of packing parameters of all the components. Again 
mixtures with values close to i = 1, are likely to form liposomes. 
Important constituents, apart from lipids, can also be included in 
preparations for different reasons. For enhancing stability; antioxidants, chelating 
agents or cholesterol (acts as fluidity buffer) can be added. Also are required 
optimization of temperature, pH and ionic strength of the medium to produce more 
stable liposomes. Addition of cryoprotectants allows their storage in frozen and 
lyophilized form. Coating with inert hydrophilic polymers also increases stability. 
To avoid aggregation of liposomes charged lipids can be incorporated. For 
prolonged presence of these in circulation, polyethylene glycol (PEG) coated 
'stealth' liposomes are used. Fusogenic liposomes are constituted by including 
glycerol, polyvinyl alcohol or reconstituted viral-membrane (virosomes). 
Preparation and properties of different types of liposome 
Natural lipids, particularly those, with aliphatic chains attached to the 
backbone by means of ester or amide bonds (phospholipids, sphingolipids and 
glycolipids) are often subject to the action of various hydrolytic (lipolytic) enzymes 
when injected into the animal or human body. These enzymes cleave off acyl chains 
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and the resulting lysolipids have destabihsing properties for the Hpid layer and cause 
the release of the entrapped bioactive component(s). As a result new types of 
vesicles, that should merely bear the name of liposomes as their components are 
lipids only by similarity of their properties to natural (phospho) lipids, have been 
elaborated. These vesicles, still named liposomes, are made of various amphiphile 
molecules (the list of components is long). The crucial feature of these molecules is 
that upon hydration they are able to form aggregation structures resembling an array 
and have properties of natural phospholipid bilayers. Among such molecules, 
various amphiphiles have been employed, such as ether lipids (Choquet et al, 1994; 
Patel and Sprott, 1999; Sprott et al, 1997; Yamauchi et al, 1996), fluorinated lipid 
(Clary et al, 1997; Gadras et al, 1999; Riess, 1994) synthetic double chain 
amphiphiles Pector et al., 1998) as well as single chain amphiphiles, such as N-
alkylindoles (Abel et al, 1995), polyhydroxyl lipids (Assadullaiahi et al, 1991), 
polyhedral non-ionic surfactants (Pector et al, 1998; Arunothayanun et a/., 1999; 
Baillie et al, 1986; Budker et al, 1996)polymerized liposomes (Chen et al, 1996; 
Chen et al, 1996) cationic amphiphiles (Budker et al, 1996), plasmalogens 
(Thompson et al, 1996) and others (Cistola et al, 1986;Hu et al, 1999; Murdan et 
al, 1999; Uchegbu et al, 1997; Uchegbu ,1998; Uchegbu et al, 1998; Vora et al, 
1998; Weissig et al, 1998). This resulted in various new formulations of vesicle 
compositions and new names given to them, such as niosomes, lederosomes, 
archeosomes, etc. The common feature of classical liposomes, i.e., made 
preferentially of phospholipids, and of vesicles made of amphiphilic molecules, was 
their ability to form dynamic lamellar structures with barrier properties separating 
the interior of the vesicles from the outside medium, the basic difference from 
micelles. One may conclude that, at present, the term "liposomes" covers not only 
phospholipid-based vesicles but also other vesicular structures with properties 
identical or similar to those of classical, natural phospholipid based liposomes 
(Figure 23). 
Several methods are available for preparation of different types of 
liposomes. In common, all the methods include the steps of lipid film hydration 
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followed by formation of the lipid bilayer and then removal of un-entrapped 
material. The most common method employed is sonication either by a probe 
sonicator or a bath type sonicator (Huang, 1969), others being high-pressure 
exclusion, rapid injection of an ethanolic solution of a lipid into an aqueous solution 
(Batzri and Kom, 1973) or by transgently increasing the pH of aqueous 
phospholipid dispersion (Hauser and Gains, 1982). Removal of detergents by 
dialysis, solvent infusion and reverse phase evaporation (Buboltz and Feigenson, 
1999) results in formation of multi-lamellar vesicles. Following dehydration/ 
rehydration method, the entrapment efficiency of liposomes can be increased. Since 
the size of liposome is an important factor in its stability and tissue distribution in 
vivo, exclusion through polycarbonate membranes is routinely used to obtain a 
more uniform size distribution in the liposome preparation. Homogenization of 
MLV results in the formation of unilamellar vesicles. It involves some or the other 
form of energy to be dissipated into the system of lipids and aqueous solvent for 
preparing liposomes. 
Nomenclature and classification of liposome 
Initially, liposomes were classified on the basis of workers who prepared 
them first, ex-Banghamosomes for sonicated multilamellar vesicles and 
Huangosomes for unilamellar vesicles prepared by dispersion of MLVs. 
Based on Structure 
Most widely accepted terminology is based on size and number of lamellae. 
Thus liposomes with more than one bilayer are multilamellar (MLV) and with 
single layer are unilamellar (ULV). ULVs can be further classified on the basis of 
out/in ratio ie. ratio of number of lipid molecules in outer monolayer to inner one. 
Basic studies on liposomal vesicles resulted in numerous methods of their 
preparation and characterization. Liposomes are broadly defined as lipid bilayers 
surrounding an aqueous space. Multilamellar vesicles (MLV) consist of several (up 
to 14) lipid layers (in an onion-like arrangement) separated from one another by a 
layer of aqueous solution as shown in Figure 24. These vesicles are over several 
hundred nanometers in diameter. Small unilamellar vesicles (SUV) are s rounded 
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by a single lipid layer and are 25-50 nm (according to some authors up to 100 nm) 
in diameter. Large unilamellar vesicles (LUV) are, in fact, a very heterogenous 
group of vesicles that, like the SUVs, are surrounded by a single lipid layer. The 
diameter of these liposomes is very broad, from 100 nm up to cell size (giant 
vesicles). Different types of liposome with details are listed bellow (Table 20). 
Type 
MLV 
OLV 
ULV 
SUV 
MUV 
LUV 
GUV 
Specifications 
Multilamellar large vesicles 
Oligolamellar vesicles 
Unilamellar vesicles 
Small unilamellar vesicles 
Medium unilamellar vesicles 
Large unilamellar vesicles 
Giant unilamellar vesicles 
Diameter 
>0.5 |im 
0.1-1.0 i^ m 
20-40 nm 
40-80 nm 
>80nm 
> 1 )j.m 
Out/in ratio 
2 to 2.4 
1.2 to 1.5 
1 to 1.2 
Table 20 Different types of liposome with details 
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Figure 23. Bilayer structure of liposome as compared with micelles 
a) Monolayer of polar lipid at air -water-boundary 
b) Micelles 
c) Liposomes in aqueous environment 
Figure 24. Multilamellar liposome 
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Based on method of preparation 
Although no information is obtained regarding properties of Hposomes, 
methods of preparation are used for classifying liposomes, such as: 
Type 
REV 
MLV-REV 
SPLV 
FAT MLV 
VET 
DRV 
Method 
Single or oligolamellar vesicles made by reverse phase 
evaporation method 
Multilamellar vesicles made by reverse phase 
evaporation method 
Stable plurilamellar vesicles 
Frozen and thawed 
Vesicles prepared by extrusion technique 
Dehydration-rehydration made vesicles 
Based on composition 
Various constituents included in preparation of liposomes can be used to 
classify them: 
Type 
Conventional liposomes 
(CL) 
• Fusogenic liposomes 
pH sensitive liposomes 
Cationic liposomes 
Characteristic 
Neutral or negatively charged 
phospholipids and Cholesterol 
With viral components 
Phospholipid such as PE or DOPE with 
either CHEMS or OA 
Cationic lipids with DOPE 
Choi and 5-10% of PEG- DSPE or GMl 
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Fate of liposomes in body 
When injected into the body, liposomes either disintegrate in bloodstream or 
they circulate and are picked up predominantly by macrophages. Actually, 
endothelial lining of healthy blood vessels forms an efficient barrier to the 
liposomal escape from circulation. However at the site of inflammation, 
endothelium is more permeable and allows extravasations of small liposomes. This 
leads to the rapid clearance of liposomes from the blood circulation and their 
capture by the organs of reticulo-endothelial system (Poste, 1983; Allen and 
Schlegel, 1988), which corresponds exactly to the same tissue distribution pattern as 
that of some pathogenic microorganisms responsible for intracellular infections. 
However, this clearance is too fast to benefit other tissues from it. PEG-coated 
stealth liposomes have long circulating times in blood circulation and may act as a 
reservoir for prolonged release of therapeutic agent. Liposomes with antibodies or 
other homing devices covalently attached to the surface makes their uptake tissue 
and cell specific, and it is better known as active delivery. 
Applications of Liposome 
The applications of liposomes in drug delivery are based on 
physicochemical and colloidal characterization such as composition, size and 
loading efficiency and the stability of the carrier, as well as their biological 
interactions with the cells. The major interactions between the liposomes and cells 
are as follows. Lipid exchange is a long-range interaction that involves the 
exchange of liposomal lipids for the lipids of various cell membranes. It depends on 
the mechanical stability of the bilayer and can be reduced by alloying the membrane 
with the cholesterol (which gives rise to greatly improve mechanical properties, 
such as increased stretching elastic modulus, resulting in stronger membranes and 
reduced permeability). The second major interaction is adsorption onto cells, which 
occurs when the attractive forces (electrostatic, electrodynamic, Vander waals, 
hydrophobic interaction and hydrogen bonding etc.) exceed repulsive forces 
(electrostatic, steric, hydration, ondulation, protrusion etc.). Adsorption onto 
phagocytic cells is normally followed by endocytosis or rarely, by fusion. The 
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fusogenic liposomes mimic the way by which several viruses (HIV, Sendai virus) 
bind and merge with cell membranes at neutral pH and subsequently release their 
content into the cytoplasm. 
Liposomes are being used for a range of therapeutic and pharmaceutical 
applications. Some of them are listed below: 
Liposomes as drug/protein delivery vehicles 
Liposomes in anti-bacterial, anti-fungal and anti-viral therapy 
Liposomes as biological response modifiers 
Liposomal drugs in tumor therapy 
Liposomes in Immunology 
Liposomes in enzyme replacement therapy 
Liposomes in gene delivery 
Liposomes in environmental cleansing 
Liposomes in cosmetics and dermatology 
Liposomes in enzyme immobilization and bioreactor technology 
Liposomes in Recombinant DNA technology 
Liposomes as artificial blood surrogates 
Liposomes as radiopharmaceutical and radiodiagnostic carriers 
However most important and wider field with which liposomes are 
associated, is drug-delivery systems and will be discussed now: 
1. Liposomes and control of multiple drug resistance 
Careful selection of proper antibiotics allows successful inhibition of 
multiplication as well as complete eradication of the pathogens from the host. Each 
kind of organism may be inhibited by specific antibiotic and also by specific drug 
dose. Therefore attributes made for selection of correct antibiotics are fundamental 
to the success of any treatment When drug entrapped in liposomes is administered, 
liposomes act as a carrier, transporting and directing antibiotics to the infected 
tissues where the drug attains fairly high concentration needed to kill the pathogens. 
As a result; resistance of the pathogen is regressed, antibiotic effectiveness is 
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enhanced, and exposure of drug to the normal cells is minimal. In addition, this also 
facilitates the diffusion of the drug preferably into the infected locus and 
persistently maintains the effectiveness for a long time. 
2. Liposomes and antifungal therapy 
Over the last several years, the frequency of life threatening fungal 
infections has increased dramatically particularly among cancer diabetic and 
immunocompromised patients (Anaissie et ai, 1992; Pfaller and Webzel, 1992; 
Richardson et al., 1991; Walsh et al, 1992). Various antifungal chemotherapeutic 
agents available include polyenes, azoles, allylamines, morpholines, flucytosine, 
griseofulvin, iodides, hydroxy stibamine and imidazole classes of drugs (Stevens, et 
al., 1995). Systemic fungal infections occur at high frequency in the immuno-
compromised patients such as cancer and AIDS patients or with renal transplant 
(Landman and Saurina, 1998; Musial et al., 1988). Drug of choice for the most 
systemic mycoses is a polyene antibiotic Amphotericin-B, that interacts with 
ergosterol in fungal cell membranes thus creating transmembrane channels and 
permitting the escape of vital ions and metabolites. This drug although very 
promising, had limited use due to its systemic toxicity. Incorporation of Amp-B in 
liposomes successfully reduces its nephrotoxicity and thus improves the therapeutic 
index (Adler-Moore and Proffitt, 2002). Numerous reports of liposomal Amp-B 
having enhanced efficacy against murine aspergillosis and candidiasis (Otsubo et 
al, 1998), and against cryptococcosis, histoplasmosis, Fusahum infections etc. 
(Graybill et al, 1982; Adler-Moore et al, 1991; Garcia et al, 2000) are available. 
Other polyene antibiotics like nystatin and kanamycin have also been liposomised 
to improve their therapeutic index (Mehta et al, 1991). Leconte et al. (1992) 
attempted the use of liposomal preparation of Itraconazole in management of 
experimental cryptococcosis and pulmonary aspergillosis (Table 21). 
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SYSTEM 
Liposomes 
Ambisome 
Amphocil 
ABELCET 
AMPHOLECT 
Mikasome 
Doxil 
Daunoxome 
EVACET'^ 
VincaXome 
Liposomes 
DRUG 
Nystatin 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amikacin 
Doxorubicin 
Daunorubicin 
Doxorubicin 
Vincristine 
Anamycin 
TARGET DISEASE 
Systemic fungal infections 
« 
Systemic fungal infections 
Systemic fungal infections 
Systemic fungal infections 
Systemic fungal infections 
Bacterial infection 
Metastatic cancers 
Metastatic cancers 
Metastatic cancers 
Solid tumors 
Kaposi's sarcoma 
COMPANY 
AroneX, USA 
NeXstar, USA 
SEQUUS, USA 
The Liposome Company, USA 
SEQUUS, USA 
NeXstar, USA 
SEQUUS, USA 
NeXstar, USA 
The Liposome Company, 
USA 
NeXstar, USA 
AroneX, USA 
Table 21. Liposome-based Antibiotics/Antineoplastics 
3. Liposomes and antiprotozoal therapy 
The first successful use of the liposomal drug delivery system in infectious 
diseases was made in the treatment of leishmaniasis. The protozoan parasite, which 
is endemic in many tropical and subtropical areas, enters and colonizes 
macrophages and thus can be targeted by liposomes. In mice, liposome 
encapsulated antimonies have been shown to be about 700-1800 times more 
effective than the free drug in controlling leishmaniasis (New et al., 1978). 
Stibamine encapsulated in mannose bearing liposomes has been used in treatment 
of the experimental leishmaniasis. Interestingly, some of the anti-fungal drugs like 
griseofulvin (New et al., 1981), Amp-B (Adler-Moore et al., 2002) and 5-
fluorocytosine were demonstrated to exhibit an enhanced efficacy against 
leishmaniasis when used in the liposomal form. The life cycle of the malarial 
parasite gets completed in different body parts of the host. Depending on its 
different life cycle stages, various liposomal formulations of antimalarials have 
been shown to be of great promise in the treatment of malarial infection. 
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Primaquine when entrapped in liposomes can cure murine malaria by using a single 
intravenous injection and the efficacy of Primaquine containing Uposomes can be 
increased upto several folds when such liposomes are made more specific for their 
target by grafting galactosyl glycolipid on their surface (Alving, 1982). 
Chloroquine, the most promising antimalarial, specific against intra erythrocytic 
stage of plasmodial life cycle, can be made very effective not only against drug 
sensitive but also drug resistant strains of P. berghei (Owais et al., 1995), by 
encapsulation in liposomes bearing antibodies against surface antigens of 
erythrocytes. 
5. Liposomes and antiviral therapy 
Liposome encapsulated macrophage stimulators, viz lymphokine, muramyl-
dipeptide and its aminobuturyl analogue, could be employed against Herpes 
simplex virus type-2 (HSV-2) infection (Koff et al., 1983). Murine Rift Valley 
fever virus, rhinovirus and murine hepatitis virus can be controlled effectively by 
using liposomal preparations of ribavarin, enviroxime and y-interferon (Szoka, 
1990). Liposomal formulation of phosphonoformate, was shown to have an 
improved immunomodulation against Rausher Murine Leukemia retroviral 
infection (Szoka, 1990). The CD4 receptors present on T cell are specifically 
recognized by glycoprotein 'gpl20' present on the HIV coat. CD4 inserted in the 
liposomal bilayer effectively cleared both free HIV and 'gp 120' bound to HIV 
infected cells (Nicolau et al., 1990). Liposome encapsulated azidothymidine has 
been shown to reduce the hematopoietic toxicity and enhance the activity of the 
drug against murine AIDS (Phillips and Tsoukas, 1992). 
6. Liposomes and antitumor therapy 
Most of the medical applications of liposomes that have reached preclinical 
and clinical stages belong to cancer ailments mainly. It has been demonstrated that 
small-sized and long circulating liposomes can passively target different tumors 
because of circulation and extravagation (owing to their small size, 50-150 nm) in 
tissues with enhanced vascular permeability (Gregoriadis et al., 1971; Gabijon and 
Papahadjopoulos, 1992). Long-circulating pegylated liposomes were able to deliver 
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between 5 to 11 times more doxorubicin to the Kaposi's sarcoma lesions than to 
normal skin, leading to overall response rates as high as 80% (Northfelt et al., 
1996). 
7. Liposomes and enzyme therapy 
While gene therapy deals with delivery of genes to the cells, enzyme therapy 
aims at treatment of disorders by using gene products i.e. enzymes. A number of 
metabolic disorders are caused by either presence of non-functional enzyme or due 
to complete absence of a particular enzyme. Enzymes are now being used as drugs 
and enzyme-loaded liposomes are regarded as novel and biocompatible 
biocatalysts. Various enzymes have been entrapped inside small or large 
unilamaller, multilamaller and giant vesicles using different methods. 
Imigluceraferase encapsulated liposomes, available under the name Cerezyme® 
was used to treat Gaucher's disease in 2001. In about 12 months, all the symptoms 
like organomegaly, anemia, thrombocytopenia subsided. Still better results are 
expected in the light of new reports concerned with treatment of liposomal storage 
disorders, Fabry disease, AIDS, adenosine deaminase deficiency, multiple sclerosis, 
chronic myeloid leukemia, juvenile arthritis and ovarian cancer. While enzyme 
therapy is still in its infancy, newer related terms are coming up the horizon. In 
Antibody-dependent enzyme prodrug therapy (ADEPT), a prodrug is converted 
only at site where its activating enzyme is delivered. Immunoliposomes attached 
enzymes are used for site-specific targeting of the required enzyme. Gene-directed 
enzyme prodrug therapy (GDEPT) is a promising two-step treatment for solid 
malignant tumors. In the first step, the gene for a foreign enzyme is administered 
and directed to the tumor, where it may be expressed using specific transcriptional 
elements. In the second step, prodrugs are administered and activated by the foreign 
enzyme expressed at the tumor. A number of approaches are now being used for 
management of diseases previously considered untreatable. 
8. Liposomes and diagnostics 
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Liposomes also find a number of uses in diagnostic assays: Annexins are 
membrane-binding poteins and a highly sensitive assay was developed for their 
determination. It relied on liposomal aggregation as monitored by turbidimetry. 
Several blood-clotting assays rely on colloidal instability of cells or different lipid 
extracts, from rabbit brains. Synthetic optimized liposomes utilizing kits are 
available that produce reliable results. A system intended for whole process quality 
assurance of nucleic acid amplification assays was developed based on the use of 
liposomes as cell-mimicking vehicles for detection of various pathogens. In ELISA, 
one antibody typically carries one labeling group. However, if the ligand is 
associated with liposomes, it could carry thousands of markers that enhance the 
signal proportionally. Receptor-ligand interactions can be accompanied by 
chromatic transitions and thus used to detect viruses. For example, a system 
consisting of polyacetylene bilayer functional zed by a sialic-acid analogue, which 
is a site-specific ligand for influenza viral haemagglutinin, undergoes a color 
change from blue to red upon binding that is observable to naked eye. 
9. Liposomes and ecology 
On large scale, liposomes may be used for cleansing of environment. For 
example, in metal ion detoxification or clearing up reactor/oil spills. Metal ions can 
be bound to liposomes with surface-attached chelators, which can then be 
precipitated. Optimistic approach towards development of new strategies has 
enabled man to overpower a number of diseases to a large extent. Liposomes have 
really proved their worth in this respect. Liposome technology has established itself 
in diverse fields such as medicine, immunology, diagnostics, cosmetics, etc and the 
list is ever increasing. Such simplicity is inherent in the structure of liposomes and 
yet such a complex array of their applications is that these are rightly called as 
Magic Bullets. In spite of the challenges encountered regarding reproducibility, 
stability and up-scaling methodologies;/uture prospects for the uses of liposomes 
are very bright. 
10, Liposomes as drug carriers 
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Drug delivery to the specific cells by targeting liposomes presents an 
attractive preposition in achieving the coveted goals in experimental clinical 
therapy. As such, the major fraction of the injected liposomes is taken up by the 
liver and spleen. Directing to other tissues therefore requires special consideration, 
some of which are following. First, the rate of uptake of liposomes by the RES must 
be diminished considerably so that liposomes can circulate in the blood long 
enough to ensure quantitative vesicle binding to the target (Fig. 23). In this respect, 
small, neutral, unilamellar liposomes composed of high melting phospholipid and 
cholestrol appear suitable. Presentation of RES with empty liposomes followed by 
administration of drug containing vesicles could also be proved to be a useful 
srtategy. However, this approach has limitation as it requires an injection of the 
plain liposomes prior to administration of the liposomised drug, which may lead to 
accumulation lipids to the toxic levels. Alternatively, it may be possible to coat the 
liposomes surface, with substances which render them less recognizable by the 
RES. One such agent poloxamer (a non ionic surfactant of the polyoxyethylene 
polyoxypropylene series), has been used with some success in reducing the rate of 
clerance of nanoparticles. Thus targeting of liposomes to any specific cell type in 
vivo requires the completion of several independent steps including access to the 
appropriate target cells, selective interaction, and uptake by the target cell with little 
or no uptake by non target cells (Figure 25). 
170 
Chapter II Review of Literature 
Ma<:;tf<a|)s|\<3§s 
Liposome 
Release in blood 
compartment 
Release from 
macrophage 
Figure 25. Schematic diagram of drug targeting mto 
APCs by liposome 
The following factors are important to the design of efficient liposomes mediated 
targeted drug delivery: 
Advantages of using liposomes 
Resemblance to membranes- The liposomes are biodegradable, inert, non-toxic 
delivery systems composed of lipids isolated from plasma membranes of the living 
cells. 
Solubilization- Liposomes may solubilise recalcitrant drugs/compounds. 
Versatile carriers- Amphipathic nature of liposomes facilitates the incorporation of 
both hydrophilic as well as hydrophobic drugs. The drugs of intermediate solubility 
can be associated with liposome interior by manipulation of liposomal internal pH 
(Mayer et al, 1986) or by addition of counter ions to form molecular complexes of 
the drug within the liposomes (Haran et al, 1993). 
Flexibility- Liposomes can be formulated as a suspension, as an aerosol or in a 
semisolid form such as gel or cream or dry powder, for their topical or parenteral in 
vivo administration. 
Directing potential- Property of liposome to be taken up by the macrophages and 
RES can be utilized for passive delivery of drugs to the liver and spleen. Surface 
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engineered versions of liposomes circumvent passive uptake by RES-predominant 
organs, have increased circulation time and deliver drugs to specific tissues. 
Duration of Action- Liposomes can help in maintaining relatively constant and 
sustained blood plasma levels of drugs and give rise to long lasting effects. 
Internalization- Liposomes are endocytosed or phagocytosed by cells, opening up 
opportunities to use them for targeting drugs, genes, enzymes etc to cells. 
Protection- Liposomes-encapsulated drugs are inaccessible to metabolising 
enzymes. Conversely, body components like RBC and heart, are not exposed 
directly to toxic effects of drugs.. 
Disadvantages of using liposomes 
• Liposomes tend to aggregate or lose entrapped drug during storage. 
• There is no suitable method of their sterilization by irradiation or by heat. 
• The macrophages of RES can take up liposomes before reaching to their 
target organ. 
• High-density lipoproteins tend to interact with liposomes, in vivo, leading to 
a loss of encapsulated species. 
• Liposome preparation techniques are difficult to scale up using traditional 
methods. 
Liposomes in antibacterial therapy 
Infections caused by intracellular pathogens, such as Brucella, Salmonella, 
Listeria, Legionella and Mycobacterium species, are difficult to treat with 
conventional anti-microbial chemotherapy because of the unfulfilled requirement 
that antibiotics should reach therapeutic levels at the intracellular site of the 
infection. When antibiotics are incorporated in liposomes, these are readily 
delivered to the endosome of macrophages, thus targeting the drug to the site of 
infection. This approach provides a remarkable enhancement in the therapeutic 
index of antibiotics and reduction in toxic effects. Gentamycin when encapsulated 
in positively charged liposomes could eliminate the B. melitensis and Klebsiella 
pneumoniae loads from the liver and spleen (Harnandez-Caselles et al., 1989).The 
same liposomal preparation of gentamycin with changed lipid composition has also 
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helped treat Salmonella dublin infections. Gentamycin encapsulated in pH-sensitive 
liposomes was also found to show increased efficacy against Salmonella 
typhimuhum in model animal. The association of tuberculosis with HIV infection 
has significantly exacerbated the situation in developed and developing countries. 
HIV infection is the highest risk factor identified so far for latent tuberculosis 
infection to progress to an active disease. Mycobacterial infections have long been 
notorious for being difficult to eradicate by conventional chemotherapy, can also be 
controlled using liposomal preparations. Liposomal encapsulation of Streptomycin, 
Isoniazid and Rifampicin can enhance efficacy of these drugs against tuberculosis 
infection (Vladirmisky et al., 1983). Different aminoglycoside class of 
antimycobacterial drugs, amikacin and gentamycin, have also been shown to avoid 
mycobacterial infection more efficiently when encapsulated in liposomes 
(Bermudez et al., 1987). Analysis of the intracellular trafficking patterns of the 
liposomal antigens reveals that after being phagocytosed by macrophages, 
liposomal antigen readily escapes from the endosomes into the cytoplasm of the 
macrophages (Alving, 1995). Ever since their invention (Bangham and Home, 
1964), liposomes have been considered possible vehicles for delivering into cells 
molecules that would otherwise not be readily internalized. Realization of this 
potential, however, has been hampered because either (i) the liposomes are rapidly 
removed from the circulation by the reticuloendothelial system, or (ii) they do not 
deliver large or highly charged molecules into cells (Chonn and Cullis, 1995; Allen, 
1994; Lasic and Papahadjopoulos 1995; Allen, 1994).The first of these handicaps 
has been overcome by the inclusion of poly (ethylene glycol)-derivatized 
phosphatidylethanolamine (PEG-PE) in the liposome membrane, resulting in much 
longer half-lives in vivo, compared with conventional liposomes (Lasic, 1993; 
Woodle and Lasic, 1992; Papahadjopoulos et al, 1991). These "sterically 
stabilized," or "Stealth," liposomes were successfully used for the treatment of 
experimental cancers in vivo (Allen et al, 1992; Vaage et al, 1994; Torchilin et al, 
1993) and liposomes containing the antitumor drug doxorubicin have been approved 
recently for the treatment of Kaposi's sarcoma (Chonn and Cullis, 1995). The 
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second handicap has been addressed by developing Hposomes that destabilize at 
mildly acidic pH (pH-sensitive liposomes) and can deliver highly charged 
encapsulated materials into cells more efficiently than non-pH-sensitive liposomes 
(Torchilin et al, 1993; Dilzgiine et ah, 1991). After liposomes enter cells via 
endocytosis, the acidic pH inside the endosomes causes pH-sensitive liposomes to 
release their aqueous contents into the cytoplasm, most likely by destabilizing the 
endosome membrane (Collins, 1995). Like other non-sterically stabilized 
liposomes, however, pH-sensitive liposomes have very short circulation times in 
vivoiLmetaL, 1989). 
Fusogenic Liposome 
The fusogenic potential of escheriosome, made up of membrane lipid from 
E. coli, has already been discussed in the Chapter 1. Besides, it is well known that 
liposome that can be triggered to release their internal content or fuse in response to 
pH stimuli can potentially respond to acidic environment in vivo (Lutwyche et al., 
1998). In this regard, fusogenic property of pH sensitive liposome also possesses 
some advantages over conventional form of liposome. pH sensitive liposome are 
basically made up of 1,2 Dioleoylphosphatidylethanolamine (DOPE), a lipid that 
adopts the non bilayer inverted hexagonal (HU) phase in isolation and an ionizable 
acidic acid lipoid such as cholesteryl hemisuccinate. At pH values above the pK of 
the acidic lipid the negatively charged form of acidic lipid can stabilize the dope in 
the bilayer organization this allowing the formation of bilayer vesicles. These 
vesicles then fuse as the pH is reduced toward he pK of acidic lipid. If the 
stabilizing lipid has a negatively charged head group with an appropriate pKa, 
endosomal acidification can neutralize the lipid charge reducing the bilayer-
stabilizing effect (Hope et al, 1998). 
In conclusion to the above discussions, we have formulated the liposomal 
forms of Gentamycin, Ceftrioxne, Cefotaxime and Cefapime and their 
chemotherapeutic efficacy was evaluated against experimental murine brucellosis. 
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Chapter II Introduction 
In the present era clinical medicines includes an extremely long list of 
different pharmaceutical products and with the better understanding of molecular 
mechanisms of diseases more such agents are added to the list every year. The task 
of avoiding undesirable drug actions affecting normal organs and tissues with 
minimal side effects is very important. Thus, the screening of biologically active 
compounds became mandatory, permitting the choice of drug with selective action 
on the appropriate organs or tissues. At the same time, many pharmacologically 
active compounds cannot be used as prospective drugs due to their undesirable 
action on normal tissues. Unfortunately, the specificity of the drug of choice is not 
based on its ability to selectively accumulate in the target organs. Normally, they are 
more or less distributed across the whole body while the specific target receives very 
little amount of the drug. Normally, this problem is compensated by administration 
of high amount of the drug, which has a potential to cause undesirable complications 
and is sometimes expensive too. The ideal solution to such problems is the targeting 
of drugs using suitable carriers like serum proteins, target specific immunoglobulins, 
synthetic polymers, liposomes, noisomes, microspheres, erythrocytes, reverse 
micelles, pharmacosomes, monoclonal antibodies, etc. (Gregoriadis 1977; 
Pozanansky and Juliano, 1984). Among these earners, liposomes show great 
potentials to effectively delivery of drugs to the site of action and also help in 
controlled the release of the drug at a predetermined rate. 
B. abortus, a Gram-negative facultative intracellular bacterium, is the 
etiologic agent of brucellosis, whose pathologic manifestations are hepatitis, 
arthritis, endocarditis, and meningitis in humans and spontaneous abortion in cattle 
(Brinley-Morgan and Corbel 1990; Corbel 1990; Madkour 2001; Sangari and 
Aguero 1996; Senaldi et al, 1999; Splitter et al, 1996). In endemic situations, 
vaccination is the only desirable way for controlling brucellosis in ruminants 
(Blasco, 1997). However, the vaccine strain can cause abortion and excrete in milk 
when sheep and goats are vaccinated during pregnancy in mass-vaccination 
programmes, thus increasing the risk of human infections (Alton and Elberg, 1967). 
Moreover, accidental inoculations can not be ruled out in veterinarians and 
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shepherds during the vaccination campaigns (Berlcelman, 2003; Blasco and Diaz, 
1993; Squarcione et al , 1990). For this reason, chemotherapeutic measures to 
control over brucellosis are still the alternative to vaccination in many countries 
where Brucella infection is endemic in nature (Ariza et al, 1985; Colmenero et al, 
1989). Treatment of brucellosis infections differs from that of other bacterial 
diseases because of several properties possessed by the brucella and the host. A 
hallmark of Brucella is the complex lipid-rich cell envelope that protects the 
organism from both the host response and anti-Brucella chemotherapy. In addition, 
Brucella is a facultative intracellular bacterium, which generally causes a more 
chronic type of disease. These properties put greater constraints on efficient therapy. 
However, the existing regimen for the treatment for brucellosis with 
doxycycline plus streptomycin are suffered from some problems including toxicity 
and side effects especially in children and pregnant women and the unsatisfactory 
patient compliance due to the double dose per day for long term. Furthermore, since 
the tuberculosis in some areas in the world is increasing, the use of rifampicin in 
non-tuberculosis patient should also be avoided. Besides, many antibiotics that are 
active in vitro are often inactive against intracellular bacteria in vivo due to poor 
penetration into the cells at doses lower than the maximum tolerated dose or their 
inactivation by lisosomal enzymes (Diamond et al, 1990). 
In warrants development of new treatment regimens to reduce the 
undesirable side effects in one hand and the in vivo therapeutic efficacy on the other 
hand. Reformulation of drugs in liposomes has provided an opportunity to enhance 
the therapeutic indices of various agents mainly through the alteration of 
biodistribution. They are versatile drug carriers, which can be used to control 
retention of entrapped drugs in the presence of biological fluids, controlled retention 
of the drugs the systemic circulation or other compartments in the body and 
enhanced vesicle uptake by target cells (Gregoriadis and Florence, 1993). Moreover, 
liposomes composed of natural lipids are biodegradable, biologically inert, weakly 
immunogenic (Rooijen and Nieuwmegen, 1980), produce no antigenic or pyrogenic 
reactions and possess limited intrinsic toxicity (Campbell, 1983). Therefore, drugs 
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encapsulated in liposomes are expected to be transported without rapid degradation 
and minimum side effects to the recipients. Antibiotics can only act against 
intracellular infections if they can penetrate the phagocytic cells. It is a well known 
fact that liposomes are able to localize in the liver and spleen, especially the RES 
component, where many pathogenic microorganisms reside; they can be therefore 
used for targeting of antibiotics on these organs to enhance the therapeutic indices of 
various agents mainly through the alteration of biodistribution. 
The efficacy of liposomised preparation of doxycycline, rifampicin, 
erythromycin, streptomycin, azithromycin, amikacin, tobramycin and 
chloramphenicol alone or in combination against brucellosis and several other 
Gram-negative bacteria were studied extensively. Liposomal encapsulation of 
aminoglycosides antibiotic has also been attempted by many workers as a mean of 
altering the distribution of the drug and reducing toxicity (Diamond et al, 
1998).Unfortunately, none of the studies report on formulation specificity designated 
to facilitate the intracellular delivery of antibiotics. Moreover, recent studies of 
liposomes made up of lipids with fusogenic properties have been shown to deliver 
their entrapped molecules in the cytosol of the target cells more efficiently than 
conventional non fusogenic type of liposomes. Thus, treatment of intracellular 
pathogen like Brucella that adopt intracellular parasitism as a strategy to avoid host 
defense, the design of liposomal drug delivery systems that undergo controlled 
fusion with cellular or endosomal membranes seem to be an interesting preposition. 
Keeping in view of the above consideration, in the present, study antibiotics 
belonging to aminoglycosides (Gentamycin) and new generation Cephalosporins 
(Ceftrioxne, Cefapime, Cefotaxime) were encapsulated in conventional liposomes, 
fusogenic liposomes made up of E. coli cell wall lipid (escheriosome), pH sensitive 
and cationic liposomes. Finally, in vivo efficacy of the drug formulations were tried 
evaluated to establish chemotherapeutic potential against experimental murine 
brucellosis. The present study can be concluded that encapsulation of antibiotics in 
escheriosome can efficiently targeted to infected cells and reduce Brucella infection 
in mice. 
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Materials and methods 
Animals 
Female Balb/c mice were obtained from CDRI, Lucknow. The experimental 
procedures on mice and the facilities used to hold the experimental animals are in 
accordance with the Animal Ethics Committee (Committee for the Purpose of 
Control and Supervision of Experiments on Animals CPCSEA, Govt, of India). 
Chemicals 
Cholesterol was purchased from Centron Research Laboratory, Mumbai, 
India used after crystallization with methanol. Egg Phosphatidylcholine was isolated 
according to the procedure described earlier in Chapter II. 
Dioleoylphosphatidylethanolamine (DOPE) was purchased from Avanti Polar Lipids 
(Alabaster, AL). Sterylamine, Cholesteryl hemisuccinate (CHEMS), Triton X-100, 
and NaCl were obtained from Sigma Chemicals Co., USA. 
Antimicrobial agent 
The antibiotics of known potencies used in this study were procured from the 
manufacturers. Gentamycin sulfate was supplied as dried lyophilized powder 
(HiMedia, India) was made up to a concentration of 25-mg/ ml with HEPES (10 mm 
HEPES, 145 mM NaCl, 0.02% sodium azide, pH 7.4) just before use. Ceftrioxne, 
cefataxime and cefapime were obtained commerciality and reconstituted in diluent 
supplied with vial as per manufacturer's instruction and our requirement of the 
experiment. Cefotaxime and Ceftrioxne from Ranbaxy, Mumbai, India whereas 
Cefepime was procured from Lupin Ltd. India. Drugs were reconstituted in diluent 
supplied with vial as per manufacturer's instruction and our requirement 
Pathogen 
The organism used was the virulent strain B. abortus 544. The bacteria were 
cultured on Tryptose phosphate media (HiMedia, India) at 37 °C during 2-3 days in 
air to the logarithmic phase. Before being used in the infection studies, the resulting 
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culture was assessed for purity and absence of dissociation by the White and Wilson 
method and selected colonies were sub cultured in TPA for 24-48 hrs at 37 °C 
(Alton etai, 1988). 
Preparation ofB. abortus cells for infection 
Before infection, the lethal dose of 5. abortus 544 in mice was determined. For this, 
a group of 10 animals were infected intraperitonealy with 10 times increasing dose 
ofB. abortus 544 cells starting from 1X10^ to 1X10'° cfu/ mice. The mortality was 
observed upto 72 hrs post infection. 
Once the lethal dose was determined, B. abortus 544 cells from the stock 
culture were grown in Tryptose phosphate broth for 48 hrs at 37 °C. After proper 
growth of bacteria, serial dilution were made on TPA plate by taking lOjil inoculum 
from each dilution and incubated for 48 hrs. Colonies were counted and the stock 
culture was centrifuged and cell pellets were washed with PBS thrice. The washed 
bacterial cells were diluted to the appropriated concentration in PBS prior to use in 
vitro. Each mouse was infected with 2X10^ cells ofB. abortus 544 intraperitoneally 
with 24 gauze needle. 
Preparation of liposome 
Egg PC/ Choi liposome and escheriosome were prepared as per the method 
described in Chapter I. 
Preparation of pH sensitive liposome 
pH sensitive liposomes were prepared as per the method described by Tahseen et al.{ 
2005). Briefly, cholesteryl hemisuccinate (CHEMS) and DOPE were mixed in the ratio of 
1:4. Antibiotic was taken in the ratio of 1:40:: drug: lipid. Briefly, all the components were 
mixed in appropriate amount of chloroform/methanol (1:1, V/V) and evaporated by agitation 
under nitrogen for at least 1 h to remove traces of solvent. Subsequently, the dried lipid film 
was hydrated with 2.0 ml of 150 niM sterile saline followed by sonication (1 h, 4 °C) in a bath 
type sonicator under N2 atmosphere. The sonicated preparation was centrifliged at 10,000x g 
for 1 h at 4 °C to remove traces of un-dispersed lipid and finally dialyzed against normal 
saline for 24 hour at 4 °C in the dark. 
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Preparation of cationic liposome 
Cationic liposomes were prepared by mixing pliosphatidylcholine, 
cholesterol and sterylamine in the ratio of 7:2:2 into 1 ml of chloroform, solvent 
(chloroform) was carefully evaporated under reduced pressure to form a lipid film 
on the wall of flask. Subsequently the dried lipid film (consisting of egg PC, 
cholesterol and sterylamine) was hydrated with 1 ml of 150 niM sterile saline by 
vortexing continuously followed by sonication (5 minutes at 4° C) in bath type 
sonicator to prepare SUVs. 
Entrapment of antibiotic and preparation of DRVs 
To entrap various antibiotics in liposome (DRVs) equal volume of plane 
liposome were mixed with stock solution of antibiotic of interest. It was followed by 
freeze thawing for at least five times and finally lyophilized to get dried powder. The 
free flowing powder was reconstituted into 500 i^ l of 150 mM sterile saline and 
centrifuged for 3 times at 10,000x g for 10 minutes. Supernatant was discarded, drug 
bearing DRVs, which settled as pellet were used for the further experimentation. 
Estimation of liposome intercalated drug 
The intercalation efficiency of various liposome entrapped antibiotics in the 
liposomes was determined spectrophotometrically as well as by HPLC method. A 
standard curve of specific antibiotic was plotted 320nm, 253nm, 234nm and 257nm 
for Gentamycin, Ceftrioxne, Cefotaxime and Cefapime respectively. The amount of 
drug associated with Liposomal formulation in methanol and determining the 
absorbance against corresponding amount of lipid in methanol as a blank (Mehta et 
ai, 1987). The amount of the entrapped antibiotic in liposome was then calculated 
from the standard curve of antibiotic solution. The intercalation efficiency of 
antibiotics in different types of liposome was also estimated by HPLC method as 
well. The sample (20 |al) was injected onto Hypersil octydecyl-saline 5|j,m particle 
size analytical coloumn (150 by 4.6 mm internal diameter). Detection was 
accomplished with a UV light detector set at required wavelengths. A standard curve 
was plotted calibrating peak area versus amount of drug injected into column. The 
elution buffer was consisting of a isocratic mixture of 0.005 M EDTA snd methanol 
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(2:8v/v). the flow rate was kepyt 1.5 nil/min and retension time was found out to be 
4.7 min. The intercalation efficiency of antibiotics in different type of liposome were 
found out to be the same order as estimated by spectrophotometer method. 
Drug Therapy 
The efficacy of liposomal drug against strain of B. abortus 544 infection in 
Balb/c mice was determined on the basis of total bacterial load (CFU) in spleen of 
the infected animals. The animals (15 in each group) were grouped in the following 
manner for the testing of various liposomal formulations of Gentamycin and 
Cephalosporin (Ceftrioxne, Cefotaxime and Cefepime). 
The chemotherapeutic potential of the liposomised formulation of various 
antibiotics was determined following two different schemes. In the first scheme, 
hposome based formulations of Gentamycin and Ceftrioxne were evaluated for their 
antibacterial activity against experimental murine brucellosis. 
In the next set, we used combination of two new generation cephalosporins 
(Cefotaxime and Cefepime) and assessed the potential of concomitant delivery of to 
suppress Brucella infection in murine model. 
First set of experimental groups 
1. PBS (Control) 
2. Empty- EggPC/CIioI liposome(Sham PL) 
3. Empty-escheriosome(Sham EL) 
4. Empty-pH sensitive liposome (Sham pL) 
5. Empty-cationic liposome (Sham CL) 
6. Free-Gentamycin (F-G) 
7. Free Ceftrioxne(F-CTR) 
8. EggPC/Chol entrapped Gentamycin (P-Lip-G) 
9. Escheriosome entrapped Gentamycin (E-Lip-G) 
10. pH sensitive liposome entrapped Gentamycin (pH-Lip-G) 
11. Cationic liposome entrapped Gentamycin (C-Lip-G) 
12. EggPC/Chol entrapped Ceftrioxne (P-Lip-CTR) 
13. Escheriosome entrapped Ceftrioxne (E-Lip-CTR) 
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14. pH sensitive liposome entrapped Ceftrioxne (pH-Lip-CTR) 
15. Cationic liposome entrapped Ceftrioxne (C-Lip-CTR) 
Second set of experimental group 
1. PBS (Control) 
2. Empty-EggPC/Chol liposome (Sham PL) 
3. Empty-Escheriosome (Sham EL) 
4. Free- Cefotaxime (F-CT) 
5. Free Cefepime (F-CP) 
6. Free- Cefotaxime + Cefepime (F-CP+CT) 
7. Egg PC/Chol entrapped Cefotaxime (P-Lip-CT) 
8. Escheriosome entrapped Cefotaxime (E-Lip-CT) 
9. pH sensitive liposome entrapped Cefotaxime (pH-Lip-CT) 
10. Egg PC/Chol entrapped Cefepime (P-Lip-CP) 
11. Escheriosome entrapped Cefepime (E-Lip-CP) 
12. pH sensitive liposome entrapped Cefepime (pH-Lip-CP) 
13. EggPC/Chol entrapped Cefotaxime+Cefepime (P-Lip-CPCT) 
14. Escheriosome entrapped Cefotaxime+Cefepime (E-Lip-CPCT) 
15. pH sensitive liposome entrapped Cefotaxime+Cefepime (pH-Lip-CPCT) 
Dosage and route of administration 
Cephalosporins @ 50 mg/kg body wt was injected intramuscularly on day 1 
and 2 post infection where as Gentamycin was given @ 5mg/kg body wt. in free as 
well as liposomised form. Control group of animals were treated with PBS only. 
Before starting of experiment, group of infected mice were injected with different 
form of sham liposomes containing same amount of lipid with no active drug 
intramuscularly to determine whether sham liposome have any effect on splenic 
clearance of Brucella. 
Quantitative assessment of fungal load in spleen 
To evaluate the role of various liposomal drug formulations in elimination of 
B. abortus 544 infection, five animals from each group were sacrificed on days 5 
and day 15 post infection to determine clearance of Brucella. Briefly, the spleens of 
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the treated animals were aseptically removed, individually weighed, blended and 
diluted in 9 volumes (1:10; w/v) of PBS. Serial 10-fold dilutions of each spleen were 
made in the same diluent and aliquot of 10|al was plated in triplicate onto tryptose 
phosphate agar culture plates. The mean and SD (n = 5) of the loglO cfu/spleen for 
each group of mice (limit of detection is <4 cfu/spleen) were calculated. A value of 
1 cfu was considered when no cfu were detected in 10)J.1 of the spleen homogenate 
seeded. The numbers of colonies were counted and the bacterial load in spleen was 
determined by multiplying with the dilution factor. 
Statistical analysis 
Data obtained by in vivo studies were subjected to log transformation to 
obtain homoscedastic treatment groups variances. All treatment groups were 
examined by the analysis of variance. Significant differences between two individual 
groups' mean were determined by Students t- test. 
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The intercalation efficiency of drugs 
In the present study the intercalation efficiency of Gentamycin, Ceftrioxne, 
Cefotaxime and Cefepime drugs in egg PC liposomes was of the order of 54% ± 4. 
The amount of drug entrapped in pH sensitive liposomes and cationic liposome 
were of the order of 46% ± 4 and 42%)± 4 respectively while escheriosome was 
found to entrap 44% ± 4. 
Effect of different type of sham liposome in mice 
The effect of treatment with sham liposome (no drug) was assessed for their 
intrinsic potential to eliminate B. abortus 544. It was found that mice treated with 
various sham liposomes have same order of bacterial load in spleen to that of the 
group of mice injected with PBS only. 
Determination of lethal dose and infective dose ofB. abortus 544 in mice 
The lethal dose for 100% of the animals on 2"'' day post infection was 
found in the groups infected with 1X10 cells. Higher doses resulted in death due 
to endotoxic shock within 12 hrs of infection. For the present study we have 
selected the dose of 2X10^ cfu/ mice as there is no mortality upto 72 hours post 
infection. . 
Antimicrobial effects of monotherapy with Gentamycin and Ceftrioxne 
To investigate the chemotherapeutic potential of different liposomal 
formulation of Gentamycin and Ceftrioxne, we compared the protective efficacy of 
free as well as egg PC/Chol, escheriosome, pH sensitive and cationic liposomal 
formulation of the antibiotics in mice infected with B. abortus 544. The efficacy of 
Gentamycin and Ceftrioxne in different forms was evaluated based on the severity 
of the infection by quantification of bacterial burden (loglO cfu) in spleen on days 
5 and 15 post treatment. 
On day 5 post treatment no significant reduction of bacterial load was 
observed among the different treatment groups. 
On day 15 post treatment, significant reduction in bacterial load in the 
spllen of animals that were treated with escheriosome encapsulated Gentamycin as 
well in mice treated with pH-sensitive liposomised drug (E-Lip-G: log 3.69; pH-
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Lip-G: log 3.62, p<0.01) while it was 3.80 in the animals treated with conventional 
egg PC/Chol liposomal form of Gentamycin. Treatment with Gentamycin 
encapsulated in cationic liposome conferred same level (C-Lip-G, log 4.14) of 
protection as obtained by treatment with Gentamycin in free form (F-G: log 4.22, 
Table 22, Figure 26). 
Further, we have also evaluated the anti-bacterial activity of Ceftrioxne in 
mice infected with B. abortus 544. Treatment, sacrifice schedule and other 
conditions were maintained in compliance of the previous experiment. The infected 
mice were treated at 24 and 48 hrs post infection with various liposomal form of 
Ceftrioxne as well as in free form at the dose of 50mg/kg body wt. Animal treated 
with Ceftrioxne both in free as well as liposomal form did not show significant 
reduction in bacterial load among the different treatment groups (Table 23). 
Significant difference in splenic load of Brucella was found only after 15 
days post treatment. Animal treated with Ceftrioxne encapsulated in pH sensitive 
liposome) as well as in escheriosome, showed better splenic clearance than other 
form of liposomal Ceftrioxne (pH-Lip-CTR: log 4.01; E-Lip-CTR: log 4.32). 
Cationic liposomal form (C-Lip-CTR: log 4.32) and eggPC/Chol liposomal form of 
Ceftrioxne (P-Lip-CTR: log 4.33) confen^ed same level splenic clearance where as 
animal treated with free form of Ceftrioxne was unable to reduce the bacterial load 
(F-CTR: log 5.08) (Figure 27). 
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Figure 26. Comparative efficacy of liposome encapsulated Gentamycin and 
Ceftrioxne against B. abortus 544 infection in mice (on day 5 post treatment) 
Anti-Brucella activity of Gentamycin and Ceftrioxne were evaluated in free form 
as well as in liposomal form. Splenic load of Brucella was expressed in 
loglOCFU/spleen on days 5 post treatment. Data revealed that liposomal 
encapsulation of Gentamycin and Ceftrioxne did not induce significant reduction 
in splenic load of pathogen as compared with untreated control (on day 5 post 
treatment). Each bar represents the mean of three determinations ±SD. 
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Figure 27. Comparative efficacy of liposome encapsulated Gentamycin and 
Ceftrioxne against B. abortus 544 infection in mice (on day 15 post treatment) 
Anti-Brucella activity of Gentamycin and Ceftrioxne were evaluated in free form 
as well as in liposomal form on day 15 post treatment. Splenic load of Brucella 
was expressed in log! OCFU/spleen. Data revealed that escheriosome 
encapsulation as well as pH sensitive liposomal form of Gentamycin and 
Ceftrioxne induced significant reduction in splenic load of pathogen as compared 
with those treated with eggPC/Chol or cationic liposomal form of drug (on day 
15 post treatment). Each bar represents the mean of three determinations ±SD. 
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Experimental 
groups (n=5) 
Control 
F-G 
E-Lip-G 
pH-Lip-G 
P-Lip-G 
C-Lip-G 
On day 5 
Post treatment 
5.534±0.071 
5.138±0.084 
5.388±0.082 
4.920±0.0479 
5.148±0.151 
5.210±0.186 
On day 15 
Post treatment 
5.567±0.107 
4.223±0.109 
3.689±0.093* 
3.624±0.079* 
3.800±0.063 
4.141±0.194 
Table 22 
Comparative efficacy of liposome encapsulated Gentamycin against 
B. abortus 544 infection in mice (on days 5 and 15 post treatment) 
• Significantly different from Control (P< 0.05) 
Experimental groups 
(n=5) 
Control 
F-CTR 
E-Lip-CTR 
pH-Lip-CTR 
P-Lip-CTR 
C-Lip-CTR 
On day 5 
Post treatment 
5.644±0.042 
5.308±0.075 
5.315±0.026 
5.129±0.070 
5.264±0.020 
5.250±0.006 
On day 15 
Post treatment 
5.632±0.042 
5.077±0.097 
4.168±0.058* 
4.093±0.074* 
4.325±0.056 
4.318±0.033 
Table 23 
Comparative efficacy of liposome encapsulated Ceftrioxne against B. 
abortus 544 infection in mice (on days 5 and 15 post treatment) 
* Significantly different from Control (P< 0.5) 
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Antimicrobial effect of combination therapy of liposomal form of 
Cephalosporins (Cefotaxime and Cefapime) 
To investigate the potential of concomitant delivery of Cefotaxime and 
Cefepime in elimination of B. abortus 544, various liposomal formulation were 
developed. The severity of the infection was assessed by quantification of bacterial 
burden in spleen on day 5 and 15 of post treatment and expressed as loglO CFU/ 
spleen. 
On day 5 post infection, both free as well as liposomal form of Cefotaxime 
was unable to induce a significant reduction in the level of splenic infection with 
respect to that control group of mice (received no treatment), hi contrast, Cefepime 
successfully reduced bacterial load from treated animals in free form (log 5.89) as 
compared with mice treated with Cefotaxime (log 6.15). 
The antibacterial efficacy was found to be more distinct when animals were 
treated with the liposomal form of drugs Cefapime (E-Lip-CP: log 5.32; P-Lip-CP: 
log 5.36; pH-Lip-CP: log 5.42). On the other hand, combination of Cefepime and 
Cefotaxime in free (CT+CP: log 5.34) as well as liposomised form did not further 
improve the splenic clearance ability of the treated mice (E-Lip-CTCP: log 5.26; P-
lip-CTCP: log5.29; pH-Lip-CTCP: log 5.31). 
We have further evaluated the potential of various drug formulations on day 
15 post treatment by assessing bacterial load. Mice treated with free form of 
Cefotaxime as well as Cefepime were unable to reduce the bacterial load 
significantly (F-CT: log 6.15 to log 5.59; F-CP: log 5.89 to 5.32). Again 
combination of Cefapime and Cefotaxime did not further improve the anti-Brucella 
effect of these drugs as evident from mean loglO cfu count in spleen (CT+CP: log 
5.13).Critical analysis of the different liposomal formulations, showed that mice 
treated with E-Lip-CP (log 5.32 to log 4.53) or pH-Lip-CP (log 5.42 to log 4.34) 
could reduce the splenic load of pathogen significantly (P<0.05) as compared those 
treated with P-CP (log 5.36 to log 5.28). Further, inclusion of Cefotaxime along 
with Cefepime did not improve the splenic clearance ability of the drug 
formulations (E-CT+CP: log4.52; pH-Lip-CTCP: log 4.29; P-CTCP: log 5.17). 
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Figure 28. Comparative efficacy of eggPC/Chol liposome encapsulated 
Cefotaxime and Cefepime against Brucella infection in mice (on days 5 and 15 
post treatment). 
Anti-Brucella activities of Cefotaxime and Cefepime were evaluated in free form as 
well as in eggPC/Chol liposome in various combinations. Splenic load of Brucella 
was expressed in loglOCFU/spleen on days 5 and 15 of post treatment. Data 
revealed that eggPC/Chol liposomal encapsulation of Cefotaxime and Cefepime did 
not induce significant reduction in splenic load of pathogen as compared with 
untreated control. Each bar represents the mean of three determinations ±SD. 
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Figure 29. Comparative efficacy of escheriosome encapsulated Cefotaxime 
and Cefepime against Brucella infection in mice (on days 5 and 15 post 
treatment). 
Anti-Brucella activities of Cefotaxime and Cefepime were evaluated in free form 
as well as in escheriosome in various combinations. Splenic load of Brucella was 
expressed in loglOCFU/spleen on days 5 and 15 of post treatment. Data revealed 
that encapsulation of Cefepime induced significant reduction in splenic load of 
pathogen on day 15 post infection. It was also evident that inclusion of 
Cefotaxime did not further improve the therapeutic efficacy of E-Lip-CP 
combination. Each bar represents the mean of three determinations ±SD. 
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Figure 30. Comparative efficacy of pH sensitive liposome encapsulated 
Cefotaxime and Cefepime against Brucella infection in mice (on days 5 and 15 
post treatment). 
Anti-Brucella activities of Cefotaxime and Cefepime were evaluated in free form as 
well as in pH sensitive liposome in various combinations. Splenic load of Brucella 
was expressed in loglOCFU/spleen on days5 and 15 of post treatment. Data 
revealed that escheriosome encapsulation of Cefepime induced significant 
reduction in splenic load of pathogen on day 15 post infection. It was also evident 
that inclusion of Cefotaxime did not further improve the therapeutic efficacy ofpH-
Lip-CP combination. Each bar represents the mean of three determinations ±SD. 
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Figure 31. Comparative analysis of combination therapy of Cefotaxime and 
Cefepime after encapsulation in various types of liposomes against Brucella 
infection in mice. 
Anti-Brucella activities of monotherapy and combination therapy of Cefotaxime 
and Cefepime in various types of Liposomal form were analyzed on day 5 and 
15 post treatment. Data revealed that encapsulation of Cefepime in 
escheriosome as well as pH sensitive liposome induced significant reduction in 
splenic load of pathogen on day 15 post infection while treatment with 
Cefotaxime was found ineffective. Treatment with combination of Cefotaxime 
and Cefepime in liposomal form did not further improve the therapeutic efficacy 
of Cefepime. 
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Experimental 
groups (n=5) 
Control 
F-CT 
F-CP 
CT+CP 
P-Lip-CT 
P-Lip-CP 
P-Lip-CTCP 
On day 5 
Post treatment 
6.271±0.112 
6.154±0.106 
5.889±0.019 
5.343±0.124 
5.859±0.167 
5.360±0.053 
5.299±0.032 
On day 15 
Post treatment 
6.012±0.125 
5.588±0.156 
5.324±0.065 
5.132±0.062 
5.441±0.061 
5.227±0.072 
5.116±0.052 
Table 24 
Comparative efficacy of eggPC/Chol liposome entrapped Cefotaxime and 
Cefepime against Brucella infection in mice 
Experimental 
groups (n=5) 
Control 
F-CT 
F-CP 
CT+CP 
E-Lip-CT 
E-Lip-CP 
E-Lip-CTCP 
On day 5 
Post treatment 
6.271±0.112 
6.154±0.106 
5.889±0.019 
5.343±0.124 
5.914±0.055 
5.326±0.036 
5.262±0.113 
On day 15 
Post treatment 
6.012±0.125 
5.588±0.156 
5.324±0.065 
5.132±0.062 
5.089±0.142 
4.525±0.180' 
4.413±0.129* 
Table 25 
Comparative efficacy of escheriosome entrapped Cefotaxime and Cefepime 
against Brucella infection in mice 
* Significantly different from Control (P< 0.5) 
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Experimental 
groups (n=5) 
Control 
F-CT 
F+CP 
CT+CP 
pH-Lip-CT 
pH-Lip-CP 
pH-Lip-CTCP 
On day 5 
Post treatment 
6.271±0.112 
6.154±0.106 
5.889±0.019 
5.343±0.124 
5.807±0.095 
5.340±0.193 
5.303±0.180 
Results 
On day IS 
Post treatment 
6.012±0.125 
5.588±0.156 
5.324±0.065 
5.132±0.062 
5.152±0.091 
4.326±0.100* 
4.288±0.047* 
Table 26 
Comparative efficacy of pH sensitive liposome entrapped Cefotaxime and 
Cefepime against Brucella infection in mice 
* Significantly different from Control (P< 0.5) 
Experimental 
groups (n=5) 
P-Lip-CT 
P-Lip-CP 
P-CTCP 
E-Lip-CT 
E-Lip-CP 
E-Lip-CTCP 
pH-Lip-CT 
pH-Lip-CP 
pH-Lip-CTCP 
On day 5 
Post treatment 
5.859±0.167 
5.360±0.053 
5.299±0.032 
5.914±0.055 
5.326±0.036 
5.262±0.113 
5.343±0.124 
5.340±0.193 
5.303±0.180 
On day 15 
Post treatment 
5.441±0.061 
5.227±0.072 
5.116±0.052 
5.089±0.142 
4.525±0.180 
4.413±0.129 
5.152±0.091 
4.326±0.100 
4.288±0.047 
Table 27 
Comparative efficacy of different combination of Cefotaxime and Cefepime after 
encapsulation in various types of liposomes against Brucella infection in mice 
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Antibiotic treatment of brucellosis differs from that of other bacterial 
diseases because of some unique features of the infection. A hallmark of Brucella is 
the complex lipid-rich cell envelope that protects the organism from both the host 
response and anti-Brucella therapy. Moreover, access of antibiotic to the bacteria is 
also questionable because of its intracellular residence. These properties put greater 
constraints on efficient use of chemotherapeutic use of drugs. To be effective, drugs 
must be able to reach the infected intracellular sites of macrophages to be effective 
at low doses (Gregoriadis, 1991; Barrow, 2001). It is a well known that liposomes 
are able to localize in the RES component, where many pathogenic microorganisms 
reside; they can be therefore used for targeting of antibiotics in these organs with 
enhanced therapeutic indices of various encapsulated agents. 
In this regard antibiotic therapy for brucellosis has remained the objective of 
many studies. In recent years, many studies have been attempted to optimize 
chemotherapeutic regimens as well as to identify novel drug or formulation for 
minimizing toxicity while increasing overall efficacy against intracellular pathogen. 
Clinical failures of treatment against brucellosis are not also due to the development 
of antimicrobial resistance, but also due to the consequence of the ability of Brucella 
to survive within the cells (Braibant et al, 2002). The intracellular parasitism 
protects Brucella against chemotherapeutic onslaught and probably explains why 
this bacterium has not required the evolutionary development of antimicrobial 
resistance as has occurred in most microorganisms (Bowden et al, 1999.). 
Nevertheless, the in vitro efficacy of some antibiotic does not necessarily 
correlate with their in vivo efficacy, because of the limited penetration of these 
antibiotics into eukaryotic cells, the niche of Brucella. The complete clearance of 
the bacteria after antibiotic treatment is a good predictor for avoiding relapses and, 
accordingly, should be considered as determinant factor for selecting the most 
adequate treatment. 
In the present study, we envisage developmait of a suitable type of 
liposome for transporting drugs into infected phagocytic cells using murine model. 
Although, egg PC/Chol liposomes are also taken up by macrophages but they are 
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not much successful in delivery of entrapped molecules to the cj^osol of the 
macrophages. It has been demonstrated that suitable type of liposomes increase the 
efficacy of antibacterial drug Gentamycin against Listeria monocytogenes, 
Mycobacterium sp., Salmonella sp. and Brucella sp. infection in mice and guinea 
pig (Vitas et aL, 1995; Hall, 1990; Baklcer -Woundengberg et al., 1988; Dees et al, 
1985; Fountain et al, 1985; Hernadez-caselles et al, 1989) 
In the present study the drug entrapped in fusogenic liposomes 
(escheriosome) showed better efficacy in terms of significant reduction of CFU in 
spleen of treated mice as compared to the conventional, non fusogenic eggPC/Chol 
liposome. The reduction of bacterial count in the spleen of mice treated with 
escheriosome entrapped drug was significantly higher than that of the conventional 
liposome. Fusogenic nature of escheriosome has already been well established and 
the potential of the intracellular delivery of different macromolecules has also been 
demonstrated by our lab (Owais et al, 2001; Faisal et al., 2003; Sharma et al, 
2006a,b). The result obtained in the present work suggestive of the fact that 
escheriosome can confer better protection when compared with non fusogenic 
conventional liposome mediated delivery of the drug. Though pH sensitive 
liposomal form different antibiotics showed comparatively better result, the 
bioavailability, non toxicity, easiest method of preparation of escheriosome may be 
considered as a good alternative in the treatment of intracellular pathogen like 
Brucella. In the present investigation, poor protection efficacy of conventional 
liposome composed of natural phospholipids and cholesterol might be due to lack 
of fusogenic potential, rapid clearance from blood by organs of the MPS 
particularly liver and spleen. 
In the present study, Gentamycin in free fonn was unable to reduce bacterial 
load because free form of the drug cannot diffuse through cellular membranes, its 
internalization and accumulation inside cells has been ascribed to pinocytosis 
(Drevets tt al., 1994). In our investigation, animals treated with Gentamycin 
encapsulated in fusogenic liposomes achieved significant reduction in bacterial 
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burden in spleen as compared to free form drug and is a clear indicative of 
successful delivery of drug into the cytosol of target cell. 
We have also evaluated antibacterial efficacy of Ceftrioxne in animals 
infected with B. abortus. Successful use of Ceftrioxne against intracellular pathogen 
was reported in many clinical reports and its use in medical and veterinary practice 
is very popular. Interestingly the data of the present study suggest that Ceftrioxne 
too was found to be more effective when used in liposomal form (both in 
escheriosome as well as in pH sensitive liposome) than the any other formulations. 
Chemotherapeutic use of third and fourth generation Cephalosporins have 
emerged as new alternatives to combat intracellular pathogens, our study also 
included evaluation of Liposomal formulation of Cefotaxime and Cefepime. It was 
found that free form of both the drugs was inefficient to lower down the number of 
intracellular bacteria. It might be due to the inability of Cephalosporins to diffuse 
intracellular location through cellular membrane (Drevets et al., 1994). 
The important aspect of the effectiveness of escheriosome encapsulated drug 
under study need to be explained more precisely. It well known that intracelliilar 
bacteria can evade the host defenses by the mechanism of prevention of phagosome-
lysosome fusion. B. abortus is first located in the perinuclear region within 
compartments resembling autophagosomes and is then delivered to the endoplasmic 
reticulum where intracellular bacterial replication takes place (Frenchick et al, 
1985; Pizarro-Cerda et al., 1998a; Detilleux et al., 1990 Pizarro-Cerda et al., 1998b). 
This special localization of B. abortus helps in direct contact between bacteria and 
liposome bearing antibiotic. Moreover, virulent Brucella can transit from early 
endosomes to autophagosomes, which apparently did not fuse with endosomes 
(Pizarro-Cerda et al., 1998a). Nonetheless, fusion between phagosomes and other 
endocytic vesicles can generally occur, so that phagosomes loaded with particles or 
pinocytic endosomes have the potential to eliminate Brucella that reside in 
accessible phagosomes (Drevets et al., 1994). B. abortus resides in accessible single 
membrane phagosomes and also in multimembranous autophagosomes (Pizarro-
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Cerda et al., 1998b), where the bacteria may escape from the antibiotics delivered to 
phagosomes. 
Finally, it can be concluded that liposome encapsulation of antibiotics was 
efficiently targeted to infected cells and help in reduction of intracellular Brucella 
infections. In addition, Gentamycin, Ceftrioxne as well as Cefapime offer better 
option than Cefotaxime in clearance of Brucella. However, some issues as the 
stability of liposome, risk of sensitization of the patients against substances 
enclosed in liposomes, altered pharmacokinetics and toxicity of the enclosed agent 
nee-d to be addressed in vivo before a clinical protocol can be scheduled. 
199 
(BiSCiograpfiy 
f^ t" '^;>ii» 
c&i6uaa)ia^Au 
1. Abel E, Fedders MF, Gokel GW. J Am Chem Soc 1995; 117: 1265-1270. 
2. Abraham EP, Duthie E. S. Lancet 11946; 455^59. 
3. Abtahi H, Salmanian AH, Rafati S, Nejad GB, Hassan ZM. Iran Biomed Jn 
2004;8:13-18. 
4. Adler-Moore JP, Proffitt RT. JAntimicrob Chemother 2002; 49: 21-30. 
5. Adler-Moore JP, Chiang SM, Satorius A, Guerra D, McAndrews B, McManus 
EJ. J Antimicrob Chemother 1991; 28: 63-71. 
6. Agrewala JN, Owais M, Gupta CM. Cytokines Mol Ther 1996; 2: 59-65. 
7. Ahmad N, Masood AK, Owais M. Cell Immunol 2001b; 210: 49-55. 
8. Ahmad N, Masood AK, Owais M. Eur JBiochem 2001a, 268: 5667-5675. 
9. Akdeniz H, Irmak H, Anlar O, Demiroz APJ. Infect 1998; 36:297-301. 
10. al Eissa YA, Kambal AM, al Nasser MN, al Habib SA, lal Fawaz M, al Zamil 
FA. Pediatr Infect Dis J1990; 9:74-79. 
11. Allen TM, Mehra T, Hansen C, Chin YC. Cancer Res 1992; 52: 2431 -2439. 
12. Allen TM, Williamson SJ, Schlegel RA. Proc Natl Acad Sci, 1988; 85: 8061-
8063. 
13. Allen TM. Adv Drug Delivery Rev 1994; 13: 285-309. 
14. Al-marari A, Tibor A, Mertens PD, BoUe X, Michel P, Godefroid J, Walravens 
K, Letesson J J. Infect Immun 2001; 69: 4816-4822. 
15. Al-Sibai MB, Qadri SMH. J Antimicrob Chemother 1990; 25:302-303 
16. Alton GG, Elberg SS. Vet Bull 1967; 37: 793-800. 
17. Alton GG, Jones LM, Angus RD, et al In: Techniques for the Brucellosis 
Laboratory. Paris: Institute National de la Recherche Agronomique, 1988. 
18. Alton GG. In K. Nielsen and JR. Duncan (ed.). Animal Brucellosis. CRC Press. 
19. Alving CR, Koulchin G, Rao M. Immunol Rev 1995; 145: 5-31. 
20. Alving CR, Steck EA, Chapman WL, Waits VB, Hendricks LD, Swartz GM, et 
a/. USA 1978; 75: 2959-63. 
21. Alving CR Biochim Biophys Acta 1992 ; 1113: 307-322. 
11. Alving CR. In: Tergetting of drugs. New York, Plenum press, 1982; p 377. 
23. Alving, CR, Yip HC, et al Ann New York Acad Sci 1995; 754: 143-152. 
24. Anaissie E. Clin Infect Dis 1992; 14: S43-51. 
25. Ariza J, Gudiol F, Pallares R, Ruff G, Femindez-Villadrich P. Antimicrob 
Agents Chemother 1985; 28:548-551. 
26. Arkema A, Huckriede A, Schoen P,Wilschut J, Daemen T. Vaccine 2000; 
18:1327-1333. 
27. Armstrong JA, Hart DA. J Exp Med 1971; 134:713-740. 
28. Arunothayanun P, Uchegbu IF, Florence AT. J Pharm Pharmacol 1999; 51: 
651-657. 
29. Arya LN, Elzer PH, Rowe GE, Enright MF, Winter AJ. J Immunol 1989; 
143:3330- 3983. 
30. AssaduUahi TP, Hider RC, McAuley AJ. Biochim Biophys Acta 1991; 1083: 
271-276. 
31. Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, 
Rochnian M, Kedar E. Vaccine 2002; 20: 505-515. 
32. Bachrach G, Banai M, Bradstein S, Hoida G, Genizi A, Bercovier H. Infect 
Immun 1994; 62: 5361. 
33. Baillie AJ, Coombs GH, Dolan TF, Laurie J. J Pharm Pharmacol 1986; 
38:502-505. 
34. Bakker-Woudenberg lAJM, ten Kate MT, Steame-CuUenL ET, Woodle MC. 
J Infect Dis 1995 ;171: 938-47. 
35. Bakker-Wounderberg lAJM, Lokerse AF, Vink van den Berg JC, Roerink 
FH. Infection 1988; 16: S155-S170. 
36. Baldi PC, Giambartolomei GH, Fernando A, Goldbaum LF, Abdo N, Carlos 
AV, Reinhold K, Fossati CA. Clinical and diagnostic Laboratory Immunology. 
July ed. 1996; p 472-476. 
37. Baldwin CL, Jiang X, Femandes DM. Trends Microbiol 1993; 1:99-104. 
-2 
38. Baldwin CL, Winter A J. Immunol Ser 1994; 60:363-380. 
39. Bang B.JComp Path Therap 1897; 10: 125-161. 
40. Bangham AD, Home RW. JMol Biol 1964; 8: 660-668. 
41. Bangham AD, Standish MM, Watkins JC. JMol Biol 1965; 13: 238-252. 
42. Barr IG, Sjolander A, Cox JC. Adv Drug Delivery Rev 1998; 32: 247-71. 
43. Barrow WW. Rev Sci Tech 2001; 20:55-70. 
44. Barthel R, Feng J, Piedrahita JA, McMurray DN, Templeton JW, Adams LG. 
Infect Immun 2001; 69: 3110-3119. 
45. Batra HV, Chand P, Ganju L, Mukherjee R, Sadana JR. Res Vet Sci 1989; 46: 
143-146 
46. Batzri S, Kom ED. Biochim Biophys Acta 1973; 298:1015. 
47. Behboudi S, Morein B, Villacres-Eriksson M. Clin Exp Immunol 1996; 105: 6-
13. 
48. Bergan T. In: VT Andriole (ed.) The quinolones, 2nd ed. Academic Press, San 
Diego, Calif.1998. p 143-182. 
49. Berkelman RL. Clin Infect Dis 2003; 37: 407-414. 
50. Berman JD, Ksionski G, ChapmanWL, Waits VB, Hanson WL. Antimicrob 
Agents Chemother 1992;36:1978-1980. 
51. Bermudez LE, Wu M, Young S. J Infect Disease 1981; 156: 510-513. 
52. Bertrand A, Bentejac MC, Biron G, Siffert M, Bostvironnois C, Roumiantzeff 
M. Dev Biol Stand 1984; 56: 547-551. 
53. Bhattacharjee AK, Izadjoo ML, Zolinger WD, Nikolikh PK, Hoover DL. 
Infect Immun 2006; 74: 5820-5825. 
54. Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C. 2002b; 70: 6549-6557. 
55. Biet F, Locht C, Kremer L. JMol Med 2002a; 80: 147-162. 
56. Blasco JM, Diaz R. Lancet 1993; 342: 805. 
57. Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Man C, Barbaren 
M, Moriyon I, Alonso-Urmeneta B, Diaz R. Vet Immun Immunopathol 1993; 
3-
^iouogva^Juu 
37: 257-270. 
58. Blasco JM. Prev Vet Med 1997; 31: 275-283. 
59. Bonventre PF, Hayes FR, Imhoff J. JBacteriol 1967; 93:445-450. 
60. Bonventre PF, Imhoff J. Infect Immun 1970; 2:89-95. 
61. Bosch JC, De Jong MCM, Franken P, et al. Vaccine 1998; 16: 265-271. 
62. Boschiroli M, Ouahrani-Bettache S, Foulongne V, Michaux-Charachon S, 
Bourg G, AUardet-Servent A, Cazevieille C, Lavigne J, et al. Microbiol 2002; 
90: 341-348. 
63. Bosilkovski ML, Caparoska S, Dimzova M. Croat Med J2004; 45:727-733. 
64. Bosseraay N. Br J Exp Pathol 1978; 59: 354-365. 
65. Bowden RA, Racaro GC, Baldi PC. Clin Diagn Lab Immunol 1999; 6: 440-443. 
66. Boyum A. ScandJClin Invest 1968;94:77-89. 
67. Braibant M, Guilloteau L, Zygmunt MS. Antimicrob Agents Chemother 2002; 
46: 3050-3053. 
68. Bretscher P, Cohn M. Science 1970; 169: 1042-1049. 
69. Brewer JM, Alexander J. Immunology 1992; 75: 570-575. 
70. Brewer JM, Alexander J. Vaccine 1994; 12:613-619. 
71. Brewer, JM., C. W. Roberts, et al. Vaccine Research 1996; 5: 77-89. 
72. Brewer, JM., C. W. Roberts, et al. Brighton. 1994; Ch. 20: 34-36. 
73. Brinley-Morgan WJ, Corbel MJ. In: Topley and Wilson'sprinciples of 
bacteriology, virology and immunology, 8* ed. Edward Amold,London, 
England. 1990; p 547-570. 
74. Brooks-Worrel BM, Splitter GA. Infect Immun 1992; 60: 2459-2464. 
75. Bruce D. Br Med J1989; 1: 1101-1132. 
76. Buboltz JT, Feigenson GW. Biochim BiophysActa 1999; 1417: 232-243. 
77. Buck JM. JAgric Res\930; 41: 667. 
78. Budker V, Gurevich V, Hagstrom JE, Bortzov F, Wolff JA. Nature Biotechnol 
1996; 14: 760-764. 
79. Campbell GA, Adams LG, Sowa BA. Vet. Immunol Immunopathol 1994; 41: 
295-306. 
80. Campbell PL Cytobios 1983;37:21-26. 
81. Canning,PC, Roth JA, Deyoe BL. J Infect Dis 1986; 154: 464-470. 
82. Capasso, L. J Infect 2002; 45: 122-127. 
83. Cassataro J, Velikovsky C, de la Barrera S, Estein L, Bruno R, Bowden K, 
Pasquevich CF, Giambartolomei G. Infect Immun 2005; 73:6537-6546. 
84. Celli J, de Chastellier, Franchini DM, Pizarro-Cerda J, Moreno E, Grovel JP. J 
ExpMed2QQ3; 198: 545-556. 
85. Chen HM, Torchilin V, Langer R. J Control Rel 1996; 42: 263-272. 
86. Chen HM, TorchilinV, Langer R. Pharm Res 1996; 13: 1378-1383. 
87. Cheville NF, Olsen SC, Jensen AE, Stevens MG, Palmer MV, Florance AM. 
Am J Vet Res\996; 57: 1153-1156. 
88. Choll C, Hans S. Clin J Microbiol 1977; 10: 221-226. 
89. Chonn A, Cullis PR. Curr Opin Biotechnol 1995; 6: 698-708 
90. Choquet CG, Patel GB, Beveridge TJ, Sprott GD. Appl Microbiol Biotechnol 
1994; 42: 375-384. 
91. Cistola DP, Atkinson D, Hamilton JA, Small DM. Biochemistry 1986; 25: 
2804-2812. 
92. Collins D. In: Liposomes as Tools in Basic Research and Industry (Philippot JR 
and Schuber F, eds), CRC Press, Inc., Boca Raton, FL 1995; p 201-214. 
93. Collins FM, Mackaness GB. J Immunol 1968; 101:83. 
94. Colmenero JD, Hernandez S, Reguera JM, Cabrera F, Rius F, Alonso A. 
Chemotherapy 1989;35:146-152. 
95. Colmenero JD, Queipo-Ortuno MI, Maria RJ, Angel Suarez-Munoz M, Martin-
Carballino S, Morata P. Diagn Microbiol Infect Dis 2002; 42:159-167. 
96. Confer AW, Tabatabi LB, Deyoubi BL, et al. Vet Microbiol 1987; 15:325-339. 
5 -
97. Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Vaccine 2001;19: 
3509-3517. 
98. Conne P, Gauthey L, Althaus B, Que JU, et al. Vaccine 1997; 15:1675-1679. 
99. Corbel M. Emerg Infect Dis 1997; 3:213- 221. 
100. Corbel MJ. In: Topley and Wilson's principles of bacteriology, virology, and 
immunology, 8th ed. Edward Arnold, London,England. 1990; p 339-353. 
101. Corbel MJ. J Med Microbiol 1997; 46: 267-269. 
102. Dalrymple-Champneys W. Lancetl\95Qdi; 1: 429-435. 
103. Dalrymple-Champneys W. Lancetl\95Qi\); 1: 477-485. 
104. Dees C, Fountain MW, Taylor IR, Shultz RD. Vet Immunol Immunopathol 
1985; 8:171-182. 
105. Del Vecchio VG, Kapatral V, Redkar RJ, Patra G, Mujer C, Los T, Ivanova N, 
Anderson I, Bhattacharyya A, Lykidis A, Reznik G, Jabloroski L, Larsen N, 
D'souza, M, Bemal A, Mazur M, Goltsman E, Selkoy E, Elzer PH, Hagius S, 
O'Callaghan D, Letesson JJ, Haselkom R, Kyrpides N, Overbeek R. Proc Natl 
AcadSci USA 2002a; 99: 443-448. 
106. Del Vecchio VG, Wagner MA, Eschenbrenner M, Horn TA, Kraycer JA, 
Estock F, Elzer P, Mujer CV. Vet Microbiol 2002b; 90: 593-603. 
107. Diamond MS, Staunton AR, de Fougerolles S, Stacker A, Gracia-Agullar J, 
Hibbs ML, Springer TA. J Cell Biol 1990; 111:3129-3139. 
108. Dorta MJ, Munguia O, Llabres M. IntJPharm 1993; 100: 9-14. 
109. Dossey BM. JHolistNurs 1998; 16: 168-196 (discussion 197-201). 
110. Dotsika E, Karagouni E, Sundquist B, et al. Scand J Immunol 1997; 45: 261-
268. 
111. DubrayG,BezardG.J««i?ec/?Fe/1980; 11:367-373. 
112. Dubray G, Plonlmet M. In: Regamey RH, Hulse EC, Valette L. (Editors). 1975, 
International seminar on brucellosis. Rabat, Dev Biol. Stand., 1976; 31: 68-91. 
113. Duzgune N, Straubinger RM, Baldwin PA, Papahadjopoulos D. In: Membrane 
Fusion (Wilschut J and Hoekstra, D, eds), Marcel Dekker, Inc., New York 
1991;p713-730. 
114. Dybing JK, Walters N, Pascual DW. InfectImmunl999; 67: 6242-6248. 
115. Dzata GK, Confer AW, Wyckoff JH. Vet Microbiol 1991; 29: 27-48. 
116. Dzata GK, John H, Wyckoff A, Confer W. Vet Microbiol 1991; 29:15-26. 
117. Easmon CS, Crane JP, Blowers A. JAntimicrob Chemotherl986; 18:43-48. 
118. Edson RS, Terrell CL. Mayo Clin Proc 1999; 74:519-528. 
119. Edwards SJ, deRopp RS, McLeod HA. Vet Rec\945; 57: 259. 
120. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Mol Immunol 
1991;28:287-294. 
121. Eldridge JH, Stass JK, Meulbroek JA, Tice TR, Gilley RM. Infect Immun 
1991;59:2978-2986. 
122. EUouz F, Adam A, Ciorbaru R, Lederer E. Biochiem Biophys Res Commun 
1974;59:13-27. 
123. Elzer PH, Kovach ME, Phillips RW, Robertson GT, Peterson KM, Roop II, 
Plasmid RM. Endley S, McMurray D, Ficht TA. J Bacteriol 2001; 183: 2454-
2462. 
124. Escande A, serre A. Int Arch Appl Immun 1982; 68: 172-175. 
125. Faisal SM, Khan MA, Nasti TH, Ahmed N, Owais M. Vaccine 2003; 21.- 2383-
2393. 
126. Foulongne V, Bourg G, Cazevieille C, Michaux-Charachon S, O'Callaghan D. 
Infect Immun 2000; 68: 1297-1303. 
127. Fountain MW, Weis SJ, Fountain AG, Shen A, Lenk RP. J Infect Dis 1985; 
152: 529-535. 
128. Freeman BA, VanaLR. J Infect Dis 1958; 102:258-267. 
129. Freund J, Casals J, Hosmer EP. Proc Soc Exp Biol Med 1937; 37:509-513. 
130. Friedland IR, McCracken GH. New EngJMed 1994; 331: 377-382. 
7-
131. GabijonA, Papahadjopoulosiochim D. BiochimBiophys Acta 1992; 1103:94. 
132. Gadras C, Santaella C, Vierling P. J Control Rel 1999; 57:29-34. 
133. Garci'a-Rodrrguez JA, Garci'a-Sa'nchez JE, Mun~oz Bellido JL, Garci'a-
Sa'nchez E, Trujillano I. Rev Esp Quimioterl989; 2:61-63. 
134. Garci'a-Rodn'guez JA, Garci'a-Sa'nchez JE, Trujillano I. Antimicrob Agents 
Chemother 1991; 35:756-759. 
135. Garcia A, Alder-Moore JP, Proffitt RT. Antimicrob Agents Chemother 2000; 
44:2327-2332. 
136. Garcia-rodriguez JA, Munoz bellido JL, Fresnadillo MJ, Trujillano I. 
Antimicrob Agents Chemotherl993; 37: 911-913. 
137. Gilliiand J, Klesius PH, Giambome J. Jn Comp Immunol Microbiol Infect Dis 
1982;5:457-468. 
138. Gluck R. J Liposome Resl995; 5:467 
139. Goldenbaum, EG, Kessel RW, Fukui GM. J Infect Dis 1966; 116:447-454. 
140. Golding B, Scott DE, Scharf O, Huanh LY, Zaitseva M, Lapham C, Eller N, 
Golding H. Microb Infect 2001; 3: 43-48. 
141. Goldsby RA, Kindt TJ, Kuby J, Osborne BA. In:"Immunology", 5th edition. W 
H Freeman & Co., January 2003. 
142. Goldstein J, Hoffman T, Frasch C, Lizzio EF, Beining PR, Hochstein D, Lee 
YL, Angus RD, Golding B. Infect Immun 1992; 60:1385-1389. 
143. Gould-Fogerite S, Kheiri M, Edghill-Smith Y, Zhang F, Wang Z, Feketeova E, 
Mannino RJ. Adv Drug Deliv Rev 1998; 6&32:273-287. 
144. Graybill JR, Graven PC, Taylor RL, Williams DM, Magee WE. J Infect 
Disl982; 145: 748. 
145. Grayson LS, Hansbrough JF, Zapata-Sirvent R, Roehrbom AJ, Kim T, Kim S. 
Critical Care Medicine 1995; 23: 84-91. 
146. Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P, Bonze MS. 
Am JMedSci 2002; 323:299-315. 
147. Gregoriadis G. In: Allison and G. Poste (Eds.), Plenum, New York, 1991. 
148. Gregoriadis G. In: Allison and G. Poste, (Eds.), Plenum, New York, 1989. 
149. Gregoriadis G, Florence AT. Drugs 1993; 45: 15-28. 
150. Gregoriadis G, Leathwood PD, Ryman BE. FEbs Lett 1971; 14: 95-99. 
151. Gregoriadis G, McCormack B. In: AC Allison and G. Poste (Eds.), Plenum, 
New York, 1993. 
152. Gregoriadis G. In: (Ed.) John Wiley, Chichester, 1988. 
153. Gregoriadis G. In: D.E.S. Stewart-Tull (Ed.), John Wiley, Chichester, 1994, 
pl45-169. 
154. Gregoriadis G. JAntimicrob Chemotherl99l; 28:39-48. 
155. Gregoriadis G. Immunol Today 1990; 11: 89-97. 
156. Gregoriadis G. Nature 1977; 265: 407-411. 
157. Gupta, R.K. Advanced Drug Delivery 1998; 32: 155-172. 
158. Guzman-Verri C, Chaves-Olarte E, Von Eichel-Streiber C, Lopez Goni I, 
Thelestam, Arvidson S, Grovel JP, Moreno E. J Biol Chem 2001; 276: 44435-
44443. 
159. HallWU. Rev Infect Dis 1990; 12:1060-1099. 
160. Hailing SM, Peterson-Burch BD, Bricker BJ, Zuemer RL, Qing Z, Li LL, 
Kapur V, Alt DP, Olsen SC. J Bacterial 2005; 187: 2715-2726. 
161. Haran G, Cohen R, Bar LK. Biochim BiophysActa 1993; 1151: 201-315. 
162. Harding CV, Collins DS, Kanangawa 0, Kanagawa O, Unanue ER. J Immunol 
1991;147:2860-2863. 
163. Harmon BG, Adams LG, Templeton JW Smith R. Am J Vet Res 1988; 49: 
1092-1097. 
164. Hauser n,Gsmsri. Proc Natl Acad Sci USA, 1982; 79: 1683 
165. Helvaci S, Tore O. J Clin Rheumatol 2004; 10:300-307. 
166. Henk L, Smits LH, Cutler JS. Afr JBiotechnol 2004; 3:631-636. 
167. Henry BS. J Infect Dis 1993; 52: 374. 
168. Heremans JF, Vaermin JP, VaemmanC. J Immunol 1963; 91: 11-17. 
169. Hernandez-CasUes T, Vera A, Crespo F, Villialin J, Gomez-Femandez JC. Am 
J Vet Res 1989; 50: 1486-1488. 
170. Holmes B, Quie PG, Windhorst DB, Pollara B, Good R. Nature 1966; 
210:1131-1134. 
171. Holzer BR, Hatz C, Schmid-Sissolak D, Gliick R, Althaus B, Egger M. Vaccine 
1996;4:982-986. 
172. Hope MJ, Mui B, Ansell S, et al. Mol Membr Biol 1998; 15: 1-14. 
173. Horn FP, Breeze RG. Ann NY Acad Sci 1999; 894:9-17. 
174. Hornef MW, Noll A, Schirmbeck R, Reimann J, Autenrieth IB. Med Microbiol 
Immunol 2000; 189: 97-104. 
175. Hu CJ, Rhodes DG. IntJPharm 1999; 185: 23-35. 
176. Huang C. Biochem 1969; 8: 344. 
177. Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding 
B. J Immunol 2003; 171:1441-1446. 
178. Huddleson IF, Stahl WH. MichAgric Exp Stn Tech Bull 1943; 182: 57. 
179. Hulse EC, Hopkins IG; Hebert CN. In: Proc VI International Congress for 
Biological Standardization, Berlin-Zehlendorf. H. Hoffman, Berlin, 1960;p 235. 
180. Ishibasi A, Ortiz V, Vargas M, Panigua J, Gonzalez C, Moreno J, Kumate J. 
Infect Immun; 56: 2953. 
181. Janeway CA, Medzhitov R. Semin Immunol 1998; 10: 349-350. 
182. Jenkin C, Benacerraf B. J Exp Med 1960; 112:403-417. 
183. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. Vaccine 1997; 15: 
814-817. 
184. Kauffmann AF, Meltzer MI, Schmid GP. Emerg Infect Dis 1997; 3:83-94. 
185. Keleti G, Feingold DS, Youngner JS. Infect Immun 1974; 10:282-283. 
186. Kerr WR, Payne DJH, Robertson L, Coombs RRA. Immunology 1967; 13: 
223-225 
-10 
^wu(>ava^Au 
187. Khuri-Bulos NA, Daoud AH, Azab SM. Pediatr Infect Dis J1993; 12:377-381. 
188. Kirby C, Gregoriadis G. Biotechnol 1984; 2: 979-984. 
189. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Antimicrob Agents 
Chemother 1990;34:967-70. 
190. Koff WC, Fddler IJ, Showwalter SD, Seniff DA, Hamper B. Infect Immun 
1983; 42: 1067. 
191. Kohler S, FoulongneV, Ouahrani-Bettache S, Bourg G, Teyssier J, Liautard 
RM, J.P. Proc Natl Acad Sci USA 2002; 99: 15711-15716. 
192. Kortepeter MG, Parker GW. Emerg Infect Dis 1999; 5:523-527. 
193. Kreutzer DL, Dreyfus LA, Robertson DC. Infect Immun 1979; 23: 737-42. 
194. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Infect Immun 2000; 6S: 
54-63. 
195. Krishnan L, Sad S, Patel GB, Sprott GD. J Immunol 2000; 165: 5177-5185. 
196. Kumana CR,Yuen KY. Drugs 1994; 47: 902-913. 
197. Kumar A, Gupta CM. Nature 1983; 303: 632-633. 
198. KumarA, Gupta CM. Biochim BiophyActa 1984; 769: 419-428. 
199. Laemmli UK. Nature 1970; 227: 680. 
200. Landman G, Saurina JM. Clin Infect Disl998; 26: 183-184. 
201. Lapaque N, Moriyon I, Moreno, E Gorvel, JP. Current opinion in Microbiol 
2005; 8: 60-66. 
202. Lasic DD, Papahadjopoulos D. Science 1995; 267: 1275-1276. 
203. Lasic DD. In: Elsevier, Amsterdam, London, New York. 1993 
204. Leconte P, Joly V, SaintJulien L, Gilliardin JM, Carban C, Yeni P. Amer Rev 
Resp Dis 1992; 145: 424. 
205. Lestrate P, Delrue RM, Danese I, Didembourg C, Taminiau B, Mertens P, 
DeBolle X, Tibor A, Tang CM. Letesson JJ. Mol Microbiol 2000; 38: 543-551. 
206. Liautard JP, Gross A, Dornand J, Kohler S. Microbiologia 1996; 12: 197-206. 
11 
1<^1. Lin J, Ficht TA. Infect Immun 1995; 63: 1409-1414. 
208. Liu D, Zhou F, Huang L. Biochem Biophys Res Commm 1989; 162: 326-333. 
Lopez Merino A, Asselineau J, Serre A, Roux J, Bascoul S, Lacave C. Infect 
Immun 1976; 13: 311-231. 
209. Lord VR, Schurig GG, Cherwonogrodzky JW, Marcano MJ Melendez G.E. Am 
J Vet Res 1995; 59.-1016-1020. 
210. Lowrie DB, Tascon RE, Silva CL. Int Arch Allergy Immunol 1995; 108:309-
3121995; 59: 1016-1020. 
211. Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X. 
Infect Immun 2006; 74: 2734-2741. 
212. Lutwyche P, Cordeiro C,Wiseman DJ, et al. Antimicrob Agents Chemother 
1998;42:2511-2520. 
213. Mackaness GB. Nature\962; 181:381-406. 
214. Madkour MM. In: Madkour's brucellosis, Springer-Verlag,New York, N.Y. 
2001. 
215. Mahajan NK, Kulshreshtha RC, Malik G, Dahiya JP. Vet Res Commun 2005; 
29:189-199. 
216. Mallick AI, Singha H, Chaudhuri P, Nadeem A, Khan SA, Dar KA, Owais M. 
Vaccine 2007; 25: 3692-3704. 
217. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Immunolo 1994; 81:661-
667. 
218. Mandal M, Lee KD. Biochim Biophys Acta 2002; 1563: 7-17. 
219. Marston JA. Great Britain Army Med Dept Rep 1861; 3: 486-521. 
220. McCIuskie MJ, Davis HL. Vaccine 2000; 18: 231 -237. 
221. McDiarmida A. Vet Rec 1957; 69: 877-879. 
222. McEwen AD. Vet Rec 1940; 52: 815. 
223. Mehta RT, Hopfer RL, McQueen RT, Juliano RL, Lopez-Berestein. 
Antimicrobe Agents Chemother 1987; 31:1897-1900. 
12 
224. Mehta RT, Hopfer RL, McQueen RT, Juliano RL, Lopez-Berestein. J Infect 
Dw 1991; 164: 1003. 
225. Mert A, Kocak F, Ozaras R, Tabak F, Bilir M, Kucukuglu S, Ozturk R, Aktuglu 
Y.Ann. Thorac Cardiovasc Surg 2002; 8:381-383 . 
226. Michaleck S, Osterhaus A, O'Hagan D, Gould-Fogerite S. In: Mucosal 
Immunology, 2"'' ed. Marcel Dekker, New York, 1998. 
227. Minor PD, John A, Ferguson M, Icenogle JV.JGen Virol 1986; 67:693-706. 
228. Mishell BE, Shiigi SM. In: New York: Freeman 1980; p 23-24. 
229. Montaraz JA, Winter AJ, Hunter DM, Sowa BA, Adams LG. Infect Immun 
1986; 51:961 
230. Moore P, McGuirk S, Adams WC, Jones JP, McGee DT, O'Hagan KH, Mills 
G. Vaccine 1995; 13: 174M749. 
231. Moreno E, Berman DT, Boettcher LA. Infect Immun 1981; 31:362-370. 
232. Mossman TR, Cherwinski H, Bond MW, Coffman RL. J Immunol 1986; 126: 
2348. 
233. Mowat AM, Donachie AM. Immunol Today 1991; 12: 383-385. 
234. Moyer NP, Holcomb LA. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, 
Yolken RH. (ed.). Manual of Clinical Microbiology, 6* ed. ASM Press, 
Washington,D.C. 1995. 
235. Munoz PM, Estevan M, Marin CM, De Miguel MJ, Grillo MJ, Barberan M, et 
al. Vaccine 2006; 24:1897-1901. 
236. Murdan S, Gregoriadis G, Florence AT. EurJPharm Sci 1999; 8: 177-185. 
237. Murillo M, Gamazo C, Goiin MM, et al. In Jn Pharmaceut 2002; 242: 341-
344. 
238. Musial CE, Cockerill FR, Roberts GD. Clin Microbiol Rev 1988; 1: 349-364. 
239. New RRC, Chance ML, Heath S. JAntimicrob Chemother 1981; 8:371. 
240. New RRC, Chance ML, Thomas SC, Peters W. Nature 1978; 272: 551 
241. Nicolau C, Tosi PR, Tudor A, Mouneimne Y, Cudd A, Loyd S, Madoulet C, 
13-
Schulz BR. In: Horizons Memb Biotech 1990. 
242. Nicoletti P. Adv Biotechnol Process 1990; 13:146-168. 
243. Nielsen K, Duncan JR. Vet Immunol Immunopathol \9%%',\9\2Q5-21A. 
244. Northfelt DW, Martin FJ, Working P, et al. J Clin Pharmacol 1996; 36: 55-63. 
245. O'Hagan DT, Jeffery H, Davis SS. Vaccine 1993; 11: 965-969. 
246. Oliveira SC, Harms JS, Banai M, Splitter GA. Cell Immunol 1996; 172: 262-
268. 
247. Oiiveria SC, Splitter GA. Vaccine 1994; 14: 959-962. 
248. Oiiveria SC, Zhu Y, Splitter GA. Gene 1992; 140: 37. 
249. Oiiveria SC, Zhu Y, Splitter GA. Immunology 1994; 83: 659-664. 
250. Otsubo T, Maruyama K, Maesaki S, Miyazaki Y, Tanaka E, Takizawa T, 
Moribe K, Tomono K, Tashiro T, Kohno S. Antimicrob Agents Chemother 
1998;42:40-44. 
251. Ott G, Barchfeld GL, Chemoff D, et al. Pharm Biotechnol 1995; 6: 277-296. 
252. Owais M, Gupta CM. EurJBiochem 2000; 267: 3946-3956. 
253. Owais M, Khan MA, Agarwala JN, Bisht D, Gupta CM. Scand J Immunol 
2001;54:1-9. 
254. Owais M, Varsheny A, Choudhury S, Chandra S, Gupta CM. Antimicrob 
Agents Chemother 1995; 39: 180-184. 
255. Palmer MV, Olsen SC, Cheville NF. Am J Vet Res 1997; 58:472-477. 
256. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang 
SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Proc Natl Acad 
Sci USA 1991; 88: 11460-11464. 
257. Papahadjopoulos D,Vail WJ, Jacobson K, Poste G. Biochim Biophys Acta 
1975;394:483-490. 
258. Partidos CD, Shaw DM, Gander B, Merkle HP, Howard CR, Steward MW. 
Vaccine Res 1994; 4: 203-209. 
14 
259. Patel GB, Sprott GD. Crit Rev Biotechnol 1999; 19:317-357. 
260. Paulsen IT, Seshadri R, Nelson KE, Eisen JA, Heidelberg JF, Read TD,Dodson 
RJ, Umayam L, Brinkac LM, Beanan MJ, Daugherty SC, Deboy RT, Durkin 
AS, Kolonay JF, Madupu R, Nelson WC, Ayodeji B, Kraul M, Shetty J, Malek 
J, Van Aken SE, Riedmuller S, Tettelin H, Gill SR, White O, Salzberg SL, 
Hoover DL, Lindler LE, Hailing SM, Boyle SM, Fraser CM. Proc Natl Acad 
Sci USA 2002;99: 13148-13153. 
261. Pector V, Gaspers J, Banerjee S, Deriemaeker L, Fuks R, Elouahabi A, 
Vandenbranden M, Finsy R, Ruysschaert JM. Biochim Biophys Acta 1998; 
1372: 339-346. 
262. Pfaller MA, Webzel R. Eur J Clin Microbiol Infect Dis 1992; 11: 287-291. 
263. Phillips NC, Tsoukas C. Blood 1992; 79: 1137. 
264. Pizarro-Cerda J, Meresse S, Parton RG, van der Groot G, Sola-Landa A, 
Lopez GI, Moreno E, Grovel JP. Infect Immun 1998b; 66: 5711-5724. 
265. Pizarro-Cerda J, Moreno E, Sanguedolce V, Mege JL, Grovel JP. Infect 
Immun 1998a; 66: 2387-2392. 
266. Ploramet M, Plommet AM. Infect Immun 1983; 41:97-105. 
267. Pluschke G, Overlith P. J Biol Chem 1981; 268:3207-3212. 
268. Podda A. Vaccine 2001; 19:2673-2680. 
269. Polt-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, Pluschk 
G. Clin Exp Immunol 1999; 117: 496-503. 
270. Poste G. Biol Cell 1983; 47: 19. 
271. Pozanansky MJ, Jiiliano RL. Pharmacol Rev 1984;36:277-336. 
272. Price CL, Horton JW, Baxter CR. Gynecology and Obstetrics 1992; 174: 414-
418. 
273. Price CL, Horton JW, Baxter CR. Surgery 1994; 115: 480-487. 
274. Qadri SM, Akhtar M, Ueno Y, Al-Sibai MB. Exp Clin Res 1988; 15:483-485. 
275. Qadri SM, Al-Sedairy S, Ueno Y. Diagn Microbiol Infect Dis 1990; 13:277-
15-
279. 
276. Ramon G., Ann Inst Pasteur 1924; 38:1 
277. Reddy R, Zhou F, Huang L, Carbone F, Bevan M, Rouse BT. J Immunol 
Methods 1991; 141: 157-176. 
278. Ribeiro LA, Azevedo V, Le Loir Y, Oliveria SC, Dieye Y, Conway PI. Appl 
Environ Microbiol 2002; 68: 910-916. 
279. Ribi E, et al. Rev Infect Dis 1984; 6: 567-572. 
280. Richardson M, Holt JN. JBacteriol 1962; 84:638-646. 
281. RichardsonMD. JAntimicroblChemother 1991;28: l-ll. 
282. Robinson HL. Vaccine 1997; 18:785-787. 
283. Rooijen N, Nieuwmegen R. Immunol Commun 1980; 9:243-256. 
284. Rosinha GMS, Myioshi A, Azevedo V, Splitter GA,01iveira, SC. J Med 
Microbiol 2002; 51: 661-61 \. 
285. Sambrook J, Russel DW. In: Molecular cloning: a laboratory manual. 3'^ '' ed. 
Cold Spring Harbor, N.Y. 2001 
286. Sangari FJ, Aguero J. Microbiologia 1996; 12:207-218. 
287. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, 
Takeda K, Zychlinsky A. Immunity 2000;12: 581-590. 
288. Sanyal SC, Lilijas A. Curr Opin Struc Biol 2000; 10: 633-636. 
289. Schurig GG, RoopII RM, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. 
Vet. Microbiol 1991; 28:171-188. 
290. Schurig GG, Sriranganathan N, Corbel MJ. Vet Microbiol 2002; 90: 479-496 
291. Senaldi G, Shaklee CLJ, Guo L, Martin T, Boone WM, Ulich TR. J Immunol 
1999; 163:6820-6826. 
292. Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Owais M. Vaccine 
2006a; 24:1800-1810. 
293. Sharma SK, Farah D, Misra-Bhattacharya S, Bajpai P, Agarwal A, Owais M. 
-16 
cSi&lioma^Ay^ 
Vaccine 2006b; 24: 948-956. 
294. Shewen PE, Wilkie BN. Infect Immun 1982; 35: 91-94. 
295. Singleton WS, Gray MS, Brown ML. J Am Oil Chem Soc 1965; 42: 53-56. 
296. Smith LD, Ficht TA. Crit Rev Microbiol 1990; 17: 209-230. 
297. Sola-Landa A, Pizarro-Cerda J, Grillo MJ, Moreno E, Moriyon I, Blasco JM, 
Grovel JP, Lopez-Goni I. Mol Microbiol 1998; 29: 125-138. 
298. Solera J, Rodriguez-Zapata M, Geijo P, Largo J, Paulino J, Saez L, Martinez-
Alfaro E, Sanchez L, Sepulveda MA, Ruiz-Ribo MD, et al. Antimicrob Agents 
Chemother 1995; 39:2061-2067. 
299. Solera JA. Espinosa P, Geijo E, Martinez-AIfaro L, Saez MA, Sepulveda, Ruiz-
Ribo MD. 1996. 
300. Solera JM, Saez L. Med Clin 1994; 102:731-738. 
301. Sonali N, McCormich AL, Thomas MS, Heath AW. Vaccine 2005; 23: 3984-
3990. 
302. Spink WW, Hall J, Finstad J, Mallet E. Bull WHO 1962; 26: 409-419. 
303. Splitter G, Oliveira S, Carey M, Miller C, Ko J, Covert J. Vet Immune 
Immunopathol 1996; 54:309-319. 
304. Sprott GD, Dicaire CJ, Fleming LP, Patel GB. Cells Mater 1996; 6: 143-155. 
305. Sprott GD, Dicaire CJ, Gumani K, Deschatelets LA, Krishnan L. Vaccine 
2004; 22: 2154-2162. 
306. Sprott GD, Tolson DL, Patel GB. FEMS Microbiol Lett 1997; 154:17-22. 
307. Sprott GD. JBioenerg Biomembr 1992;24:555-66. 
308. Squarcione S, Maggi P, Lo Caputo S, et al. Ital Med Lav 1990; 12: 25-26. 
309. Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehle MJ. Infect Immun 1990; 
2048-2055. 
310. Steeg PS, Johnson HM, Oppenheim JJ. J Immunol 1982; 129: 2402-2406. 
311. Stefanos SK, Anastasia NM, Dimitrios NC, George VP. Hellenic J Cardiol 
2003; 44: 222-225. 
17 
312. Stevens MG, Hennager SG, Olsen SC, Cheville NF. J Clin Microbiol 1994; 
32:1065-1066. 
313. Szoka F, Papahadjopoulus CE. Proc Natl Acad Sci USA, 1978; 75: 4194 
314. Tabatabai LB, Pugh GW. Vaccine 1994; 12: 912-924. 
315. Tabatabain LB, Pugh GW, Stevens MG, Philips M, McDonald TJ. Am J Vet 
Res 1992; 53: 1900-1907. 
316. Tahseen HN, Masood AK, Owais M. Journal Antimicrob Chemother 2005. 
317. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. 
iVa/wre 1990; 344: 873-875. 
318. Takayama K, Olsen M, Datta P and Hunter RI. Vaccine 1991; 9: 257-265 
319. Latum FM, Detilleux PG, Sacks JM, Hallin SM. Infect Immun 1992; 60: 2863-
2869. 
320. Laylor AW, McDiarraid A. Vet Rec 1949; 61: 317-318. 
321. Lhakur SD, Thapliyal DC. Ind J Comp Microbiol Immunol Infect Dis 2002; 
23:101-110. 
322. Lhompson DH, Gerasimov OV, Wheeler JJ, Rui YJ, Anderson VC. Biochim 
BiophysActa 1996; 1279: 25-34. 
323. Limms LM. Res Vet Sci 1979; 27: 347-53. 
324. Limony JF, Gillespie JH, Scott FW, Barlough JE. In.-Hagan and Bruner's 
Microbiology and Infectious Diseases of Domestic Animals, 8* ed. Comstock 
Publishing Associates, Ithaca, NY. 1988; pl35-152 
325. Lomai MA, Johnson AG. J Biol Resp Mod 1989; 8: 625-643. 
326. Lorchilin VP, Zhou F, Huang L. J Liposome Res 1993; 3: 201-255. 
327. Loth LE, Cobb JA, Boyle SM, Roop, RM. Vet Microbiol 1995; 45: 171-183. 
328. Lowbin U, Stawnehn L, Gordon J. Proc Natl Acad Sci USA 1979; 76:4350. 
329. Lrinchieri G. Immunol Today 1993; 14:335-338. 
18 
330. Uchegbu IF, Duncan R. IntJPharm 1997; 155: 7-17. 
331. Uchegbu IF, Schatzlein AG, Tetley L, Gray AI, Sludden J, Siddigne S , Mosha 
E. J Pharmacol 1998; 50: 453-458. 
332. USBWP, Department of the Army. US Army Activity in the US Biological 
Warfare Programs, Vols 1 and 2. Washington, DC: HQ, DA; 24 February 1977. 
333. Vaage J, Donovan D, Loftus T, Abra R, Working P, Huang A. Cancer 1994;73: 
2366-2371. 
334. Van Etten EWM, van den Heuvel-de Groot C, Bakker-Woudenberg lAJM. J 
Antimicrobial Chemother 1993; 32: 723-739. 
335. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, 
Bowden RA, Bruno L, Fossati CA, Spitz M. Infect Immun 2002; 70: 2507-2511. 
336. Vemulapalli R, Cravero S, Clavert CL, Toth TE, Sriranganathan N, Boyle SM, 
Rosseti OL, Schuring GG. Clin Diagn Lab Immunol 2000; 7: 114-118. 
337. Vitas AI, Diaz R, Gamazo C. FEMS Microbiol Lett 1995; 130:231-236. 
338. Vladimirsky MA, Ladigina. BiomedPharmacother 1982; 36:375-377. 
339. Vogel FR; Powell MF. In: Vaccine Design: Subunit and adjuvant approach. 
New york. Plenum Press, 1995;pl41-228. 
340. Vora B, Khopade AJ, JainNK. J Control Rel 1998; 54: 149-165. 
341. Vtoavic MS. Dissertation Abstracts Int 1975; 358:4723. 
342. Walsh TJ. In: J Sutcliffe and NH Georgopapadakou ed. Chapman and Hall, 
New york 1992; p 249-373. 
343. Wang LI, Frash CE. Infect Immun 1984; 46:408. 
344. Warren S, Vogel F, Chendid L. Annual Rev Immunology 1986; 4: 369-388 
345. Wassef NM, Alving CR, Richards RL. Immunol Methods 1994; 4: 217. 
346. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. Vaccine 2000; 18: 1755-
1762. 
347. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes. J Pharm Res 
19 
1998; 15:334-337. 
348. WHO Report. Report of WHO meeting, Geneva, Switzerland. WHO/EMC 
/ZDI/98, 14-15, 11-12 Dec. 1997 
349. Wilkinson PC. J Immunol 1966; 96:457-463. 
350. Wilkinson PC. Rev Infect Dis 1980; 2:293 
351. Williams RS, Johnston SA, Riedy M, DeVit MJ, McEUigott SO, Sanford JC. 
Proc Natl AcadSci USA 199U 88:2726-2730. 
352. Winter AJ, Rowe G E. Vet Immunol Immunopathol 1988; 18: 149-163. 
353. Winter AJ, Rowe GE, Duncun JR, Eis MJ, Widom J, Ganem B, Morein B. 
Infect Immun 1988; 56: 2808-2817. 
354. Winter AJ, Rowe GE. Vet Immun Immunopathol 1983; 18:149-163. 
355. Winter AJ, Schurig GG. Boyle SM, Sriranganathan N, Bevins JS, Enright FM, 
Elzer PH, Kopek D. Am J Vet Res 1996; 57: 677-683. 
356. Wolf JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL. 
Science 1990;247:1465-1468. 
357. Woodle MC, Papahadjopoulos D. Methods Enzymol 1989; 71: 193-217. 
358. Wyckoff-III JH, Howland JL, Catherine M, Scott OC, Smith RA, Anthony 
WC. Vet Microbiol 2005; 111: 77-87. 
359. Yaraauchi K, Doi K, Kinoshita M. Biochim Biophys Acta 1996; 1283: 163-169. 
360. Yip HC, Karulm AY, Taiy-Lehmami M, Heese MD., Radeke H, Heeger PS, 
Trezza RP, Heinzel PP, Forsthuber T, Lehmann PV. J Immunol 1999; 162: 
3942-3949. 
361. YoungBA. Br Med J1995; 311: 1697-1700. 
362. Zahringer U, Knirel YA, Lindner B, Helbig JH, Sonesson A, Marre R. 
Rietschel ET. Prog Clin Biol Res 1995; 392:113-139. 
363. ZhanY, Cheers C. Infect Immunol 1995; 63: 1387-1390 
20 
cOwuoa^ia/iAu 
364. Zinneman HH, Glenchur H, Hall WH. J Immunol 1959; 83:206-212. 
365. Zurbriggen R, GliickR. Vaccine 1999; 17:1301-1305. 
21-
RESUME 
AMIRUL ISLAM MALLICK 
interdisciplinary Bioteclnnoiogy Unit 
A.M.U. Aiigarli - 202001, India 
Home: 91-03443-250041 
Work: 91-0571-2720388 
Mobile: 91-9359513073 
Email: dramirul(5)redlffmail.coni 
OBJECTIVE 
To undertake dedicated research in the field of Immunology, Molecular Biology, 
Biotechnology for the welfare and upliftment of human and animal health status. 
RESEARCH EXPERIENCE: 
Nov 2004- Present Interdisciplinary Biotechnology Unit, Aligrh Muslim 
University, Aligarh, India. 
• Thesis Title: Fusogenic liposome based vaccines 
against some infectious diseases. 
•Techniques for preparing Liposomes from various 
sources viz. egg PC, E. colt, S. cervisae, blood, 
ganglioside e t c Drug/antigen entrapment in SUV's and 
their in vivo delivery. 
Sept 2001-Oct 2003 Dept of Microbiology and Immunology, College of Vet 
Science, CSA University of Agrl. & Technology, 
Kanpur, U.P.India. 
•M.V.Sc research topic:'lmmunomodulatory role of 
probiotic (Saccharomyces cerews/ael 026) and herbal 
performance enhancer in broilers' 
EDUCATIONAL QUALIFICATION: 
Name of 
Examination 
Madhyamik 
Pariksha (10* 
Class) 
Higher 
Secondary 
Examination 
(12* Class) 
Bachelor of 
Vet.Scs. 
&Animal 
Husbandry 
(B.V.Sc&A.H 
Master in 
Vet.Scs 
(M.V.Sc) 
Ph.D 
(Completing) 
Year of 
passing 
1994 
1996 
2001 
2003 
2007 
Board 
/University 
West Bengal Board 
of Secondary 
Education 
West Bengal Council 
of Higher Secondary 
Education 
West Bengal 
University Of Animal 
& Fishery Scs, 
Kolkata.W.B 
C. S. A. Univ. of 
Agriculture & 
Technology, Kanpur, 
U.P. 
A.M. University, 
Aligarh, U.P. 
Subjects 
Beng, Eng, Math, 
Ph.Scs, Life.Scs, 
Hist.Geo, Biology 
Eng,Beng,Math, 
Phy,Chem,Biologi 
cal Science 
All Subjects 
recommended by 
I.C.A.R 
Microbiology 
&lmmunology 
Biotechnology 
Div/ 
Class 
1st 
1st 
1st 
1st 
%of 
Marks 
81.33 
74.70 
67.63 
84.60 
SCHOLARSHIP/AWARD 
• National Scholarship from 1994 to 2001. 
• P.G. Merit Scholarship from 2001-2003. 
• Senior Research Fellowship (SRF) from Feb'06 to 31 st March, 2007 in CSiR 
funded project entitled "Evaluation fibrin mediated delivery of antifungal, 
antigens and immunomodulators against murine cryptococcosis". 
TRAINING /WORKSHOP ATTENDED: 
1 "Diagnosis of equine abortion (EHV-1 infection ) using Mab-based ELISA 
and PCR" at National Research Centre on Equines, Hisar, Haryana, India (28* 
Jan to 10* Feb 2002). 
2. "Cells stress and apoptosis" organized by Society of Immunology And 
Immunopathology (SUP) at Panthnagar, G. B. Pant Agrl. University, Pantnagar. 
Uttaranchal (August 2003). 
3. "Molecular and immunological methods(PCR, ELISA, Flow cytometry, RFLP 
and Microarrays)" at Central JALMA Institute of Leprosy and Other 
Mycobacterial diseases, Agra, india. (Feb 13-15,2004) 
4. International workshop on 'Biodiversity informatics & Microbial Culture 
collection' organized by American society for Microbiology & Dept.of 
Biotechnology, Govt, of India; on 23-27Aug, 2004 at Bioinformatics Centre, 
University of Pune, India. 
5. DBT sponsored Workshop entitled "Use of bioinformatics in genomic level" 
held at Interdisciplinary Biotechnology Unit, A.M.U. Aligarh, India, on dated 22 
Feb-25 Feb 2006. 
PARTICIPATION IN SYMPOSIA / CONFERENCES: 
(1) National symposium on "Immunomodulation in Health and Disease", 
organized by Society for Immunology and Immunopathology (SUP), at College of 
Veterinary Sciences, G.B, Pant University of Agriculture & Technology, 
Pantnagar, Uttaranchal, India on December 14-15, 2001. 
(2) National symposium on "Recent Trends in Diagnostics and Therapeutics of 
Animal Diseases", organized by Indian Society on Veterinary Medicine, at 
College of Veterinary and Animal Science, Rajasthan Agricultural University, 
Bikaner, Rajasthan, India on February 14-16, 2002. 
(3) National symposium on "Prospects and Challenges for better Livestock and 
Poultry Health Management Employing Conservation and Molecular 
Approaches" organized by Indian Association of Veterinary Microbiologists, 
Immunologists and Specialists in Infectious Diseases (lAVMI), -at Division of 
Animal Health, ICAR Research Complex for NEH region, Umroi Road, Umiam, 
Meghalaya, India on February 7-9, 2003. 
(4) National Symposium on "Diversification of Poultry for Nutritional Security" 
organized by Indian Poultry Science Association (IPSA), held at Central Avian 
Research Institute, Izatnagar, Bareilly, and U.P., INDIA from March 27-28 , 2003. 
(5) National symposium on "Challenges In emerging WTO scenario of milk, meat 
and poultry industry, organized by Indian Association for the Public Health 
Specialists (lAVHS) MA&FSU, Nagpur, India 20-22 Sep. 2003. 
(6) 3"^  convention of SUP and National symposium on "Cytokines and signal 
transduction," held act central JALMA Institute for Leprosy and other 
Mycobacterial diseases, Agra, India from 13-15 Feb. 2004. 
(7) 4* Indian Veterinary congress and 11"^ annual conference of India Association 
for the Advancement of Veterinary Research and National symposium on 'Newer 
concept and challenges in animal health and production in the wake of 
WTO, IPR, Trade Barriers and Certification of standards, 27-28 Feb. 2004 at 
IVRI, Barielly.lndia 
(8) International Symposium on 'Diet in Causation & prevention of Cancer' & 
XXXth Annual Conference of Environmental Mutagen Society of India, 
March 17-19, 2005, ITRG, Lucknow., India and presented poster entitled 
"Immunomoduiator tuftsin augments the anticancer effect of etoposide" 
(9) South Asian and VII Annual National Conference of Indian Congress of Forensic 
Medicine and Toxicology(ICFMT) organized by Department of Forensic Medicine 
and Toxicology, Jahwahrlal Nehru Medical College, Aligarh Muslim University, 
Aiigarh, U.P., India on March24-25, 2007. 
PUBLICATIONS/COMMINICATIONS: 
(1) Arora, S and Mallick, A.I (2003). Screening of milk for antimicrobial residues 
using Bacillus subtilis disc assay. Journal of Veterinary Public Health, 1 ;89-90. 
(2) Kumar,H., Mallick, A.I. and Hajra, S. (2003). Prevalence of Echinococcus 
granulosa infection in domestic animals. Journal of Veterinary Public Health, 
1:81-82. 
(3) Mallick, A.I., Singh, D.P. and Nasrin, S. (2004). Immunomodulatory role of 
probiotic {Saccharomyces cerevisiae1026) and herbal performance enhancer in 
broWers.Journal of Immunology and Immunopathology, 6(S-1): 102-103. 
(4) Khan, M.A., Nasti, T.H., Saima, K., Mallick, A.I., Firoz, A., Wajhaul, H., Ahmed, 
N.and Owasis, M.(2004). Co-administration of immunomoduiator tuftsin and 
lipomised nystatin can combat less susceptible Candida albicans infection in 
temporarily neurotropic mice. FEfvIS Immmunology and Microbiology 
(ELSEVIER), 41(2004): 249-258. 
(5) Mallick Al, Singha H, Chaudhuri P, Nadeem A, Khan SA, Dar KA, Owais 
M. Vaccine 2007; 25: 3692-3704. 
(6) Mallick Al, Singha H, Khan, S, AnwarT, Ansari MA.Khalid R; Chaudhuri 
P, Owais M.2007. Escherlosome mediated delivery of recombinant 
ribosomal L7/L12 protein confers protection against murine brucellosis. 
(In press -yaccine) 
(7) Singha, H., Mallick, A.I., Jana, C, Isore, D.P., Gowsami, T.K., Srivastava, S.K, 
Owais, M. and Chaudhuri, P. Escheriosomes entrapped DNA vaccine 
expressing Brucella abortus Cu-Zn superoxide dismutase fused to IL-18 
confers protection against experimental murine brucellosis. (Communicated) 
PROFESSIONAL AFFILIATIONS 
1. Society for Immunology and Immunopathology (SUP) 
2. Indian Association of Veterinary Public Health 
Specialists (lAVPHS) 
3. Indian Journal of Animal Health, W. B Veterinary Association, 
Kolkata. 
